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The overall aim of this thesis was to investigate the potential of omega-3 
polyunsaturated fatty acids (n-3 PUFA), particularly from algal sources, as regulators of 
gut microbiota development, behaviour and associated inflammatory and metabolic 
outcomes.  
In chapter 2, omega-3 supplemented (O3+), omega-3 deficient (O3-) and control 
diets were compared for their effect on behaviour and gut microbiota development in 
both adolescence and adulthood. O3- impaired communication, social and depression-
related behaviours, whereas O3+ enhanced cognition. These behavioural changes were 
associated with alterations to gut microbiota composition and inflammatory outcomes 
such that O3- mice displayed an elevated Firmicutes:Bacteroidetes ratio and blunted 
systemic LPS responsiveness. Contrastingly, O3+ mice displayed greater fecal 
Bifidobacterium and Lactobacillus abundance and dampened hypothalamic-pituitary-
adrenal axis activity. These results suggest that the beneficial effects of n-3 PUFA on 
neurobehavioural development are closely associated with comprehensive alterations in 
gut microbiota composition, HPA-axis activity and inflammation. 
Chapter 3 further assessed the role of n-3 PUFA on the cecal microbiota and 
metabolome. n-3 PUFA status induced subtle changes to the cecal microbiota in 
mothers and their offspring and, in addition, O3+ induced increased production of 
energy metabolites. O3- reduced production of short chain fatty acids. These results 
indicate that n-3 PUFA modulate cecal microbiota composition and function, which 
may have implications for chronic disease risk. 
In chapter 4, the transgenic fat-1 mouse model was utilised to examine the 
effects of maternal n-3 PUFA on offspring obesity risk. Offspring of mothers with a 




reduced weight gain was associated with reduced gut permeability and changes to the 
gut microbiota and inflammatory outcomes. These results indicate that maternal n-3 
PUFA status can significantly influence offspring adiposity through changes associated 
with gut microbiota. 
Algae are potent sources of n-3 PUFA and pose potential as alternative 
sustainable sources of such fatty acids than fish. However, little research has examined 
the effect of algae-derived n-3 PUFA on health. The aim of Chapter 5 was to screen the 
anti-inflammatory bioactivity of n-3 PUFA-rich algae lipid extracts. Exposure of the 
algae lipid extracts to lipopolysaccharide-stimulated THP-1 macrophages significantly 
reduced production of the pro-inflammatory cytokines IL-6 and IL-8 and the expression 
of a number of pro-inflammatory genes associated with toll-like receptor and 
chemokine activity. These data reveal that such n-3 PUFA-rich algae lipid extracts pose 
potential as anti-inflammatory functional ingredients. 
The aim of chapter 6 was to investigate the suitability of yoghurt as a food 
matrix in which to supplement an n-3 PUFA-rich lipid extract of Pavlova lutheri. 
Addition of the extract had little negative effect on the techno-functional properties of 
yoghurt. Furthermore, addition of the extract dose-dependently increased concentrations 
of n−3 PUFA. However, sensory analysis revealed that supplemented yoghurts were not 
well accepted. These results suggest that addition of this extract to yoghurt is a suitable 
method to increase n-3 PUFA concentration. 
Finally, Chapter 7 discusses the major findings and general conclusions arising 



















Algae-Derived Polyunsaturated Fatty Acids: 
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Polyunsaturated fatty acids (PUFA) have been shown to exert a multitude of 
beneficial health effects. Growing evidence suggests that dietary omega-3 (n-3) 
PUFA, which are abundant in foods of marine origin, play a major role in early 
development and in the prevention and treatment of chronic disease, notably 
inflammatory disease. Recent research has highlighted mechanisms by which the 
well-characterised fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic 
acid (DHA), and less common PUFA, such as docosapentaenoic acid (DPA) and 
stearidonic acid (SDA) ameliorate disease-causing physiological processes. Such 
PUFA are responsible for gene and cytokine expression, eicosanoid production, 
neurodevelopment and gut microbiota composition among other processes, all of 
which can significantly affect human health. The western diet, however, is 
deficient in n-3 PUFA and abundant in other lipids, notably n-6 PUFA and 
saturated fats. Hence, increasing n-3 PUFA consumption may contribute to 
improved public health outcomes linked to chronic disease. Algae pose potential 
as a vast and untapped resource of n-3 and n-6 PUFA, one that may be more 
resourceful and sustainable than fish. This chapter will discuss established and 
recent evidence for the role of dietary PUFA in chronic disease, notably their 
effects on inflammatory disorders and brain development and function. 
Furthermore, the bioactive properties of algae-derived PUFA and their potential as 









As the incidence of nutritionally-linked chronic disease increases worldwide 
(Laslett et al., 2012, Shaw et al., 2010, Kelly et al., 2008), nutrition-based 
prevention and treatment strategies are continuously being explored. Dietary n-3 
polyunsaturated fatty acids (n-3 PUFA) have shown the potential to regulate 
pathways that lead to chronic diseases, and since the 1970s, when the low 
incidence of cardiovascular disease in Greenland Inuits was associated with a high 
fish intake (Bang et al., 1971, Bang et al., 1976, Dyerberg et al., 1975), 
investigations into the health benefits of long-chain omega-3 (n-3) PUFA have 
increased dramatically. Dietary long-chain n-3 PUFA are now known to exhibit 
cardioprotective (Adkins and Kelley, 2010), anti-inflammatory (Calder, 2006), 
immunomodulatory (Sijben and Calder, 2007), cognitive (Dangour et al., 2009), 
neurobehavioural (Boucher et al., 2011), anti-proliferative (Yang et al., 2012), 
anti-cancer (Chapkin et al., 2007) and anti-microbial (Huang and Ebersole, 2010) 
properties, amongst others. Hence, these functional fatty acids may assist in the 
treatment and prevention of chronic diseases such as obesity, cardiovascular 
disease (CVD), Alzheimer’s disease (AD) and inflammatory bowel disease (IBD). 
Evidence associating these bioactive molecules with such multifactorial effects 
has led to an abundance of fortified foods and hence a rapid increase in PUFA 
health claims (Agostoni, 2010). The western diet, however, is characterised by an 
imbalance in the ratio of n-6/n-3 PUFA intake. It is estimated that humans evolved 
on a ratio of 1:1 however this ratio in the western diet may be as high as 10-40:1 
(Simopoulos, 2002). Hence the proportions of dietary lipids are critical in the 




The most bioactive n-3 PUFA are the long-chain n-3 PUFA, which are 
derived from marine sources, notably oily fish. Microalgae, macroalgae 
(seaweeds) and certain microorganisms are capable of de novo PUFA synthesis 
and hence represent a potentially vast and untapped resource of these fatty acids, 
one that may be more resourceful and sustainable than fish. Macroalgae are known 
producers of marine bioactive compounds, and are largely exploited for their 
nutritional properties in Asian diets. Microalgae are a diverse group of unicellular 
organisms found in marine, freshwater and subaerial environments, comprised of 
thousands of different species, most of which have not been studied in detail, yet 
some are already exploited as sources of bioactive ingredients such as PUFA. 
PUFA profiles vary widely across algal species, and thus they may be resources of 
common as well as lesser-known unsaturated fatty acids. However, much has yet 
to be discovered about the compositional and functional properties of algal PUFA, 
and hence their potential as disease-preventing functional food ingredients.  
 
 
2. THE STRUCTURE AND BASIC FUNCTION OF PUFA 
 
2.1. PUFA Structure and Metabolism 
PUFA are hydrocarbon chains, bound by 2 or more double bonds, and terminate in 
a methyl group at one end and a carboxyl group at the other. The reactive carboxyl 
group readily combines with alcohol groups to form various lipid-based molecules 
such as triglycerides and phospholipids. PUFA are characterised primarily by the 
number and position of their double bonds, which allows them to be classified into 




PUFA are synthesized from the essential fatty acid precursor linoleic acid (LA, 
18:2), whilst n-3 PUFA are synthesized from the essential fatty acid α-linolenic 
acid (ALA, 18:3). LA and ALA are termed ‘essential’ as they cannot be produced 
de novo in mammals, due to a predisposed genetic lack of the Δ-15 desaturase 
enzyme. Thus LA and ALA must be obtained extrinsically from the diet. These 
two fatty acids are primarily found in plant sources such as soybean, canola, 
flaxseed and sunflower oils. Land plants such as these lack the enzymatic capacity 
to further metabolize LA and ALA into longer chain molecules and hence do not 
generally contain long-chain PUFA. 
In mammalian tissues LA and ALA are subject to a series of elongation 
and desaturation reactions giving rise to longer chain PUFA (Fig. 1). The n-3 
(ALA) and n-6 (LA) PUFA synthesis pathways are competitive, such that they 
occur adjacently, competing for the same enzymes. Thus, up-regulation of one 
pathway can lead to down-regulation of the other. These reactions rely on a 
combination of elongases, Δ-5 and Δ-6 desaturases (Sprecher et al., 1999). 
Arachidonic acid (AA, 20:4) is the major product of the n-6 pathway and 
eicosapentaenoic acid (EPA, 20:5) and docosahexaenoic acid (DHA, 22:6) are the 
major products of the n-3 pathway, however, a number of intermediate and less 
common fatty acids are produced along these reaction chains. Hence humans can 
obtain long-chain PUFA from non-marine based plant sources via tissue 
conversion of LA and ALA to longer chain PUFA. However, the n-3 conversion 
process from ALA to EPA/DHA is inefficient (Burdge and Wootton, 2002, 
Burdge et al., 2003, Arterburn et al., 2006), thus it is necessary to obtain a 
majority of n-3 fatty acids directly from the diet. The inefficiency of this 




2012, Le et al., 2009), thus dietary intake of PUFA becomes even more essential 
in such cases. Dietary EPA and DHA are abundant in oily fish such as tuna, 
salmon and mackerel, and are also found in other food sources such as eggs and 
algae. 
 
2.2. PUFA Functions 
PUFA have a number of structural and functional roles in human tissues. Most 
notably, they form the core structure of the phospholipid bilayer in all cell 
membranes, regulating fluidity and rigidity, and cell signalling. Distribution of 
PUFA in the phospholipid bilayer of cell membranes varies according to dietary 
intake and cell type. For example, brain and retinal cells contain a higher 
proportion of DHA in comparison to most other cell types (Arterburn et al., 2006). 
DHA represents up to 60% of total fatty acids in the rod outer segment in the 
retina (Giusto et al., 2000). Cell PUFA composition is readily altered by diet and 
hence a high dietary intake of certain PUFA will be reflected by cell PUFA 
accumulation. Research has also shown that tissue DHA content following 
supplementation is dose-dependent (Arterburn et al., 2006). Although a certain 
amount of conversion and even retroconversion (Vidgren et al., 1997, Brenna et 
al., 2009) occurs between fatty acids in vivo, it is limited, thus it has been 
suggested that the most effective way to increase the tissue content of a certain 
fatty acid is dietary supplementation with that fatty acid (Arterburn et al., 2006). 
Aside from structural properties, PUFA also regulate a number of 
functional and metabolic processes. PUFA possessing 20 carbons, notably AA and 
EPA, are capable of producing potent lipid mediators, termed eicosanoids. There 




(LT) and thromboxanes (TX), along with a number of subclasses, all of which 
play differing roles in inflammatory regulation (Calder, 2006). In recent times, 
DHA (22:6 n-3) and n-6 docosapentaenoic acid (n-6 DPA, 22:5 n-6) have been 
shown to produce other eicosanoid-like lipid mediators such as resolvins and 
protectins, which can also regulate inflammation (Dangi et al., 2009, Dangi et al., 
2010, Serhan et al., 2002). 
PUFA are known ligands for peroxisome proliferator-activated receptors 
(PPAR) which function as nuclear receptors and transcription factors by activating 
genes that regulate a number of activities including lipid metabolism and storage. 
PUFA are also capable of activating a number of other transcription factors and 
receptors such as nuclear factor kappa B (NF-κB) and toll-like receptor 4 (TLR-4) 
and thus are potent regulators of gene expression (Jump, 2002). Additionally, 
similar to other fatty acids, PUFA also provide a very good source of energy, as 
well as regulating plasma lipids and circulating cholesterol (Kelley et al., 2007). 
 
2.3. The Health Effects of PUFA 
As a consequence of their vital structural and metabolic functions, PUFA are 
responsible for a number of health effects as outlined below. By producing 
eicosanoids and regulating gene expression, PUFA play a significant role in 
inflammatory disorders. Inflammation is a complex biological process in which 
the body’s immune responses are stimulated, and in some cases over-stimulated, 
in response to harm, such as the presence of pathogenic bacteria or physical 
damage to tissues. Low-grade chronic inflammation has recently been identified as 
the cornerstone of a number of chronic disorders including obesity (Wellen and 




rheumatoid arthritis (RA) (Choy and Panayi, 2001), AD (Akiyama et al., 2000) 
and IBD (Fiocchi, 1998). As potent regulators of inflammatory gene expression 
and precursors to eicosanoids, dietary PUFA play a major role in the onset, 
prevention and treatment of such inflammatory disorders. The role of PUFA and 
algal PUFA in inflammatory disorders will be discussed in the following sections. 
AD, another inflammatory disorder, is characterized by the build-up of amyloid 
plaques in the brain, a symptom which occurs in tandem with neuroinflammatory 
processes. This plaque accumulation leads to brain cell degeneration and cognitive 
decline in the elderly (Leon et al., 2010, Janus et al., 2000). n-3 and certain n-6 
PUFA have been shown to protect against age-related neuro-inflammation and 
cognitive impairment (Labrousse et al., 2012) and hence may play a role in the 
prevention of AD. This, in recent times, has led to PUFA-fortified dietary products 
specifically designed for brain health (www.nutricia.ie/souvenaid/) (Nutricia). 
PUFA have also been shown to be important for brain development. During the 
neonatal and early postnatal periods there is a significant dietary requirement for 
PUFA leading to a rapid uptake of DHA and AA in the infant brain (Schiefermeier 
and Yavin, 2002). Hence, the concentration of PUFA is high in human breastmilk. 
The role of PUFA and algal PUFA in brain development and decline will be 
discussed in the following sections. 
One of the earliest known benefits of long-chain PUFA was in terms of 
cardiovascular health. As mentioned above, Greenland Inuits were noted for their 
lack of cardiovascular diseases in the 1970s and this was attributed to their high 
intake of PUFA from fish (Bang et al., 1971, Dyerberg et al., 1975). Dietary n-3 
PUFA contribute to cardiovascular health by increasing the beneficial cholesterol, 




triglycerides (TAG) and low density lipoprotein (LDL) cholesterol (Kelley et al., 
2007). n-3 PUFA are also potent inhibitors of platelet aggregation, hence may be 
beneficial in preventing the build-up of atherosclerotic lesions (Phang et al., 2009). 
Recent research has associated long-chain n-3 PUFA with anti-microbial effects 
(Huang and Ebersole, 2010), but there is a lack of in vivo data to validate this 
association. Similarly, PUFA have been associated with gut health by enhancing 
the adhesion capabilities of beneficial probiotics (Kankaanpää et al., 2001, Bomba 
et al., 2002, Bomba et al., 2003). In addition, n-3 PUFA appear to exert beneficial 
effects on the gut microbiota and the intestinal inflammatory environment 
(Robertson et al., 2016). n-3 PUFA have been also been associated with anti-viral 
effects (Morita et al., 2013) and anti-proliferative (Yang et al., 2012) effects which 
could have profound implications for the prevention of the progression of viral 
related diseases and certain cancers.  
 
 
3. DIETARY PUFA IN HEALTH AND DISEASE 
 
3.1. PUFA and Inflammatory Disease 
3.1.1. Inflammation in Disease 
The immune system is vital to combat injury and infection, however immune 
response can be harmful to the host if it is activated in an unregulated manner for a 
long period of time. Acute inflammatory response is beneficial to the host in cases 
of short-term infection or injury as it helps to fight infection and repair injured 
tissue. However, over-production of inflammatory mediators, immune activation 




inflammation, can cause immune molecules to attack and damage host tissues, 
which can lead to pathological disease progression. 
Inflammation is a process of the body’s innate immune system that occurs 
in response to infection or injury and manifests itself in the form of swelling, heat 
and redness. This process can also occur at a chronic subclinical level. The 
presence of a pathogen (such as pathogenic bacteria, viruses and parasites) in a 
host system activates the immune system in order to locate, identify and eliminate 
the invading pathogen. Immune system activation also occurs in response to other 
stimuli including physical injury, surgery or the presence of tumour cells, in an 
effort to heal and resolve. The presence of these stressors initiates increased blood 
flow and blood vessel permeability in order to allow immune cells to cross from 
the blood stream to the site of infection/injury. A number of biochemical 
modulators and cell types are involved in this process and they interact and 
communicate with each other in order to regulate immune response and resolve 
the infection/injury. The dominant immune cells are leukocytes such as 
monocytes, macrophages, lymphocytes and granulocytes. These cells adhere to 
endothelial cells supported by the increased expression of adhesion molecules 
such as intercellular adhesion molecule-1 (ICAM-1) and vascular adhesion 
molecule-1 (VCAM-1), and then transverse the permeable capillary membranes 
from the bloodstream into the affected tissue. Once at the affected site, leukocytes 
release potent biochemical molecules depending on the strength, stage and type of 
inflammatory stimulus. Lipopolysaccharide (LPS) is a common example of an 
inflammatory stimulus. LPS is an integral part of Gram-negative bacterial cell 
walls, and once identified by host immune cells, can stimulate the release of 




These mediators are wide ranging in structure and function and include cytokines, 
eicosanoids, reactive oxygen species (ROS) and a number of other biochemical 
molecules which all play differing roles in the inflammatory response. Some of 
these mediators can have anti-inflammatory or even both pro- and anti-
inflammatory activities under different conditions, as well as having the ability to 
‘switch-off’ inflammation, and hence, immune and inflammatory responses vary 
greatly under differing stress conditions. 
When the inflammatory process becomes unregulated, it can supplement 
chronic inflammatory disease states. IBD (Fiocchi, 1998), RA (Choy and Panayi, 
2001), AD (Wyss-Coray, 2006) and CVD (Ridker et al., 2000) are just a number 
of disorders that can progress as a result of unregulated chronic inflammation. In 
certain cases such as RA, these inflammatory disease states are alleviated through 
the use of non-steroidal anti-inflammatory drugs (NSAID). However, as 
inflammation is now recognised as a cornerstone of chronic disease states such as 
obesity and type-2 diabetes, nutritional rather than pharmacological treatments are 
being sought after as long-term remedies. 
 
3.1.2 Processes by Which PUFA Regulate Inflammation 
PUFA make up a significant proportion of the phospholipid membrane of immune 
cells such as monocytes and macrophages, and their incorporation into these cells 
is significantly altered by dietary PUFA intake (Endres et al., 1989, Gibney and 
Hunter, 1993). The n-6 PUFA AA constitutes a significant proportion of the fatty 
acids in immune cell phospholipids, whereas n-3 PUFA such as EPA and DHA are 
present at much lower levels. Numerous cellular, animal and human trials have 




incorporation of these fatty acids into immune cell membranes in place of n-6 fatty 
acids such as AA (Caughey et al., 1996, Lee et al., 1985). PUFA are directly and 
indirectly responsible for the production of potent inflammatory mediators and 




Eicosanoids are a group of potent inflammatory mediators produced by the 20-
carbon PUFA EPA and AA, and hence play a key role in inflammation. As 
previously mentioned, AA makes up a significant proportion of the fatty acids in 
immune cell membranes, alongside lower proportions of other fatty acids such as 
EPA and DHA. The presence of an inflammatory stimulus, such as LPS, activates 
phospholipase A2 which in turn releases AA from the phospholipid membrane. 
The free AA is then oxidised by either cyclooxygenase (COX), lipoxygenase 
(LOX) or cytochrome P450 enzymes to produce immune-modulating eicosanoids 
(Figure 2). The COX pathway is a target for pain relieving drugs such as aspirin 
(Smith and Willis, 1971). Aspirin targets the COX pathway and prevents the 
production of pro-inflammatory eicosanoids from the prostanoid group.  
Eicosanoids are classified in 2 distinct groups, the prostanoids 
(prostaglandins and thromboxanes) which are products of COX, and the 
leukotrienes which are products of LOX, and within these groups, there are a 
number of individual eicosanoids each with varying potencies and functions. 
Other groups of eicosanoids such as hydroxyeicosatetraenoic acid (HETE) and 
hydroxypero-xyeicosapentaenoic acid (HEPE) have also been identified and are 




AA but can also be products of EPA oxidation following release from 
phospholipids. 
In general, AA eicosanoids are considered proinflammatory and EPA 
eicosanoids are considered less inflammatory or anti-inflammatory (Wada et al., 
2007). Hence, a high level of AA in the phospholipid membranes of cells results in 
a high level of substrate for inflammatory eicosanoids. Replacement of AA with 
EPA in membranes through the diet thereby increases the level of substrate for 
less inflammatory eicosanoids and hence reduces inflammatory disease risk. 
However, in recent times it has been shown that this is not always the case. 
Prostaglandin E2 (PGE2), an AA-derived eicosanoid, has been shown to display 
both pro- and anti-inflammatory effects (Levy et al., 2001), and additionally, it has 
been shown that both PGE2 (an AA- derived eicosanoid) and PGE3 (an EPA-
derived eicosanoid) have equivalent potencies with regard to inhibition of the 
proinflammatory cytokines TNFα and IL-1β in human mononuclear cells (Miles et 
al., 2002). Hence, eicosanoid metabolism is highly complex and can vary greatly 
under different conditions.  
PUFA have long been recognised as mediators of inflammation 
(Samuelsson, 1983, Tilley et al., 2001), and by acting as substrates for 
eicosanoids, dietary PUFA have since been recognised as mediators of 
inflammatory processes and immune function (Calder, 2002, James et al., 2000). 
Studies in vitro and intervention trials in humans and animals have repeatedly 
shown that dietary long-chain omega-3 PUFA, primarily EPA and DHA, reduce 
the production of inflammatory eicosanoids (Gibney and Hunter, 1993, Trebble et 
al., 2003). Much of this evidence has focused on dietary fish oil supplementation 




eicosanoids PGE2 (Endres et al., 1989, Lee et al., 1985) and the 4 series 
leukotrienes (Weaver et al., 2009). In recent times there has been increasing focus 
on the anti-inflammatory effects of the individual omega-3 PUFA, EPA and DHA, 
rather than the combination of PUFA in fish oil (Peterson et al., 1998, Weldon et 
al., 2007), and it has been reported that these PUFA exert differential effects on 
eicosanoid and other inflammatory mediator production (Corey et al., 1983, 
Kelley et al., 1999). A study in 2012 by Norris and Dennis provided the most in-
depth analysis of differential eicosanoid production following in vitro 
supplementation with EPA, DHA or AA and subsequent inflammatory stimulation 
(Norris and Dennis, 2012). This research showed that DHA reduced AA-derived 
COX eicosanoids (primarily the 2 series prostaglandins) more effectively than 
EPA in mice macrophages. Furthermore, it was shown that a significant 
proportion of EPA was elongated to DPA in EPA-supplemented cells. Subsequent 
supplementation of cells with DPA showed that it was the only PUFA released 
from cells at a comparable level to AA following inflammatory stimulation, and 
hence competed for COX enzymes and reduced pro-inflammatory AA eicosanoid 
production. These results suggest a major role for n-3 DPA in eicosanoid 
metabolism and hence the inflammatory process. Indeed, it has been postulated 
that DPA n-3 may directly affect inflammation by producing its own eicosanoid-
like molecules (Kaur et al., 2011b), but such compounds have yet to be identified.  
Because of its ability to compete for the same enzymes as AA and 
influence eicosanoid production, EPA was initially considered as the sole anti-
inflammatory n-3 PUFA. However, recent research has elucidated a novel group 
of eicosanoid-like molecules derived from DHA in addition to EPA. These 




anti-inflammatory activity than some EPA-derived eicosanoids in a number of 
immune cells (Serhan et al., 2008). Additionally, resolvins exhibit the novel ability 
to resolve or switch-off inflammation, rather than prevent its initiation. Resolvin 
synthesis following PUFA supplementation has been widely examined in cell and 
animal models, where fish oil, EPA and DHA supplementation have been shown 
to increase resolvin production in mice (Serhan et al., 2000). However, there have 
been few reported studies in humans that measured resolvin production following 
PUFA supplementation (Mas et al., 2012). Further clinical trials may identify the 
anti-inflammatory role of resolvins in humans. There is also growing interest in 
some of the DHA-derived neuroprotectins because of their potent activity in the 
brain and their ability to prevent neurodegeneration (Serhan et al., 2004). Further 
examination of these metabolites may have significant implications for identifying 
compounds to fight neurodegenerative diseases such as Alzheimer’s disease 
(Lukiw et al., 2005). The growing interest into resolvins and protectins has also 
led to the discovery of n-6 DPA derived resolvins. These molecules have been 
identified and characterized and shown in mice models to have anti-inflammatory 
activity and alleviate experimental colitis (Dangi et al., 2009, Dangi et al., 2010, 
Chiu et al., 2012). 
 
Gene Transcription and Gene Expression 
In addition to their role in eicosanoid production, PUFA can also modulate 
inflammation through altered gene-expression. NF-κB is a transcription factor that 
plays a major role in inflammatory activation, by activating pro-inflammatory 
genes. Cytosolic NF-κB is inactive and is composed of 3 subunits, IκB, P65 and 




causes phosphorylation and ubiquitination of the inhibitory IκB subunit and hence 
the active NF-κB translocates to the nucleus and activates pro-inflammatory genes 
(Figure 3). However, long-chain omega-3 PUFA such as EPA and DHA can 
prevent NF-κB activation and hence prevent the up-regulation of pro-
inflammatory genes. This has been identified in human macrophages, where 
binding of NF-κB to DNA was significantly decreased following DHA 
supplementation (Weldon et al., 2007) and EPA supplementation (Zhao et al., 
2004). The mechanisms by which omega-3 PUFA prevent NF-κB activation were 
recently reported. Omega-3 PUFA were found to activate G protein-coupled 
receptor 120 (GPR120) on the surface of macrophages, and GPR120 then prevents 
the signalling cascade caused by LPS activation of TLR4, and hence prevents the 
activation of NF-κB (Oh et al., 2010). Additionally, EPA and DHA act as ligands 
for PPARs, which act as nuclear receptors and transcription factors for genes 
associated with lipid metabolism and inflammation. When activated by PUFA, 
PPARs bind with retinoid X receptors (RXR) which then alter transcription and 
expression of particular genes. Much research has investigated the activation of 
PPARs, particularly PPARγ, by PUFA and the subsequent anti-inflammatory 
response (Li et al., 2005). Inflammatory gene expression changes have also been 
observed following EPA and DHA supplementation in human studies. Bouwens et 
al. (2009) reported a change in expression of 1040 genes from peripheral blood 
mononuclear cells (PBMC) isolated from healthy individuals following 26 weeks 
of EPA+DHA supplementation (Bouwens et al., 2009). The gene expression 
changes showed marked decreases in inflammatory and atherogenic pathways. 
EPA and DHA supplementation resulted in the reduced expression of a number of 




inflammatory eicosanoid synthesis. Hence, this study showed that long-term EPA 
and DHA supplementation can up regulate the anti-inflammatory gene expression 
profile in human PBMCs. 
 
Cytokine Production 
The up-regulation of pro-inflammatory genes stimulates the production of pro-
inflammatory cytokines, which are potent forms of inflammatory mediators. 
Cytokines are potent, fast-acting and have a short half-life, and can affect cell 
proliferation, differentiation, apoptosis and acute phase response. These molecules 
are primarily produced by immune cells such as monocytes and macrophages, but 
other cells such as adipocytes have also been shown to have the ability to produce 
cytokines and hence elucidate a role of inflammation in obesity (Tilg and 
Moschen, 2006). Interleukin 6 (IL-6), IL-1β and Tumor Necrosis Factor-alpha 
(TNFα) are the classic pro-inflammatory cytokines, and show marked elevations 
in cases of sepsis (Cavaillon et al., 2003), fever (Netea et al., 2000), and IBD 
(Rogler and Andus, 1998). In vitro cell culture studies have shown the ability of 
EPA, DHA and fish oil to reduce the production of IL-1β, TNFα and IL-6 
following inflammatory stimulation with LPS (Weldon et al., 2007, Zhao et al., 
2004), most likely by preventing activation of NF-κB and inflammatory genes. 
The reduction of proinflammatory cytokines and increase in anti-inflammatory 
cytokines such as IL-10 and IL-4 has been shown in murine models of colitis and 
dermatitis following n-3 PUFA supplementation (Whiting et al., 2005, Renier et 
al., 1993, Sierra et al., 2006). 
Human intervention studies have primarily involved dietary 




PBMCs and cytokine production. These studies have shown consistent evidence 
that omega-3 PUFA supplements decrease inflammatory TNFα, IL-6 and IL-1β 
production (Endres et al., 1989, Caughey et al., 1996, Vedin et al., 2008) however 
it seems that this effect is dose-dependent and relies on large supplementary doses 
(>2g/day), and lower doses were reported to have no effect (Thies et al., 2001, 
Wallace et al., 2003). It has also been shown in a cross-sectional study of over 
3,000 subjects that fish consumption of >300g/week results in significantly 
decreased levels of IL-6, TNFα and C-reactive protein (CRP) compared with non-
fish consumers (Zampelas et al., 2005), most likely due to the high levels of 
omega-3 PUFA in fish.  
 
Interaction with gut microbiota 
In recent times, the gut microbiota has been identified as a critical regulator of 
immune and metabolic health (Patterson et al., 2016). Comprised of all the 
microbial species in the intestines, the gut microbiota plays key roles in 
inflammation, intestinal permeability, nutrient absorption, neuroendocrine 
signaling and a number of other physiological processes (Marchesi et al., 2016). A 
complex relationship exists between commensal gut bacteria and intestinal 
epithelial cells which uniquely modifies the host intestinal environment. This 
relationship is strongly influenced by diet through modulation of gut microbiota 
composition. Studies from germ-free animals have demonstrated that the 
composition of the gut microbiota independently regulates obesity and metabolic 
health (Ridaura et al., 2013). 
The role that both n-3 and n-6 PUFA play in the gut-microbiota 




PUFA intake is reflected in the fatty acid composition of intestinal tissues, which 
contributes to a pro-inflammatory intestinal environment. Conversely, higher n-3 
intake and subsequent incorporation into intestinal tissue can result in dampened 
intestinal inflammation (Kaliannan et al., 2015). In addition, n-3 PUFA and n-6 
PUFA can directly interact with commensal gut microbiota by modulating the 
adhesion of certain species to intestinal epithelial cells (Bomba et al., 2003, 
Kankaanpää et al., 2001). n-3 PUFA have also been shown to stimulate the 
production of a number of antimicrobial peptides, including intestinal alkaline 
phosphatase (IAP), which scavenge LPS-producing bacteria such as e. coli 
(Kaliannan et al., 2015). Hence dietary PUFA play a critical role in the host 
intestinal environment by interacting with both host tissues and resident microbes. 
Patterson et al demonstrated that microbiota composition is dependent 
upon type of dietary fat, with Bifidobacteria being more abundant following fish 
oil feeding (Patterson et al., 2014). Similarly, Caesar et al reported that a lard oil 
rich diet induced dysbiosis and elevated white adipose tissue inflammation in 
comparison to a diet rich in fish oil (Caesar et al., 2015). Wall et al showed a novel 
link between gut microbiota and host tissue fatty acid composition in both rodents 
and pigs (Wall et al., 2009, Wall et al., 2010, Wall et al., 2012). Oral 
administration of Bifidobacterium breve species significantly altered liver, adipose 
and brain fatty acid composition. Most interestingly, n-3 docosapentaenoic acid 
was significantly increased in the brain of the probiotic fed animals. Conversely, it 
has been shown that n-3 PUFA consumption in pharmacological excess (18% 
energy) can stimulate the overgrowth of opportunistic pathogens in the gut 




al., 2015), however the doses used in these studies may not be biologically 
relevant. 
The role of algae-derived PUFA on the gut microbiota has yet to be 
examined, however recent data suggests that EPA and DHA from microalgal oils 
elevate abundance of both bifidobacteria and lactobacillus in mice (Robertson et 
al., 2016). Further research must now address the role of dietary PUFA intake on 
both the developing and developed microbiota in humans to supplement the little 
data already available (Andersen et al., 2011). Clinical research such as this will 
provide novel evidence for the role of dietary fat type on the gut microbiota and 
associated outcomes and may help public health guidelines for PUFA intake.  
 
Other Processes 
A number of other mechanisms by which PUFA regulate inflammation have been 
reported. Dietary supplementation with EPA and DHA have been shown to reduce 
leukocyte chemotaxis to the site of inflammation in ex vivo studies of human 
leukocytes (Lee et al., 1985); reduce the expression of adhesion molecules such as 
ICAM-1 and VCAM-1 which allow stimulated macrophages to adhere to 
endothelial cells (Yamada et al., 2008); reduce the production of reactive oxygen 
species (ROS), when supplemented at high levels (Luostarinen and Saldeen, 
1996); and disrupt membrane lipid raft assembly, which are rich in saturated fatty 
acids, play a role in T-cell response and cell-signalling (Calder, 2011) and alter gut 






3.1.3 PUFA Supplementation and Inflammatory Disease Outcome 
 
Obesity and metabolic disease 
Obesity and its associated metabolic abnormalities are heavily influenced by an 
altered immune environment. Adipose tissue inflammation, characterized by 
macrophage accumulation and cytokine production, is a hallmark of adipogenesis 
leading to fat mass accumulation (Greenberg and Obin, 2006). Dietary lipids play 
a role in this process partially through the regulation of inflammation. n-3 PUFA 
and n-6 PUFA appear to play opposing roles in this process. Caesar et al showed 
that n-3 PUFA dampen white adipose inflammation through a mechanism 
involving toll-like receptor activity and modification of gut microbiota 
composition (Caesar et al., 2015). As well as regulating the adipose immune 
system, n-3 PUFA also upregulate UCP-1 expression in both brown and white 
adipose tissue thereby influencing thermogenesis and energy metabolism (Kim et 
al., 2015). 
Evidence from clinical trials is conflicting regarding n-3 PUFA 
supplementation, weight loss and the resolution of inflammation. These 
discrepancies may be due to supplementation dose, length and indeed inter-
individual differences in underlying tissue PUFA status. Itariu et al reported that 
eight-week supplementation with fish oil in non-diabetic obese patients 
significantly reduced inflammation in adipose tissue and circulation (Itariu et al., 
2012). Fish oil supplementation in obese pregnant women has also been shown to 
dampen adipose and placental inflammation (Haghiac et al., 2015). The effect of 




however a meta-analysis reported that fat mass is significantly reduced in obese 
subjects following fish oil supplementation (Du et al., 2015). 
 
Rheumatoid Arthritis 
RA is an autoimmune disorder that involves uncontrolled infiltration of B-
lymphocytes, T-lymphocytes and macrophages to the synovium surrounding 
joints, and hence over-production of inflammatory cytokines TNFα, IL-1β, IL-6 
and IL-8. There have been a number of intervention trials using a wide range of n-
3 PUFA doses, from 1-7g per person daily (Kremer et al., 1985, Kremer et al., 
1987, van der Tempel et al., 1990, Lau et al., 1993, Cleland et al., 1988), that have 
resulted in significant improvements in qualitative clinical outcomes such as 
duration of morning stiffness, joint swelling and grip strength. Perhaps the most 
replicated improved outcome following supplementation is reduced use of non-
steroidal anti-inflammatory drugs (NSAID) during PUFA supplementation (Calder 
and Zurier, 2001). A small number of meta-analyses assessing alleviation of RA 
symptoms following n-3 PUFA supplementation have been carried out (Fortin et 
al., 1995, Goldberg and Katz, 2007, Lee et al., 2012, MacLean et al., 2004), the 
details of which are summarised in Table 1. Goldberg and Katz (2007) analyzed 
17 randomized controlled trials of 3-4 month PUFA supplementation and found 
standard mean differences of -0.26 for patient reported joint pain intensity; -0.43 
for minutes of morning stiffness; -0.29 for number of painful and/or tender joints; 
and -0.4 for NSAID consumption. The meta-analysis of Fortin et al. (1995) found 
comparable evidence for reduction in number of tender joints and morning 
stiffness, whereas Maclean et al. (2004) reported conflicting conclusions that may 




recent meta-analysis by Lee et al. (2012) reported a standard mean difference of 
NSAID use as -0.518. Trends towards reduction in other outcomes such as 
morning stiffness and tender joint count were found but did not reach statistical 
significance. 
Thus, much of this evidence warrants the use of omega-3 PUFA 
supplements in RA cases, but more research needs to be undertaken to examine 
dose response, as low-dose supplementation has been reported as having little 
effect (Remans et al., 2004). Additionally, further research is needed in order to 
understand which fatty acid, or combinations of fatty acids are most effective in 
treating RA. 
 
Inflammatory Bowel Disease 
IBD is a pathological autoimmune disorder that has been shown to react to dietary 
PUFA supplementation in animal models and some human clinical trials (Whiting 
et al., 2005, Belluzzi et al., 1996). IBD is a term to describe two disorders, Crohn’s 
Disease and Ulcerative Colitis, and involves intestinal inflammation and can range 
widely in severity. Ulcerative Colitis occurs in the colon and involves 
inflammation of the intestinal mucosa. Crohn’s disease, however, can occur at any 
part of the digestive tract from mouth to anus, and similarly is characterized by 
mucosal inflammation. Animal models of colitis are suitable for studying IBD and 
have shown promising results in terms of omega-3 PUFA supplementation and 
reduction of colonic damage and inflammatory processes in IBD (Whiting et al., 
2005). 
However, results from human clinical trials have been conflicting. A small 




human IBD with regard to histological scoring and maintenance of IBD remission 
(Belluzzi et al., 1996), however the available systematic reviews and meta-
analyses fail to conclude that supplementary PUFA have a profound effect (Table 
2). Turner et al. (2011) have established that there is insufficient evidence to 
associate dietary omega-3 PUFA with maintenance of remission of Ulcerative 
Colitis and Crohn’s Disease in a meta-analysis of 9 randomised controlled trials 
(Turner et al., 2011). Maclean et al. (2005) and Cabré et al. (2012) both conclude 
in systematic reviews that current evidence shows little benefit of dietary omega-3 
PUFA in human IBD clinical trials (MacLean et al., 2005, Cabré et al., 2012). 
Similar to RA, supplementary dose may play a role in IBD, and hence higher 
prescribed doses may be more effective. Indeed, further research into the role of 
the microbiota in IBD may elucidate mechanisms behind therapeutic effectiveness 




Asthma is an inflammatory disease that involves broncho-constriction as a result 
of overproduction of inflammatory eicosanoids, and thus holds promise to be 
modulated by dietary fatty acid supplementation. However, systematic reviews of 
the literature have all concluded that current evidence is insufficient to make any 
recommendations regarding PUFA supplementation and asthma (Reisman et al., 
2006), and that large randomised clinical controlled trials are necessary in order to 
analyse any associations. Promising evidence has been generated for the 
prevention and treatment of other inflammatory disorders such as diabetes, non-
alcoholic fatty liver disease (NAFLD) (Parker et al., 2012) and cardiovascular 




supplementation. The evidence for the use of omega-3 PUFA supplementation in 
the prevention and treatment of certain inflammatory diseases is robust. However 
the question that remains to be answered refers to the effective dose of 
supplementation required to provide a therapeutic effect. Hence, it remains to be 
confirmed if omega-3 PUFA supplementation in inflammatory disorders is a 
nutritional or pharmacological solution (Calder, 2013). 
 
3.1.4 Algal PUFA and Inflammatory Disease 
Much of the aforementioned research employed the use of fish oil or fish-derived 
PUFA, but there are a growing number of trials examining the anti-inflammatory 
effect of algal oils and algal-derived PUFA. Rats fed an algal oil from 
Schizochytrium sp. containing n-6 DPA (16% of total fatty acids) and DHA (40% 
of total fatty acids) exhibited significantly reduced inflammation in a rodent paw 
edema model compared with control and compared with an oil from 
crypthecodinium cohnii which contained DHA (42% of total fatty acids) but no 
DPA n-6 (Nauroth et al., 2010). This result identified for the first time the anti-
inflammatory potential of DPA n-6, but also the potential of a microalgal oil as an 
anti-inflammatory dietary supplement. Anti-inflammatory effects have also been 
observed in studies examining macroalgal PUFA. Khan et al. (2007) isolated EPA 
and stearidonic acid (SDA) from the seaweed Undaria pinnatifida and reported 
that these PUFA reduced phorbol myristate acetate (PMA) induced inflammation 
in mice when applied topically (Khan et al., 2007). The brown seaweed Ishige 
okamurae was shown to alleviate allergic inflammation by reducing histamine 
release and modulating inflammatory cytokine production in human basophilic 




PUFA. Indeed maternal and lifelong n-3 deficiency or supplementation with an 
algal oil appeared to modulate the immune response in mice, an effect that 
appeared to be associated with changes to the gut microbiota (Robertson et al., 
2016). A meta-analysis of eleven clinical trials found that algae-derived n-3 PUFA 
significantly reduced circulating triglycerides and increased both high density 
(HDL) and low density (LDL) lipoprotein cholesterol (Bernstein et al., 2012). 
Cholesterol metabolism is intrinsically linked with the immune system and plays 
an important role in chronic disease, notably inflammatory disease.  
 
 
3.2. PUFA and Brain Health 
 
3.2.1. Modulating Brain FA Composition 
Perhaps one of the most important roles of dietary PUFA is in brain health, from 
brain and retinal development, to brain maintenance, to prevention of brain 
degeneration. Lipid content can reach up to 40% in the brain’s grey matter, over 
60% in white matter and up to 80% myelin (O'Brien and Sampson, 1965b), 
whereas the essential fatty acids i.e. LA, ALA and their longer chain derivatives 
such as AA and DHA, can make up to 20% of brain dry weight (Muskiet et al., 
2006). The accumulation, distribution and interconversion of the various fatty 
acids in the brain varies over the lifespan (O'Brien and Sampson, 1965a) and 






3.2.2. PUFA and Brain Development 
Rapid accretion of the fatty acids DHA and AA occurs in the foetal brain during 
the last trimester in utero and these fatty acids are vital in neurodevelopment 
(Clandinin et al., 1980). It has been shown that DHA and AA are preferentially 
transported across the placenta from mother to foetus in place of other fatty acids 
(Campbell et al., 1996, Haggarty et al., 1997). During growth and development 
DHA subsequently remains as the most abundant PUFA in the brain, making up 
approximately 8% of brain dry weight, with AA constituting up to 6% of dry 
weight (Muskiet et al., 2006). 
Foetal fatty acid accumulation however, is dependent on the fatty acids 
available, and hence foetal brain fatty acid accretion is highly dependent on 
maternal diet. Elias et al. (2001) have shown that concentrations of fatty acids in 
maternal phospholipids at 35 weeks of gestation were significantly related to fatty 
acids present in infant plasma lipids at birth (Elias and Innis, 2001). Additionally, 
animal models of n-3 PUFA deficiency have identified the important role of these 
fatty acids in development and physiological homeostasis. Maternal DHA 
deficiency altered neurogenesis in embryonic rat brains, measured by thickness of 
the cortical plate (Coti Bertrand et al., 2006). Similarly, deprivation of n-3 PUFA 
in the maternal and infant diets of rhesus monkeys resulted in delayed retinal and 
neuronal development as measured by visual acuity (Neuringer et al., 1986). 
PUFA deficiency in infants was found as a result of un-supplemented 
formula feeding compared with breastfed infants. Post-mortem fatty acid analysis 
was undertaken on infants’ brains who were breastfed or formula fed (Farquharson 
et al., 1992) and results showed that DHA content of brains of breastfed infants 




infants fed a long-chain omega-3 PUFA source or displaying higher erythrocyte 
DHA levels show better visual acuity development compared with those with 
lower DHA levels (Birch et al., 1992, Makrides et al., 1993). A meta-analysis has 
also associated breast-feeding with improved cognitive development when 
compared to formula fed infants (Anderson et al., 1999), an effect that is likely to 
be attributed in part to dietary DHA and other PUFA present in human milk. 
Hence, recommendations have followed that all infant formula be supplemented 
with long-chain fatty acids, specifically AA and DHA (Koletzko et al., 2005). 
There is however conflicting evidence for the association between PUFA 
supplemented formula and cognitive development. A recent meta-analysis showed 
no improvement in cognitive development after 1 year in infants fed PUFA 
supplemented formula compared with unsupplemented formula (Qawasmi et al., 
2012). These data matched results from previous meta-analyses (Simmer et al., 
2008, Smithers et al., 2008) regarding PUFA supplementation of infant formula 
and cognitive development. Thus, further studies are required to determine 
optimum dose response for neurodevelopment, and the effects at different stages 
of development from foetus to infant. 
Supplemented formulas primarily obtain PUFA from microalgal sources, 
as discussed below. This is partly due to the ability of microalgae to produce a 
specific fatty acid rather than a mixture, as is found in fish oil. Additionally, fish 
oil poses the risk of containing harmful levels of pollutants and contaminants such 
as mercury that can be harmful to infant health, hence algae provide a safer and 





3.2.3. PUFA and Brain Maintenance 
The maintenance of ordinary brain function is vital to prevent the onset of brain 
degenerative disorders during ageing. Depression and stress are both brain related 
disorders that have clinical and biochemical as well as psychological components 
(McEwen, 2011, Jacobs et al., 2000). These disorders have significant 
implications in the progression of neurodegeneration in later life, and hence by 
preventing depression and stress-related pathologies via dietary intervention, it is 
possible to slow or prevent brain degeneration (Jacobs et al., 2000). 
Chronic and acute stress activates the hypothalamus-pituitary-adrenal 
(HPA) axis in the brain which stimulates the production of glucocorticoid 
hormones cortisol in humans and corticosterone in animals (Lupien et al., 2009). 
Regulation and modulation of this pathway can dampen the harmful response of 
stress on the brain and neuronal cells, and this can be achieved via a nutritional 
approach. Chronic stress can alter triglyceride and phosphatidylethanolamine 
omega-6/omega-3 ratio as shown in monkeys (Laugero et al., 2011), and hence 
suggests a relationship between fatty acid status and stress. In a recent study, 
omega-3 PUFA supplemented rats exhibited significantly lower HPA activation, 
corticosterone peak and stress-induced weight loss compared to control or omega-
3 PUFA deficient rats following long-term induced stress by restraint (Hennebelle 
et al., 2012). Similarly, DHA deficiency at the pre-weaning period increased HPA 
activation through elevated serum corticosterone levels and increased anxiety-like 
behaviour following short-term induced stress in comparison to a DHA adequate 
diet, and in comparison to DHA deficiency at post-weaning (Chen and Su, 2013). 
These results suggest that dietary DHA adequacy is essential in alleviating short-




life could lead to stress and anxiety in later life. Stress also includes an 
inflammatory component and this was shown in mice injected with the pro-
inflammatory cytokine IL-1β, who subsequently displayed anxiety and stress-like 
behaviour (Song et al., 2008). Ethyl-EPA supplementation diminished stress-
induced inflammatory factors such as PGE2 and increased the anti-inflammatory 
cytokine IL-10. This was coupled with a reduced rise in corticosterone and 
reduced anxiety-like behaviour in comparison to animals supplemented with AA. 
In humans, the effect of omega-3 fatty acid status and supplementation has 
been examined in relation to stress-associated inflammation. Stimulated 
production of TNFα and IFN-γ following psychological stress, an academic 
examination, was significantly lower in students with higher serum omega-3 
PUFA levels, compared with those with low serum omega-3 PUFA levels (Maes 
et al., 2000). Similarly students supplemented with omega-3 PUFA displayed 
reduced production of LPS stimulated IL-6 production and reduced anxiety-like 
symptoms during a psychological stress, the day prior to an exam (Kiecolt-Glaser 
et al., 2011). Observational studies have also associated omega-3 PUFA status 
with psychological distress in Inuit women (Lucas et al., 2009). 
Stress and anxiety are linked closely to depressive disorders and hence 
suggest a role for PUFA in treating depression. Depression is majorly 
underestimated in terms of its impact globally as a disease. According to the 
World Health Organisation, depression is the fourth leading cause of disease 
burden globally, and is expected to rise to second place by the year 2020, only 
behind heart disease (Murray and Lopez, 1996). Depressive symptoms can be 




pathways and hence depression pathology is a complex process that is not full 
understood (Logan, 2003). 
The consumption of fish, which contain high PUFA levels, is strongly 
inversely associated with rates of depression globally (Hibbeln, 1998), such that 
countries which consume the highest levels of fish, display the lowest rates of 
major depression. In randomised controlled trials, omega-3 PUFA 
supplementation has been shown to improve depressive symptoms, but similar to 
other disease pathologies, optimum PUFA supplementary dose is still to be 
realised. Peet and Horrobin (2002) undertook a dose response clinical trial of 
ethyl-EPA supplementation on depressed patients and found that 1g/day ethyl-
EPA supplementation improved depression in those who were unresponsive to 
standard therapy, and this dose was more effective than 2g/day or 4g/day (Peet and 
Horrobin, 2002). However, clinical trials have displayed conflicting results 
(Bourre, 2005), for example depressed patients who received 2g/day DHA 
supplement for 6 weeks showed no improvement in depressive symptoms 
(Marangell et al., 2003). It has been suggested that EPA is more effective in 
treating depressive symptoms than DHA, but larger clinical trials are warranted to 
understand effective dose and length of supplementation (Logan, 2003). 
The neuro-inflammatory component of depression is being realised and has 
been examined in cell culture (Lu et al., 2010) and observational human studies 
(Dinan et al., 2009). Dinan et al. (2009) demonstrated the association between 
PUFA status, inflammatory mediators and major depression by examining the 
fatty acid and cytokine profiles of plasma from depressed patients and controls 
(Dinan et al., 2009). It was shown that plasma AA and IL-6 levels were 




EPA/AA ratio was significantly lower in depressed patients who did not respond 
to previous antidepressant treatment compared to controls. The authors concluded 
that major depression is associated with a proinflammatory phenotype and an 
elevated omega-6/omega-3 PUFA ratio. A meta-analysis of 10 double-blind 
placebo-controlled trials found a significant effect of omega-3 PUFA 
supplementation in treating clearly defined depression (effect size 0.69), however 
the authors cite a number of limiting factors such as publication bias and 
‘unblinding’ due to fishy taste of supplements (Lin and Su, 2007). This meta-
analysis also discusses the issue of dose and length of supplementation, and the 
need for larger randomised controlled trials. 
 
3.2.4. PUFA and Neurodegeneration 
Alzheimers disease (AD) is a form of dementia that involves degeneration of the 
brain in ageing, and currently has no cure. The psychological degeneration 
associated with AD is characterized by short-term memory loss and cognitive 
decline. Biological degeneration of the brain in AD is characterized by the 
formation of neural amyloid plaques, the accumulation of Tau protein, death of 
neuronal cells, neuro-inflammation, and hence alteration of synaptic plasticity. 
The impact and importance of this disease is increasing rapidly due to the 
increasing age of the population and it is expected that the number of people living 
with dementia will increase from 35.6 million in 2010, to 115.4 million in 2050 
(Alzheimer's Disease International, 2009). As in early life and brain development, 
the intake of long-chain omega-3 PUFA in later life is also extremely important, in 
particular, PUFA have been shown to prevent the neurodegenerative processes 




and treatment. There are many mechanisms by which PUFA exert their effects on 
the ageing brain, one of which is through the regulation of inflammation. 
Inflammation is one of the primary components in the pathogensis of AD 
(Akiyama et al., 2000) and supplementary PUFA have been shown to dampen the 
inflammatory effect of AD-associated inflammation in cell, animal and human 
models (Orr et al., 2012). Much of this research has focused on DHA and EPA but 
a study by Kelly et al. (2009) showed that dietary n-3 DPA in aged rats 
downregulated microglial activation and activation of cell stress molecules such as 
caspase-3, suggesting that n-3 DPA has a role to play in the prevention of brain 
degeneration (Kelly et al., 2011). Additionally, the discovery of neuroprotectins, 
the DHA derived anti-inflammatory eicosanoids, suggest a role for these 
molecules in protection against AD (Lukiw et al., 2005). Aside from neuro-
inflammation, PUFA can also regulate AD-related processes such as regulation of 
cholesterol and apolipoprotein E (ApoE), regulation of cell signalling and 
alteration of lipid raft assembly, as discussed by Boudrault et al. (2009) (Boudrault 
et al., 2009). 
Data from human trials suggest an association between long term PUFA 
status and risk of Alzheimer’s disease, but further research is needed to identify a 
conclusive role for supplementary PUFA in the prevention and treatment of AD. 
Participants in the highest quartile for DHA status in the Framingham Heart Study 
had a 47% reduced risk of dementia in a 9-year prospective follow-up study 
(Schaefer et al., 2006) compared with those in lower quartiles of DHA status. 
Similarly, higher fish consumption was associated with reduced cognitive decline 
over a 5-year period in individuals aged 70-89 (van Gelder et al., 2007). However, 




supplementary PUFA in the treatment or prevention of AD and cognitive decline. 
No effect was observed on cognitive performance in patients with mild to 
moderate AD receiving 1.7g DHA and 0.6g EPA for 6 months, but a small 
significant improvement was observed in a subgroup of patients with very mild 
AD (Freund-Levi et al., 2006). Similarly, no significant effect of 2g algal DHA 
supplement for 18 months was observed in Alzheimer’s patients with regards to 
improvements in cognitive performance (Quinn et al., 2010). Other studies have 
also reported no observable effect (Chiu et al., 2008). Meta-analyses have 
identified associations between PUFA status, fish consumption and the slowing of 
cognitive decline as well as improvement in mild cognitive impairment, but have 
failed to identify an association between PUFA intake and the treatment of AD 
(Fotuhi et al., 2009, Mazereeuw et al., 2012). These results suggest that the role of 
PUFA in AD progression may lie in n-3 PUFA adequacy or deficiency, but further 
large-scale clinical trials are required in order to find clearer evidence relating to 
PUFA dose, length of supplementation and stage of disease in AD. 
 
3.2.5. Algal PUFA and Brain Health 
Algal extracts have displayed therapeutic potential to reduce inflammation 
associated with brain degeneration. Ecklonia cava, a brown seaweed, showed anti-
inflammatory and anti-oxidant effects in LPS-stimulated microglial cells by 
reducing NF-kB activation and inhibiting PGE2, nitric oxide (NO) and COX-2 
(Jung et al., 2009). Similarly, neuro anti-inflammatory effects have been observed 
in murine hippocampal and microglial cells following exposure to extracts from 
the seaweeds Ulva conglobata and Neorhodomela aculeate (Jin et al., 2006, Lim 




anti-inflammatory effect, it is likely that PUFA play a role, and hence suggest that 
algal PUFA can help in the prevention of brain degeneration. Indeed recent studies 
have suggested that microalgal oil supplementation can prevent behavioural 
deficits in animals related to depression (Weiser et al., 2015). Furthermore, 
maternal and lifelong omega-3 supplementation with an algal oil has been shown 
to benefit early-life behavioural development related to communicative behaviour 
and cognition in mice (Robertson et al., 2016). These behavioural outcomes were 
also associated with dampeneing of the corticosterone response to stress, 
suggesting algal n-3 PUFA can dampen activity within the HPA-axis. A number 
of PUFA supplements marketed for brain health use algae as a source of EPA and 
DHA, such as Life’sDHA™ produced by DSM (www. lifesdha.com). 
A recent study has shown the benefit of algae-derived DHA on memory 
function and learning in patients with age-related cognitive decline (Yurko-Mauro 
et al., 2010). A large trial involving 485 subjects examined the impact of dietary 
supplementation with 900mg/day of DHA derived from Schizochytrium sp. for 24 
weeks. Patients taking the supplement showed a two-fold reduction in errors in 
visuospatial learning and memory tests compared with those taking placebo. 
Plasma DHA levels also significantly correlated with cognitive improvements, and 
hence showed a significant role for algal PUFA supplementation in the 
improvement of age-related cognitive decline. 
 
 
4. THE EMERGING USE OF ALGAL PUFA 
As PUFA are considered essential for early infant development (Fleith and 
Clandinin, 2005) and important for the prevention of chronic disease in later life, 




recommendations for PUFA in parallel with existing recommended daily intakes 
for essential nutrients. The World Health Organisation (WHO) recommends the 
intake of 2 portions of oily fish per week in order to obtain sufficient dietary EPA 
and DHA (200-500 mg) (FAO/WHO, 2003), and similar recommendations are 
provided by a number of health organisations throughout the world (Kris-Etherton 
et al., 2009). 
There are a number of barriers to fish consumption, notably a rapid global 
decline in fish stocks (Branch et al., 2011, FAO Fisheries and Aquaculture 
Department, 2010), and similarly barriers to fish oil consumption such as 
undesirable taste and smell. Furthermore, increasing levels of toxic metals such as 
mercury have been detected in fish which if consumed over a long period of time 
can be detrimental to human health (Kris-Etherton et al., 2002). The realisation of 
the beneficial effects of PUFA in early infant development and disease prevention 
has led to a significantly increased demand for these lipids, primarily in the 
industrial production of infant formula. Thus there is a need for alternative sources 
of long-chain PUFA in order to meet commercial demands and health-related 
requirements and hence prevent the onset of chronic disease. 
Macroalgae and microalgae present a vast and relatively untapped resource 
of marine fatty acids, thus providing an alternative source to declining fish stocks 
and a solution to increasing PUFA demand. Unlike fish, the thousands of different 
species of marine algae and microbes are capable of de novo production of long-
chain PUFA (Ratledge, 2004). De novo production of PUFA occurs through a 
unique system as a result of specific enzymatic and genetic properties in certain 
species of microalgae (Metz et al., 2001). PUFA are subsequently obtained by fish 




The potential of microalgae as direct sources of fatty acids is now being 
realised and is leading to the large-scale production of PUFA supplements (Ward 
and Singh, 2005) and research into their exploitation for biofuels (Hu et al., 2008). 
Production of lipids from microalgae and other microorganisms, known as single 
cell oil (SCO) production, was only proposed in recent times and is now being 
exploited at industrial levels (Ratledge, 2004). Algal PUFA production is more 
economical than biofuel production (Ratledge and Cohen, 2008) and hence a 
number of large-scale producers are now focusing on nutritional PUFA production 
as opposed to biofuels. Crypthecodinium cohnii is just one example of microalgal 
species currently cultivated and exploited at an industrial scale for the production 
of PUFA, primarily for the supplementation of infant formula (de Swaaf et al., 
2003, Sijtsma and de Swaaf, 2004). A number of Schizochytrium species have 
been assessed for their PUFA production potential (Sijtsma and de Swaaf, 2004), 
and are also of increasing interest due to their ability to produce relatively high 
concentrations of other fatty acids such as n-6 and n-3 DPA (Hauvermale et al., 
2006). There is also growing interest in algal production of PUFA other than DHA 
and AA. For example, microalgal production of EPA has significant importance 
because of its association with cardiovascular health, however until recent times 
EPA production from purified algal oil could not compete economically with that 
of fish oil (Belarbi et al., 2000). P. tricornutum (Yongmanltchal and Ward, 1992), 
Nannochloropsis sp. (Zittelli et al., 1999), and a number of other species can 
produce relatively high concentrations of EPA under specific conditions but must 
overcome issues of low specific growth rate and low cell density in order to reach 
industrial production potential. The realisation that heterotrophic microalgae are 




PUFA production using different algal species without the dependence on light as 
an energy source (Perez-Garcia et al., 2011, Wen and Chen, 2003), as is the case 
with phototrophic species. In 2011, a group from the University of Göttingen 
determined the fatty acid profiles of over 2000 microalgae species and presented 
considerable variation in lipids between species (Lang et al., 2011). This data 
suggests that there is still much to be learned about the potential of the significant 
diversity of microalgae that exist for industrial PUFA production.  
In macroalgae, lipid content is typically quite low (~2-5% of dry weight), 
but the proportion of these lipids that occur as PUFA can be relatively high (up to 
70%) (Dawczynski, 2007). The ratio of omega-6 to omega-3 PUFA is also at an 
optimum dietary level in a number of macroalgal species (< 4:1) (van Ginneken et 
al., 2011, Pereira et al., 2012). Due to the low lipid content, cultivation of 
macroalgae for PUFA at an industrial level offers less potential than microalgae, 
however due to their broad content of functional compounds, macroalgae 
represent an emerging and beneficial product as whole foods in the functional 
foods market. Furthermore, there is an increasing interest in the genetic 
manipulation of land plants in order to produce long-chain n-3 PUFA (Napier and 
Sayanova, 2005, Qi et al., 2004). Further research into this area will require the 
close study and use of a number of macroalgae and microalgae species in order to 
identify specific genes and enzymes involved in PUFA synthetic pathways. With 
such a diverse range and large number of species yet to be examined, marine 
macroalgae, microalgae and certain microorganisms possess considerable potential 






Dietary long-chain n-3 PUFA have significant beneficial effects on a number of 
chronic disorders associated with inflammation, and in addition are essential for 
neurodevelopment and the prevention of cognitive decline. However 
recommendations of PUFA intakes vary widely between countries, most likely 
due to the lack of clarity in PUFA dose and their therapeutic effect in a number of 
diseases. Conflicting evidence for the impact of n-3 PUFA supplementation in 
clinical trials may be due to ineffective doses or length of supplementation, or 
inter-individual differences in underlying PUFA tissue status. Hence, future 
research must consider underlying tissue PUFA composition in addition to the n-
6/n-3 ratio as an important biomarker of PUFA status. Further research into the 
role of dietary PUFA on the gut microbiota may also elucidate a novel mechanism 
by which dietary lipids regulate the inflammatory response. 
The role of algae as sources of PUFA must be investigated and applied 
further. The potential of algae as sources of PUFA and other bioactives is globally 
under-recognised, and further research and exploitation of these organisms holds 
promise for the benefit of human nutrition and pharmacology. In order to cope 
with projected increases in population and decreases in food availability, it will be 
vital to examine novel food sources such as algae. Hence, the incorporation of 
algae as functional foods in the western diet poses great potential to reduce chronic 
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Elaborated from (Patterson et al., 2012). 
*It has been hypothesized that n-3 DPA may produce resolvin-like molecules (Kaur et al., 2011a). 
Abbreviations: LA, Linoleic acid; GLA, Gamma linolenic acid; DGLA, Dihomo gamma linolenic acid; 
AA, Arachidonic acid; DPA, Docosapentaenoic acid, ALA, Alpha linolenic acid; SDA, Stearidonic acid; 
EPA, Eicosapentaenoic acid; DHA, Docosahexaenoic acid; PG, Prostaglandins; TBX, Thromboxanes; LT, 
Leukotriene. 
 
Figure 1. Metabolism of omega-3 and omega-6 PUFA in humans. Omega-3 and omega-
6 PUFA metabolism involves a number of elongase and desaturase enzymes which are 












Abbreviations: EPA, Eicosapentaenoic acid; DHA, Docosahexaenoic acid; AA, Arachidonic acid; PLA2, 
Phospholipase A2; COX, Cyclooxygenase; LOX, Lipoxygenase; PG, Prostaglandin; TBX, Thromboxane; 
LT, Leukotrienes. 
 






































Figure 3. Process by which dietary PUFA regulate inflammatory response through 
activation of GPR120 and preventing the activation of NF-κB and subsequent gene 
transcription. The presence of LPS, a bacterial endotoxin, is detected by TLR4, which 
subsequently results in activation of the inactive cytosolic NF-κB, through 
phosphorylation and ubiquitination of the inhibitory IκB subunit. The active NF-κB then 
translocates to the nucleus where it acts as a transcription factor for a number of 
inflammatory genes. Inflammatory gene transcription leads to the up-regulation of genes 
involved in the expression of pro-inflammatory cytokines, eicosanoids and enzymes. The 
presence of omega-3 PUFA, such as EPA and DHA, in the cell prevents this process. 
Omega-3 PUFA activate the GPR120 receptor which prevents the activation of NF-κB 







Table 1. Meta-analyses investigating the role of n-3 PUFA supplementation in 
rheumatoid arthritis
Meta-analysis No. of studies 
involved 
Primary outcomes Conclusions/Comments 
Fortin et al.  
(1995) (Fortin et 
al., 1995) 
10 Significant reduction in: 
- Tender joint count (RD =  -2.9) 
- Minutes morning stiffness (RD = -25.9) 
 
Non significant change in: 
- Swollen joint count 
- Grip strength 
- Patient/Physician global assessment 
- Visual analogue scale 
 
‘There was a modest, statistically 
significant improvement in tender joint 
count and morning stiffness in patients 
with RA treated with dietary fish oil 
supplementation for 3 months as compared 






17 Significant reduction in: 
- Joint pain intensity (SMD = -0.26) 
- Minutes morning stiffness (SMD = -0.43) 
- Painful/tender joint count (SMD = -0.29) 
- NSAID use (SMD = -0.4) 
 
Non significant change in: 
- Physician assessed pain 
- Ritchie articular index 
 
‘n-3 PUFAs are an attractive adjunctive 
treatment for joint pain associated with 
rheumatoid arthritis, inflammatory bowel 
disease, and dysmenorrhea’ 
 
Lee et al. (2012) 
(Lee et al., 2012) 
10 Significant reduction in: 
- NSAID use (SMD = -0.518) 
 
Non significant reduction in: 
- Tender joint count 
- Swollen joint count 
- Minutes morning stiffness 
- Physical functioning 
- Pain 
- Physician/patient global assessment 
‘Use of omega-3 PUFAs at dosages of >2.7 
g/day for >3 months may be effective at 
reducing NSAID use in RA patients. 
Additional studies are needed to explore 
clinical effects including the NSAIDs 
sparing effect of omega-3 PUFAs in RA’ 
 
- Despite not reaching statistical 
significance, there was a trend for 
improved tender joint count, swollen joint 
count, morning stiffness and physical 
functioning. 
 
MacLean et al. 
(2004) (MacLean 
et al., 2004) 
9 Non significant reduction in: 
- Pain 
- Swollen joint count 
- Patient global assessment 
- Erythrocyte sedimentation rate 
 
A qualitative assessment found that 6 out of 7 
studies reported a reduced requirement for anti-
inflammatory  drugs and corticosteroids during 
omega-3 PUFA supplementation 
 
 
‘The available evidence suggests that 
omega-3 fatty acids reduce tender joint 
counts and may reduce requirements for 
corticosteroids, but does not support an 
effect of omega-3 fatty acids on other 
clinical outcomes’ 
The studies examined in this meta-analysis 
included a study of ALA supplementation 
and one which involved transdermal rather 
than dietary administration of PUFA. 
Inappropriate study inclusion and 
conclusions may affect the results and 









No. of studies 
involved 
Primary outcomes Conclusions/Comments 
Turner et al. (2011)  
Meta-analysis (Turner 
et al., 2011) 
9 Maintenance of remission of IBD was significant for 
Crohns Disease patients during PUFA 
supplementation  (RR = 0.77) however studies were 
heterogeneous.   Exclusion of a small paediatric trial 
from the                   meta-analysis resulted in the RR 
no longer being significant. 
 
For Ulcerative Colitis there was no significant         
reduction in relapse rate following PUFA     
supplementation (RR = 1.02) 
 
 
‘The existing data do not 
support routine treatment with 
n-3 fatty acids for maintaining 
remission in IBD’ 
 
This meta-analysis purely 
focussed on maintenance of 
IBD remission rather than 
improvement of clinical 
outcomes during disease state 
 
MacLean et al. (2005) 
(MacLean et al., 2005) 
Systematic review 
13 PUFA supplementation had a small significant 
improved effect on IBD clinical score in 3 out of 5 
studies examined. Endoscopic score significantly 
improved in 3 studies following supplementation, 
but discrepancy in results of one study suggest a 
Type 1 or Type 2 error. 
Histological score did not change in 2 out of 3 
studies following supplementation 
IBD remission and relapse were not significantly 
changed following supplementation 
Reduction in the use of immunosuppressive drugs 
varied widely across studies, but some showed 




‘The available data are 
insufficient to draw 
conclusions about the effects 
of 
n-3 fatty acids on clinical, 
endoscopic, or histologic 
scores or 
induced remission or relapse 
rates’ 
 
Cabré et al. (2012) 
(Cabré et al., 2012) 
Systematic review 
19 Active ulcerative colitis appeared to improve 
following PUFA supplementation in 7/7 trials 
examining histological, endoscopic, steroid use and 
remission data. 
Inactive ulcerative colitis was not significantly 
changed following supplementation as measured by 
relapse rate      in 4 trials. 
Two trials examining active Crohns disease 
identified no significant effect on remission 
following enteral supplementation, however one of 
these studies used     solely ALA as the 
supplementary PUFA 
Six trials examined inactive Crohns disease by 
assessment of remission, where four of these trials 
showed no difference in remission rates between 
PUFA     supplemented groups and placebo  
 
 
‘The available data do not 
allow to support the use of 
omega-3 PUFA 
supplementation for the 
treatment of both active and 
inactive inflammatory bowel 
disease’ 
  
The authors note the potential 
effect of study heterogeneity 
on the inconclusive results 
alongside the limitations of a 
small number of randomized 
controlled trials and 
inappropriate study designs 










Food for thought: The role of nutrition in the 
microbiota-gut- brain axis 
 
  






 Recent research has provided strong evidence for the role of the commensal gut 
microbiota in brain function and behaviour. Many potential pathways are involved in 
this bidirectional communication between the gut microbiota and the brain such as 
immune mechanisms, the vagus nerve and microbial neurometabolite production. 
Dysbiosis of gut microbial function has been associated with behavioural and 
neurophysical deficits, therefore research focused on developing novel therapeutic 
strategies to treat psychiatric disorders by targeting the gut microbiota is rapidly 
growing. Numerous factors can influence the gut microbiota composition such as health 
status, mode of birth delivery and genetics, but diet is considered among the most 
crucial factors impacting on the human gut microbiota from infancy to old age. Thus, 
dietary interventions may have the potential to modulate psychiatric symptoms 
associated with gut-brain axis dysfunction. Further clinical and in vivo studies are 
needed to better understand the mechanisms underlying the link between nutrition, gut 





 The microbial population residing in the small and large intestine represents the 
largest microbial population of the human microbiota. Estimates suggest that bacterial 
cells within the gut microbiota outnumber human eukaryotic cells by ten to one 
(Hamady and Knight, 2009). Moreover, the genes encoded by the gut microbiota, the 
gut microbiome, outnumber the human genome by one hundred to one (Qin et al., 
2010). This complex ecosystem is formed mainly by bacteria, but also viruses, archae, 
protozoa and fungi. Due to the advances in genomic technologies it has been possible to 
unravel around 75% of the adult gut microbiota bacterial composition, which is 
predominantly composed of the Firmicutes and Bacteroidetes phyla (Collado et al., 
2012). Furthermore, the gut microbiota plays a major role in host health by shaping the 
development of the immune system, metabolizing dietary nutrients (such as fatty acids, 
glucose and bile acids) and drugs, digesting complex indigestible polysaccharides and 
synthesizing vitamins and bioactive molecules (Lankelma et al., 2015). 
 Throughout different life stages, various changes occur in the microbial diversity 
of humans. Early studies suggested that the fetus first came in contact with microbes 
during birth. However, it has been posited that as early as the prenatal period, an initial 
inoculum of microbes may be translocated via the bloodstream and placenta from the 
mother to the fetus, thus contradicting the “sterile womb” hypothesis (Borre et al., 
2014). After birth, the first colonizers of the gut are facultative anaerobes such as 
Streptococcus, Enterobacteriaceae and Staphylococcus. These colonizers consume 
oxygen, creating an anaerobic environment leading to an increase of Clostridium, 
Bacteroides and Bifidobacteria, which are strict anaerobes. During this early post-natal 
period, diet (breast milk/formula feeding) plays a key role in shaping the gut microbiota 
composition (Thum et al., 2012). This unstable infant gut microbiota with low diversity 




the second year of life onward, the microbial composition undergoes an important shift 
toward the stable gut microbiota profile of the adult, which is composed mainly of 
Bacteriodetes and Firmicutes. During healthy adulthood the gut microbiota remains 
relatively stable until ageing, when considerable changes occur (Claesson et al., 2012).  
 The intestinal microbes are markedly affected by numerous factors such as host 
genetics, mode of delivery, lifestyle (urbanization and global mobility), medical 
interventions (use of antibiotics, vaccinations and hygiene) and health status (Burokas et 
al., 2015). Furthermore, diet has repeatedly shown to be one of the most important 
factors affecting gut microbiota establishment and composition throughout the lifespan 
(Lankelma et al., 2015). Indeed, more than 50% of the variation of gut microbiota has 
been related to dietary changes (Zhang et al., 2010) and major changes in diet during 
adulthood can modify the microbiota in a matter of days (David et al., 2014). 
Furthermore, an alteration of gut microbiota and metabolism, through dietary or other 
environmental influences, can cause a state of dysbiosis, which is characterized by an 
overgrowth of potentially pathogenic organisms (pathobionts) (Kamada et al., 2013). 
This change in the balance of symbionts/pathobionts can induce reduced intestinal 
barrier function (leaky gut) and subsequent chronic inflammation. Such dysbiosis may 
be associated with some metabolic and inflammatory disorders, visceral pain and even 
alterations to central nervous system functioning (DuPont and DuPont, 2011, Sekirov et 
al., 2010). Hence the relationship between the gut microbiota, chronic inflammation and 
the central nervous system (CNS) suggests that microbial dysbiosis could alter brain 
function and hence contribute to behavioural and cognitive abnormalities (Cryan and 
Dinan, 2012). A wealth of preclinical research is now showing potential for the 





 Given such evidence, there is a growing appreciation for the importance of the 
gut microbiota in health and disease, including mental health. Bearing in mind that diet 
is one of the most crucial factors in the development of the human gut microbiota from 
infancy to old age, this review focuses on the role of the gut-brain axis in brain function 
and behaviour and the potential nutritional interventions to target this axis as psychiatric 
disease therapies.  
 
2. How does diet influence human microbiota? 
 The human gut harbours over ten thousand species of microorganisms (Eckburg 
et al., 2005), hence such taxonomic diversity requires a wide array of nutrients and 
energy sources for normal microbial growth and function. Narrowing of host dietary 
diversity and reduced intake of essential nutrients can therefore reduce availability of 
substrates for specific microbial growth and contribute to intestinal dysbiosis. Over 
recent decades, modern dietary patterns have undergone major compositional changes, 
with increased intakes of red meat, high fat foods, and refined sugars. This 
‘Westernization’ of diets together with sedentary lifestyles results in modifications to 
the gut microbiota, which may partially contribute to the higher incidences of chronic 
inflammatory disorders, such as cardiovascular disease, obesity, depression, allergies, 
diabetes and autoimmune disorders (Maslowski and Mackay, 2011). It is therefore clear 
that in order to improve the nutritional value of food and thus, human health, it is 
essential to understand the biological interactions between the diet and microbiota.  
 Many human studies have assessed dietary impact on the gut microbiota. 
However, as is the case with many human studies, they are limited by the difficulties to 
control potential confounding variables such as habitual diets and lifestyle behaviours. 
Moreover, it is worth noting that, typically, sequencing of the human gut microbiota is 




composition of the different intestinal segments. Despite these limitations, much of this 
human data is useful to assess the role of varying dietary patterns on microbiota 
composition and function.  
 
Rural vs Western diet 
 Many studies comparing rural and western communities have revealed 
specific gut microbiota adaptations to their respective environments. The adaptations to 
westernization have resulted in an important loss of several bacterial species, and hence 
subsequent reduction in microbial diversity and stability. Recent studies have clearly 
showed this reduction in microbiota diversity such as the one comparing an Italian 
urban control group compared to a hunter–gatherer community (Schnorr et al., 2014). 
Moreover, recent investigations have reported the impact of diet on the microbial 
biodiversity within different human populations (De Filippo et al., 2010). African 
children, who consume a low-fat and high-fibre diet, presented less potentially 
pathogenic bacteria and greater degree of diversity and microbial richness than 
European children consuming a high-fat diet (Western diet). African children had a 
depletion in Firmicutes and a greater abundance of the phylum Bacteroidetes 
(Xylanibacter and Prevotella), while European children showed a significant increase of 
Firmicutes (Feacalibacterium and Acetitiomaculum) and Enterobacteriaceae (Shigella 
and Escherichia) (De Filippo et al., 2010). Similar findings were observed in terms of 
an increase of Prevotella genus in rural African populations compared to US Americans 
(Ou et al., 2013).  
 
Mediterranean diet 
 The Mediterranean diet is characterised by an abundance of fruits, vegetable, 




gold-standard for optimum health. A recent study showed the ability of a 
Mediterranean-inspired anti-inflammatory diet to reduce inflammation in Crohn’s 
disease. The results demonstrated a small reduction of the acute phase protein C-
reactive protein (CRP), an increase in Bacteriodetes and Clostridium clusters and a 
decrease in Proteobacteria and Bacillaceae population (Marlow et al., 2013). Similarly 
De Filippis et al recently observed that Italian subjects with a high adherence to a 
Mediterranean diet had greater abundance of Prevotella and short chain fatty acids. 
Conversely, those with low adherence had higher urinary trimethylamine oxide 
(TMAO), which has associations with gut dysfunction, cardiovascular disease and 
colorectal cancer (De Filippis et al., 2015).  
 
Vegetarian/vegan diets 
 Vegetarian diets have also gained recognition as a healthy and therapeutic 
dietary pattern for a number of chronic diseases, while vegan diets may confer 
protective benefits beyond that of vegetarian diets (Glick-Bauer and Yeh, 2014). Vegan 
diets may have protective effects against metabolic and inflammatory diseases. 
Moreover, they appear to lead to a unique gut microbiota profile characterized by a 
reduction of pathobionts (Glick-Bauer and Yeh, 2014).  Some studies have shown that 
vegetarian and vegan diets significantly decrease microbial counts of Bacteroides 
fragilis compared to an omnivore diet (Ferrocino et al., 2015). Another study comparing 
vegetarian to omnivore diet observed a higher ratio (%) of Bacteroides–Prevotella, 
Bacteroides thetaiotaomicron, Clostridium clostridioforme and Faecalibacterium 
prausnitzii but a lower ratio (%) of the Clostridium cluster XIVa in vegetarian diet 







 Numerous studies support the idea that diets rich in plant fibres may promote the 
diversification of the microbiota by promoting hydrolytic bacteria and stimulating the 
production of short chain fatty acids (De Filippo et al., 2010). High-fibre diets have 
been positively associated with Actinobacteria and Bacteriodetes abundance (Wu et al., 
2011). One study showed that three diets with different fibre-rich whole grains (barley, 
brown rice or combination of both) increased microbial diversity, the 
Firmicutes/Bacteroidetes ratio, and the abundance of the genus Blautia in fecal samples 
(Martínez et al., 2013). Furthermore, the administration of whole grain barley induced 
an increase in Bifidobacteria which is considered a positive indicator of prebiotic 
activity (Carvalho-Wells et al., 2010). A recent study found an elevation of 
Bifidobacteria and a reduction of Bacteroides spp. and Clostridium histolitycum group 
in a cohort of overweight adults after administration of prebiotics (GOS) (Vulevic et al., 
2013). Davis et al showed as well that an administration of GOS increased abundance of 
Bifidobacteriaceace and decreased Bacteroidaceae (Davis et al., 2011). 
 
High-fat diets  
 Over the last few decades, the increase in the consumption of high-fat diets has 
been associated with the obesity epidemic (Torres-Fuentes et al., 2015). Many studies 
have shown that high-fat diets lead to a decrease in Bacteroidetes and an increase in 
Firmicutes (Murphy et al., 2015). These effects may be associated with increased gut 
permeability, a higher capacity for energy harvest and storage, and inflammation 
(Murphy et al., 2015). Several studies have focused on dietary supplementation as a 
possible way to attenuate the gut microbiota dysbiosis and metabolic impairments 
produced by high-fat diets. For example, polyphenols, conjugated linoleic acid and 




displayed an improvement of gut microbiota dysbiosis (den Besten et al., 2015, 
Roopchand et al., 2015, Chaplin et al., 2015).  
 
High-protein diets 
 The western diet has experienced a considerable increase in protein content in 
recent times. This has led to much research examining variations in macronutrients 
intake in order to manage body weight (Johnstone, 2012). Dietary proteins undergo 
luminal proteolysis and subsequent metabolism by the large intestine microbiota 
triggering the production of numerous amino acid-derived metabolites such as phenols, 
indoles, amines, sulphide, ammonia and monocarboxylic acids (Nyangale et al., 2012).  
 Dietary protein intake in humans has been positively associated with the 
Bacteroides enterotype (Wu et al., 2011). An animal-based diet in humans showed an 
increase in the abundance of bile-tolerant microorganisms 
(Alistipes, Bilophila and Bacteroides) and a decrease in the levels of Firmicutes that 
metabolize dietary plant polysaccharides (Roseburia, Eubacterium 
rectale and Ruminococcus bromii) (David et al., 2014). Interestingly, Clarke et al. 
showed the importance of exercise in the relationship between the microbiota, host 
immunity and host metabolism, and the important role played by the diet. They 
compared male elite professional rugby players to healthy male controls, finding a 




3. Gut-Microbiota-Brain Communication  
 As previously discussed, diet significantly modifies host gut microbiota 




host is capable of extracting from its diet, from nutrients to bioactive signalling 
molecules such as neurometabolites, vitamins and short-chain fatty acids (SCFA) (Tan 
and O’Toole, 2015). Many of these molecules such as serotonin and gamma-
aminobutyric acid (GABA), have neuro-active functions due to their capacity to 
modulate neural signalling within the enteric nervous system and consequently 
influence brain function and host behaviour (Wall et al., 2014). This gut-brain axis, the 
bidirectional communication system between the gastrointestinal system and the CNS, 
plays an important role in homeostasis between neural (both enteric and central nervous 
systems), hormonal and immunological signalling (Cryan and Dinan, 2012). Through 
this complex network the gut can influence the brain via visceral messages, and 
conversely, the brain is able to influence gastrointestinal functions (like motility, 
secretion and mucin production) and immune functions, such as the modulation of 
cytokine production by cells of the mucosal immune system (Tracey, 2009). 
 Both luminal nutrients and gut microbiota metabolites stimulate 
enteroendrocrine cells (EECs) located throughout the gastrointestinal (GI) tract, which 
represents the largest endocrine organ in the human body (Rehfeld, 2003). These EECs 
contain most of the nutrient receptors such as those for amino acids, peptones, SCFAs, 
long-chain fatty acids (LCFAs) and oleoylethanolamide (OEA) (Figure 1). Molecular 
sensing by these EEC’s are crucial in the control of multiple functions during digestion, 
the initiation of neural and hormonal responses or changes in mucosal ion transport 
which controls appetite, insulin secretion and motility (Furness et al., 2013). Moreover, 
as the nervous and endocrine signalling between the gut and the brain is essential for the 
modulation of many GI functions, the sensing receptors of the gut that control the 
release of many hormones play a key role (Figure 1).  Several interacting factors such as 
diet and microbiota composition modulate the activation of different sensory receptors 




which can induce a number of functional GI changes. Interestingly, increasing evidence 
indicates that animals fed on a high-fat diet present numerous changes in 
gastrointestinal function, particularly in the secretion and signalling of gastrointestinal 
hormones, which may predispose to an increase in energy intake, and consequently, to 
weight gain and obesity (Little et al., 2007).  
 In addition to its role as a sensory organ, the gut forms part of the enteric 
nervous system, which makes up a comprehensive division of the autonomic nervous 
system, containing between 200 and 600 million neurons (Furness et al., 2013). The 
vagus nerve (the major nerve of the parasympathetic division of the autonomic nervous 
system) is crucially involved in bidirectional signalling between the gastrointestinal and 
nervous systems (Figure 2). A landmark study by Bravo et al (Bravo et al., 2011) found 
that probiotic modulation of the gut microbiota induced behavioural and neurochemical 
changes in mice. However, this was not apparent in mice that had undergone vagotomy 
suggesting a crucial role for the vagus nerve in the gut-brain axis. 
 The human intestine also acts as an endocrine organ through direct and indirect 
production of microbial metabolites and neurometabolites such as short chain fatty acids 
(SCFAs), vitamins and neurotransmitters, which have also been shown to influence gut-
brain interactions (Burokas et al., 2015). GABA and serotonin are neurotransmitters that 
can influence host behaviour and are produced directly or indirectly by certain 
commensal microbes (Barrett et al., 2012, Reigstad et al., 2015). SCFAs including 
butyrate, propionate and acetate can be produced by species such as Roseburia spp and 
Faecalibacterium following fermentation of indigestible polysaccharides (Brestoff and 
Artis, 2013). Butyrate and propionate can modulate brain functioning, in particular 





 The role of the gut microbiota in immune activation also has strong associations 
with neurological functioning. The gut microbiota regulate intestinal epithelial barrier 
integrity and hence control the translocation of viable bacteria or bacterial endotoxins 
into the bloodstream (Bischoff et al., 2014). Increased intestinal permeability can lead to 
increased lipopolysaccharide (LPS) in the bloodstream, which increases inflammatory 
status. Diet and obesity significantly alter gut microbiota composition and hence have 
been shown to affect inflammatory status. Cani et al showed that prebiotic 
supplementation dampened inflammatory status and improved gut barrier function in 
genetically obese mice (Cani et al., 2009). Many supporting studies have demonstrated 
the potential for high fat and other obesogenic diets to promote inflammation and 
microbiota-targeted interventions, such as prebiotics and probiotics to reverse 
inflammatory status (Everard et al., 2014). Chronic inflammation has been linked to a 
number of neurological disorders including depression and dementia (Yong, 2010) and 
hence microbiota-associated chronic inflammation may influence risk of such disorders. 
 Due to the fact that many of these gastrointestinal pathways significantly 
influence neurological function, there is potential for dietary interventions that increase 
bacterial metabolism and promote growth of beneficial bacteria, to positively modulate 
the gut-brain axis and improve symptoms of psychiatric illness. Moreover, bearing in 
mind the potential link between the gut microbiota and anxiety-related behaviour 
(Burokas et al., 2015), research has recently focused on the health benefits of probiotic 
administration on psychiatric illnesses (Dinan et al., 2013b). 
 
 
4. Microbiota-targeted dietary interventions and behavioural outcomes 
 The gut microbiota have been implicated in a number of clinical 




aetiology and treatment of psychiatric disorders has come to light in recent times (Sarris 
et al., 2015). The development of next generation sequencing technologies has also 
allowed for increased understanding of human gut microbial composition in healthy and 
disease states and how environmental factors such as diet influence this composition.  
 
Probiotic interventions 
 A number of studies have reported certain probiotic strains, primarily 
Lactobacillus and Bifidobacteria, to enhance brain function in both rodents and humans. 
Hence there is potential for ‘psychobiotics’ (live organisms that, when ingested, confer 
a benefit to host psychiatric health) to modulate the gut microbiota and act as therapies 
for psychiatric disorders (Dinan et al., 2013a). Table 1 summarizes a non-
comprehensive list of human and preclinical studies investigating the role of probiotics 
in behaviours associated with psychiatric illness. Despite the promising evidence in 
animals, these results have yet to be fully translated into humans. However with larger 
randomised controlled trials, there is potential for psychobiotics to be effective 
psychiatric therapeutics.  
 
Dietary interventions 
 Many studies have shown a clear association between the gut microbiota and 
behavioural alterations, and given that gut microbiota is affected by diet, the 
composition of the diet may be a crucial factor contributing to these behavioural 
changes, as summarized in table 2.  
 Large macronutrient alterations as reflected in western style diets have been 
shown to induce microbial dysbiosis, which has been linked to impaired cognition. 
Magnusson et al examined microbiota compositional changes following high fat, high 




mice (Magnusson et al., 2015b).  Lactobacillus was significantly increased in the high 
sucrose group whereas Erysipelotrichales was significantly increased in the high fat 
group. High fat and high sucrose both had increased Coriobacteriales and reduced 
Bacteroides. Both high-energy treatments induced impaired cognition in the Morris 
water-maze and step-down latency tasks. In addition these behavioural changes 
displayed significant correlations with the alterations in Lactobacillus, 
Erysipelotrichales, Coriobacteriales and Bacteroides. These results suggest that the 
cognitive changes induced by the western-style diets are mediated through alterations to 
the gut microbiota. Jørgensen et al performed a similar study with the same treatment 
groups and found similar correlations between microbiota alteration and memory which 
was also associated with inflammatory status (Pyndt Jørgensen et al., 2014).  
  Li et al also reported diet-induced changes to microbial diversity to improve 
cognition and working memory in mice. In this study, a meat-containing diet led to 
greater gut microbiota diversity than found in the control diet group. Moreover, the 
meat-containing diet group had improved working and reference memory on the hole-
board open field test and less anxiety-like behaviour, assessed during the novel 
encounter in the hole-board open field (Li et al., 2009a). 
 Mental decline is increased by obesity, which may be in part regulated by gut 
microbiota dysbiosis. A recent study showed that an obese-type microbiota, induced by 
high-fat feeding, induced cognitive disruptions when transplanted into healthy rodents 
(Bruce-Keller et al., 2015b). The high-fat diet microbiota led to a significant increase of 
anxiety-like behaviour in the elevated plus maze, open field, and marble burying test. 
Moreover, this transfer of the high-fat diet microbiota decreased the cued fear memory 
in comparison to mice that received microbiota from chow-fed mice. Furthermore, 
inflammatory markers in the medial prefrontal cortex and intestinal permeability were 




signalling pathways may be key mediators of microbiota-brain communication. These 
interesting results revealed that even in the absence of obesity, an obese-type microbiota 
profile could induce behaviour deficits similar to those seen in obesity and hence 
suggesting the potential for microbiota-based dietary interventions to treat obese-
associated psychiatric disorders. In addition, Ohland et al reported a western-style diet 
to induce anxiety-like behaviour in mice, as assessed in the Barnes maze (Ohland et al., 
2013b). Moreover, western-style diet feeding increased the Firmicutes/Bacteriodetes 
ratio, and the abundance of Proteobacteria and Spirochaetes as well as reducing total 
SCFA contents. This increased anxiety-like behaviour was not apparent in mice who 
had been fed a western-style diet supplemented with the probiotic Lactobacillus 
helveticus. Another study found that mice on a high-fat diet presented major shifts in the 
gut microbiota (increase of Firmicutes and decrease of Bacteroidetes and Tenericutes) 
and a robust anxiety phenotype (Kang et al., 2014). A diet deficient in Mg, increased 
depressive-like behaviour and altered the gut microbiota, which suggested that 
magnesium deficiency could be a mediator of the behavioural effects through an altered 
gut microbiota (Winther et al., 2015). Interestingly, a significant correlation was found 
between the gut microbiota of the diet deficient in Mg and a decrease in hippocampal 
IL-6 levels, suggesting that this immune-modulation could be the mechanism by which 
diet induced changes in the gut microbiota composition alter behaviour (Winther et al., 
2015). A similar study found that a diet deficient in Mg decreased bacterial diversity 
and altered anxiety-like behaviour (Pyndt Jørgensen et al., 2015).  
 Certain prebiotics have the potential to influence central nervous system 
functioning through stimulation of specific microbial growth and production of SCFAs. 
Tarr et al reported that a social disruption stressor significantly altered gut microbiota 
composition in mice, which resulted in anxiety-like behaviour and a reduction in the 




Interestingly, supplementation of the human milk oligosaccharides 3′Sialyllactose or 
6′Sialyllactose, which have anti-inflammatory properties and stimulate bifidobacterial 
growth, prevented the stressor-induced alterations to the gut microbiota, in addition to 
preventing the behavioural, microbial and neurophysical defects (Tarr et al., 2015).  
 A number of small clinical controlled trials have assessed the efficacy of certain 
prebiotics on psychological outcomes with promising results. Schmidt et al 
demonstrated that 3-week supplementation with a GOS prebiotic, which has been 
shown to stimulate bifidobacteria growth, in healthy volunteers significantly reduced 
waking cortisol response, a stress hormone strongly linked to anxiety and depression 
(Schmidt et al., 2015). Moreover, a Bimuno®-galactooligosaccharides cohort 
demonstrated altered behavioural outcomes through a decrease in attentional vigilance 
to negative versus positive information in a dot-probe task compared to placebo. It is 
interesting to note, however, that fructooligosaccharide (FOS) supplementation had no 
effect. These results suggest that shaping of microbiota composition through prebiotic 
intake could influence behavioural outcomes (Schmidt et al., 2015). In humans, 
prebiotic supplementation with trans-galactooligosaccharide (trans-GOS) not only 
enhanced bifidobacterial growth and improved bloating symptoms, but in addition 
significantly reduced anxiety scores in IBS sufferers (Silk et al., 2009). 
 
Conclusions and future implications 
 It is evident that there are a number of major metabolic, endocrine and neural 
pathways connecting the gut and the brain. Indeed, the trillions of microbes and 
microbial by-products within the gut contribute to the plasticity of these pathways. 
Despite the rapid growth of this area of research, it is still in its infancy. Relatively little 
is known about the extent to which bacterial metabolites can influence brain function, 




technologies. In addition, the complexity of the pathways involved in the gut-brain axis 
contributes to the difficulty of identifying true mechanisms of action. Moreover, the role 
of individual nutrients to affect signalling within these pathways requires further 
examination. Sequencing technologies have grown extensively in recent times allowing 
deeper insight into gut microbial composition and associations between altered 
microbiota and psychiatric illnesses. Further research in this field should address 
mechanistic evidence for gut microbiota to alter brain and behaviour. The majority of 
the data available is preclinical and few of these promising studies have been translated 
into humans, which warrants the need for more clinical trials in the area. There are very 
little data reporting clinical interventions targeting the microbiota in psychiatric illness. 
Indeed, diet has a significant impact on the microbiota and hence dietary interventions 
can beneficially modulate microbial diversity and function. Caution must be taken on 
assigning the term ‘probiotic’ to a specific strain of bacteria until its health effects can 
be replicated in both humans and animals. Indeed, commercial availability of true 
‘psychobiotics’ (a live bacteria that may benefit mental health) will only become 
apparent after rigorous human trials. Prebiotics and other larger dietary interventions, 
including dietary fats and polyphenols also pose potential to alter the gut-brain axis and 
hence neuropsychiatric disorders, and may be feasible as long-term interventions for 
mental health.  
 In conclusion, diet-induced gut microbiota modifications may be associated 
with brain dysfunction, behavioural and metabolic deficiencies. The emerging evidence 
of a microbiota-gut-brain axis dysregulation in certain neuropsychiatric disorders 
warrants further clinical and in vivo studies to investigate gut microbiota-targeted 
interventions as novel therapeutic strategies. Indeed, dietary interventions to treat 
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Table 1. Probiotic interventions and behavioural outcomes 
Intervention Species Health status Microbiota changes Behavioural/neurochemical outcomes References 
Lactobacillus casei Humans Healthy ____ ↑ mood (self reported)                                   ↓ memory 




Healthy anxious strain 
(BALB/c) ____ 
↑ memory and cognitive performance 
(novel object recognition, barnes maze, 
fear conditioning) 
(Savignac et al., 
2015) 
VSL#3 Rats Aged ↑Bacteroidetes 
↓ deficit in age-related LTP                           
↓ microglial activation                         
↑BDNF and synapsin 




Healthy or fed western-
diet 
Normalized the increase in 
proteobacteria following 
"western diet" feeding 
↑ memory (Barnes maze)                              
↓ anxiety-like behaviour (Barnes maze) 
(Ohland et al., 
2013a) 
Bacteroides fragilis Mice MIA treated 
Restored relative abundance 
of lachnospiraceae following 
MIA treatment 
↓ anxiety-like behaviour (Open field)            
↑ communication (ultrasonic vocalization) 
↓stereotyped behaviour (marble burying) 
(Hsiao et al., 
2013) 
Lactobacillus casei Humans Chronic fatigue syndrome 
↑Bifidobacteria                       





Rats Healthy ____ ↓anxiety (conditioned defensive burying) (Messaoudi et al., 
2011) Humans Healthy ____ ↓anxiety 
Bifidobacteria 
infantis Rats Healthy ____ 
↓proinflammatory immune response             
↑ tryptophan 







Microbiota data not reported 
however probiotic group 
significantly less likely to 
experience severe bowel 
















____ ↓visceral pain (colorectal distension) (McKernan et al., 2010) 
Lactobacillus 
rhamnosus Mice 
Healthy anxious strain 
(BALB/C) ____ 
↓corticosterone, anxiety behaviour, 
depressive behaviour. Altered GABA 
receptor expression 





Table 2. Microbiota-targeted dietary interventions and behavioural outcomes  
Diet Species Intervention length Microbiota changes Behavioural outcomes 
Biochemical outcomes                                
(possible mechanisms) Reference 
High-fat diet Mice 13weeks 
↑Firmicutes (mainly 
Ruminococcaceae and 
Lachnospiraceae)                         
↓ Bacteroidetes (S24-7 ) 
↓ Burrowing  (Burrowing Test)                                           
↓ Memory (Morris water maze 
test) 
No difference between diet groups was 
observed for sucrose preferences, LPS, 
cholesterol, HbA1c, BDNF and the 
cytokines IL-1α, IL-1β, IL-6, IL-10, IL-
12(p70), IL-17 and TNF-α.                                                                     
Low-grade levels of the systemic 
inflammatory mediators IL-6, IL-12p70 
and IL-17A correlated to memory, 




High-fat diet Mice 2-5weeks 
↑Clostridiales and 
Erysipelotrichales                                                              
↓ Bacteroides 
No significant differences from 
the control mice, except for 
remaining focused on the old 
platform position during the 
reversal probe trial 
____ (Magnusson et al., 2015a) 





Lactobacillus) and  
Lactococcus                                                                                                                                                                       
↓ Bacteroides 
↓ Learning (Morris water maze 
test)                                                     
Cognitive deficits (in spatial 
short-term memory)                                                  
Impairments in early development 
of a spatial bias for long-term 
memory, short-term memory and
reversal training, compared to 
mice on normal diet. 









Analysis plots illustrating 
differences in GM 
composition.                                                                                                                                                       
The GM profile of MgD 
mice differed significantly 
from mice fed a standard 
control diet 
↑ FST- Increased immobility
(depressive-like phenotype) 
Strong tendency towards decreased 
mRNA IL-6 levels in the MgD mice. The 
GM of MgD mice correlated  
significantly to hippocampal IL-6 levels 
(Winther et 
al., 2015) 




↓ Bacterial diversity of the 
gut                                                                                                                    
Principal component 
analysis plots illustrating 
differences in GM 
composition between mice 
fed a control diet or an 
MgD diet 
Altered anxiety-like behaviour (↓ 
Latency to enter the light 







diets Mice 3months ↑ Bacterial diversity 
↑ Working and reference 
(temporary and long-term) 
memory.                                                                            
↓  Anxiety-like behaviour 
____ (Li et al., 2009b) 
Western-style 
diet high in fat Mice 21 days 
↑ Firmicutes/Bacteriodetes 
ratio                                                                                                                      
↑ Abundance of 
Proteobacteria and 
Spirochaetes. 
Altered anxiety-like behaviour 
↓ total levels of SCFAs in cecal contents                                 
↓ levels of acetic, propionic and butyric 
acids                                                                      











confirmed the presence of 
distinct core microbiota 
between groups, with 
alterations in α- and β-
diversity, modulation in 
taxonomic distribution, and 
Disrupted exploratory, cognitive, 
and stereotypical behaviour 
Disrupted markers of intestinal barrier 
function                                                                 
↑ circulating endotoxin                                  
↑  lymphocyte expression of ionized 
calcium-binding adapter molecule 1                                               
↑ toll-like receptor 2                                       
↑ toll-like receptor 4 
(Bruce-








Abbrevitations: HAD, Hospital Anxiety and Depression scale; SCFAs, short-chain fatty acids; GM, gut microbiota; LPS, Lipopolysaccharide ; 
HbA1c, hemoglobin A1c ; BDNF, brain-derived neurotrophic factor
statistically significant 
alterations to metabolically 
active taxa 
High-fat diet Mice 8weeks 
↑ Firmicutes                                                                                                        
↓ Bacteroidetes and 
Tenericutes 
































Figure 1. Interaction between luminal nutrients, gut microbiota metabolites and gut sensory 
receptors: the key communication pathways between endocrine, neuronal and immune systems. 
Dietary composition determines the type of nutrients that reach the luminal gastrointestinal tract. 
Different dietary patterns can alter the composition of the gut microbiota and consequently the production 
of their metabolites, which can influence: epithelial permeability by acting on the cells from the immune 
system (1), activity of enteroendocrine cells (2) or tight junction protein function (3). The gut luminal 
content is continuously monitored by the intestine to optimize nutrient assimilation and protect against 
hazards which can affect its integrity. Therefore, the intestine is conferred with a range of sensory 
receptors which interact with major effector systems such as the endocrine system, the nervous system, 
the gut immune system, and the nonimmune defence systems of the gut. Hormone release triggered by the 
activation of nutrient-specific receptors found on the enteroendrocrine cells, occurs along the 
gastrointestinal tract from the stomach to the large intestine. There are several types of enteroendocrine 
cells such as L cells or I cells with sensory receptors that stimulate the release of different types of 
hormones (4), which have a wide range of effects such as satiety through the hypothalamus, 
gastrointestinal motility and acid secretion. Abbreviations: Aas, aminoacids; Ach, acetylcholine; APCs, 
antigen-presenting cells; CCK, cholecystokinin; DA, dopamine; GABA, gamma-aminobutyric acid; GIP, 
gastric inhibitory peptide; GLP, glucagon-like peptide; IPANs, intrinsic primary afferent neuron; LCFAs, 
long-chain fatty acids; NE, norepinepherine; OEA, oleoylethanolamide; PYY, peptide YY; SCFAs, short-







Figure 2.  Impact of diet on the gut microbiota and routes of communication involved in the gut-
brain axis.   
Diet is one of the most crucial factors in the development of the human gut microbiota. Different dietary 
patterns can change the gut microbiota composition by keeping a balanced diversity of the gut microbiota 
(symbiosis) or causing a state of dysbiosis which is characterized by an overgrowth of potentially 
pathological organisms (pathobionts). A state of dysbiosis leads to an increased inflammation and leaky 
gut.  Many mechanisms have shown to be involved in this bidirectional pathway between the gut 
microbiota and brain including vagus nerve signalling, immune activation, tryptophan metabolism and 
production of microbial metabolites and neurometabolites. Many of these bacterial metabolites 
significantly impact neurological function, therefore there is potential for dietary interventions that 
increase bacterial metabolism and promote growth of beneficial bacteria, to beneficially modulate the gut-
brain axis and modulate CNS function. Abbreviations: GABA, gamma-aminobutyric acid; DA,dopamine 













Based on the literature discussed here in chapter 1.1 and 1.2, there are a number of 
questions to be addressed in this thesis: 
 
1. How does omega-3 sufficiency or deficiency interact with the microbiota 
composition and function, especially in early life? 
2. How does this microbiota-lipid interaction impact metabolic and behavioural 
health outcomes? 
3. Can algae act as novel functional foods to induce such health effects associated 
with long-chain omega-3 fatty acids? 
 
Hence, the overarching hypothesis that underlies this thesis is that long-chain omega-3 
fatty acids enchance the gut microbiota environment in early life thereby supporting 
metabolic health and behavioural development. In addition, algae, as novel sources of 












Omega-3 polyunsaturated fatty acids critically 
regulate behaviour and gut microbiota 












Background: Neurodevelopment is strongly influenced by maternal and early-
postnatal diet. Omega-3 polyunsaturated fatty acids (n-3 PUFA) are vital structural 
and functional components of the developing brain. The gut microbiota is also 
influenced by n-3 PUFA status, however, little is known about the role of maternal 
and early-life n-3 PUFA intake on offspring gut microbiota development and 
subsequent interactions with central nervous system functioning and behavioural 
outcomes.  
Methods: Pregnant female C57BL/6 mice and their male offspring were fed a control 
(CON), omega-3 deficient (O3-) or omega-3 supplemented (O3+) diet. Cognitive, 
depressive and social behaviours were assessed through a battery of behaviour tests in 
the male offspring at both adolescence (week 4-5) and adulthood (week 11-13). 
Hypothalamic-pituitary-adrenal axis (HPA) activation was assessed by analysis of 
stress-induced corticosterone production. Fecal microbiota composition was analysed 
by 16S sequencing at both adolescent and adulthood. In addition, stimulated spleen 
cytokine levels were assessed. 
Results: n-3 PUFA interventions induced subtle changes in offspring early-life and 
adolescent behaviours, which were further evident in adulthood, such that O3- 
animals displayed impaired communication, social and depression-related behaviours 
and O3+ animals displayed enhanced cognition. O3- mice displayed an elevated 
Firmicutes:Bacteroidetes ratio and blunted systemic LPS responsiveness. 
Contrastingly, O3+ mice displayed greater fecal Bifidobacterium and Lactobacillus 
abundance and dampened HPA-axis activity. 
Conclusions: Neurobehavioural development related to cognitive, anxiety and social 
behaviours, is highly dependent upon in utero and lifelong n-3 PUFA availability. In 
addition, neurobehavioural changes induced by altering n-3 PUFA status are closely 
associated with comprehensive alterations in gut microbiota composition, HPA-axis 









Neurodevelopment is characterised by rapid structural, neurochemical and molecular 
changes in the central nervous system (CNS) during both the prenatal and early 
postnatal periods. These critical physiological changes however, are uniquely 
sensitive to environmental stressors such as maternal health status and socioeconomic 
class (Reynolds et al., 2014, Talge et al., 2007, Hackman et al., 2010). Nutrition, in 
particular, plays a fundamental role in the growth and development of the infant brain, 
with particular importance being placed on the first ‘1000 days’, referring to the nine 
months in utero and the first two years of life (Goyal et al., 2015, Wopereis et al., 
2014). Due to the high metabolic demands of the brain during such a vulnerable 
developmental period, inadequate nutrient intake can inhibit normal 
neurodevelopment and may cause neurofunctional, structural and behavioural deficits 
that persist into later life (Seckl and Meaney, 2004, Bale et al., 2010). Indeed 
malnutrition, referring to the underrepresentation or overrepresentation of particular 
nutrients, has recently been recognised as a key contributor to mental illnesses such as 
major depressive disorders and cognitive impairment in adulthood (Sarris et al., 
2015). However, particular aspects of neurodevelopment, such as synaptic pruning, 
continue late into the second or third decade of life (Crews et al., 2007) suggesting 
that the impact of nutrition on brain function and mental health is critical during the 
adolescent period. Indeed several psychiatric disorders including schizophrenia, 
substance abuse and mood disorders begin to appear during this maturation period of 
the brain, in adolescence (Davidson et al., 1999, Paus et al., 2008, Kessler et al., 2001, 
Spear, 2013, O'Connor and Cryan, 2014, McVey Neufeld et al., 2016), suggesting 
that this may be a critical timeframe in which inadequate nutrition may impose its 





One of these nutritional inadequacies associated with impaired mental health is 
omega-3 PUFA intake (Edwards et al., 1998, Innis, 2008). The CNS is rich in both 
long-chain omega-6 (n-6) and omega-3 (n-3) PUFA, particularly arachidonic acid 
(AA; n-6) and docosahexaenoic acid (DHA; n-3), which are crucial for infant brain 
development, comprising roughly 20% of brain dry weight (Muskiet et al., 2006). n-3 
and n-6 PUFA cannot be synthesized de novo in mammalian tissue and hence are 
considered ‘essential’ fatty acids, that must be obtained from the diet.  For infants, 
PUFA uptake occurs via the placenta during pregnancy and through breast milk 
during lactation, suggesting that maternal PUFA intake is critical to meet sufficiency 
(Innis, 2005). Long-chain n-3 PUFA, in particular, play vital roles in synaptic 
plasticity, dopaminergic and serotonergic neurotransmission (Chalon, 2006), 
hypothalamic-pituitary-adrenal axis (HPA-axis) activity (Chen and Su, 2013), 
hippocampal neurogenesis (Calderon and Kim, 2004) and a number of other 
neurological functions as shown in many animal studies (Bazinet and Layé, 2014). 
Through these mechanisms, it has been demonstrated that long-chain n-3 PUFA 
supplementation can protect against corticosterone-induced neuronal stress in vitro 
(Pusceddu et al., 2015c) and improve anxiety, depressive and cognitive behaviours in 
rodents (Pusceddu et al., 2015b, Labrousse et al., 2012). 
However, in recent times the westernisation of modern diets has led to drastic 
decline in n-3 PUFA intake in place of n-6 PUFA. Humans evolved on a n-6/n-3 
PUFA dietary ratio of around 1-2:1 however the modern ratio has increased 
dramatically to as high is 20-30:1 in the western diet (Simopoulos, 1999). This 
deficiency in n-3 PUFA intake in early life is associated with impaired psychomotor 
development, attention, cognition, visual acuity (Burgess et al., 2000, Innis and 
Friesen, 2008, SanGiovanni et al., 2000, Helland et al., 2003) and in addition has been 





et al., 2015), dementia (Cunnane et al., 2012) and major depressive disorders in later 
life (Peet et al., 1998). Hence, it has been suggested that an imbalanced n-6/n-3 ratio 
and relative n-3 deficiency can contribute to adolescence-sensitive mental disorders in 
animals, even across consecutive generations (Bondi et al., 2014). In Europe, for 
example, depression prevalence appears to be higher in Northern Europe than in the 
Mediterranean region where fish consumption, a potent source of n-3 PUFA, is much 
greater (Ayuso-Mateos et al., 2001).  
The development of the brain during the early postnatal period occurs 
adjacently to the development of the complex microbiome that resides in the human 
intestine. Increasing evidence has revealed the interdependence of the brain’s 
development on microbiota development (Borre et al., 2014, Sampson and 
Mazmanian, 2015). The microbiota–gut–brain axis, referring to the bidirectional 
network of communication between the intestinal gut microbiota, the gut, and the 
brain, interacts through inflammatory, nervous and endocrine systems to modulate 
immunological, gastrointestinal (GI) and CNS functions (Mayer et al., 2014). The 
mechanisms by which commensal microorganisms influence brain function are 
unclear but are slowly being resolved (Cryan and Dinan, 2012). Some evidence 
suggests that gut microbiota influence permeability at the gut epithelial barrier and 
hence control the passage of pro-inflammatory bacterial endotoxins such as LPS into 
circulation, which is elevated in certain neuropsychiatric disease states (Kelly et al., 
2015). In addition certain species within the microbiota can influence mammalian 
behaviour through vagus nerve signalling and production of neurometabolites such as 
neurotransmitters and short chain fatty acids (SCFA) (Bravo et al., 2011, Cryan and 
Dinan, 2012). Moreover, studies from germ-free mice have shown that blood-brain 
barrier development and permeability are highly influenced by gut microbes (Braniste 





neurogenesis (Ogbonnaya et al., 2015) and microglia activation (Erny et al., 2015). 
Hence, alterations to gut microbiota composition in early life through environmental 
influences such as birth mode, antibiotics and diet can induce perturbations of the 
developing gut microbiota (Bäckhed et al., 2015) which may impact 
neurodevelopment and potentially lead to brain dysfunction, behavioural impairments 
and metabolic deficiencies later in life. Due to the strong interaction between diet and 
the gut microbiota, it has been suggested that the role of dietary changes in 
influencing brain biochemistry and behaviour may be mediated through changes in 
gut microbiota composition and function (Seira Oriach et al., 2016). In addition to 
improving neurological outcomes, n-3 PUFA have demonstrated a beneficial impact 
on the gut microbiota in mice, by increasing bifidobacteria growth, reducing 
enterobacteria growth and subsequently dampening inflammatory responses 
associated with metabolic endotoxemia (Kaliannan et al., 2015). Furthermore it has 
been shown that long-chain n-3 PUFA supplementation can correct the perturbations 
in the mouse gut microbiota induced by early life stress (Pusceddu et al., 2015a). In 
light of recent evidence of a gut-microbiota-brain axis, we hypothesize that the 
behavioural outcomes related to altered early-life n-3 PUFA status may be correlated 
with changes in the gut microbiota. 
Here we examine the effects of in utero and early life n-3 deficiency or 
supplementation on depressive, cognitive and social behaviours during adolescence 
and adulthood in C57BL/6 mice, and examine correlations with inflammatory 







2. MATERIALS AND METHODS  
2.1. Animals 
C57BL/6J female and male mice, aged 8 week-old on arrival were purchased from 
Harlan Laboratories, UK.  Food and water was available ad libitum and animals were 
maintained on a 12:12-h dark–light cycle with temperature at 20 ± 1°C. After a week 
of habituation, females were mated with males and fed with either control standard 
chow, n-3 PUFA supplemented diet or n-3 PUFA deficient diet from gestational day 
0. Male offspring were group-housed 3-4 per cage and weaned on to the same 
mothers corresponding diets (n=10 per dietary group) after lactation, at week 4. 
Moreover, 4 week-old C57BL/6J male mice, purchased from Harlan Laboratories, 
UK, were used as the conspecifics on the three chamber test. 
Body weight was recorded weekly during the 13 weeks of dietary treatment. 
All experiments were conducted in accordance with the Directive 2010/63/EU and 
were approved by the Animal Experimentation Ethics Committee of University 
College Cork #2012/036.  
 
2.2. Diets   
Diets consisted of 1) control standard chow (CON); 2) Omega 3 polyunsaturated fatty 
acid supplemented diet (O3+) (~1g Eicosapentaenoic acid (EPA) + Docosahexaenoic 
acid (DHA) /100g diet); or 3) Omega 3 polyunsaturated fatty acid deficient diet (O3-). 
The O3+ diet was prepared with microalgal oil rich in EPA/DHA (life’sOmegaTM45 – 
DSM, Netherlands). All three diets, which were matched for macronutrient content 
and differed only in fatty acid profile, were formulated by Harlan Laboratories, Inc. 
(Madison, WI, USA). The detailed macronutrient and fatty acid compositions of the 





PUFA in the O3+ diet, diets were kept in air-sealed bags, in the dark, at 4ºC. Diets 
were changed and weighed twice per week.  
 
2.3. Experimental design 
The experimental design is illustrated in Figure 1. C57BL/6J mothers were fed for 6 
weeks, during pregnancy and lactation. Male offspring were subsequently weaned 
onto the same diets as their mothers. At both adolescence (4-5 weeks) and adulthood 
(11-13 weeks), male offspring underwent a battery of behavioural tests over a period 
of 2 weeks. Behavioural tests were conducted in sequence from the least to the most 
stressful test. In addition isolation-induced ultrasonic vocalization (USV) and nesting 
behaviour were performed at postnatal day (PND) 9 and week 8 respectively in male 
mice. At 13 weeks old, animals were sacrificed by cervical dislocation and tissue 
samples collected were rapidly harvested. 
 
2.4. Behavioural testing 
2.4.1. Three chamber test 
The three-chamber test was performed to assess sociability and social novelty as 
described previously (Desbonnet et al., 2014). Test mice and conspecific mice (novel 
or familiar mice) were habituated to the testing room 30min prior to testing.  The test 
was conducted in a rectangular box split into three connecting chambers. The test 
consisted of 3 sequential 10 min phases: (1) Habituation: the test mouse was allowed 
to explore the three empty chambers; (2) Sociability: an unfamiliar mouse was placed 
in an inner mesh wire cage in one chamber, an object was placed in the opposite 
chamber and the central chamber was empty; (3) Social novelty, the object was 





mouse. During the three phases, the test mouse was placed in the middle chamber. All 
mice, test mice & conspecifics, were sex and age matched. The chamber was cleaned 
and the bedding was replaced between trials. All three phases were recorded and the 
time actively interacting with the object, the familiar mouse and the novel mouse 
were measured by an experimenter blind to the experimental groups. 
 
2.4.2. Forced swim test 
The forced swim test (FST) was carried out to determine depression-like behaviour as 
previously described (Cryan et al., 2001, Mombereau et al., 2004, Thakker et al., 
2005). Mice were individually placed in a Pyrex cylinder (internal diameter of 24 cm 
× 21 cm), containing 15 cm-depth water at 23-25ºC, for 6min. Every mouse was 
recorded for 6 min and the immobility time was scored for the last 4 min by an 
experimenter blinded to the experimental groups. A mouse was recognised as 
immobile when it was floating and making only small movements necessary to keep 
the head and body above the surface of the water. Water was changed between each 
mouse to remove odors and the researcher remained in the testing room during the 
test. 
 
2.4.4. Novel object recognition 
Novel object recognition (NOR) test, used to assess memory and learning, was 
conducted as described previously (Burokas et al., 2014, Pusceddu et al., 2015b) with 
minor modifications.  Mice were habituated to the room for 30min. prior to the test. 
The test consisted of three 10 min phases where mice were individually placed in a 
box (30 × 30 × 20 cm) and allowed to explore.  On Day 1, the habituation phase, no 





on adjacent corners of the box, approximately 5 cm from each wall. On Day 3, after 
48h, one of the objects was replaced by a novel object.  After each phase animals 
were returned to their home cages. Object exploration is defined as the time when the 
animal’s nose comes within a 2cm radius of the object. Memory was defined by the 
discrimination index for the novel object (DI) as the difference of time mice spent 
investigating between the novel and the familiar object divided by the total time 
exploring both objects. [Discrimination Index, DI= (Novel Object Exploration time - 
Familiar Object Exploration time)/(Novel Object Exploration time + Familiar Object 
Exploration time)]. The box and objects were cleaned between trials. 
 
2.4.5. Isolation-induced Ultrasonic Vocalization (USV)  
Isolation-induced ultrasonic vocalization (USV) were assessed to determine the 
intensity of an aversive affective state and the communicative behaviour between pup 
and mother (Scattoni et al., 2009). Parameters for this isolation protocol were 
established based on previous published USV parameters (Hofer et al., 2002). The 
animals were habituated to the room for 30 min. Pups were individually isolated from 
their mother and littermates at PND9, and placed in a clean plastic container into a 
sound-attenuating chamber. Pup’s vocalizations were recorded with an ultrasound 
sensitive microphone (US Mini-2 bat detector, Summit, Birmingham, USA) placed 
above the isolated pup and tuned in the range of 60-80 kHz, for 3 min. Once 
completed the mice were returned to their home cage. 
 
2.4.6 Fear conditioning  
Fear behaviour was determined by the freezing behaviour of mice, which is defined as 





al., 2009) differentiates between context and context/cue related behavioural 
responses within the same procedure.  
Day 1 (Training day) involved 3 min of baseline recording, followed by 6 
light/tone conditioned stimulus (CS) and shock [unconditioned stimulus (US)] 
pairings with an interval of 1 min. Pairings consisted of the cue [e.g., a combined light 
(260 lx) and tone exposure (70 dB)] for 20 s and an electric footshock (0.4 mA) 
during the last 2 s of the cue.  
Days 2-3, at 24 and 48 h after conditioning, the same experimental procedure 
as Day 1 was repeated in absence of shocks to test for memory and extinction of the 
conditioned fear response. The procedure lasted 12 min per mouse per day. After each 
procedure mice were returned to their home cage and the FC chambers were cleaned 
between subjects. 
 
2.5. Stress-induced Corticosterone production  
Blood samples were taken to assess the HPA axis in response to an acute stress (FST), 
through the analysis of corticosterone levels in plasma at different time points. First, a 
blood sample was taken before the FST as a corticosterone baseline level. After the 
acute stress every mouse was single-housed for 2 hours of recovery while blood 
samples at 5 different time points were taken: (1) 15min, (2) 45min, (3) 90min, and 
(4) 120min. Bleeding was performed in a separate room to the FST test room.  Blood 
samples (50-70 ul) were taken from the tail and were placed in heparin-coated 
capillary tubes. The blood samples were centrifuged at 9198g for 15min. and plasma 
was collected in to new tubes and stored at -20ºC. Plasma was diluted 1:40 and total 






2.6. Tissue Harvesting 
Trunk blood was collected in potassium EDTA (Ethylene Diamine Tetra Acetic Acid) 
tubes and centrifuged for 15min at 7774g. Plasma was then isolated and stored at -
80ºC for future cytokine analysis. Brains were gross dissected upon the culling days 
and snap frozen on dry ice. Right hemisphere regions were utilized for brain fatty acid 
composition analysis and left hemisphere regions were used for gene expression. 
Weights from livers, adrenals, and fats pads (epididymal, subcutaneous, mesenteric) 
were measured and tissues were snap frozen for further analysis, such as long chain 
fatty acid (LCFA) composition analysis. Moreover, spleens were collected and kept in 
media until the preparation of splenocytes.  
 
2.7. RNA isolation and synthesis cDNA  
Total RNA was isolated from the hippocampus and amygdala using the mirVana™ 
miRNA Isolation Kit as per manufacturer's instructions (Thermo Fisher Scientific). 
Briefly, tissue was homogenised using a denaturing lysis solution. The lysate was 
then extracted using phenol–chloroform and ethanol was then added to the solution 
before being filtered over a glass–fibre filter. The filter was then washed and finally 
the RNA was eluted with 100μl of a low-ionic strength solution. Isolated RNA was 
stored at −80 °C until further processing. RNA concentration was quantified using the 
ND-1000 spectrophotometer (NanoDrop®) and RNA quality was assessed using the 
Agilent 2100 Bioanalyzer.  
After the RNA extraction, equal amounts of RNA were reverse transcribed to 
cDNA using a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, 







2.8. Real-time RT-PCR 
Probed cDNA amplification was performed in a 20 μL reaction consisting of 10 μL 
KiCqStart qPCR Ready Mix with ROX (Sigma), 0.1 μL of primer (final concentration 
250 nM), 1 μL cDNA template, and 8.8 μL RNase-free water run in duplicate in a 96-
well plate (Applied Biosystems) and captured in real time using the StepOne Plus 
System (Applied Biosystems). β‐actin was used as the housekeeping gene. Relative 
gene expression was adjusted to a housekeeping gene and quantified using the 2-
∆∆CT method. Primer sequences for PCRs are listed in Table S3.  
 
2.9. Spleen Cytokine Assay 
Spleens were collected immediately following sacrifice and cultured. To culture 
spleen cells, first the spleens where homogenised in media [RPMI (with L-glutamine 
and sodium bicarbonate, R8758 Sigma) + FBS (F7524, Sigma) + Pen/Strep].  The 
homogenate was then filtered over a 70um strainer, centrifuged at 200g for 5min and 
resuspended in media. Cells were counted and seeded (4,000,000/mL media). After 
2.5h of adaptation, cells were stimulated with lipopolysaccharide (LPS-2 μg/ml) or 
concanavalin A (ConA-2.5 μg/ml) for 24h. Following stimulation, the supernatants 
were harvested to assess the cytokine release using Proinflammatory Panel 1 (mouse) 
V-PLEX Kit (Meso Scale Discovery, Maryland, USA) for TNFα, IL-10, IL-1β and 
IL-6. The analyses were performed using MESO QuickPlex SQ 120, SECTOR 
Imager 2400, SECTOR Imager 6000, SECTOR S 600. 
 
2.10. Tissue fatty acid analysis 
Fatty acid analysis on peripheral tissues and brain regions was performed as follows. 
Lipids were extracted from tissues using chloroform:methanol (2:1 v/v) as previously 





prepared using 10 ml 0.5 N NaOH in methanol and heating at 90 °C for 10 min, 
followed by the addition of 10 ml 14% BF3 in methanol for 10 min at 90 °C (Park 
and Goins, 1994). FAME were recovered with hexane. To limit degradation of 
FAME, samples were dried over anhydrous sodium sulphate (0.5 g) for 1 h, 
concentrated under nitrogen and stored at −20 °C until analysis by gas 
chromatography (GC). FAME separation was performed via GC (Agilent 7890B, 
Agilent Technologies, Santa Clara, CA, USA) with flame ionisation detection 
(Chrompack CP Sil 88 column, Chrompack, JVA Analytical, 100 m × 0.25 mm 
internal diameter, 0.25 μm film thickness) and helium as the carrier gas. The GC 
column oven cycle was programmed initially at 80 °C for 8 min followed by an 
increase by 8.5 °C/min to a final column temperature of 200 °C. Sample injection (0.5 
μl) was automated (CTC Autosampler, Model 80) on an Aglient Multimode Inlet on-
column temperature programmable injector. Peak integration was performed using the 
Agilent OpenLAB Chemstation software (Version A.01.06.111). Identification of 
individual FAME was achieved by comparison of retention times with pure FAME 
standards (Nu-Chek Prep, Elysian, MN, USA) and quantification against an internal 
standard (C17:0). Results are expressed as g/100 g total FAME. 
 
2.11. DNA extraction and 16S sequencing 
Total bacterial metagenomic DNA was extracted from fecal pellets using a 
commercial DNA extraction kit (QIAmp DNA Stool Mini Kit, Qiagen, UK) 
following an initial repeated bead beating step to increase final DNA yield (Fouhy et 
al., 2015). Quantification of DNA was carried out using the Nanodrop 1000 (Thermo 





V3-V4 amplicons for Illumina sequencing were generated according to the 16S 
metagenomic sequencing library protocol (Illumina). Briefly, an initial PCR reaction 
utilised primers specific for amplification of the V3-V4 region of the 16S rRNA gene, 
(Forward primer 5’ 
TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCA
G; reverse primer 5’ 
GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGGTATCT
AATCC). PCR product clean-up and purification was achieved using the Agencourt 
AMPure XP system (Labplan, Dublin, Ireland). A second PCR reaction incorporated 
a  unique indexing primer pair each sample (Illumina Nextera XT indexing primers, 
Illumina, Sweden). The products were again purified using the Agencourt AMPure 
XP system. Samples were quantified using the Qubit broad range DNA quantification 
assay kit (Bio-Sciences, Dublin, Ireland). Following quantification, samples were 
pooled in equimolar amounts 4nM) and sequenced at Eurofins Genomics, Germany, 
using Illumina MiSeq 2x300 bp paired end sequencing.  
 
2.12. Bioinformatics  
300 bp paired-end reads were assembled using FLASH with parameters of a 
minimum overlap of 20 bp and a maximum overlap of 120 bp (Magoč and Salzberg, 
2011). The QIIME suite of tools, v1.8.0, was used for further processing of paired-
end reads, including quality filtering based on a quality score of > 25 and removal of 
mismatched barcodes and sequences below length thresholds (Caporaso et al., 2010). 
Denoising, chimera detection and operational taxonomic unit (OTU) grouping were 
performed in QIIME using USEARCH v7 (Edgar, 2010). Taxonomic ranks were 
assigned by alignment of OTUs using PyNAST to the SILVA SSURef database 





and calculated based on weighted and unweighted Unifrac distance matrices 
(Lozupone et al., 2011). Principal coordinate analysis (PCoA) plots were visualised 
using EMPeror v0.9.3-dev (Vázquez-Baeza et al., 2013). 
 
2.13. Statistical Analysis 
Statistical analyses were carried out using SPSS version 19 (Armonk, NY, USA). 
Results are presented as mean ± standard error of the mean (SEM). Differences 
between treatment groups were assessed by one-way analysis of variance (ANOVA) 
followed by Tukey’s multiple comparison post-hoc test. Non-parametric data from 
16S sequencing analyses were subject to Kruskal-Wallis tests followed by Mann-
Whitney tests. False discovery rate (FDR) correction was assessed at p<0.05. The 








3.1. Body composition and food intake   
Offspring weights were recorded weekly at the beginning of weaning (postnatal week 
4) until sacrifice at week 13 (Figure 2 A). Results of two-way ANOVA revealed a 
significant effect of time [F(9,269)=228.4, p<0.0001)] and a significant effect of diet 
[F(2,269)=12.15, p<0.0001)] but no significant interaction between the factors. Tukey 
HSD post-hoc testing revealed no significant differences in body weight between 
groups from week 4 to week 9, however, body weight was significantly reduced in the 
O3- group at week 10 and week 11 compared with the O3+ group (p<0.05) (Figure 2 
A). These differences in body weight coincided with the second battery of 
behavioural testing. 
Both subcutaneous fat [F(2,27)=5.88, p=0.0076)] and epididymal fat [F(2,27)=5.79, 
p=0.0081)] mass was significantly lower in the O3- group compared with O3+ (p < 
0.01) (Figure 2 B and C), however, there were no significant differences compared 
with CON. Interestingly, adrenal gland weight was significantly lower [F(2,27)=4.029, 
p=0.0294)]  in the O3+ group compared with CON (Figure 2 D). 
 
3.2 Fatty acid analysis 
Feeding of CON, O3+ and O3- diets elicited significantly different fatty acid 
compositions between all groups in maternal milk and eight different brain regions as 
shown in Table 1 and Table S4. Maternal milk was significantly higher in total n-3 
PUFA content and significantly lower in n-6 AA content in the O3+ group compared 





Similar trends were observed in each brain region examined (prefrontal cortex, 
amygdala, hippocampus, frontal cortex, striatum, hypothalamus, cerebellum, brain 
stem). DHA was the most abundant PUFA in each brain region of the CON and O3+ 
groups, ranging from 7-16% of total fatty acids. There were no significant differences 
in DHA content between CON and O3+ in the prefrontal cortex, frontal cortex, 
hippocampus or hypothalamus however DHA was significantly higher in the 
amygdala, striatum, cerebellum and brain stem of the O3+ animals. Conversely, 
relative concentrations of DHA and total n-3 PUFA in the O3- group were less than 
half that of the CON and O3+ groups for each brain region examined, ranging from 3-
7% of total fatty acids. In contrast to the other two groups, the most abundant PUFA 
within all brain regions of the O3- groups were n-6 AA and n-6 DPA (22:5 n-6), 
ranging from 5-9% and 2-8% respectively. n-6 DPA was undetectable or present in 
very low concentrations (0.1%) in all brain regions of the CON and O3+ groups. 
 
3.3. Behavioural tests 
 
3.3.1. Ultrasonic vocalization 
As revealed by Mann Whitney test there was a significant effect of diet on the number 
of calls at PND9 after isolation from their mother and littermates (Figure 3A). The 
number of calls from the O3- group was significantly lower compared to the CON 
(U=60.5, p=0.052) and the Omega 3 O3+ group (U=47, p=0.011).  
 
3.3.2. Forced Swim Test 
Depression-like behaviour is represented as a function of immobility time. One-way 





[F(2,29)=0.325, p=0.726], but there was a diet effect on the time spent immobile in 
adulthood  [F(2,29)=3.312, p=0.05] (Figure 3B). Further, post-hoc analysis showed that 
there was a statistical difference on the immobility time between the controls and the 
omega-3 deficient diet group (p=0.042). Altogether, these data show that omega-3 
PUFA deficient mice presented a depressive-like phenotype displayed by a significant 
greater immobility during the forced swim test compared to the control group. 
 
3.3.3. Novel Object Recognition 
One-way ANOVA showed an overall dietary effect in adolescence 
[F(2,29)=3.297,p=0.05] and adulthood [F(2,29)=7.189, p=0.003)] (Figure 3C). Post-hoc 
analysis revealed that O3+ showed enhanced cognition compared with O3- at 
adolescence (p=0.04). Furthermore, at adulthood, O3+ improved cognitive 
performance, shown by enhanced memory, compared to both CON (p=0.019) and 
O3- (p=0.004). 
 
3.3.4 Three Chamber Test 
During adolescence, one-way ANOVA did not show an overall effect of diet on the 
time spent actively interacting with the object [F(2,29)=0.483, p=0.622] and the mouse 
[F(2,29)=0.939, p=0.403] (Figure 4). Furthermore, there was no significant effect of 
diet on the time spent interacting with the familiar mouse [F(2,29)=0.453, p=0.641] and 
the novel mouse [F(2,29)=0.042, p=0.959]. 
During adulthood, one-way ANOVA revealed a significant effect of diet on 
time spent interacting with the object [F(2,29)=10.540, p<0.001] and the mouse 





group spent significantly more time interacting with the object compared to the 
control group (p<0.001) and the omega-3 supplemented group (p=0.05). Moreover, 
the omega-3 deficient group spent significantly less time interacting with the mouse 
compared to the control group (p<0.001) and the omega-3 supplemented group 
(p<0.001). 
Furthermore, one-way ANOVA showed no significant effect of diet on the 
time spent interacting with the familiar mouse [F(2,29)=1.819, p=0.182] and the novel 
mouse [F(2,29)=1.500, p=0.241]. 
 
3.3.5. Fear Conditioning 
Cue-induced and contextual fear conditioning are shown in Figure 5. 
Adolescence-context component: During acquisition, two-way ANOVA repeated 
measures revealed a significant effect of time [F(7,175)=56.988, (p<0.001)], no 
interaction between time vs diet  [F(14,175)=1.561, (p=0.095)], and no significant 
effect of diet with respect to time [F(2,25)=1.909, p=0.169]. During 
memory/extinction at 24h, two-way ANOVA repeated measures revealed a 
significant effect of time  [F(7,175)=7.373, (p=<0.001],  no interaction between time 
vs diet  [F(14,175)=1.297, (p=0.393)], and  a significant effect of diet respect to time 
[F(2,25)=5.070, p=0.014]. Furthermore, Tukey’s HSD posthoc showed significant 
differences between O3+ vs O3- at Cxt 2 (p=0.002), Cxt3 (p=0.045), Cxt6 (p=0.048), 
Cxt7 (p=0.015) and Cxt8 (p=0.042). Moreover, there was a significant difference 
between CON vs O3- at Cxt8 (p=0.051). During memory/extinction at 48h, two-way 
ANOVA repeated measures revealed a significant effect of time  [F(7,175)=5.849, 





significant effect of diet with respect to time [F(2,25)=2.946, p=0.071]. Post-hoc 
analysis further showed significant differences between O3+ and O3- at Cxt1 
(p=0.050), Cxt4 (p=0.021) and Cxt7 (p=0.025) 
  Adolescence-cue component: During acquisition, two-way ANOVA repeated 
measures revealed a significant effect of time [F(5,125)=62.139, p<0.001)],  no 
interaction between time vs diet [F(10,125)=0.855, p=0.577)], and  no significant 
effect of diet with respect to time [F(2,25)=1.628, p=0.216]. Post-hoc analysis further 
showed significant differences between O3+ and O3- only at Cue6 (p=0.037). During 
memory/extinction at 24h, two-way ANOVA repeated measures revealed no 
significant effect of time [F(5,125)=1.329, p=0.256],  no interaction between time vs 
diet [F(10,125)=0.737, p=0.688], and  no significant effect of diet respect to time 
[F(2,25)=3.235, p=0.056]. Tukey HSD post hoc test further revealed a significant 
difference between O3+ and O3- at Cue4 (p=0.05). During memory/extinction at 48h, 
two-way ANOVA repeated measures revealed significant effect of time [F 
(5,125)=4.831, p<0.001], no interaction between time vs diet [F(10,125)=0.364, 
p=0.960], and  no significant effect of diet respect to time [F(2,25)=5.325, p=0.012]. 
Tukey HSD post hoc test showed significant differences between O3+ and O3- at 
Cue4 (p=0.009) and at Cue6 (p=0.027). 
Adulthood-context component: During acquisition, two-way ANOVA 
repeated measures revealed a significant effect of time  [F(7,189)=27.347, p<0.001],  
no interaction between time vs diet  [F(14,189)=1.558, p=0.094], and a significant 
effect of diet with respect to time [F(2,27)=4.452, p=0.021]. Tukey HSD test further 
revealed significant difference between O3+ and O3- at Cxt3 (p=0.009), Cxt4 
(p=0.008) and at Cxt6 (p=0.024). Moreover, there were significant differences 





memory/extinction at 24h, two-way ANOVA repeated measures revealed a 
significant effect of time [F(7,189)=9.703, p<0.001], no interaction between time vs 
diet [F(14,189)=1.557, p=0.095], and a significant effect of diet with respect to time 
[F(2,27)=5.112, p=0.013]. Tukey HSD post hoc test further showed significant 
differences between O3+ and O3- at Cxt3 (p=0.004) and at Cxt4 (p=0.017), and a 
significant difference between CON and O3+ at Cxt2 (p=0.024). During 
memory/extinction at 48h, two-way ANOVA repeated measures revealed significant 
effect of time [F(7,189)=12.273, p<0.001],  no interaction between time vs diet 
[F(14,189)=0.741, p=0.731], and no significant effect of diet respect to time  48h 
[F(2,27)=1.353, p=0.275]. Post-hoc analysis further showed no significant 
differences. 
Adulthood-cue component: During acquisition, two-way ANOVA repeated 
measures revealed a significant effect of time [F (5,135)=21.070, p<0.001], no 
interaction between time vs diet [F(10,135)=1.765, p=0.073], and no significant effect 
of diet on respect to time during Acq [F(2,27)=1.679, p=0.205]. Tukey HSD showed 
significant differences at Cue4 between O3+ and O- (p=0.006) and between CON vs 
O3+ (p=0.014). During memory/extinction at 24h, two-way ANOVA repeated 
measures revealed significant effect of time [F(5,135)=2.296, p=0.049],  no 
interaction between time vs diet [F(10,135)=1.036, p=0.417], and no significant effect 
of diet with respect to time [F(2,27)=2.377, p=0.112]. Post-hoc analysis further 
showed significant differences between O3+ and O3- at Cue4 (p=0.012). During 
memory/extinction at 48h, two-way ANOVA repeated measures revealed a 
significant effect of time [F (5,135)=1.942, p=0.091], no interaction between time vs 
diet [F(10,135)=0.353, p=0.964], and no significant effect of diet with respect to time 






3.4. HPA axis response to acute stress  
Two-way ANOVA repeated measures revealed a significant effect of time 
[F(4,88)=251.028, p<0.001)], significant interaction between time and diet 
[F(8,88)=3.001, p=0.005)] within groups and a trend for a significant effect of diet with 
respect to time between the groups [F(2,22)=3.059, p=0.067)] during adolescence 
(Figure 6A). At 45min post stress Tukey HSD post-hoc showed that O3+ was 
significantly lower compared with both CON (p=0.004) and O3- (p=0.011). O3+ 
corticosterone was also significantly lower at 90 min compared with CON (p=0.005) 
and O3-(p=0.035). 
Two-way ANOVA repeated measures showed a significant effect of time 
[F(4,96)=425.104, (p<0.001)], no significant interaction between time and diet 
[F(8,96)=0.887, (p=0.531)] within groups, and no significant effect of diet with 
respect to time between the groups [F(2,22)=3.059, p=0.067)] on the corticosterone 
recovery in response to acute stress (forced swim test) during adulthood (Figure 6B). 
One-way ANOVA revealed a significant effect of diet on delta corticosterone 
after an acute stress during adolescence [F(2,24)=9.825, p=0.001] (Figure  6C). Further 
Tukey HSD post-hoc showed decreased levels of delta corticosterone in the O3+ in 
comparison to CON (p=0.001). During adulthood, one-way ANOVA showed no 
effect of diet on delta corticosterone [F(2,26)=0.522, p=0.600] (Figure  6D).       
                                                         
3.5. Spleen cytokine production after stimulation with ConA and LPS 
Omega-3 dietary intervention showed no significant effect on TNFα [F (2,26)=2.739, 





One-way ANOVA revealed a significant effect of diet on the splenic production of 
both tumor necrosis factor (TNFα) [F (2,27)=4.765, p=0.018] and Interleukin 10 (IL-
10) [F(2,27)=6.135, p=0.007] after stimulation  with Concanavalin A (ConA) (Figure 
7A). Furthermore, Tukey HSD post-hoc test showed that O3- significantly decreased 
ConA-induced TNFα release in comparison to the control (p=0.023). Moreover, O3- 
presented a significant reduced production of IL-10 in comparison to both CON 
(p=0.027) and O3+ (p=0.008). 
After a splenic stimulation with LPS, one-way ANOVA revealed a significant 
effect of diet on the release of TNFα [F(2,28)=3.742, p=0.037]; while there was no 
significant effect of diet on IL-10 release [F(2,27)=2.590, p=0.09] (Figure 7B). Tukey 
HSD post-hoc showed significant decreased levels of TNFα in O3- (p=0.030) 
compared with O3+.  
 
3.6. Microglial gene mRNA expression levels in hippocampus and amygdala 
One-way ANOVA revealed a significant effect of diet on CD206 mRNA expression 
in hippocampus [F(2,23)=4.574, p=0.022] (Figure 8A), but only a trend toward a 
significant effect in the amygdala [F(2,22)=3.219, p=0.061] (Figure 8B) during 
adulthood. Further Tukey HSD post-hoc test showed a significant lower mRNA 
expression of CD206 in the O3- group compared to the O3+ group (p=0.027) in the 
hippocampus. No other differences were observed between treatment groups for other 







3.7.   Compositional Analysis of Fecal Microbiota 
MiSeq sequencing of the faecal microbiota resulted in a total of 3.4 million sequenced 
reads, corresponding to an average of 56,509 reads per sample. To remove any bias 
from variation in sample read numbers, samples were rarefied to 25,000 reads.  
In both adolescence and adulthood samples, distinct clustering and separation 
of the O3- samples from the CON and O3+ samples was observed (Figure 9A). 
Phylogenetic diversity was assessed using the Chao1, Simpson, Shannon and number 
of observed species indices. During adolescence, microbial diversity was significantly 
greater in the O3- group compared with both CON and O3+ as assessed by the Chao1 
index and number of observed species. There were no significant differences between 
groups in microbiota diversity in adulthood. Interestingly however, results trended 
towards increasing diversity in both CON and O3+ from adolescence to adulthood, 
but decreased diversity in O3-. Principle coordinate analysis (PCoA) of the 
unweighted UniFrac showed distinct clustering of samples based on dietary group 
(Figure 9B). 
Analysis of relative abundances at phylum and genus levels suggested that 
fecal microbiota composition differed significantly between dietary groups at both 
adolescence and adulthood (Figure 9C-G and Table S5 and S6). Bacteroidetes and 
Firmicutes were the most abundant phyla in each group at both time-points, and 
relative proportions of both taxa differed between treatment groups at adolescence. 
Bacteroidetes made up 51.09% of relative abundance at phylum level in O3+ animals, 
whereas O3- displayed 45.45%, which was significantly lower than CON (55.18%). 
In contrast, Firmicutes were present in significantly higher proportions in O3- animals 
(42.49%) compared with O3+ (30.88%). These major differences in the two most 





O3- animals at adolescence compared with both other groups. None of these 
differences were observed in adulthood, however differences were observed for other 
taxa. Actinobacteria, the phylum to which the genus Bifidobacterium belong, was 
significantly greater in abundance in O3+ animals during adolescence compared with 
both other groups. Conversely, Tenericutes was significantly less abundant in O3+ 
animals compared with both CON and O3-. Candidate division TM7 was significantly 
less abundant in O3- animals. 
At genus level, O3+ mice had significantly greater proportions of 
Bifidobacterium and Lactobacillus during adulthood compared with both other 
groups, which were not seen during adolescence. Moreover the ratio of 
bifidobacteria/enterobacteria was significantly greater in the O3+ groups at both 
adolescence and adulthood. O3- animals exhibited significantly less abundance of 
taxa within the Bacteroidales family including Bacteroidales S24-7 uncultured and 
Bacteroides at adolescence and Parabacteroides at adulthood. Conversely Bilophila, 
Gelria and Lachnospiraceae uncultured were present in significantly greater 
abundance in O3- animals. Anaeroplasma, Clostridium and Peptostreptococcaceae 












There is a growing appreciation of the role of nutrition in maintaining brain health 
and behaviour. In these studies we have demonstrated that adolescent 
neurobehavioural development is highly sensitive to in utero and early life dietary n-3 
fatty acid exposure, in which n-3 deficiency impairs communicative behaviour. 
Moreover, these behavioural outcomes observed in adolescence are further evident in 
adulthood with continued supplementation or deficiency of n-3 fatty acids, such that 
n-3 deficiency increases depressive behaviour, impairs social behaviour and fear-
induced freezing behaviour, and n-3 supplementation enhances cognition. Finally, 
these neurobehavioural changes are closely associated with wide-ranging alterations 
in gut microbiota composition, HPA-axis activity and inflammation.  Hence, these 
results suggest that neuropsychiatric disorders, including those emerging during 
adolescence, such as stress-related disorders, mood disorders and social disorders may 
be influenced by maternal and early life omega-3 PUFA intake and subsequent 
changes in gut microbiota and inflammation. 
Evidence has shown that nutritional challenges during early-life 
developmental periods can have a detrimental impact on development and can induce 
functional and structural physiological impairments that persist throughout the 
lifespan (Barker et al., 1993, Skinner et al., 2010, Seckl and Meaney, 2004). The 
results presented here further support this hypothesis and provide evidence of the 
essentiality of n-3 PUFA for the prevention of behavioural deficiencies in later life. 
These data are highly relevant to modern public health due to the rapid decline of n-3 






In states of n-3 deficiency, enzymatic elongation and desaturation of PUFA occur 
primarily in the n-6 pathway resulting in increased production of long-chain n-6 
PUFA, notably AA and n-6 DPA (Coti Bertrand et al., 2006). Interestingly, this was 
observed here in the O3- mother’s breast milk, and was further reflected in all eight 
brain regions of O3- offspring, such that n-6 DPA and AA were significantly higher, 
and DHA was significantly lower compared with CON and O3+ groups. It has 
previously been shown that n-6 22:4, n-6 DPA and AA partially replace DHA in rat 
cortices during early development following n-3 deficiency (Greiner et al., 2003). 
This n-6/n-3 imbalance has been associated with deficits in spatial task performance 
(Lim et al., 2005), suggesting that DHA deficiency during brain development may 
lead to irreversible damage to certain brain functions. Here, it is likely that such 
drastic conversion of n-3 to n-6 fatty acids in the developing CNS contributed to the 
behavioural deficits observed in later life.  
However, it is unclear at what stage during prenatal or postnatal 
neurodevelopment, n-3 PUFA deficiency may induce its negative effects on the brain. 
Nutrient sufficiency in the postnatal diet may not correct all neurodevelopmental 
deficits induced by prenatal nutritional inadequacies. Moreover, neurodevelopment 
continues past childhood. Adolescence is a critical period at which diet may influence 
neurodevelopment (O'Connor and Cryan, 2014). Stress, impulsivity and emotional 
instability are all elevated in adolescence (McVey Neufeld et al., 2016) and hence 
dietary insufficiencies during development may exacerbate such behaviours. Our data 
reflected certain dietary-induced changes in early-life behaviours. Firstly, through 
analysis of isolation-induced ultrasonic vocalization (USV), our results demonstrated 
that social and communicative behaviour in omega-3 deficient animals was impaired 
as early as PND9, suggesting that prenatal and maternal fatty acid status can strongly 





with animal models of neurodevelopmental disorders such as autism spectrum 
disorder (Hsiao et al., 2013). Furthermore it has been previously shown that prenatal 
ethanol exposure, which can induce brain DHA deficiency, results in deficits in USV 
in offspring which are normalized following postnatal DHA supplementation 
(Wellmann et al., 2015). These findings have strong clinical relevance. Social and 
communicative deficits identified so early in the postnatal development give 
indications that maternal diet, particularly omega-3 deficiency, may influence 
progression of ASD-related deficits in communication. Importantly however, the 
previously published work by Wellmann and colleagues suggests that it may be 
possible to reverse these communicative and social deficits through adequate nutrition 
in the postnatal period. 
Interestingly there were no differences observed between dietary groups in 
social behaviour or depression-like behaviour at adolescence. Nesting behaviour and 
anxiety behaviours were also unaffected by diet at either time-point (Figures S6 and 
S7). However, adolescent offspring from the O3+ group exhibited significantly 
enhanced cognition compared with O3- animals. Dietary n-3 deficiency has 
previously been associated with disrupted memory and learning in rodents (Catalan et 
al., 2002, Moriguchi et al., 2000, Yamamoto et al., 1987, Bondi et al., 2014) whereas 
n-3 supplementation has demonstrated positive effects (Carrié et al., 2000, Lafourcade 
et al., 2011, Labrousse et al., 2012, Ferraz et al., 2011) which have been associated 
with enhanced hippocampal neurogenesis (Cao et al., 2009, He et al., 2009, Dyall et 
al., 2010). Hippocampal BDNF mRNA was assessed as a marker of neurogenesis 
however no differences were observed between groups (Figure S4). In humans, the 
role of maternal n-3 supplementation in child cognitive development is unclear 
(Gould et al., 2013). The discrepancies in these data may be due to differences in age 





mediating cognitive processes, continue to increase past childhood into adolescence 
reaching around 15% of total fatty acids (Carver et al., 2001) as observed here in 
mice. These lipid compositional changes in the frontal cortex during adolescence 
coincide with vital structural changes such as synaptic pruning and white matter 
maturation (Glantz et al., 2007, Paus et al., 1999), suggesting that the adolescent 
period may be a critical timeframe in which omega-3 PUFA exert their effects on 
cognitive processes.  
We subsequently examined these behavioural phenotypes in adulthood and 
found that the behavioural outcomes assessed in adolescence were more evident in 
adulthood with continued long-term omega-3 supplementation or deficiency. Despite 
no differences at adolescence, sociability was significantly impaired in O3- animals at 
adulthood, which has previously been demonstrated following maternal feeding with 
a diet rich in n-6 PUFAs (Jones et al., 2013). In addition, the enhanced cognitive 
effects seen in O3+ animals at adolescence compared with O3- were further apparent 
at adulthood, in which O3+ showed enhanced cognition compared with both O3- and 
CON. This has been demonstrated previously by Janssen et al (Janssen et al., 2015) 
who showed that early life DHA adequacy enhanced cognitive performance in male 
mice in adulthood compared with DHA deficiency. Finally, depression-like 
behaviour, which was not influenced by diet at adolescence, was significantly 
increased in O3- animals at adulthood, measured by immobility time in the forced 
swim test. Importantly this difference in immobility time was independent of 
locomotor activity, which was not different between groups as observed in the open 






Fear-conditioning can be utilized in order to examine fear-induced memory and the 
cognitive aspects of anxiety and stress-related behaviours (Brinks et al., 2009, Bravo 
et al., 2011, Takeuchi et al., 2003). Importantly, different neurobiological substrates 
have been shown to underlie contextual and cue-induced fear learning (Kim et al., 
1991, Zimmerman and Maren, 2010, Phillips and LeDoux, 1992). Here, O3- animals 
displayed significantly greater freezing behaviour compared with O3+ animals during 
both contextual and cue fear-conditioning conditions in adolescence which endured 
into adulthood. These data are in line with previous studies which have shown that n-
3 deficiency increases and n-3 supplementation decreases freezing behaviour in mice 
during fear-conditioning (Takeuchi et al., 2003, Yamada et al., 2014). Together the 
data presented here supports the concept that n-3 PUFA significantly alter plasticity in 
both hippocampal and cortico-amygdalar circuits that underlie contextual and cue-
induced fear-induced freezing behaviour. 
It has been previously shown that n-3 deficiency increases and n-3 
supplementation decreases immobility in the forced swim test (Huang et al., 2008, 
Park et al., 2012, Weiser et al., 2015, DeMar et al., 2006, Chen and Su, 2013, 
Lafourcade et al., 2011). This behavioural phenotype has been associated with 
alterations in corticosterone production and HPA-axis activity (Chen and Su, 2013) as 
was also observed here. The design of this study did not allow us to distinguish 
between the effect of n-3 interventions prenatally compared with posnatally. 
However, Chen and Su previously demonstrated that pre-weaning n-3 deficiency 
caused depression-like behaviour in adulthood while a post-weaning n-3 deficiency 
did not have any effect (Chen and Su, 2013).  
Importantly, the observed differences between adolescent and adulthood 





onset occurs for different psychiatric disorders (Paus et al., 2008). These data suggest 
that reduced n-3 intake in early life can induce subtle psychiatric abnormalities during 
adolescence associated with communicative behaviour and fear-induced memory. 
Continued n-3 deficiency into later life can induce further psychiatric deficits and 
worsen behavioural outcomes associated with depressive behaviour and social 
behaviour in adulthood. Recent studies have begun to compare and exhibit the 
differences between adolescent and adult behavioural changes induced by differing n-
3 PUFA status in rodents (Weiser et al., 2015, Bondi et al., 2014). Therefore, it is 
possible that due to the complex structural rearrangement that occurs in the brain at 
adolescence, differences in underlying nutritional status on behavioural outcomes 
may not become overly apparent until brain development is complete in adulthood. 
We further examined biological outcomes induced by altering n-3 status that 
may explain the observed behavioural changes. O3+ adolescent animals displayed 
enhanced corticosterone recovery following a forced stress compared with both other 
groups. Interestingly, these differences disappeared in adulthood, contrasting to the 
trends seen in behavioural analysis. In addition to dampened corticosterone response, 
adrenal gland weight was significantly lower in O3+ animals. Increased adrenal gland 
weight has previously been associated with lower social rank in mice and primates 
(Shively and Kaplan, 1984, Davis and Christian, 1957) which has implications for 
stress-reactivity. The HPA axis is an important neuroendocrine system that is 
subjected to programming by early life events. Pubertal corticosterone and stress 
reactivity are greater than at adulthood (Goldman et al., 1973, Romeo et al., 2004, 
McVey Neufeld et al., 2016), which may account for the differences between the two 
time points assessed here. This suggests that nutritional inadequacies such as omega-3 
deficiency that alter HPA-axis activity may exacerbate the already altered stress 





3 PUFA supplementation can dampen HPA-axis activity in early life, however it is 
unclear whether these changes in corticosterone stress response are correlated with the 
altered depressive phenotypes observed in adulthood. n-3 PUFA therefore may 
enhance negative feedback within the HPA axis. However, it has been recently shown 
that n-3 PUFA deficiency does not impair negative feedback within the HPA axis and 
instead the effects on emotional deficits are mediated through inactivation of 
glucocorticoid receptor signalling in the prefrontal cortex (Larrieu et al., 2016). It is 
possible that this also occurs through GABA-receptor mediated pathways (Chen and 
Su, 2013) or reduced cortical neuronal atrophy (Larrieu et al., 2014) as has been 
suggested previously. 
The close link between HPA axis activity and immune system activity suggest 
that the effects of n-3 PUFA supplementation or deficiency on corticosterone 
production and subsequent behaviours may be regulated by inflammatory status. 
Interestingly our results found that omega-3 deficiency led to a blunted systemic LPS 
and ConA responsiveness, dampening anti-inflammatory IL-10 in ConA-stimulated 
macrophages and proinflammatory TNFa production in ConA and LPS-stimulated 
splenocytes, as has been shown previously through maternal dietary interventions 
(Myles et al., 2013). Moreover, as PUFAs have the capacity to cause dramatic 
changes in TLR4 (Norris and Dennis, 2012, Shi et al., 2006), this altered response to 
LPS found in n-3 deficient group may be due to modifications in the sensitivity of 
toll-like receptor 4 (TLR4), which is the receptor for LPS and plays a critical role in 
innate immunity (Poltorak et al., 1998, Kawai and Akira, 2010). Immune-neural 
interactions have strong implications for behavioural outcomes (McCusker and 
Kelley, 2013). Impaired social behaviour has been associated with disrupted spleen 
cytokine production in mice, although these results are strain dependent (Schwartzer 





altered immune response and low-grade chronic inflammation as shown in animals 
(You et al., 2011) and in humans which may be associated with increased bacterial 
translocation into the bloodstream (Kéri et al., 2014). 
The altered inflammatory status was also reflected in the brain. mRNA 
expression of CD206, an anti-inflammatory M2 microglial marker, was significantly 
up-regulated in the hippocampus of O3+ mice compared with O3- mice, but not 
compared with controls. However, no significant differences were observed between 
groups for other markers of microglial activation (Figure S3). Microglial activation 
has been implicated in depression, schizophenia and bipolar disorder (Réus et al., 
2015). DHA has previously been shown to upregulate the anti-inflammatory 
microglial marker CD206 positive cells following traumatic brain injury in rats 
(Harvey et al., 2015). It is possible therefore, that CD206 expression may play an 
intermediary role in the protective effects of n-3 PUFA on brain function and 
behavioural deficiencies associated with excess inflammation. Here however, as no 
down-regulation of CD206 was observed in O3- animals, further evidence is 
warranted to establish whether n-3 PUFA play a true role in CD206 expression. 
Furthermore, our data suggested that the behavioural and inflammation 
associated changes may be regulated by gut microbiota. Recently it has been 
suggested that n-3 and n-6 PUFA differentially contribute to risk of systemic low-
grade chronic inflammation by altering gut microbiota composition, gut permeability 
and hence systemic circulation of LPS (Kaliannan et al., 2015). Interestingly, our data 
showed that the neurobehavioural changes induced by the O3+ and O3- diets were 
closely associated with wide ranging compositional changes in the developing 
microbiota. Bifidobacteria have been shown to enhance intestinal epithelial integrity, 





related behavioural deficits in rodents (Savignac et al., 2015). Here, there was a trend 
towards increased Bifidobacteria in O3+ animals at adolescence, which became 
significant compared with both other groups at adulthood. Similarly the ratio of 
bifidobacteria to the LPS-producing enterobacteriaceae was significantly greater in 
O3+ animals at adolescence, an effect that strengthened in adulthood. A similar trend 
was observed for significantly increased Lactobacillus species in the O3+ animals at 
adulthood but not at adolescence. Interestingly, diets high in fat and sugar have been 
linked with decreased Lactobacillales and a higher ratio of Firmicutes:Bacteroidetes 
as observed here, which have been associated with brain dysfunction and behavioural 
changes (Bruce-Keller et al., 2015, Pyndt Jørgensen et al., 2014, Magnusson et al., 
2015). Interestingly, these results are associated somewhat with the behavioural data. 
It appeared that differences between groups in abundance of certain species including 
Bifidobacteria and Lactobacillus were not apparent at adolescence but became 
significantly evident in adulthood following continuation of each respective diets. In 
addition, a number of significant correlations were observed between microbiota and 
delta corticosterone, including a positive correlation between corticosterone area 
under the curve and Firmicutes abundance (Figure S1). Due to the evidence of a gut-
microbiota-brain axis in a number of neuropsychiatric disorders (Cryan and Dinan, 
2012), these results have relevance for a novel mechanistic hypothesis by which n-3 
PUFA exert their influence on brain function and behaviour. It is possible that the 
neuroprotective effects of omega-3 PUFA are not solely attributed to their direct 
incorporation into neural tissues but indirectly through their beneficial effects on gut 
microbiota composition and subsequent inflammatory status as described here and 
previously (Kaliannan et al., 2015). 
 In humans, major depressive disorder has been associated with altered 





(Kéri et al., 2014). This data demonstrates a link between gut microbiota and 
inflammatory-associated mental disorders. Gut permeability is downregulated by 
bifidobacteria (Cani et al., 2007) and conversely is upregulated by a higher 
firmicutes:bacteroidetes ratio (Lam et al., 2012). Hence, the translocation of bacteria 
and their associated endotoxins across the epithelial barrier, as regulated by 
microbiota composition, may contribute to immune-associated changes in depressive 
and other behaviours as reported here.   
The data presented here provide novel evidence for the role of early-life 
omega-3 PUFA status on the progression of social, depressive and cognitive 
behavioural disorders. It has been shown previously that n-3 fatty acids can improve 
behavioural deficits in adults, however, less is known about prenatal and early 
postnatal n-3 PUFA status on the progression of certain mood, social and anxiety 
disorders. It has been speculated that the relative increase in the prevalence of certain 
neuropsychiatric disorders in the last 30 years is concurrent with drastically declining 
n-3 PUFA intake in place of n-6 PUFA. Fish consumption, a potent source of dietary 
long-chain n-3 PUFA, is class dependent in developed western countries. Lower 
socioeconomic classes consume less fish (Darmon and Drewnowski, 2008, 
Galobardes et al., 2001) and have greater mental illness prevalence particularly in 
adolescence (McLaughlin et al., 2012). Due to the essentiality of n-3 fatty acids in 
neuronal composition and function, especially in early development, it is likely, as 
shown here, that dietary deficiency in these fatty acids can substantially impair 
behavioural development which may be first recognised at adolescence. Sufficient 
intake of n-3 PUFA in utero and in early life, are essential for the adequate 
development of the complex gut-microbiota-brain axis, and therefore ensure the 
correct function of immunological, gastrointestinal (GI) and CNS systems. Moreover 





3 PUFA exert their beneficial effects on the brain. These data and others therefore 
warrant further research and public health advice on increasing maternal, perinatal 
and lifelong omega-3 PUFA intake for the prevention of neuropsychiatric illnesses 
during critical early-life developmental stages and in later life. 
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  Mother's Milk Prefrontal Cortex Amygdala Hippocampus 
  Control O3+ O3- Control O3+ O3- Control O3+ O3- Control O3+ O3- 
SFA                      14:0 10.8 ± 1.2 6.8 ± 0.3 8.5 ± 1.5 0.1 ± 0 0.1 ± 0.1 0.1 ± 0 0.7 ± 0.1 1 ± 0.2 0.9 ± 0.2 0.9 ± 0.1 0.9 ± 0 0.9 ± 0 
16:0 29 ± 0.4a  33.6 ± 1.1b  27.3 ± 0.7a  39.3 ± 0.7a  36.7 ± 1.2a b  34.2 ± 0.6b  36.8 ± 0.8a  35.9 ± 0.5a b  34.6 ± 0.6b  31.8 ± 0.6 31.6 ± 0.7 31.3 ± 0.2 
18:0 7.4 ± 0.5a  13.3 ± 1.3b  8.6 ± 0.6a  30.9 ± 0.4a  29.6 ± 0.7a b  27.9 ± 0.3b  29.8 ± 0.5a  28.6 ± 0.3a b  27.8 ± 0.3b  26.4 ± 0.3 26 ± 0.4 25.6 ± 0.2 
20:0 n.d. n.d. 0.1 ± 0 n.d. n.d. n.d. n.d. n.d. n.d. 0.4 ± 0 0.3 ± 0 0.3 ± 0.1 
Total SFA  47.3 ± 1.3a b  53.8 ± 2.6a  44.5 ± 2.7b  70.2 ± 1.1a  66.4 ± 1.9a b  62.2 ± 0.9b  67.3 ± 1.3a  65.5 ± 0.6a b  63.2 ± 0.8b  59.4 ± 0.9 58.9 ± 1.1 58.1 ± 0.4 
MUFA                     16:1 3.5 ± 0.1a  2.4 ± 0.3b  3.2 ± 0.3a b  n.d. n.d. n.d. 0.4 ± 0.2 0.2 ± 0.1 0.2 ± 0.1 0.8 ± 0.1 1 ± 0.2 0.8 ± 0.1 
18:1t n-9 n.d. n.d. 0.1 ± 0 n.d. n.d. n.d. n.d. n.d. n.d. 0.2 ± 0.1 0.2 ± 0.1 0.2 ± 0.1 
18:1c  n-9 29.9 ± 1.6 26.6 ± 0.9 33.8 ± 3.4 11.1 ± 0.4 12.1 ± 0.5 11.7 ± 0.3 15.9 ± 0.2 15.6 ± 0.2 15.5 ± 0.1 16.3 ± 0.3a  16.5 ± 0.3a  15 ± 0.2b  
18:1 t n-7 2.6 ± 0.2a  1 ± 0.1b  3 ± 0.1a  1.7 ± 0.1a  1.7 ± 0.2a  2.6 ± 0.1b  1.6 ± 0.1a  1.6 ± 0.1a  2.1 ± 0.1b  2.5 ± 0.1a b  2.4 ± 0.1a  2.7 ± 0.1b  
20:1 0.9 ± 0.1a  0.1 ± 0.1b  1.5 ± 0.2c  n.d.a  1.5 ± 0.6a b  0.7 ± 0.3b  n.d. n.d. n.d. 1.2 ± 0.2a  3.1 ± 0.5b  2.3 ± 0.4a b  
Total MUFA  36.9 ± 1.8a b  30.1 ± 1.3a  41.6 ± 3.7b  12.8 ± 0.5a  15.3 ± 0.5b  15.1 ± 0.4b  17.9 ± 0.3 17.6 ± 0.2 17.9 ± 0.2 21 ± 0.4a  23.2 ± 0.4b  21.1 ± 0.2a  
PUFA                    n-6 PUFA                    18:2 n-6 12.4 ± 0.7 12 ± 0.5 11.1 ± 0.8 n.d. n.d. n.d. 0.3 ± 0.2 0.3 ± 0.2 0.1 ± 0 1 ± 0.1 1.2 ± 0.2 0.9 ± 0.2 
18:3 n-6 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 0.2 ± 0 0.3 ± 0 0.3 ± 0 
20:3 n-6 0.5 ± 0.1a  0.1 ± 0b  0.7 ± 0.1a  n.d. n.d. n.d. n.d. n.d. n.d. 0.3 ± 0.1a b  0.4 ± 0a  0.1 ± 0b  
20:4 n-6 1.1 ± 0.1a  0.2 ± 0.1b  1.2 ± 0.1a  5.7 ± 0.3a  4.9 ± 0.5a  8.5 ± 0.1b  5.6 ± 0.6a  5.7 ± 0.3a  8.2 ± 0.3b  7.1 ± 0.2a  5.3 ± 0.3b  7.7 ± 0.2a  
22:4 n-6 0.2 ± 0a  n.d.b  0.4 ± 0c  0.4 ± 0.1a  0.2 ± 0.1a  2 ± 0.1b  0.8 ± 0.2a  0.5 ± 0.1a  1.9 ± 0.1b  1.7 ± 0.1a  0.8 ± 0.1b  2.3 ± 0.1c  
22:5 n-6 n.d. n.d. 0.1 ± 0 n.d.a  n.d.a  7.5 ± 0.2b  n.d.a  n.d.a  5.3 ± 0.2b  n.d.a  n.d.a  5 ± 0.2b  
Total n-6 PUFA  14.3 ± 0.8 12.3 ± 0.6 13.4 ± 0.9 6.1 ± 0.4a  5.1 ± 0.6a  18 ± 0.4b  6.8 ± 0.8a  6.4 ± 0.3a  15.4 ± 0.5b  10.2 ± 0.3a  8 ± 0.3b  16.4 ± 0.3a  
 
                  n-3 PUFA                    18:3 n-3 1 ± 0.1 0.5 ± 0.2 0.5 ± 0.3 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
20:5 n-3 0.1 ± 0 0.3 ± 0.2 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
22:5 n-3 0.2 ± 0a b  0.5 ± 0.3a  n.d.b  n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
22:6 n-3 0.3 ± 0a  2.4 ± 0.5b  n.d.a  10.8 ± 0.5a  13.3 ± 1.1a  4.7 ± 0.2b  8 ± 0.5a  10.6 ± 0.4b  3.5 ± 0.3c  9.3 ± 0.4a  9.9 ± 0.6a  4.5 ± 0.2b  
Total n-3 PUFA  1.5 ± 0.2a  3.8 ± 1.1b  0.5 ± 0.3a  10.8 ± 0.5a  13.3 ± 1.1a  4.7 ± 0.2b  8 ± 0.5a  10.6 ± 0.4b  3.5 ± 0.3c  9.3 ± 0.4a  10 ± 0.6b  4.5 ± 0.2c  
Total PUFA  15.8 ± 0.9 16.1 ± 1.6 13.9 ± 1 17 ± 0.8a  18.3 ± 1.7a  22.7 ± 0.4b  14.8 ± 1.3a  17 ± 0.7a b  18.9 ± 0.7b  19.6 ± 0.6a b  18 ± 0.9a  20.8 ± 0.4b  
n6:n3 9.6 ± 0.9 4.2 ± 1.1 424.7 ± 343.1 0.6 ± 0 0.4 ± 0 3.9 ± 0.2 0.8 ± 0.1 0.6 ± 0 4.6 ± 0.3 1.1 ± 0 0.8 ± 0 3.7 ± 0.2 
 
 





































Figure 1. Experimental design. CON, O3+ or O3- diets were provided during the pre-natal and 
post-natal periods until adulthood.  C57BL/6 (n=10 per group) male offspring underwent a 
battery of testing related to sociability, memory and learning, depression and anxiety. Isolation-
induced ultrasonic vocalization (iUSV) was performed at PND9 and nesting behaviour was 
performed during week 8. At 13 weeks old, animals were sacrificed by cervical dislocation and 
samples collected.  
Abbreviations: W, week; PND, Postnatal day; USV, Ultrasonic vocalization; N, 3CH, three chamber test; NOR, 
novel object recognition; DMB, defensive marble burying; LDB, light dark box; EPM, elevated plus maze; FC, fear 



















Figure 2. Effects of omega-3 status on body composition. (A) There were no significant 
differences between groups at sacrifice in body weight however O3- displayed reduced weight 
compared with O3+ during a battery of behavioural testing in adulthood (weeks 10-12). O3- 
also resulted in significantly reduced subcutaneous (B) and epididymal (C) fat weight compared 
with O3+. (D) Adrenal gland weight was significantly reduced in O3+ compared with control. 
Data shown as mean ± SEM. n= 9-10 per group . *p < 0.05, CON vs. O3+ or O3- group; # p < 





























































































































Figure 3. Effects of omega-3 dietary intervention on isolation-induced ultrasonic 
vocalizations, depression-like behaviour and cognition. (A) At PND9, O3- diet caused a 
significant reduction of number of calls in comparison to both the CON and the O3+ group (n= 
9-10 per group). (B) Omega-3 dietary intervention caused no significant differences in 
immobility time during adolescence. However, dietary O3- caused a depression-like phenotype 
during the forced swim test compared with the CON group in adulthood (n=10 per group). (C) 
O3+ displayed enhanced memory compared with O3- in both adolescence and adulthood. 
Furthermore, O3+ enhanced memory compared with the CON in adulthood (n= 10 per group). 
Data shown as mean ± SEM. *p < 0.05, ** p < 0.01, ***p < 0.001 CON vs. O3- or O3+; # p < 












Figure 4. Effects of omega-3 dietary intervention on social behaviour. Omega-3 dietary 
intervention caused no significant differences on sociability and social novelty in adolescence. 
O3- caused sociability impairments compared with both the CON and O3+ groups in adulthood. 
However, there were no differences between different dietary interventions in social novelty 
during adulthood (n= 9-10 per group). Data shown as mean ± SEM. ***p < 0.001 CON vs. O3- 


















































































































































































































































































































































































































































































Figure 5. Fear Conditioning during Adolescence and Adulthood.  During acquisition, day 1, 
in both context (A) and cue (B) components all the groups exhibited good learning at 
adolescence.  There were no significant differences between groups in baseline freezing 
behaviour. During memory/extinction, days 2 and 3, O3- presented a significant higher % of 
freezing compared mainly to O3+ during both context (A) and cue (B) components. During 
acquisition, day 1 in adulthood, in context component (C), no differences were observed 
between groups in the baseline freezing behaviour. . Moreover, O3- froze significantly higher 
than O3+, but overall all groups presented good learning as shown in the cue component (D).  
During day 2 of memory/extinction, O3- group presented a significant higher % of freezing for 
few cues compared mainly to O3+ during both context (C) and cue (D) components. At day 3 of 
memory/extinction, all the groups presented the same % of freezing. Data shown as mean ± 
SEM. n= 9-10 per group. Two-way ANOVA repeated measures followed by Tukey HSD post-
















Figure 6. Effects of omega-3 dietary intervention on HPA-axis response to acute stress. (A) 
O3+ enhanced corticosterone recovery in response to acute stress compared to CON and O3- in 
adolescence. (B) However, there were no differences in corticosterone recovery between the 
different dietary interventions with respect to time during adulthood. (C) O3+ presented 
significantly decreased delta corticosterone in comparison with CON in adolescence. 
Nonetheless, dietary intervention showed no significant differences in delta corticosterone in 
adulthood (D). Data shown as mean ± SEM. n=7-9 per group, ** p < 0.01, ***p < 0.001 CON 








































































































Figure 7. Effects of omega-3 dietary intervention on spleen cytokine production following 
stimulation with lipopolysaccharide (LPS) and concanavalin A (ConA). O3+ caused 
significant differences on cytokine release levels of tumor necrosis factor (TNFα) and 
Interleukin 10 (IL-10) after LPS and ConA stimulation. (A) O3+ caused no effects on the 
release of TNFα and IL-10 after ConA stimulation, while O3- significantly decreased spleen 
levels of TNFα and IL-10 after stimulation with ConA compared with the controls. Moreover, 
O3- presented a significant decrease of IL-10 after stimulation with ConA compared to the O3+ 
group. (B) O3- significantly decreased spleen levels of TNFα after stimulation with LPS in 
comparison to the CON group. There was a trend to decreased levels of IL-10 cytokine in the 
O3- group after stimulation with LPS (p=0.09). Data shown as mean ± SEM. n= 8-10 per group. 




























































Figure 8. Effects of omega-3 dietary intervention on gene expression of CD206 in 
Hippocampus and Amygdala. (A) O3- group had significant lower mRNA expression of 
CD206, a microglial anti-inflammatory marker, in the hippocampus compared to the O3+ 
group. (B) There was no effect of dietary intervention on the mRNA expression of CD206 in 













































































































































































Figure 9. Effects of omega-3 status on fecal gut microbiota diversity. Principle coordinate 
analysis (PCoA) of gut microbiota composition based on unweighted UniFrac revealed distinct 
separation and clustering of the O3- group away from both CON and O3+ groups (A). Analysis 
of adolescent fecal microbiota revealed significantly greater α diversity in the O3- groups 
compared with both CON and O3+ as measured by the chao1 and number of observed species 
indices (p<0.05) (B). No significant differences in α diversity were observed in at adulthood. 
n=6-10 per group. Analysis by non parametric Kruskall Wallis test followed by multiple 









































































































































































































Figure 10. Effects of omega-3 status on fecal gut microbiota composition. Phylum level 
distributions were significantly altered by omega-3 status at both adolescence and adulthood 
(A). Family and genus level distributions were also significantly altered at adolescence and 
these changes were further strengthened into adulthood (B). Analysis by non parametric 
Kruskall Wallis test followed by multiple comparisons by Mann-Whitney. * significantly 












































































































































































Figure 11. LDA scores of gut microbiota composition following omega-3 interventions. 
LDA scores of taxa significantly altered by omega-3 status in adulthood are shown in (A) (LDA 
scores >2 and significance of p<0.05 as determined by Wilcoxon signed-rank test). Heatmap 
distribution of significantly altered taxa in adulthood reveals distinct differences between 
treatment groups (B). The most differentially abundant taxa in adulthood following dietary 



























Figure S1. Correlations between AUC of plasma corticosterone levels after stress and fecal 
microbiota in adolescence. O3+ showed significantly decreased AUC in comparison to CON 
in adolescence (A). However, dietary intervention showed no significant differences in AUC in 
adulthood (B). Regression analysis revealed positive correlation between corticosterone AUC 









Figure S2. Correlations between delta corticosterone and fecal microbiota in adolescence. 
Regression analysis revealed positive correlation between delta corticosterone and Tenericutes 
(A) and Anaeroplasmataceae (C). Furthermore, regression analysis revealed negative 























































































































Figure S3. Effects of omega-3 dietary interventions on microglia gene expression in 
Hippocampus and Amygdala. (A) Omega-3 dietary intervention causes no significant 
differences on microglial pro-inflammatory markers mRNA expression and (B) no significant 
differences on the mRNA expression of TGF-b, a microglial anti-inflammatory marker, in both 






















Figure S4. Effects of omega-3 dietary interventions on BDNF gene expression in the 









































Figure S5. Effects of omega-3 dietary intervention on locomotor activity during 
adolescence and adulthood. There were no significant differences between groups in the total 


















Figure S6. Effects of omega-3 dietary intervention on anxiety-like behaviours in both 
adolescence and adulthood. (A) In adolescence, omega-3 dietary intervention caused no 
significant differences on the number of marbles buried in the defensive marble burying (DMB) 
test. Moreover, no significant changes were seen in the latency time, number of transitions and 
time spent in light area in the light dark box (LDB). (B) In adulthood, no significant differences 
were found in DMB. Furthermore, there were no significant differences in the % of time spent 






































Figure S7. Effects of omega-3 dietary intervention on nesting.  Omega-3 dietary intervention 





































Abbreviations: O3+, Omega 3 polyunsaturated fatty acid supplemented diet; O3-, Omega-3 polyunsaturated fatty acid deficient 
diet; LA, Linoleic acid (C18:2 n-6) ; ALA, Alpha linolenic acid (C18:3 n-3); EPA, Eicosapentaenoic acid (C20:5 n-3); DHA, 









  Control O3+ O3- 
Protein (% by weight) 18.3 18.3 18.3 
Carbohydrate (% by weight) 56.7 56.5 56.7 
Fat (% by weight) 10 10 10 
Protein (% of Kcal) 18.8 18.8 18.8 
Carbohydrate (% of Kcal) 58.2 58 58.2 
Fat (% of Kcal) 23.1 23.2 23.1 
Kcal/g 3.9 3.9 3.9 
LA (% by weight) 2.6 2.6 2.6 
ALA (% by weight) 0.4 0.4 0 
EPA (% by weight) 0 0.35 0 
DHA (% by weight) 0 0.66 0 
n-6 (% by weight) 2.6 2.6 2.6 






Table S2. Fatty acid profile of diets 
 
% Total fatty acids Control O3+ O3- 
Saturated fatty acids (SFA) 
   8:0 3.4 2.2 3.6 
10:0 3.1 2 3.3 
12:0 27 16.9 29 
14:0 11.1 7.25 12.3 
16:0 9 10.9 8.5 
18:0 7.9 5.9 8.7 
Total SFA 59.8 44 64.4 
Monounsaturated fatty acids (MUFA) 
   18:1 7.1 13.3 6.5 
Total MUFA 7.3 13.3 6.7 
Polyunsaturated fatty acids (PUFA) 
   18:2 n-6 25.7 25.4 22.4 
18:3 n-3 4.2 4.1 tr 
20:4 n-6 0 0.26 0 
20:5 n-3 0 3.2 0 
22:5 n-3 0 1 0 
22:6 n-3 0 5.7 0 
n6 25.7 25.66 22.4 
n3 4.2 14 0 




Table S3. Primer sequences and accession numbers. 
 Accession number Forward primer Reverse primer 
Β-Actin NM_007393.4 GTGCTTCTAGGCGGACTGTTAC GCTCCAACCAACTGCTGTC 
IL-1β NM_008361.3 TGCCACCTTTTGACAGTGATG TGATGTGCTGCTGCGAGATT 
CD68 NM_001291058.1 GGGGCTCTTGGGAACTACAC GTACCGTCACAACCTCCCTG 
CD206 NM_008625.2 GTGGGGACCTGGCAAGTATC CACTGGGGTTCCATCACTCC 
TGF-β NM_011577.1 CGTCAGACATTCGGGAAGCA TGCCGTACAACTCCAGTGAC 
CX3CR1 NM_009987.4 GGAAGCCCAAGAGCATCACT GTTGTTCATGGAGTTGGCGG 







Table S4. Fatty acid composition of selected brain regions
  Frontal Cortex Striatum Hypothalamus Cerebellum Brain stem 
  Control O3+ O3- Control O3+ O3- Control O3+ O3- Control O3+ O3- Control O3+ O3- 
SFA  
   
      
   
      
   14:0 0.6 ± 0a b  0.7 ± 0.1a  0.6 ± 0b  0.5 ± 0.1 0.5 ± 0.1 0.4 ± 0 1.1 ± 0 1.1 ± 0.2 0.8 ± 0.1 0.4 ± 0.1 0.3 ± 0.1 0.3 ± 0.1 0.5 ± 0.1 0.4 ± 0.1 0.4 ± 0 
16:0 28.2 ± 0.1a b  29.1 ± 0.5a  27.8 ± 0.3b  34.5 ± 0.6 34.2 ± 0.6 33 ± 0.7 38.9 ± 0.3 38.8 ± 0.9 38.4 ± 0.8 28.7 ± 0.4 28.5 ± 0.1 27.9 ± 0.2 23.9 ± 0.4 24.6 ± 0.3 23.6 ± 0.3 
18:0 24.8 ± 0.1a b  25.2 ± 0.3a  24.2 ± 0.1b  29.2 ± 0.3 28.7 ± 0.4 28.4 ± 0.3 31.1 ± 0.1 31.2 ± 0.4 30.8 ± 0.4 25.1 ± 0.2a  24.5 ± 0.1b  24.6 ± 0.1a b  23.7 ± 0.2 23.8 ± 0.2 23.8 ± 0.2 
20:0 0.3 ± 0 0.3 ± 0 0.3 ± 0 n.d. n.d. n.d. n.d. n.d. n.d. 0.1 ± 0 0.1 ± 0 0.2 ± 0 0.6 ± 0a  0.6 ± 0a  0.8 ± 0b  
Total SFA  53.9 ± 0.3a b  55.3 ± 0.8a  52.8 ± 0.3b  64.2 ± 0.9 63.3 ± 1 61.8 ± 1 71.2 ± 0.4 71.2 ± 1.3 70 ± 1.2 54.3 ± 0.6 53.4 ± 0.2 53 ± 0.3 48.8 ± 0.6 49.4 ± 0.4 48.5 ± 0.5 
MUFA  








   16:1 0.7 ± 0 0.8 ± 0 0.7 ± 0 n.d. 0.1 ± 0 0.1 ± 0 0.1 ± 0 n.d. n.d. 0.1 ± 0 0.2 ± 0 0.1 ± 0 0.1 ± 0 0.1 ± 0 0.1 ± 0 
18:1t n-9 0.3 ± 0a b  0.3 ± 0a  0.2 ± 0b  n.d. n.d. n.d. 0.1 ± 0 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
18:1c  n-9 15.5 ± 0.1a  16 ± 0.2b  14.9 ± 0.2c  13.3 ± 0.3 14.3 ± 0.4 13.5 ± 0.3 15 ± 0.2 15.2 ± 0.6 15.6 ± 0.5 17.6 ± 0.2a  19 ± 0.1b  16.4 ± 0.1c  24.6 ± 0.2a  25.7 ± 0.1b  23.3 ± 0.1c  
18:1 t n-7 3.4 ± 0a  3 ± 0.1b  3.6 ± 0c  2.5 ± 0.1a  2.4 ± 0.1a  2.9 ± 0.1b  2.1 ± 0 2.2 ± 0.1 2.4 ± 0.2 4.1 ± 0.1a  3.7 ± 0b  4.6 ± 0.1c  4.7 ± 0.1a  4.3 ± 0.1b  4.9 ± 0.1c  
20:1 0.9 ± 0 0.9 ± 0.1 0.9 ± 0 0.6 ± 0.1 0.6 ± 0.1 0.8 ± 0.1 n.d. 0.3 ± 0.1 0.2 ± 0.1 2.1 ± 0.1 2.3 ± 0.1 2.1 ± 0.1 4.7 ± 0.1 4.8 ± 0.1 4.8 ± 0.1 
Total MUFA  20.8 ± 0.1 21 ± 0.2 20.3 ± 0.2 16.4 ± 0.4 17.3 ± 0.6 17.2 ± 0.4 17.2 ± 0.3 17.7 ± 0.8 18.3 ± 0.6 24 ± 0.4a  25.2 ± 0.2b  23.3 ± 0.1c  34 ± 0.3a  35 ± 0.2b  33.1 ± 0.3c  
PUFA  








   n-6 PUFA  








   18:2 n-6 0.9 ± 0.1a  0.8 ± 0a b  0.7 ± 0b  n.d.a b  0.2 ± 0.1a  n.d.b  n.d. n.d. 0.2 ± 0.1 0.4 ± 0a  0.4 ± 0a  0.3 ± 0b  0.4 ± 0 0.4 ± 0 0.3 ± 0 
18:3 n-6 0.1 ± 0 0.2 ± 0 0.1 ± 0 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
20:3 n-6 0.4 ± 0a  0.5 ± 0b  0.2 ± 0c  n.d. n.d. n.d. n.d. n.d. n.d. 0.1 ± 0a  0.1 ± 0a  n.d.b  0.2 ± 0a  0.3 ± 0a  0.1 ± 0b  
20:4 n-6 7.9 ± 0.1a  6.2 ± 0.1b  9.1 ± 0.1c  7.2 ± 0.2a  5.9 ± 0.2b  8.3 ± 0.2c  4.1 ± 0.1a b  3.2 ± 0.2a  4.8 ± 0.3b  6.2 ± 0.1a  4.2 ± 0.1b  8.1 ± 0.1c  5.3 ± 0.1a  3.7 ± 0.1b  6.2 ± 0.1c  
22:4 n-6 2 ± 0a  1.2 ± 0b  2.9 ± 0.1c  1.4 ± 0.1a  0.7 ± 0.1b  2.3 ± 0.1c  0.9 ± 0a  0.4 ± 0.1b  1.5 ± 0.1c  1 ± 0.1a  0.4 ± 0b  2.3 ± 0c  2.2 ± 0.1a  1.1 ± 0b  3.7 ± 0.1c  
22:5 n-6 n.d.a  0.1 ± 0a  8 ± 0.2b  n.d.a  n.d.a  5.3 ± 0.2b  n.d.a  n.d.a  2.1 ± 0.2b  n.d.a  n.d.a  5.6 ± 0.2b  n.d.a  n.d.a  3.9 ± 0.1b  
Total n-6 PUFA  11.4 ± 0.1a  8.9 ± 0.2b  21.1 ± 0.3c  8.7 ± 0.3a  6.8 ± 0.3b  15.9 ± 0.5c  5 ± 0.1a  3.6 ± 0.3a  8.5 ± 0.5b  7.6 ± 0.2a  5.2 ± 0.1b  16.3 ± 0.2c  8 ± 0.2a  5.4 ± 0.2b  14.1 ± 0.3c  
  








   n-3 PUFA  








   18:3 n-3 n.d. n.d. n.d. n.d. n.d. 0.3 ± 0.3 n.d. n.d. n.d. n.d. 0.4 ± 0.2 0.5 ± 0.2 n.d. n.d. n.d. 
20:5 n-3 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
22:5 n-3 n.d. 0.1 ± 0.1 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 0.2 ± 0 n.d. 
22:6 n-3 14 ± 0.2a  14.7 ± 0.5a  5.8 ± 0.2b  10.7 ± 0.3a  12.6 ± 0.5b  4.8 ± 0.2c  6.5 ± 0.1a  7.5 ± 0.4a  3.2 ± 0.2b  14.1 ± 0.1a  15.8 ± 0.2b  7 ± 0.2c  9.2 ± 0.2a  10.1 ± 0.2b  4.3 ± 0.1c  
Total n-3 PUFA  14 ± 0.2a  14.8 ± 0.6a  5.8 ± 0.2b  10.7 ± 0.3a  12.6 ± 0.5b  5 ± 0.3c  6.5 ± 0.1a  7.5 ± 0.4a  3.2 ± 0.2b  14.1 ± 0.1a  16.3 ± 0.3b  7.4 ± 0.3c  9.2 ± 0.2a  10.3 ± 0.2b  4.3 ± 0.1c  
Total PUFA  25.4 ± 0.2a  23.7 ± 0.7b  26.8 ± 0.3a  19.4 ± 0.5 19.4 ± 0.8 20.9 ± 0.6 11.6 ± 0.3 11.1 ± 0.7 11.7 ± 0.7 21.7 ± 0.3a  21.4 ± 0.2b  23.7 ± 0.3c  17.2 ± 0.4a  15.7 ± 0.3b  18.4 ± 0.3c  





Table S5. Relative abundance of genera from adolescent microbiota 
  Adolescence 
Genus CON O3+ O3- p-value q-value 
Alistipes 16.3 17.2 16.5 0.89 1 
Bacteroidales S24-7 uncultured  15.8 16.2 10.7 0.004 0.047 
Lactobacillus 13.2 11.1 12.0 0.772 1 
Bacteroides 12.0 7.09 5.97 0.034 0.216 
Lachnospiraceae uncultured 6.01 6.64 9.32 0.046 0.233 
Odoribacter 5.91 4.80 5.9 0.287 0.574 
Ruminococcaceae uncultured 4.76 4.03 6.03 0.242 0.529 
Rikenellaceae RC9 gut group 3.36 3.56 3.97 0.827 1 
Akkermansia 3.21 10.86 6.66 0.623 0.907 
Allobaculum 3 3.51 4.78 0.776 1 
Bifidobacterium; 2.74 4.69 2.98 0.13 0.406 
Ruminococcaceae Incertae Sedis 1.8 1.46 2.52 0.177 0.477 
Clostridium 1.43 0.2 1.07 0.006 0.06 
Rikenella 1.21 1.53 1.93 0.205 0.526 
Parasutterella 1.10 0.86 0.55 0.227 0.526 
Turicibacter 0.790 0.307 0.722 0.321 0.607 
Peptostreptococcaceae uncultured 0.763 0.156 1.828 <0.001 0 
Lachnospiraceae Incertae Sedis 0.717 0.688 0.624 0.833 1 
Oscillibacter 0.709 0.427 0.794 0.09 0.35 
Parabacteroides 0.656 0.645 0.527 0.893 1 
Clostridiales uncultured bacterium 0.643 0.782 0.528 0.253 0.537 
Anaerotruncus 0.512 0.404 0.600 0.267 0.550 
Anaeroplasma 0.457 0.153 0.292 0.05 0.233 
Desulfovibrio 0.443 0.296 0.258 0.14 0.406 
Family XIII Incertae Sedis 0.442 0.293 0.226 0.022 0.171 
Coprococcus 0.352 0.203 0.362 0.039 0.228 
Escherichia-Shigella 0.284 0.526 0.358 0.858 1 
Mucispirillum uncultured 0.240 0.081 0.099 0.22 0.526 
Roseburia 0.226 0.134 0.286 0.034 0.216 
Peptococcaceae uncultured 0.139 0.103 0.133 0.454 0.722 
Candidate division TM7 uncultured other 0.128 0.212 0.206 0.229 0.526 
Ruminococcus 0.113 0.076 0.114 0.438 0.713 
Enterorhabdus 0.110 0.129 0.148 0.674 0.944 
Bilophila 0.101 0.130 0.365 0.007 0.061 
Anaerovorax 0.0880 0.0708 0.122 0.086 0.350 
Christensenellaceae uncultured 0.0627 0.0616 0.0372 0.233 0.526 
Family XIII Incertae Sedis uncultured 0.0627 0.0984 0.0492 0.833 1 
Thalassospira 0.0587 0.0676 0.0592 0.635 0.907 
Marvinbryantia 0.0347 0.0012 0.002 0.145 0.406 
Christensenella 0.0289 0.0388 0.0428 0.073 0.319 
Peptococcus 0.0244 0.0196 0.0408 0.112 0.406 
Unidentified 0.0187 0.0152 0.0232     
Mollicutes RF9 uncultured bacterium other 0.0124 0.0092 0.026 0.137 0.406 
Erysipelotrichaceae uncultured 0.0116 0.0056 0.0048 0.499 0.759 
Lachnospiraceae uncultured bacterium 0.0111 0.0116 0.018 0.705 0.968 
Pseudobutyrivibrio 0.0076 0 0.1164 <0.001 0 
Erysipelotrichaceae Incertae Sedis 0.0040 0.0164 0.0104 0.141 0.406 
Ruminococcaceae uncultured bacterium 0.0027 0.0004 0.0032 0.049 0.233 
Clostridiales uncultured rumen bacterium 0.0018 0.0016 0 0.307 0.597 
Hydrogenoanaerobacterium 0.0009 0.0024 0.0016 0.495 0.759 





Streptococcus 0.0004 0.0004 0.0008 0.996 1 
Clostridiaceae uncultured 0.0004 0.0016 0.0012 0.587 0.874 
Mogibacterium 0.0004 0.0016 0.0016 0.389 0.648 
Coriobacteria uncultured 0 0 0.0452 <0.001 0 
Barnesiella 0 0.0008 0 0.139 0.406 
Prevotella 0 0 0 1 1 
Prevotellaceae uncultured 0 0 0 1 1 
Flavobacterium 0 0 0 1 1 
Cyanobacteria 4C0d-2 uncultured bacterium 0 0 0 1 1 
Cyanobacteria 4C0d-2 uncultured organism other 0 0 0 1 1 
Staphylococcus 0 0.0012 0.0008 0.387 0.648 
Aerococcus 0 0 0 1 1 
Lactococcus 0 0 0 1 1 
Candidatus Arthromitus 0 0 0.0064 0.387 0.648 
Anaerostipes 0 0 0 1 1 
Blautia 0 0 0.0012 0.387 0.648 
Gelria 0 0 0.0264 <0.001 0 
alpha proteobacterium 0 0 0 1 1 
Mollicutes RF9 uncultured bacterium other 0 0 0 1 1 




Table S6. Relative abundance of genera from adulthood microbiota 
 
  Adulthood 
Genus CON O3+ O3- p-value q-value 
Akkermansia 21 10.2 23.4 0.309 0.585 
Bacteroidales S24-7 uncultured  14.3 15.6 12.1 0.304 0.585 
Alistipes 11.2 13.7 12.9 0.619 0.833 
Odoribacter 8.55 8.61 5.95 0.096 0.292 
Lachnospiraceae uncultured 7.43 7.25 7.66 0.816 0.952 
Ruminococcaceae uncultured 4.93 5.14 6.27 0.651 0.853 
Bacteroides 4.07 3.39 2.93 0.495 0.722 
Lactobacillus 3.4 9.56 2.72 0.015 0.081 
Ruminococcaceae Incertae Sedis 3.04 2.72 3.42 0.57 0.782 
Allobaculum 2.62 4.33 2.75 0.178 0.429 
Rikenellaceae RC9 gut group 2.60 2.53 3.03 0.883 0.966 
Rikenella 2.53 2.47 2.01 0.67 0.853 
Peptostreptococcaceae uncultured 2.44 0.78 4.85 0.002 0.028 
Bifidobacterium 2.13 6.32 1.66 0.004 0.047 
Oscillibacter 1.02 0.47 1.13 0.093 0.292 
Mucispirillum uncultured 0.983 0.6 0.245 0.56 0.782 
Parasutterella 0.868 1.208 1.12 0.385 0.654 
Lachnospiraceae Incertae Sedis 0.790 0.471 0.624 0.196 0.429 
Desulfovibrio 0.668 0.769 0.31 0.181 0.429 
Anaerotruncus 0.652 0.56 0.653 0.666 0.853 
Clostridiales uncultured bacterium 0.572 0.419 0.279 0.123 0.359 
Parabacteroides 0.506 0.499 0.257 0.028 0.14 
Bilophila 0.471 0.254 0.318 0.737 0.889 
Family XIII Incertae Sedis 0.441 0.3 0.324 0.226 0.479 
Escherichia-Shigella 0.438 0.143 0.323 0.08 0.292 





Ruminococcus 0.273 0.142 0.358 0.096 0.292 
Coprococcus 0.245 0.169 0.273 0.268 0.548 
Christensenellaceae uncultured 0.227 0.122 0.090 0.041 0.177 
Anaeroplasma 0.226 0.022 0.205 0.014 0.081 
Candidate division TM7 uncultured other 0.222 0.266 0.101 0.007 0.049 
Anaerovorax 0.125 0.084 0.146 0.139 0.389 
Peptococcaceae uncultured 0.104 0.114 0.137 0.392 0.654 
Enterorhabdus 0.0951 0.1352 0.1447 0.174 0.429 
Roseburia 0.0702 0.1160 0.1353 0.411 0.654 
Family XIII Incertae Sedis uncultured 0.0684 0.2160 0.0353 0.168 0.429 
Clostridium 0.0604 0.0164 0.0033 0.092 0.292 
Clostridiales uncultured rumen bacterium 0.0551 0.0284 0 0.011 0.07 
Peptococcus 0.0511 0.0556 0.0587 0.864 0.966 
Thalassospira 0.0391 0.0472 0.0420 0.777 0.922 
Mollicutes RF9 uncultured bacterium other 0.0316 0 0 0.06 0.233 
Unidentified 0.0302 0.0164 0.0260     
Pseudobutyrivibrio 0.0284 0.0132 0.0300 0.274 0.548 
Christensenella 0.0276 0.0264 0.0627 0.041 0.177 
Prevotella 0.0116 0.0008 0 0.711 0.881 
Mollicutes RF9 uncultured bacterium other 0.0098 0.0192 0.0060 0.005 0.049 
Erysipelotrichaceae Incertae Sedis 0.0084 0.0136 0.0060 0.452 0.688 
Lachnospiraceae uncultured bacterium 0.0076 0.0104 0.0053 0.88 0.966 
Ruminococcaceae uncultured bacterium 0.0040 0.0024 0.0007 0.355 0.637 
Erysipelotrichaceae uncultured 0.0036 0.0160 0.0007 0.043 0.177 
Blautia 0.0031 0 0 0.411 0.654 
Clostridiaceae uncultured 0.0027 0.0020 0.0020 0.927 0.998 
Candidatus Arthromitus 0.0022 0.0064 0 0.196 0.429 
Mogibacterium 0.0018 0.0016 0.0007 0.53 0.757 
Hydrogenoanaerobacterium 0.0013 0.0012 0.0013 0.869 0.966 
Cyanobacteria 4C0d-2 uncultured bacterium 0.0009 0 0.3367 0.007 0.049 
Streptococcus 0.0009 0.0044 0.0027 0.325 0.599 
Marvinbryantia 0.0009 0.0036 0.0020 0.188 0.429 
Barnesiella 0.0004 0.0004 0 0.717 0.881 
Prevotellaceae uncultured 0.0004 0 0 0.411 0.654 
Coriobacteria uncultured 0 0 0.1360 <0.001 0.000 
Flavobacterium 0 0 0 1.000 1 
Cyanobacteria 4C0d-2 uncultured organism other 0 0 0.1000 0.006 0.049 
Staphylococcus 0 0 0 1.000 1 
Aerococcus 0 0 0 1.000 1 
Enterococcus 0 0 0.0613 <0.001 0 
Lactococcus 0 0 0 1.000 1 
Anaerostipes 0 0.0176 0 0.472 0.703 
Gelria 0 0 0.0133 <0.001 0.000 
alpha proteobacterium 0 0 0 1.000 1 













SUPPLEMENTARY MATERIALS AND METHODS 
 
Nesting Behaviour 
Nesting was carried out on PND 56 mice (week 8). Mice were single-housed over 
night into a clean cage and given a paper tissue as a nest-building material. In the 
morning after, nest quality was scored by a blinded researcher to the experimental 
conditions using a rating scale of 0-4 (0-paper tissue untouched; 4-perfect nest). After 
the nest scoring, mice were returned to their home cage. 
 
 
Defensive marble burying 
The defensive marble burying (DMB) test measures compulsive and anxious 
behaviour, indicating higher levels of anxiety at high number of marbles buried.  
Mice were habituated to the room for 30min. prior to the test. After the habituation, 
mice were placed individually in small cages, in which 20 glass marbles were equally 
distributed on top of 4cm – deep bed of sawdust and a wire lid placed on top of the 
cage. Mice were left undisturbed for 30 min, after which the number of buried marble 
(more than 2/3 of their surface buried) was counted.  
 
Light Dark Box  
The light/dark box (LDB) test is a conflict-based anxiety test whereby the tendency to 
explore a novel environment contrasts against the natural aversion of mice to brightly 
lit spaces (Crawley 2000). The apparatus consisted of a Plexiglas enclosure divided 
into two compartments (one light and one dark) by a partition in which there was a 
small opening at the floor level. The light aversive compartment (two thirds) was 
open-roofed, with walls of transparent Plexiglas and was brightly illuminated by a 60-





(one third) was closed-roofed and was constructed of black Plexiglas. Mice were 
habituated to the room for 30min. prior to the test. After the habituation, mice were 
individually placed in the center of the light compartment, facing away from the 
partition and allowed to explore the apparatus freely for 10 min. The apparatus was 
cleaned thoroughly between subjects. The number of light–dark transitions, time 
spent in the light compartment, and latency to enter the dark, were recorded by a 
blinded observer. 
 
Elevated plus maze 
The elevated plus maze (EPM) is used to assess anxiety-related behaviour and is 
based on the conflict mice experience between the attraction and the fear for a novel 
environment. The EPM was carried out as described previously (Cryan et al. 2003). 
The apparatus was made of an elevated cross plastic maze (1 m from the floor), 
comprising two open and two closed arms (50 cm × 5 cm × 15 cm walls), respectively 
constituting the fearful and safe areas. Mice were habituated to the room for at least 
60 minutes prior to testing. Experiments occurred under red light (~9 lux.) used to 
illuminate the open arms. Mice were individually placed into the center of the maze 
facing an open arm to avoid direct entrance into a closed arm and leave the mice free 
choice for open or close arm and were allowed 6-min of free exploration.  The 
apparatus was cleaned with 10% ethanol between subjects and mice were placed back 
into their home cage in the end of the trial. Experiments were videotaped and the time 
spent in each arm, and the number of entries, were scored (entrance in one arm being 
defined as all four paws inside the arm) by a blinded observer. Mice often exhibit 
increased defecation when placed in an anxiety-provoking environment (Barone, 






The open field (OF) test is used to assess the response to a novel stressful 
environment and locomotor activity. In this study, we used the habituation phase of 
the NOR test as an open field, therefore the conditions (lux and dimensions) were not 
the appropriate ones to run an accurate OF. Mice were tracked and monitored for 10 
minutes using Ethovision videotracking system (Noldus Information Technology). 
The distance moved, the velocity, time in the center zone and transitions between 
zones (center- outer) in the open field. Mice were placed back into the home cage 




















Impact of dietary omega-3 polyunsaturated fatty 









Background: Omega-3 polyunsaturated fatty acids (PUFA) are essential lipids that play 
crucial roles in immune-regulation, cardioprotection and neurodevelopment. Recent 
evidence suggests that the effects that different dietary fats have on such outcomes are 
mediated through changes in gut microbiota composition. However, little is known 
about how varying omega-3 status impacts gut microbiota between mother and 
offspring and the effect not only on microbiota composition by also on functionality. 
 
Methods: Female C57BL/6 mice were assigned to one of three diets [control (CON), 
omega-3 supplemented (O3+) or omega-3 deficient (O3-)] during gestation and male 
offspring were continued on the same diet as previous maternal diet for 12 weeks. 
Following sacrifice, cecal content of mothers and offspring were collected for 16S 
sequencing and metabolomics analysis. Short chain fatty acid analysis was performed 
by gas-chromatography. Plasma and stimulated-spleen cytokine production were also 
assessed. 
 
Results: O3- male displayed significantly less % fat mass and greater % lean mass than 
O3+ and CON. Omega-3 status induced subtle changes to gut microbiota composition 
such that O3+ mothers had significantly lower Lachnospiraceae and 
Firmicutes:Bacteroidetes ratio whereas O3- offspring had great abundance of 
Tenericutes, Anaeroplasma and Coriobacteriaceae. Metabolomics analysis revealed a 
significant increase in cecal metabolites involved in energy metabolism in O3+ 
including α-ketoglucaric acid, malic acid and fumaric acid. O3- animals displayed 
significantly reduced acetate, butyrate and cecal short chain fatty acid production. O3+ 
displayed a significantly higher IL-10/TNFα ratio in ConA-stimulated splenocytes. 
 
Conclusions: Dietary omega-3 PUFA subtly regulate gut microbiota homeostasis such 
that omega-3 deficiency induces a state of compositional and functional disturbance. 
These gut microbiota alterations induced by omega-3 PUFA may mediate changes in 









The gut microbiota is a virtual ‘organ’ referring collectively to all of the 
microorganisms residing in the gastrointestinal tract (GIT). In recent times, much 
research has indicated the essentiality of this microbial biomass for human health from 
birth to old age due to the role it plays in host immunity and metabolic health (Claesson 
et al., 2012, O'Toole, 2012). Furthermore, disruption to the composition and function of 
the gut microbiota has been associated with a wide range of physiological and even 
mental health disorders (Seira Oriach et al., 2016, Cryan and Dinan, 2012). Due to the 
‘flexible’ nature of the gut microbiota, it is highly susceptible to change by a number of 
environmental stressors to the host including infection, medication use, stress, birth 
mode and diet (Bäckhed et al., 2015). Alongside increasing incidence of c-section 
births, antibiotic use and stress, the western lifestyle is uniquely characterised by a diet 
rich in fat and refined sugar and low in fibre. The metabolic outcomes of this 
modernised diet have been well characterised, however the rates of obesity, diabetes 
and chronic metabolic disease have continued to increase (Cordain et al., 2005). 
Expanding knowledge of the role of the gut microbiota in such disorders indicates the 
potential for this microbial ‘organ’ as a new mechanism and target by which nutritional 
interventions may prevent onset of diet-related metabolic disorders. Therefore it is 
essential to understand how nutritional deficiencies impact on gut microbiota 
composition and conversely how nutritional interventions can restore normal 
composition and function. 
Despite much evidence pointing to the role of excess sugar and saturated fatty 
acid (SFA) intake in the epidemic of diet-induced metabolic disease, one of the most 
drastic changes in the western diet over the last five decades has been the intake of 
omega-3 polyunsaturated fatty acids (n-3 PUFA) relative to omega-6 polyunsaturated 





evolved on an n-6/n-3 PUFA ratio of around 1-2:1, however the modern diet, which is 
high in n-6 PUFA-rich vegetable oils, has contributed to a modern n-6/n-3 PUFA ratio 
of 20-30:1 (Simopoulos, 2002). This drastic increase in n-6 PUFA combined with 
declining n-3 PUFA intake, which are found in oily fish, nuts and seeds, has 
contributed to relative n-3 deficiency which has likely spanned 2-3 generations since 
the 1970s (Simopoulos, 1999). n-3 deficiency has hence been associated with 
progression of a number of chronic metabolic disorders. Maternal nutritional 
deficiencies have also been proven to increase offspring disease risk in later life, as 
shown by the Barker Hypothesis (Barker et al., 1993). Hence, it is possible that trans-
generational nutritional inadequacies, such as n-3 PUFA deficiency, across 2-3 
generations may further compound the effects on later life disease risk.  
Both n-6 and n-3 PUFA are integral components of cell membranes and their 
metabolism is dependent upon competition within the same enzymatic pathway. Hence, 
increased availability of n-6 PUFA leads to increased n-6 metabolism and 
incorporation into cell membranes in place of n-3. n-3 and n-6 PUFA however, have 
differential bioactivities with respect to inflammation (Calder, 2006), cardioprotection 
(Simopoulos, 2008) and adiposity (Simopoulos, 2016). It has previously been shown 
that rats fed a high dietary ratio of n-3/n-6 PUFA gain less weight and are protected 
against obesity-linked inflammation through TLR-4-related mechanisms than those fed 
a diet high in SFA or with low n-3/n-6 ratio (Liu et al., 2013). Similarly, maternal diet 
with elevated n-3/n-6 ratio in mice is associated with protection against adipose 
inflammation, liver triglyceride deposition and offspring obesity compared to a low 
dietary n-3/n-6 ratio (Heerwagen et al., 2013).   
It has been observed that the gut microbiota plays a critical role in metabolic 
health and immune regulation (Cani et al., 2009). For example, chronic low grade 





inflammatory cytokine production and increased circulation of the bacteria-derived 
endotoxin lipopolysaccharide (LPS), which is a TLR-4 agonist, resulting in 
downstream immune activation through NF-kB (Cani et al., 2008). Concentrations of 
LPS in circulation are dependent upon the integrity of tight junctions at the intestinal 
epithelial barrier, which is critically regulated by interaction between endothelial cells 
and the gut microbiota (Cani et al., 2007). It has also been observed that a high n-6 
dietary intake induces gut microbiota dysbiosis resulting in increased intestinal 
permeability, metabolic dysfunction and adipose tissue inflammation, which is reversed 
by n-3 feeding (Lam et al., 2012). Similarly, Caesar at al. have shown that a diet 
containing fish oil, rich in long-chain n-3 PUFA, reverses adipose tissue inflammation 
through TLR signalling which is mediated through comprehensive changes in gut 
microbiota composition (Caesar et al., 2015). Similarly, it has been suggested that the 
beneficial effects of long-chain n-3 fatty acids on metabolic endotoxemia are mediated 
through increased production of the LPS-scavenging antimicrobial peptide, intestinal 
alkaline phosphatase (IAP) (Kaliannan et al., 2015). 
The effects of n-3 and n-6 PUFA on mature microbiota composition have 
recently been investigated (Patterson et al., 2014), however less data are available on 
the role of maternal and early-life n-3 PUFA intake on the development of microbiota 
from birth. Gibson et al suggested that maternal fish oil supplementation in 
pharmacological excess (18 % energy) led to the overgrowth of opportunistic 
pathogens such as Bilophila wadsworthia and Enterococcus faecium in offspring 
microbiota and altering of macrophage homeostasis (Gibson et al., 2015). Similarly, it 
has been shown that parental long-chain n-3 PUFA intake at high levels altered 
offspring gut microbiota composition and dampened the immune response in mice 
offspring (Myles et al., 2013). These studies however, provided n-3 PUFA in 





addition did not examine the progression of microbiota development in the offspring 
from birth to adulthood.  
Despite a number of reports describing the role of dietary fat on host 
microbiota composition, there is a lack of data on the effect on cecal metabolite 
production. Recently Daniel et al provided a comprehensive report of the cecal 
metabolomic alterations induced by a high fat diet in mice, which provided novel 
insights into the functional metabolic changes induced by a high-fat diet induced 
microbiota (Daniel et al., 2014). The effect of n-3 PUFA on liver metabolite production 
has previously been outlined (Depner et al., 2013) however there is a lack of data of 
their effect on cecal metabolomics and the functional effects this may have on host 
physiology. 
We previously reported results from this study in which varying n-3 PUFA 
availability altered microbiota composition (Robertson et al., 2016). Here, additional 
data from the same study design, we aimed to investigate the impact of omega-3 
deficiency and omega-3 supplementation on the microbiota composition of mothers 
and their male offspring in mice. In addition, we sought to examine the impact on 
microbiota functionality by examining cecal metabolite production and associations 
with inflammatory status.  
 
 
2. MATERIALS AND METHODS  
2.1. Animals 
Eight-week old male and female C57BL/6J mice were purchased from Harlan 
Laboratories, UK. Animals were kept in the University College Cork animal facility on 
a 12:12 h light-dark cycle at 20 ± 1°C. After acclimatisation, female and males 





omega-3 supplemented (O3+), omega-3 deficient (O3-) diet from gestational day 0. 
Male offspring (n=10 per group) were randomised within treatment groups, group-
housed (3-4 per cage) and weaned on to the same mothers corresponding diets.  
Food intake and body weight were recorded weekly during 13 weeks of dietary 
treatment. Fat and lean body mass were measured using a Minispec mq bench-top 
NMR spectrometer (Bruker Instruments) before sacrifice. All experiments were 
conducted in accordance with the Directive 2010/63/EU and were approved by the 
Animal Experimentation Ethics Committee of University College Cork #2012/036. 
 
2.2. Diets  
Dietary intervention was provided during pre-natal (pregnancy and lactation) and 
through post-natal period until adulthood. The three dietary treatments were matched 
for macronutrient content and differed only in fatty acid profile, as follows: 1) control 
standard chow (CON); 2) Omega 3 polyunsaturated fatty acid supplemented diet (O3+) 
- 1g Eicosapentaenoic acid + Docosahexaenoic acid /100g diet; 3) Omega 3 
polyunsaturated fatty acid deficient diet (O3-). The O3+ diet was prepared with 
microalgal oil rich in EPA/DHA (life’sOmegaTM45 – DSM, Netherlands). Diets were 
formulated and supplied by Harlan Laboratories, Inc. (Madison, WI, USA), which were 
matched for macronutrient content and differed only in fatty acid profile. The detailed 
compositions and fatty acid profiles of the three diets are shown in Table S1 and S2.   
  
2.3. Experimental design 
Fig. S1 illustrates the experimental design. Briefly, C57BL/6J females were assigned 
one of the three diets at gestational day 0. Upon confirmation of pregnancy, males were 





during pregnancy and lactation. Male offspring were subsequently weaned onto the 
same diets as their mothers until adulthood (12 weeks). Fecal samples were collected 
from mothers during lactation. Fecal samples were collected from offspring at both 
adolescence (4 weeks old) and adulthood (12 weeks). Mother’s were sacrificed at 
weaning. At 13 weeks old, offspring were sacrificed by decapitation and samples 
collected. 
 
2.4. Tissue Harvesting 
Mice were sacrificed by decapitation and trunk blood was collected in potassium 
EDTA tubes. Plasma was prepared by collecting supernatant following centrifugation 
of blood samples for 15 min at 8000 g. The red blood cell pellet was washed 3 times 
with a five-fold volume of PBS and centrifugued at 1000 g for 5 min prior to fatty acid 
analysis. Dissected tissues were weighed, snap frozen in liquid nitrogen and stored at -
80ºC until further analysis.  
 
2.5. Tissue fatty acid analysis 
Fatty acid analysis was performed on mothers milk, epididymal fat, red blood cell and 
liver tissues. Briefly, lipid extraction was performed using chloroform:methanol (2:1 
v/v) as previously described (Folch et al., 1957). Methylation of lipid extracts was 
performed using 10 ml 0.5 N NaOH in methanol and heating at 90 °C for 10 min, 
followed by the addition of 10 ml 14% BF3 in methanol for 10 min at 90 °C (Park and 
Goins, 1994). Fatty acid methyl esters (FAME) were resuspended in hexane and 
analysed by gas chromatography (GC). 
Separation of FAME was performed via GC (Agilent 7890B, Agilent 
Technologies, Santa Clara, CA, USA) with flame ionisation detection (Chrompack CP 





μm film thickness) and helium as carrier gas. The GC column oven cycle was 
programmed as follows: 80 °C for 8 min followed by an increase by 8.5 °C/min to a 
final column temperature of 200 °C. Sample injection (0.5 μl) was automated (CTC 
Autosampler, Model 80) on an Aglient Multimode Inlet on-column temperature 
programmable injector. Peak integration was performed using the Agilent OpenLAB 
Chemstation software (Version A.01.06.111). Identification of individual FAME was 
done by comparison of retention times with pure FAME standards (Nu-Chek Prep, 
Elysian, MN, USA). Results are expressed as g/100 g total FAME. 
 
2.6. Plasma and spleen cytokine analysis 
For cytokine analysis, plasma was prepared from whole blood and stored at -80 °C 
prior to analysis. Spleens were collected immediately following sacrifice and stored in 
RPMI cell culture medium prior to splenocyte culturing. For splenocytoe culturing, the 
spleen of each animal were homogenised in media [RPMI (with L-glutamine and 
sodium bicarbonate, R8758 Sigma) + FBS (F7524, Sigma) + Penicillin/Streptomycin] 
and the homogenate was filtered over a 70um strainer, centrifuged at 200 g for 5 min 
and resuspended in media. Cells were counted and cultured in 6-well plates (4,000,000 
cells/mL media). After 2.5h of incubation at 37 °C, cells were stimulated with 
lipopolysaccharide (LPS-2 μg/ml) or concanavalin A (ConA-2.5 μg/ml) for 24h and 
incubated at 37 °C. Following stimulation, the supernatants were collected and stored at 
-80 °C until analysis. Cytokine production in the supernatants was assessed using a 
chemoilluminescence V-PLEX Kit (Proinflammatory Panel 1 - mouse) (Meso Scale 
Discovery, Maryland, USA) for TNFα, IL-10, IL-1β and IL-6 according to 
manufacturers instructions. The plate was read using a MESO QuickPlex SQ 






2.7. DNA extraction and 16S sequencing 
 Total bacterial metagenomic DNA was extracted from the cecal content of mothers 
following sacrifice after 6 weeks dietary treatment. DNA from the cecal content of 
offspring was also extracted after sacrifice after 12 weeks DNA was extracted using a 
commercial DNA extraction kit (QIAmp DNA Stool Mini Kit, Qiagen, UK). An initial 
repeated bead-beating step was performed prior to DNA extraction in order to increase 
final DNA yield. DNA quantification was performed using a Nanodrop 1000 (Thermo 
Scientific, Ireland) and stored at -20°C until analysis. 
16S MiSeq sequencing was performed using the 16S metagenomic sequencing 
library protocol (Illumina) as previously described (Fouhy et al., 2015). The V3-V4 
variable region of the 16S rRNA gene was amplified from the DNA using two PCR 
reactions and clean-up steps. The initial PCR reaction utilised primers specific for 
amplification of the V3-V4 region of the 16S rRNA gene (Forward primer 5’ 
TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCAG; 
reverse primer 5’ 
GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGGTATCTA
ATCC). Confirmation of PCR product size was performed by visualisation on an 
agarose gel via gel electrophoresis. PCR product clean-up and purification was 
achieved using AMPure XP magnetic beads (Labplan, Dublin, Ireland). The second 
PCR reaction was subsequently done to index and barcode individual samples in order 
for samples to be pooled and sequenced together in one flow cell. Samples were 
demultiplexed for analysis after sequencing. A unique indexing primer pair was used 
for each sample (Illumina Nextera XT indexing primers, Illumina, Sweden). PCR 
product size was again confirmed via gel electrophoresis and samples were cleaned and 
purified a second time using AMPure. Samples were quantified using the Qubit broad 





quantification, samples were normalized to an equal concentration (4nM) and pooled 
together for analysis. The sample pool was denatured and diluted to 4pM and MiSeq 
sequencing was performed according to Illumina guidelines by the Eurofins sequencing 
facility (Eurofins, Germany) using a 2 x 300 cycle V3 kit.  
 
2.8. Bioinformatics  
300 bp paired-end reads were assembled using FLASH with minimuma and maximum 
overlap parameters of 20 bp and 120 bp respectively (Magoč and Salzberg, 2011). 
Further processing of paired-end reads, including quality filtering based on a quality 
score of > 25 and removal of mismatched barcodes and sequences below length 
thresholds was performed using the QIIME suite of tools, v1.8.0 (Caporaso et al., 
2010). Denoising, chimera detection and operational taxonomic unit (OTU) grouping 
were performed in QIIME using USEARCH v7 (Edgar, 2010). Taxonomic ranks were 
assigned by alignment of OTUs using PyNAST to the SILVA SSURef database release 
111 (Quast et al., 2013). Alpha and beta diversities were generated in QIIME and 
calculated based on weighted and unweighted Unifrac distance matrices (Lozupone et 
al., 2011). Principal coordinate analysis (PCoA) plots were visualised using EMPeror 
v0.9.3-dev (Vázquez-Baeza et al., 2013). 
 
2.9. Metabolomics 
 Metabolomics analysis of cecal water was performed as follows. Cecal water was 
prepared by the addition of sterile water to cecal content (~ 100mg) followed by 
vortexing. Bacteria and other solids were pelleted by centrifugation at 16,000 g for 30 
mins. The supernatant was removed, placed in a clean tube and centrifuged again at 





through a VectaSpin microcentrifuge 0.2µm filter (Sigma Aldrich) at 10,000 g. The 
resulting filtrate was stored at –20°C until analysis. 
Derivatisation of cecal water samples for gas chromatography mass 
spectrometry (GC-MS) was carried out using methylchloroformate (MCF) as 
previously described (Smart et al., 2010) with slight modifications. Analysis was 
carried out using GC (Agilent 6890N) coupled with a quadropole detector (Agilent 
5975B). The system was controlled by ChemStation (Agilent technologies). Data were 
converted to netCDF format using Chemstation (Agilent), before being imported into 
Matlab R2014b (Mathworks Inc, Natick, MA, United States) and processed using 
PARAFAC2 to obtain relative concentrations for each peak. PARAFAC2 was applied 
using the PARADISe software. Samples were analysed in randomised order. 
 
2.10. Short chain fatty acid analysis 
Short chain fatty acids (SCFA) were analysed by gas chromatography (GC). 1ml of 
sterile Milli-Q water was added to a known amount of mice cecal content (approx. 
100mg). The sample was vortexed thoroughly and allowed to stand at room 
temperature for 10 min. Bacteria and other solids were pelleted by centrifugation at 
10,000 g for 5 min and the supernatant was filtered into clean tubes. An internal 
standard (10mM 2-ethylbutyric acid (Sigma)) was subsequently added to each sample 
in duplicate. Samples were vortex mixed and centrifuged again at 10,000 g for 3 min 
then transferred to clean vials. SCFA were analysed by GC (Varian 3800 flame 
ionization) fitted with a ZB-FFAP column (30m x 0.32mm x 0.25, Phenomenex, 
Torrance, CA, USA). Helium was used as a carrier gas at a flow rate of 1.3ml/min. The 
GC oven cycle was programmed at 100 °C for 0.5min which increased by 8 °C/min to 
180 °C, held for 1 min, then increased by 20 °C/min to a final temperature of 200 °C, 





240 °C, respectively. Peak integration was performed using the Varian Star 
Chromatography Workstation Software version 6.0. A standard curve of SCFA 
standard solutions was used for comparison of retention times and for identification and 
quantification of individual sample peaks. 
 
2.11. Statistical Analysis 
Parametric statistical analyses were performed using GraphPad Prism version 6 (La 
Jolla, CA, USA). Non-parametric analyses of microbiota and metabolomic data were 
performed usign SPSS version 20 (Armonk, NY, USA). Results are presented as mean 
± standard error of the mean (SEM). Significant differences between treatment groups 
were assessed by one-way analysis of variance (ANOVA) followed by Tukey’s 
multiple comparison post-hoc test. Significant differences between non-parametric data 
were assessed by Kruskal-Wallis tests followed by Mann-Whitney to determine 
differences between individual groups. False Discovery Rate analysis was calculate at 


















3.1.Body composition and dietary intake   
 
Offspring weights (males and females) were significantly lower (p=0.031) in O3- 
animals compared with O3+ animals at weaning (week 4) (Fig. 1A), however there 
were no significant differences in final body weights or dietary intakes between groups 
(Fig. 1 B and C).  
At sacrifice, % total fat mass was significantly lower (P=0.0004) and % lean 
body mass significantly higher (p=0001) in the O3- group compared with both other 
groups (Fig. 1 D and E). 
 
3.2.Fatty acid analysis 
Fatty acid analysis revealed distinct differences in tissue fatty acid profiles between 
groups (Table 1). In epididymal fat, liver and red blood cells, n-6 ARA content was 
significantly higher in O3- animals and significantly lower in O3+ animals compared to 
CON. n-3 PUFA were not detected in the epididymal fat or red blood cells of O3- 
offspring and contributed a minor proportion of fatty acids in the liver (0.3%). 
Contrastingly, in epididymal fat, liver and red blood cells, DHA accounted for 2.2%, 
17.3% and 6.5% of fatty acids in O3+ mice respectively, whereas in CON mice DHA 
accounted for 0.1%, 8% and 3.8% of total fatty acids in these tissues. Linoleic acid 
(LA) was significantly lower in O3- epididymal tissue compared to both other groups. 
 
3.3.Plasma and stimulated-spleen cytokine production 
There were no significant differences between treatment groups in circulating plasma 





significant effect of diet on the IL-10/TNF-α ratio in ConA-stimulated splenocytes [F 
(2,26)=4.614, p=0.019] (Fig. 2). Tukey HSD post-hoc testing showed that O3+ group 
displayed a significantly increased IL-10/TNF-α ratio compared with CON (p<0.05) 
and a non-significant increase compared with O3- group (p=0.082). 
 
3.4.Composition of cecal microbiota 
16S sequencing of the cecal microbiota resulted in a total of 3.1 million sequenced 
reads, corresponding to an average of 68,534 reads per sample. To remove any bias 
from variation in sample read number, samples were rarefied to 25,000 reads. 
Phylogenetic alpha diversities revealed some difference between treatment 
groups (Fig. 3). Cecal microbiota diversity was significantly lower in both O3+ and 
O3- mothers compared with CON as assessed by the Simpson index. Similarly, alpha 
diversity was significantly lower in both O3+ and O3- mothers compared with CON 
group as assessed by the Shannon index, however O3- group also displayed 
significantly lower diversity compared with O3+ group. No significant differences in 
alpha diversity were observed in any of the offspring groups.  
Principle coordinate analysis (PCoA) revealed no distinct clustering of 
treatment groups in mothers however in offspring, there was clear clustering and 
separation of the O3- group away from both other groups (Fig. 3). 
The overall phylum level distribution was similar between mothers and their 
offspring (Fig. 4 and Fig. 5), however relative abundance analysis of different taxa at 
phylum level revealed some differences between treatment groups. Firmicutes and 
Bacteroidetes were the most abundant phyla in each group in both mothers and 
offspring. O3+ mothers displayed greater proportional abundance of Bacteroidetes and 
a lower Firmicutes:Bacteroidetes ratio compared with CON. These differences were 





proportional abundance of Tenericutes and Cyanobacteria compared with both other 
groups. Deferribacteres was significantly greater in both O3+ and O3- offspring 
compared with CON group. 
A small number of significant differences were also observed at family and 
genus level distributions, many of which showed similar trends between mothers and 
offspring. There was a trend towards greater Coriobacteriaceae and coriobacteria 
abundance in O3- mothers which became significant in O3- offspring. Similarly, O3- 
mothers displayed non-significant increases in both Gelria and Anaeroplasma, which 
were significantly different in their offspring compared with both other groups. 
Lachnospriaceae and coprococcus were present in significantly lower abundance in 
O3+ mothers, compared with both other groups. In addition, Enterobacteriaceae were 
significantly less abundant in both O3+ and O3- offspring compared with CON. 
 
3.5.Composition of cecal metabolome 
Supervised modeling using principle least squares discriminant analysis (PLS-DA) of 
the cecal metabolome revealed separation of the O3+ group from both O3- and CON 
(Fig. 6). These observed differences in the O3+ animals were driven by significantly 
greater abundance of metabolites involved in energy metabolism. Notably α-
ketoglucaric acid was significantly increased in O3+ compared with CON groups. 
Fumaric acid and malic acid were significantly increased in O3+ compared with both 
CON and O3-. Contrastingly, O3+ animals revealed significantly lower abundance of a 
number of other metabolites including valine containing compound peptide and glycine 
containing compound peptide. O3- group revealed significantly lower abundance of 
benzeneacetic acid compared with CON and significantly increased 






3.6.Cecal short chain fatty acid production 
Cecal short chain fatty acid (SCFA) production was significantly altered by diet as 
displayed in Fig 7. Overall, the O3- group displayed significantly reduced production 
of total SCFA compared with CON (p<0.05) (Fig. 7), which was driven by significant 
reductions in acetate (p<0.05) and butyrate (p<0.05) production. However, O3+ group 
also demonstrated a significant reduction in butyrate production compared with CON 
(p<0.05). There were no significant differences observed between groups for content of 




The gut microbiota is a complex ecosystem that has a significant impact on metabolic 
health through interactions with the diet. Here, we report the impact of varying dietary 
omega-3 on cecal microbiota composition and metabolite production, which may 
provide novel information for future microbiota-targeted nutritional therapies. Briefly, 
we have shown that maternal omega-3 supplementation produces offspring of greater 
weight than omega-3 deficiency. This is further evident in the offspring that continued 
on the same dietary regime through to adulthood, such that dietary omega-3 deficiency 
resulted in reduced % fat mass and greater % lean mass in adolescence and adulthood, 
compared with omega-3 supplementation or CON diet. Omega-3 supplementation or 
deficiency also induced subtle changes to the cecal microbiota composition in both 
mothers and their offspring. This change in gut microbiota composition is also reflected 
in metabolite production such that omega-3 supplementation results in greater 
abundance of energy metabolites in cecal water. Conversely, cecal short chain fatty 
acid production appeared to be reduced by omega-3 deficiency. Finally these changes 





changes in inflammatory status such that dietary omega-3 increases the IL-10/TNFα 
ratio in splenocytes in response to ConA stimulation. 
A number of intervention and large observational studies have shown that both 
greater n-3 PUFA intake and fish intake, especially fatty fish, significantly reduce 
incidence of preterm birth and increase infant birth weight, (Carlson et al., 2013, 
Leventakou et al., 2014, Salvig and Lamont, 2011). Here we have shown that, at 
weaning, offspring of O3+ mothers had significantly greater weight than O3-, although 
this was not significantly different to CON. Infant weight has important implications 
for infant development and has been associated with later life disease risk (Huxley et 
al., 2007). Low birth weight, for example, is associated with poor long term-health 
outcomes (Frankel et al., 1996). Lower umbilical cord DHA is associated with lower 
birth weight and vice versa (Elias and Innis, 2001), therefore omega-3 deficiency may 
impair various aspects of development including neurodevelopment (Coti Bertrand et 
al., 2006). The reason for omega-3 induced increases in infant weight are unclear but it 
has been suggested that n-3 PUFA may prolong gestation by interfering with the 
production of certain prostaglandins, notably PGF2a and PGE2, which play a role in 
uterine contractions (Olsen et al., 1986). However, in this study, birth weight solely 
differed between the treatment groups, which were not significantly different to the 
control.  
Interestingly, at sacrifice, O3- mice displayed significantly reduced % fat mass 
and increased % lean mass compared with both other groups. n-3 PUFA have 
consistently reported anti-obesigenic properties through white adipose tissue 
thermogenesis and other mechanisms (Kim et al., 2015, Simopoulos, 2016). The 
animals in this study, however, were not obese and hence the observed loss in % fat 
mass in the O3- mice compared with CON is of note. Tissue linoleic acid (LA) is 





et al., 2016, Naughton et al., 2016, Simopoulos, 2016). In this study, however, LA and 
other n-6 fatty acids were not increased in the O3- diet in place of n-3 PUFA. 
Moreover, O3- LA was in fact not different to CON in the liver, tended to be lower 
than CON and O3+ in red blood cells (p=0.07) and was significantly lower than CON 
in epididymal adipose tissue. Total n-6 PUFA, however, were not different between 
groups in epididymal tissue and all other n-6 fatty acids were present in concentrations 
of <0.5%. The unexpected reduction of LA in O3- epididymal tissue is likely due to it’s 
rapid conversion into AA and other longer chain n-6 PUFA due to n-3 deficiency and 
hence a lack of competition for desaturase and elongase enzymes in the n-3 pathway. 
Therefore, interestingly, these results suggest that LA plays a more significant role in 
the regulation of fat mass than other n-6 PUFA, and in cases of n-3 deficiency, where 
dietary n-6 PUFA are not increased and tissue LA is converted to its longer n-6 
substrates, reduced tissue LA may lead to loss of fat mass. This may explain the 
observed difference in body composition and is supported by previous work showing 
that LA has a positive correlation with weight and fat mass (Wang et al., 2016). In the 
O3+ animals, as expected, peripheral tissues all displayed elevated levels of omega-3 
fatty acids, which were absent or present in minor proportions in O3- animals. 
n-3 PUFA have potent anti-inflammatory activities through the production of 
eicosanoids and resolvins (Calder, 2006). By interfering with signalling pathways such 
as NF-kB, n-3 PUFA and their products of metabolism dampen the production of pro-
inflammatory cytokines and inflammatory gene expression. The results presented here 
suggest that dietary O3 increased the ratio of IL-10/TNFα production in ConA-
stimulated splenocytes. IL-10 is an anti-inflammatory cytokine produced by T 
regulatory cells that is involved in the resolution of inflammation and hence 
inflammatory homeostasis, especially in the gut. Contrastingly, TNFα is a key 





Using the same experimental design, it has previously been shown that absolute 
production of IL-10 and TNFα is dampened in O3- animals suggesting muted systemic 
responsiveness to LPS (Robertson et al., 2016). In the present study however, the ratio 
of these two opposing cytokines is significantly lower in O3- following ConA 
stimulation and trends towards reduction in unstimulated cells (p=0.097). The IL-
10/TNFα ratio is an established marker of inflammatory balance and has been 
associated with cardiovascular disease and diabetes outcomes (Hashem et al., 2008, 
Moreli et al., 2015). In this study, the elevated n-6/n-3 ratio of the O3- animals may 
have stimulated a relative increase in the production of proinflammatory eicosanoids, 
which are produced by AA, which was significantly increased in peripheral tissues. 
This is a probable cause of the pro-inflammatory profile observed in splenocytes in this 
study.  
The mechanisms by which n-3 PUFA interact with the gut microbiota are 
slowly being resolved (Kaliannan et al., 2016). It has recently been suggested that n-6 
PUFA stimulate a pro-inflammatory intestinal environment characterized by increased 
gram-negative bacteria such as Enterobacteriaceae, increased gut permeability and 
subsequent translocation of LPS across the epithelial barrier. It has been suggested that 
n-3 PUFA resolve this cascade of events through the stimulation of Bifidobacterium 
growth and intestinal alkaline phosphatase (IAP) production, an antimicrobial peptide 
that scavenges LPS (Kaliannan et al., 2015). Interestingly, this was examined in a 
transgenic model of endogenous n-3 production suggestion that n-3 PUFA may have an 
indirect as well as direct interaction with the commensal microbiota. However, no 
differences were observed in jejenum IAP in the present study (Fig. S2). n-3 PUFA 
also modulate gut microbiota composition in infants. Previously it has been shown that 
certain species within the Bacteroidetes phyla are elevated following fish oil 





was partially reflected in our data in which maternal Bacteroidetes were significantly 
increased in O3+ and the Firmicutes:Bacteroidetes ratio significantly reduced. This 
may have relevance for later life health consequences due to the observation of an 
elevated Firmicutes:Bacteroidetes ratio in obesity (Murphy et al., 2010) and its 
association with chronic inflammation which was also reflected here in stimulated 
splenocytes. PCoA and LeFSe analysis revealed that differential abundance of a 
number of species within the O3- offspring microbiota contributed to the separation 
from O3- and CON. These included a significant increase in taxa within the 
Tenericutes phylum as well as elevated coriobacteriaceae and anaeroplasma. 
Tenericutes have previously been shown to be elevated in high fat diet fed mice and are 
correlated with obesity-associated metabolic parameters (Lecomte et al., 2015). 
Similarly, coriobacteria were elevated in obese subjects, an effect that was normalized 
by gastric bypass surgery suggesting that this species is present as an effect or may 
even contribute to metabolic deficiencies (Zhang et al., 2009). Furthermore, 
Anaeroplasma, a species within the Tenericutes phylum, was significantly increased in 
mice following l-carnitine feeding. This was associated with elevated trimethylamine-
N-oxide (TMAO), a key metabolite involved in cardiovascular disease progression 
(Koeth et al., 2013). Interestingly, this suggests that the role of n-3 PUFA status in 
cardiovascular disease may be somewhat mediated through changes in the gut 
microbiota that stimulate pro-atherogenic metabolite production. Interestingly, 
Lachnospiraceae was significantly reduced in O3+ mothers. It has been shown that a 
mixture of fish oil and flaxseed oil feeding significantly reduced Lachnospiraceae 
abundance in mice compared with a high saturated fat diet (Patterson et al., 2014).  
The overall microbiota composition was very similar between mothers and 
offspring, with the most abundant taxa being Lachnospiraceae uncultured, Alistipes, 





at both time points. However through PCoA analysis, it appeared that compositional 
differences between groups were more evident in offspring, which may be due to 
longer dietary exposure.  Interestingly, these cecal compositional data appeared to 
differ from previously published fecal data from the same treatment groups (Robertson 
et al., 2016). It was previously shown that the fecal microbiota from these treatment 
groups appeared to be more enriched in Actinobacteria, Peptostreptococcaceae and 
Lactobacillus. In the previous study, fecal Bifidobacterium, a member of the phylum 
Actinobacteria, and Lactobacillus were significantly higher in O3+. Overall, the 
composition of all other major taxa were similar, however more differences were 
evident between treatment groups in the fecal compositional analysis. This comparison 
of data suggests that the cecal microbiota may differ significantly from the fecal 
microbiota due to altering composition within different regions of the intestinal tract. 
Segmental differences have been previously observed in the gut microbiota (Marteau et 
al., 2001). This is of particular note in this study as a majority of PUFA are absorbed in 
the upper intestinal tract (Niot et al., 2009). Therefore, these data suggests that a certain 
proportion of dietary PUFA reach the caecum and interact directly with the cecal 
microbiota differently to the colonic microbiota or alternatively exert differing indirect 
effects on the intestinal environments of these two regions, which modifies microbial 
composition.   
We further analysed the composition of the cecal metabolome to assess 
whether the observed differences in microbiota composition induced by varying n-3 
PUFA status resulted in modifications to the metabolic activity of the cecal microbiota. 
This is the first study to examine the effect of n-3 PUFA supplementation or deficiency 
on the cecal metabolome. However, previously, the liver metabolome was assessed in 
the context of n-3 PUFA (Depner et al., 2013). Indeed, the cecal metabolome has been 





markers of fat and carbohydrate metabolism. The interaction between the metabolic 
activity of the microbiota and tissue fatty acid composition has also previously been 
examined (Wall et al., 2012). It has been shown that modulation of the microbiota 
through feeding of a Bifidobacterium probiotic can significantly increase both adipose 
tissue and brain n-3 PUFA composition in mice and pigs (Wall et al., 2009; ). These 
results suggest that there is a close relationship between dietary fat intake and the 
metabolic activity of the gut microbiota. In this study, PCoA loading plots in the 16S 
sequencing data revealed distinct clustering of the O3- group away from O3+ and 
CON. Interestingly, in the PLS-DA analysis of the metabolomics data, it appeared that 
differences between groups were driven by alterations to the O3+ group. Further 
analysis of this data revealed that the metabolites strongly contributing to this 
separation were those involved in energy metabolism. Fumaric acid and malic acid 
were significantly elevated in O3+ compared with both other groups. α-ketoglucaric 
acid was also increased in O3+ as well as O3- compared with CON group. The 
microbiota has previously proven essential for energy metabolism. Malic acid, fumaric 
acid and other energy metabolites involved in the tricarboxylic acid (TCA) cycle were 
previously shown to be significantly increased in the serum of conventionally raised 
animals compared with germ free animals (Velagapudi et al., 2010). Furthermore, 
using predicted functional metagenomics, it has been shown that the TCA cycle is 
downregulated on a high fat diet, an effect which is reversed with high intensity 
exercise (Denou et al., 2016). Hence these results may suggest that O3+ has a 
beneficial effect on energy metabolism through compositional changes in the gut 
microbiota and its subsequent metabolic activity particularly regarding the TCA cycle. 
These results, however, should be interpreted with caution due to the relative flux of 
the TCA cycle in different disease states and as significant differences exist between 





those observed here, are decreased in the urinary metabolome of the obese Zucker rat 
but increased in ob/ob mice (Williams et al., 2005, Zhao et al., 2010, Salek et al., 
2007). Therefore no strict conclusions can be made about this effect of O3+ on the 
cecal metabolome but these novel data may provide useful information for future 
studies about the role of n-3 PUFA in the metabolic activity of the commensal 
microbiota. 
A more targeted analysis of cecal short chain fatty acid (SCFA) production 
revealed that O3- significantly reduced the production of acetate, butyrate and total 
SCFAs. O3+ also significantly reduced butyrate production. SCFAs are typically the 
fermentation products of indigestible dietary fibres and function as the key energy 
source for colonocytes (Byrne et al., 2015). A number of studies have shown their 
importance in the regulation of cholesterol, glucose and lipid metabolism, therefore, 
impaired SCFA production has been associated with metabolic disruption and chronic 
disease progression (den Besten et al., 2013). Interestingly, the combined effect of 
DHA and butyrate has previously been shown to induce Ca2+-dependent apoptosis in 
coloncytes, a process which may reduce colon cancer progression (Kolar et al., 2007). 
Therefore the observed impairment of SCFA production in O3- suggests that such a 
deficiency in n-3 PUFA disrupts the homeostatic intestinal environment, which may 
have implications for metabolic disease. Indeed, certain taxa involved in SCFA 
production, namely members of the Clostridiaceae family, were not detected in O3- 
microbiota suggesting that n-3 PUFA deficiency in the diet resulted in absence of 
SCFA-producing bacteria among the gut microbiota. Interestingly however, the 
observed disruptions to SCFA production in O3- were not due to differences in 






Long-chain n-3 PUFA have consistently reported beneficial effects for 
cardiovascular, immune and metabolic health, however the role they play in 
modulating the gut microbiota composition has remained unclear and their role on the 
metabolic activity of the microbiota has not been examined previously. These results 
suggest that dietary n-3 PUFA play a crucial role in modulating host body composition 
and inflammatory status. Furthermore, these physiological outcomes may be partially 
induced by significant alterations to gut microbiota composition and metabolic activity. 
Dietary omega-3 deficiency appears to induce gut microbial imbalance, which may 
contribute to impaired SCFA production. Conversely, greater omega-3 intake induces a 
more anti-inflammatory profile and enhances cecal production of energy metabolites 
possibly through modulation of gut microbiota composition. Further research is 
required to elucidate the long-term impact of such altered microbiota and metabolomic 
profiles on chronic disease progression. Due to the global trends of increasing omega-6 
intake in place of omega-3, these results warrant the recommendation for greater 
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Figure 1. Effects of omega-3 status on body composition. (A) Male and female offspring of 
O3- mothers weighed significantly less than O3+ offspring at weaning (week 4). There were 
no significant differences between groups in final body weight (B) or dietary intake (C). O3- 
caused significantly decreased fat mass (D) and increased lean mass (D) compared with CON 
and O3+. Data shown as mean ± SEM. n= 9-10 per group (A, C-H). n= 3 cages per group for 
dietary intake (B). *p < 0.05, CON vs. O3+ or O3- group; # p < 0.05, ## p < 0.01, ### p < 0.001 









































































































































































Figure 2. Effects of omega-3 dietary intervention on cytokine levels after 
lipopolysaccharide (LPS) and concanavalin A (ConA) spleen stimulation. Omega-3 
dietary intervention causes significant differences on cytokine release levels of tumor necrosis 
factor (TNFα) and Interleukin 10 (IL-10) after LPS and ConA stimulation. (A) O3+ caused no 
effects on the release of TNFα and IL-10 after ConA stimulation, while O3- significantly 
decreased spleen levels of TNFα and IL-10 after stimulation with ConA compared to the 
CON. Moreover, (A) the deficient group presented a significant decrease of IL-10 after 
stimulation with ConA compared to the O3+ group.  Thus, (B) the O3- significantly 
decreased spleen levels of TNFα after stimulation with LPS in comparison to the CON group. 
(B) There was a trend to decreased levels of IL-10 cytokine in the O3- group after stimulation 
with LPS. O3+ induced a significantly greater IL-10/TNFα ratio following ConA stimulation 
(C). Data shown as mean ± SEM. n= 8-10 per group. *p < 0.05, CON vs. O3- or O3+ group; 























































































































































Figure 3. Effects of omega-3 PUFA on cecal gut microbiota diversity. Principle coordinate 
analysis (PCoA) revealed no distinct clustering of treatment groups in mothers (A). In 
offspring, there was distinct clustering of the O3- group away from both O3+ and CON (B). 
Alpha diversity of cecal microbiota was significantly reduced in both O3+ and O3- mothers 
as measured by the Simpson (D) and Shannon (E) indices. O3- alpha diversity was 
significantly lower than O3+ as measured by the Shannon index (E). There were no 
significant differences in alpha diversity between offspring treatment groups. In addition no 
differnces were observed in mothers or offspring using the Chao1 index (C) or number of 
observed species (F). Data shown as mean ± SEM. n= 4-5 per group for mothers and 9-10 per 


































































































































































































































Figure 4. Effects of omega-3 PUFA on taxonomic composition of the cecal microbiota. 
At phylum level O3+ mothers displayed significantly greater Bacteroidetes and a 
significantly lower Firmicutes:Bacteroidetes ratio, where as Tenericutes were significantly 
higher in O3- offpspring (A). At family and genus level, lachnospiraceae was significantly 
lower in O3+ mothers while coriobacteriaceae and anaeroplasma were significantly greater 
in O3- offspring (B). Data shown as mean ± SEM. n= 4-5 per group for mothers and 9-10 per 
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Figure 5. Differential abundance of gut microbiota taxa following omega-3 intervention. 
LDA scores of taxa significantly altered by omega-3 status in offspring  are shown in (A) 
(LDA scores >2 and significance of p<0.05 as determined by Wilcoxon signed-rank test). The 
most differentially abundant taxa in adulthood following dietary intervention are represented 
as a cladogram in (C) as generated from LEfSe data in (A). Heatmap distribution of 
significantly altered taxa in adulthood reveals distinct differences between treatment groups 
(B).  n=9-10 per group. Analysis by non parametric Kruskall Wallis test followed by multiple 













































































































































































































Figure 6. Omega-3 PUFA-induced changes to the cecal metabolome. Partial least squares 
discrimination analysis (PLS-DA) revealed differences in the cecal metabolomic profile 
between groups that were driven by changes in O3+ (A). The metabolites contributing most 
strongly to the separation were those involved in energy metabolism and others (B). “?” 






Figure 7. Cecal short chain fatty acid production. O3- displayed significantly reduced 
cecal acetate (A), butyrate (D) and total short chain fatty acid (SCFA) (E) production. O3+ 
also displayed significantly reduced butyrate production (D). There were no significant 
differences in propionate (B) or isobutyrate (C) production. Data shown as mean ± SEM. n= 






























































































































































SFA, Saturated fatty acids; MUFA, Monounsaturated fatty acids, PUFA, Polyunsaturated fatty acids
  Epididymal fat Liver Red blood cells 
  CON O3+ O3- CON O3+ O3- CON O3+ O3- 
SFA  
   
  
 
    
 
  
14:0 6.3 ± 0.1a 5.1 ± 0.1b 6.5 ± 0.1a 1.2 ± 0.2a  0.8 ± 0.1b  1.3 ± 0a  2 ± 0.2 2 ± 0.2 1.7 ± 0.1 
16:0 20.7 ± 0.3a 24.8 ± 0.2b 21 ± 0.4a 24.6 ± 0.5a  25.2 ± 0.4a  22.4 ± 0.2b  35.3 ± 1 36.3 ± 1 35.1 ± 0.6 
18:0 2.7 ± 0.1 2.7 ± 0.1 2.8 ± 0.1 11.9 ± 0.4 12.7 ± 0.5 11.3 ± 0.2 19.1 ± 1.1 17.5 ± 1.2 20 ± 0.9 
20:0 0.1 ± 0 0.1 ± 0 0.1 ± 0 0.4 ± 0 0.3 ± 0.1 0.2 ± 0 0.3 ± 0.1 0.3 ± 0 0.3 ± 0 
Total SFA  29.8 ± 0.4a 32.7 ± 0.3b 30.4 ± 0.6a 38.1 ± 0.7a  39 ± 0.8a  35.2 ± 0.2b  56.6 ± 1.9 56.1 ± 2.1 57.1 ± 1.4 
MUFA 
   
            
16:1 8.8 ± 0.3 8 ± 0.3 8.3 ± 0.3 3.5 ± 0.2a  2.1 ± 0.2b  3.7 ± 0.1a  2.2 ± 0.3 2.3 ± 0.4 1.5 ± 0.2 
18:1t n-9 0.1 ± 0a 0.1 ± 0b 0.1 ± 0a n.d. n.d. n.d. 0.1 ± 0 n.d. n.d. 
18:1c  n-9 2.2 ± 0.1 4.1 ± 2.7 3.2 ± 0.1 16.1 ± 0.5a  12.4 ± 0.9b  18.7 ± 0.5a  13.6 ± 1.2 15.2 ± 1.5 11.5 ± 0.7 
18:1 t n-7 31.4 ± 0.3a b 25.2 ± 2.9a 33.6 ± 0.4b 2.7 ± 0.1a  1 ± 0.1b  4.3 ± 0.3c  1.7 ± 0.1a  1.2 ± 0b  1.8 ± 0.1a  
20:1 0.6 ± 0a 0.4 ± 0b 0.7 ± 0c 0.5 ± 0.1a  0.3 ± 0a  0.7 ± 0b  0.6 ± 0.2 2.1 ± 1 3.1 ± 1.3 
Total MUFA  43.1 ± 0.6a 37.4 ± 0.6b 46 ± 0.8c 22.8 ± 0.7a  15.8 ± 1.1b  27.4 ± 0.7c  18.1 ± 1.6 20.8 ± 1.8 17.9 ± 1.3 
PUFA  
   
            
n-6 PUFA  
   
  
 
    
 
  
18:2 n-6 24.7 ± 0.3a 24 ± 0.4a b 23 ± 0.4b 18 ± 0.3a  16.2 ± 0.3b  17.6 ± 0.3a  10 ± 0.7 9.7 ± 0.9 7.7 ± 0.5 
18:3 n-6 0 ± 0 0 ± 0 0 ± 0 0.1 ± 0a b  n.d.a  0.2 ± 0.1b  0.1 ± 0 n.d. n.d. 
20:3 n-6 0.1 ± 0a 0 ± 0b 0.2 ± 0a 1.2 ± 0.2a  0.6 ± 0.1b  1.3 ± 0a  0.8 ± 0.1a  0.3 ± 0b  0.8 ± 0.1a  
20:4 n-6 0.2 ± 0a 0.1 ± 0b 0.4 ± 0c 10.1 ± 0.2a  4.7 ± 0.2b  14.1 ± 0.2c  9.4 ± 0.6a  3.6 ± 0.3b  12 ± 0.5c  
22:4 n-6 0 ± 0a 0 ± 0a 0 ± 0b 0.1 ± 0.1a b  n.d.a  0.3 ± 0.1b  0.8 ± 0.1a  n.d.b  1.7 ± 0.2c  
22:5 n-6 0 ± 0a 0.1 ± 0b 0.1 ± 0c 0.1 ± 0.1a  n.d.a  3.6 ± 0.1b  n.d.a  n.d.a  2.8 ± 0.3b  
Total n-6 PUFA  25.1 ± 0.2 24.4 ± 0.4 23.6 ± 0.5 29.6 ± 0.4a  21.5 ± 0.3b  37.1 ± 0.5c  21 ± 0.6a  13.6 ± 0.7b  25 ± 1.3c  
    
  
 
    
 
  
n-3 PUFA  
   
  
 
    
 
  
18:3 n-3 1.9 ± 0a 2.3 ± 0.1b 0 ± 0c 0.8 ± 0.1a  1 ± 0a  n.d.b  0.3 ± 0.1a b  0.3 ± 0.1a  n.d.b  
20:5 n-3 0 ± 0a 0.4 ± 0b 0 ± 0a 0.5 ± 0.1a  4.1 ± 0.2b  n.d.a  0.1 ± 0a  2.1 ± 0.2b  n.d.a  
22:5 n-3 0 ± 0a 0.4 ± 0b 0 ± 0a 0.2 ± 0.1a  1.4 ± 0.2b  n.d.a  0.2 ± 0.1a b  0.6 ± 0.2a  n.d.b  
22:6 n-3 0.1 ± 0a 2.2 ± 0.1b 0 ± 0a 8 ± 0.3a  17.3 ± 0.4b  0.3 ± 0.2c  3.8 ± 0.3a  6.5 ± 0.4b  n.d.c  
Total n-3 PUFA  2.1 ± 0a 5.4 ± 0.2b 0 ± 0c 9.5 ± 0.2a  23.7 ± 0.6b  0.3 ± 0.2c  4.3 ± 0.3a  9.5 ± 0.6b  n.d.c  
Total PUFA  27.2 ± 0.2a 29.9 ± 0.5b 23.6 ± 0.5c 39.1 ± 0.6a  45.2 ± 0.6b  37.4 ± 0.7a  25.3 ± 0.9 23.1 ± 1 25 ± 1.3 
n6:n3 12.1 ± 0.3 4.5 ± 0.1 n/a 3.1 ± 0.1 0.9 ± 0 n/a 5 ± 0.3 1.5 ± 0.1 n/a 
Chapter 3 

















Figure S1. Experimental timeline.  Following confirmation of mating, pregnant C57BL/6 
dams were assigned to one of three diets; CON, O3+ or O3- for the duration of gestation (19-21 
days) and lactation (21 days). Male offspring (n=10 per group) were weaned onto the same diet 
as their mothers at PND21 until 12 weeks. Fecal samples were collected from mothers during 
gestation and from offspring at both adolescence (week 4) and adulthood (week 10). At 13 






















Figure S2. Plasma cytokine levels during adulthood. Dietary interventions revealed no 













































































Fig S3. Jejenum intestinal alkaline phosphatase production. There were no significant 


































Abbreviations: O3+, Omega 3 polyunsaturated fatty acid supplemented diet; O3-, Omega-3 polyunsaturated fatty acid deficient 
diet; LA, Linoleic acid (C18:2 n-6) ; ALA, Alpha linolenic acid (C18:3 n-3); EPA, Eicosapentaenoic acid (C20:5 n-3); DHA, 









  CON O3+ O3- 
Protein (% by weight) 18.3 18.3 18.3 
Carbohydrate (% by 
weight) 56.7 56.5 56.7 
Fat (% by weight) 10 10 10 
Protein (% of Kcal) 18.8 18.8 18.8 
Carbohydrate (% of 
Kcal) 58.2 58 58.2 
Fat (% of Kcal) 23.1 23.2 23.1 
Kcal/g 3.9 3.9 3.9 
LA (% by weight) 2.6 2.6 2.6 
ALA (% by weight) 0.4 0.4 0 
EPA (% by weight) 0 0.35 0 
DHA (% by weight) 0 0.66 0 
n-6 (% by weight) 2.6 2.6 2.6 










































































% Total fatty acids CON O3+ O3- 
Saturated fatty acids (SFA) 
   8:0 3.4 2.2 3.6 
10:0 3.1 2 3.3 
12:0 27 16.9 29 
14:0 11.1 7.25 12.3 
16:0 9 10.9 8.5 
18:0 7.9 5.9 8.7 
Total SFA 59.8 44 64.4 
Monounsaturated fatty acids (MUFA) 
   18:1 7.1 13.3 6.5 
Total MUFA 7.3 13.3 6.7 
Polyunsaturated fatty acids (PUFA) 
   18:2 n-6 25.7 25.4 22.4 
18:3 n-3 4.2 4.1 tr 
20:4 n-6 0 0.26 0 
20:5 n-3 0 3.2 0 
22:5 n-3 0 1 0 
22:6 n-3 0 5.7 0 
n6 25.7 25.66 22.4 
n3 4.2 14 0 
Total PUFA 29.9 39.66 22.4 
Saturated fatty acids (SFA) 
   8:0 3.4 2.2 3.6 
10:0 3.1 2 3.3 
12:0 27 16.9 29 
14:0 11.1 7.25 12.3 
16:0 9 10.9 8.5 
18:0 7.9 5.9 8.7 
Total SFA 59.8 44 64.4 
Monounsaturated fatty acids (MUFA) 
   18:1 7.1 13.3 6.5 
Total MUFA 7.3 13.3 6.7 
Polyunsaturated fatty acids (PUFA) 
   18:2 n-6 25.7 25.4 22.4 
18:3 n-3 4.2 4.1 tr 
20:4 n-6 0 0.26 0 
20:5 n-3 0 3.2 0 
22:5 n-3 0 1 0 
22:6 n-3 0 5.7 0 
n6 25.7 25.66 22.4 
n3 4.2 14 0 
Total PUFA 29.9 39.66 22.4 










Genus CON O3+ O3- P-value q-value 
Lachnospiraceae uncultured 22 14 17 0.024 0.399 
Ruminococcaceae uncultured 13 11 10 0.104 0.568 
Bacteroidales S24-7 uncultured 9.7 16.3 8.7 0.083 0.568 
Alistipes 9.6 11.1 10.6 0.607 0.917 
Ruminococcaceae Incertae Sedis 7.8 6.7 8.8 0.188 0.577 
Odoribacter 4.6 5.4 4.6 0.997 1 
Mucispirillum uncultured 4.4 2.9 5.5 0.566 0.893 
Anaerotruncus 3.1 2.6 2.6 0.26 0.577 
Bilophila 2.8 2.9 4 0.248 0.577 
Lactobacillus 2.7 1 3.8 0.15 0.577 
Oscillibacter 2.5 1.5 2.7 0.089 0.568 
Lachnospiraceae Incertae Sedis 2.3 1.4 2.2 0.116 0.577 
Bacteroides 2.1 3.6 4.4 0.58 0.895 
Rikenellaceae RC9 gut group 2 2.9 2.2 0.516 0.833 
Rikenella 1.3 1.5 0.9 0.3 0.609 
Desulfovibrio 1.3 0.6 0.5 0.206 0.577 
Escherichia-Shigella 1.2 0.6 0.7 0.176 0.577 
Coprococcus 1.1 0.7 1.5 0.006 0.399 
Clostridiales uncultured bacterium 1 2.9 2 0.037 0.399 
Allobaculum 0.73 0.42 0.64 0.401 0.722 
Akkermansia 0.66 6.17 3.18 0.249 0.577 
Anaeroplasma 0.46 0.06 0.25 0.363 0.716 
Peptococcaceae uncultured 0.45 0.41 0.38 0.713 0.993 
Parasutterella 0.35 1.71 1.04 0.224 0.577 
Turicibacter 0.33 0.06 0.11 0.233 0.577 
Roseburia 0.24 0.16 0.21 0.514 0.833 
Bifidobacterium; 0.19 0.34 0.4 0.285 0.595 
Parabacteroides 0.19 0.23 0.19 0.904 1 
Anaerovorax 0.17 0.07 0.12 0.248 0.577 
Ruminococcus 0.16 0.09 0.02 0.045 0.399 
Peptococcus 0.14 0.11 0.08 0.174 0.577 
Peptostreptococcaceae uncultured 0.14 0.33 0.13 0.867 1 
Candidate division TM7 uncultured other 0.12 0.11 0.06 0.165 0.577 
Clostridium 0.1 0.01 0 0.424 0.734 
Christensenellaceae uncultured 0.1 0.15 0.09 0.373 0.716 
Family XIII Incertae Sedis 0.079 0.093 0.054 0.269 0.579 
Enterorhabdus 0.036 0.032 0.024 0.677 0.961 
Christensenella 0.031 0.027 0.041 0.482 0.815 
Lachnospiraceae uncultured bacterium 0.027 0.029 0.068 0.846 1.000 
Thalassospira 0.026 0.183 0.047 0.096 0.568 
Other 0.026 0.038 0.057 0.03 0.399 
Family XIII incertae sedis uncultured 0.022 0.018 0.011 0.212 0.577 
Aerococcus 0.011 0.005 0.01 0.824 1 
Erysipelotrichaceae Incertae Sedis 0.009 0.004 0.009 0.256 0.577 
Hydrogenoanaerobacterium 0.008 0.006 0.006 0.87 1 
Mogibacterium 0.006 0.007 0.002 0.191 0.577 
Ruminococcaceae uncultured bacterium 0.006 0.007 0.006 0.673 0.961 
Mollicutes RF9 uncultured bacterium other 0.005 0.007 0 0.017 0.399 
Erysipelotrichaceae uncultured 0.003 0.003 0 0.144 0.577 
Gelria 0.002 0 0.013 0.122 0.577 
Staphylococcus 0.001 0.002 0.017 0.839 1 






Pseudobutyrivibrio 0.001 0.002 0.006 0.089 0.568 
Coriobacteria uncultured 0 0 0.017 0.043 0.399 
Barnesiella 0 0.001 0.002 0.645 0.954 
Prevotella 0 0 0 1 1 
Prevotellaceae uncultured 0 0 0 1 1 
Flavobacterium 0 0 0 1 1 
Cyanobacteria 4C0d-2 uncultured bacterium 0 0 0 1 1 
Cyanobacteria 4C0d-2 uncultured organism other 0 0 0.009 0.043 0.399 
Lactococcus 0 0 0 1 1 
Streptococcus 0 0 0 1 1 
Candidatus Arthromitus 0 0 0 1 1 
clostridiaeceae uncultured 0 0 0 1 1 
Anaerostipes 0 0 0 1 1 
Blautia 0 0 0 1 1 
Marvinbryantia 0 0 0.001 0.407 0.722 
Clostridiales uncultured rumen bacterium 0 0.001 0 0.407 0.722 
alpha proteobacterium 0 0 0 1 1 
Mollicutes RF9 uncultured bacterium other 0 0 0 1 1 








Genus CON O3+ O3- P-value q-value 
Lachnospiraceae uncultured 17 16 15 0.195 0.433 
Alistipes 12 11 12 0.653 0.861 
Ruminococcaceae Incertae Sedis 9.7 8.6 9.6 0.545 0.774 
Ruminococcaceae uncultured 9.7 9.2 8.5 0.514 0.745 
Odoribacter 9.5 13.1 12.2 0.211 0.454 
Bacteroidales S247 uncultured bacterium 6.9 6.2 5.2 0.184 0.433 
Mucispirillum uncultured bacterium 3.6 6.2 6.9 0.032 0.162 
Bacteroides 3.4 3.7 3.7 0.964 1 
Rikenella 3 2.8 3 0.88 1 
Oscillibacter 3 2 3 0.077 0.288 
Rikenellaceae RC9 gut group 2.6 2.7 3.2 0.174 0.426 
Lachnospiraceae Incertae Sedis 2.6 1.4 1.6 0.008 0.063 
Clostridiales uncultured uncultured bacterium 2.6 3 3.1 0.772 0.962 
Anaerotruncus 2.4 2.9 2.5 0.135 0.398 
Akkermansia 2.1 2.5 1.9 0.449 0.664 
Lactobacillus 1.2 0.5 0.8 0.973 1 
Bilophila 1.1 1.1 1.2 0.99 1 
Parasutterella 0.94 0.91 0.77 0.928 1 
Allobaculum 0.74 0.79 0.4 0.246 0.499 
Coprococcus 0.66 0.44 0.58 0.303 0.552 
Parabacteroides 0.6 0.97 0.58 0.723 0.917 
EscherichiaShigella 0.58 0.23 0.28 0.004 0.036 
Desulfovibrio 0.51 1.12 0.57 0.023 0.148 
Christensenellaceae uncultured 0.43 0.41 0.41 0.564 0.785 
Bifidobacterium 0.38 0.3 0.19 0.271 0.534 
Anaerovorax 0.3 0.26 0.41 0.031 0.162 
Ruminococcus 0.26 0.47 0.48 0.655 0.861 
Peptococcaceae uncultured 0.23 0.24 0.25 0.918 1 
Anaeroplasma 0.21 0.05 0.51 0.001 0.014 
Peptostreptococcaceae uncultured 0.2 0.1 0.19 0.169 0.426 






TM7 uncultured bacterium Other 0.15 0.19 0.1 0.105 0.339 
Family_XIII_Incertae_Sedis__Incertae_Sedis 0.13 0.11 0.15 0.287 0.551 
Roseburia 0.13 0.17 0.17 0.072 0.284 
Pseudobutyrivibrio 0.11 0.07 0.08 0.828 0.985 
Turicibacter 0.11 0.01 0.11 0.092 0.325 
Peptococcus 0.1 0.12 0.11 0.894 1 
Thalassospira 0.1 0.19 0.12 0.157 0.413 
Enterorhabdus 0.04 0.02 0.03 0.038 0.180 
Other 0.04 0.1 0.05 0.246 0.499 
Erysipelotrichaceae Incertae Sedis 0.03 0.05 0.04 0.832 0.985 
Lachnospiraceae uncultured bacterium 0.03 0.02 0.02 0.195 0.433 
Clostridium 0.03 0.08 0 0.003 0.030 
Family XIII Incertae Sedis uncultured 0.02 0.03 0.02 0.947 1 
Christensenella 0.02 0.02 0.03 0.331 0.585 
A 4C0d2 uncultured bacterium Other Other 0.008 0 0.208 0.003 0.030 
Hydrogenoanaerobacterium 0.008 0.016 0.008 0.045 0.200 
RF9 uncultured bacterium Other 0.007 0.036 0.007 0.072 0.284 
A 4C0d2 uncultured organism Other Other 0.006 0 0.275 0.001 0.014 
Mogibacterium 0.005 0.005 0.004 0.976 1.000 
Ruminococcaceae uncultured bacterium 0.004 0.005 0.005 0.704 0.909 
uncultured_Mollicutes_bacteriumOther 0.004 0 0 0.015 0.107 
Prevotellaceae uncultured 0.003 0 0 0.14 0.398 
Erysipelotrichaceae uncultured 0.003 0.001 0 0.136 0.398 
Blautia 0.002 0 0 0.387 0.585 
Prevotella 0.001 0 0 0.387 0.585 
Coriobacteriaceae uncultured 0 0 0.038 <0.0001 0.002 
Barnesiella 0 0.002 0.004 0.096 0.325 
Flavobacterium 0 0 0 0.387 0.585 
Staphylococcus 0 0.001 0 0.387 0.585 
Aerococcus 0 0 0 1 1 
Enterococcus 0 0 0.001 0.296 0.552 
Lactococcus 0 0.006 0 0.387 0.585 
Streptococcus 0 0 0 0.996 1 
Clostridiaceae Candidatus Arthromitus 0 0.006 0 0.146 0.399 
Clostridiaceae uncultured 0 0.001 0 0.786 0.962 
Anaerostipes 0 0.158 0 0.341 0.585 
Marvinbryantia 0 0 0 0.627 0.856 
Gelria 0 0 0.177 <0.0001 0.002 
wr0007 uncultured alpha proteobacterium 0 0 0 0.387 0.585 





IAP enzyme activity  
Jejenum intestinal alkaline phosphatase (IAP) enzyme activity was carried out using a 
commercial alkaline phosphatase assay kit (Abcam, Cambridge, UK) as per manufacturers 
instructions and results expressed as ug IAP/minute reaction time/mg protein. Protein 
concentration of jejenum tissue was assessed using Bradford reagent as per manufacturers 





















Maternal omega-3 and omega-6 fatty acids 
differentially regulate offspring susceptibility to 












Background: Dietary omega-3 polyunsaturated fatty acids (n-3 PUFA) have anti-
obesigenic properties compared with n-6 PUFA. The pathogenesis of obesity however 
has its origins in the fetal and neonatal periods, therefore maternal PUFA status may 
influence offspring susceptibility to obesity. Furthermore, little is known about the role 
of the gut microbiota in the interaction between maternal n-3 PUFA status and offspring 
weight gain. 
 
Methods: Wild type (WT) offspring of WT and transgenic fat-1 mice, that 
endogenously produce n-3 PUFA, were placed on a high fat diet (HFD) to assess the 
role of maternal n-3 PUFA status on obesity susceptibility. Offspring were also fostered 
to mothers of the opposite genotype at birth to compare the role of prenatal and 
postnatal n-3 PUFA status. Weight gain, body composition, gut permeability, 
inflammatory markers and gut microbiota composition were all assessed following 3 
months HFD feeding. 
 
Results: Offspring born to a fat-1 mother or fostered to a fat-1 mother during lactation 
gained significantly less weight than those of WT mothers (189-196% vs. 232%) 
suggesting that maternal n-3 PUFA in utero or during lactation reduce HFD-induced 
weight gain in offspring. Offspring n-3 PUFA dietary exposure during lactation, via 
milk, resulted in greater n-3 tissue accumulation than in utero n-3 exposure (p<0.05). 
Similarly, the effects on the gut microbiota were primarily driven by the mother’s 
phenotype during lactation such that fat-1 mothers reduced gut permeability (p<0.05), 
Firmicutes, Clostridia, Lachnospiraceae and increased Akkermansia and Bacteroidetes 
in offspring. The changes in microbiota composition induced by maternal n-3 PUFA 
status persisted throughout life after HFD-feeding and after differences in tissue PUFA 
status disappeared.   
 
Conclusions: Elevated maternal n-3 PUFA status during pregnancy and/or lactation led 
to significantly reduced weight gain in offspring fed HFD following weaning. This is 
associated with comprehensive alterations to the offspring microbiota, which persist 
throughout life. Maternal n-3 PUFA supplementation poses potential as a therapeutic 









Obesity is one of the biggest global public health issues, which negatively impacts the 
long-term health of millions of people around the world. Obesity comorbidities include 
insulin resistance, hypertension and dyslipidemia, which contribute to increased risk of 
chronic diseases such as diabetes, cardiovascular disease and dementia (Ogden et al., 
2007). In recent times, the age of obesity onset has progressively declined such that 
childhood obesity has now become a major public health concern (de Onis et al., 2010). 
Childhood obesity is expected to affect 9.1% of pre-school children globally by the year 
2020 which will significantly increase long-term chronic metabolic disease risk. As a 
result, much research has begun to investigate how maternal and early-life nutrition 
impacts offspring health outcomes in later life. Evidence from the Barker Hypothesis 
and the Dutch Hunger Winter suggests that maternal nutritional inadequacies adversely 
affect fetal metabolic programming in the offspring leading to negative health 
consequences in later life such as greater cardiovascular disease risk (Barker et al., 
1993). Indeed, the adoption of the modern Western Diet has revealed that maternal 
obesity and over-nutrition also contribute to elevated long-term metabolic disease risk 
for infants (Boney et al., 2005, Laitinen et al., 2001, Gaillard, 2015). A number of 
mechanisms have been proposed to contribute to this phenomenon such as maternal or 
placental inflammation (Heerwagen et al., 2013, Catalano and deMouzon, 2015) and 
epigenetics (Heerwagen et al., 2010) however, a clear understanding is lacking. 
Consequently, there is limited evidence about which maternal dietary interventions may 
prevent such metabolic disruptions to the fetus or neonate and reduce later-life disease 
risk. 
 In recent times, obesity and a number of associated chronic diseases have been 
characterized by alterations to the gut microbiota (Patterson et al., 2016). Gut 
‘dysbiosis’ or imbalance is often characterized by elevated abundance of pathogenic 






lipopolysaccharide (LPS), an endotoxin that stimulates TLR-4-induced inflammation. 
Low-grade chronic inflammation is the hallmark of metabolic endotoxemia, an 
inflammatory condition that may play a causal role in obesity pathogenesis (Cani et al., 
2008). By stimulating the growth of pathogenic microorganisms, hypercaloric and pro-
obesigenic diets impair the integrity of the gut epithelial barrier leading to subsequent 
translocation of bacterial-derived LPS across the intestinal wall and into circulation. As 
an agonist of TLR-4, LPS initiates an inflammatory cascade that involves the 
upregulation of transcription factors such as NF-kB, inflammatory gene expression and 
inflammatory cytokine production such as IL-6, TNFa and IL-1 β. This cascade of 
events occurs not only in circulation but also in adipocytes promoting adipogenesis, 
adipose tissue ‘whitening’ and subsequently, obesity (McArdle et al., 2013). However, 
selective targeting of the microbiota by prebiotics to restore microbial balance can 
prevent/correct this cascade of events, which dampens the inflammatory response, 
restores metabolism and subsequently reduces obesity (Cani et al., 2007, Cani et al., 
2009, Everard et al., 2014). 
 Disruption of normal commensal gut microbiota composition can occur during 
early-life which may have implications for future metabolic health. The composition of 
the infant gut microbiota is mediated by maternal health status, antibiotics, birth 
delivery mode and early-life feeding practices (Bäckhed et al., 2015). Hence, 
disruptions to early-life microbiota development can induce a state of dysbiosis that 
disrupts metabolic, immunological and even central nervous system functioning, which 
elevates chronic disease risk in later life. Indeed, a parental western diet is associated 
with elevated plasma LPS and heightened colonic immune responses in standard chow-
fed mice offspring (Myles et al., 2013). These immune modulating responses were 
dependent upon the comprehensive changes induced to the offspring microbiota, as a 
result of the parental diet. Consequently, as the maternal microbiota correlates with that 






composition may therefore enhance infant microbiota development. Recently, it was 
shown that selective modulation of the obese murine maternal microbiota, through 
prebiotic feeding, significantly reduced offspring adiposity, which was associated with 
beneficial changes to the offspring microbiota such as enhanced Bifidobacteria 
abundance (Paul et al., 2016).  
 Although it has been shown that high fat diets contribute to perturbation in gut 
microbial balance and inflammation-induced obesity, recent evidence suggests that 
saturated and polyunsaturated fats (PUFA) differ in their interaction with the gut 
microbiota and subsequent metabolic outcomes (Patterson et al., 2014, Caesar et al., 
2015). Omega-3 (n-3) and omega-6 (n-6) play opposing roles in the inflammatory 
response (Calder, 2006). n-6 PUFA typically up-regulate inflammation by acting as 
precursors to pro-inflammatory eicosanoids. Alternatively, n-3 PUFA resolve 
inflammation by competing within the same enzymatic pathway, thereby reducing n-6 
metabolism and the subsequent inflammatory cascade. The western diet however is 
characterized by high n-6/n-3 PUFA ratio, which many have suggested has contributed 
to the epidemic of chronic inflammatory diseases such as obesity (Simopoulos, 2002). 
The evolutionary ratio of n-6/n-3 PUFA has been estimated at 1:1, however this has 
increased to 10-50:1 in the modern western diet (Simopoulos, 2002). The importance of 
this ratio in metabolic disease has been widely studied in human and animals, and there 
is convincing evidence that lowering the n-6/n-3 ratio can restore disrupted metabolism 
in the context of chronic disease (Simopoulos, 2008, Simopoulos, 2016). From an early-
life perspective, lowering the n-6/n-3 ratio in obese mothers can reduce offspring weight 
gain and associated inflammatory outcomes in mice (Heerwagen et al., 2013). Similar 
results have been reported for improving insulin sensitivity (Hussain et al., 2013). 
Furthermore, observational and intervention studies in humans have found negative 
correlations for n-3 PUFA status and positive correlations for n-6 status and offspring 






 Indeed, n-6 and n-3 PUFA appear to have opposing effects on gut homeostasis. 
Relative to dietary n-6 PUFA, n-3 PUFA reduce Enterobacteriaceae abundance, elevate 
Bifidobacterium abundance and dampen intestinal inflammation partially through the 
up-regulation of certain anti-microbial peptides (Kaliannan et al., 2015). Similarly, 
unlike n-6 PUFA, n-3 PUFA prevent weight gain and metabolic disruptions induced by 
early-life antibiotic exposure (Kaliannan et al., 2016). The result of early-life n-3 PUFA 
status on the developing microbiota has also been explored (Robertson et al., 2016). We 
have recently reported that early-life n-3 PUFA deficiency induces a state of gut 
dysbiosis and behavioural impairments even before adolescence, suggesting a role for n-
3 PUFA within the developing gut-brain axis (Robertson et al., 2016).  
 Data on the role of maternal n-3 PUFA on offspring microbiota are limited. 
Recent evidence suggests that high doses of maternal fish oil supplementation impair 
the immune response in offspring and lead to the overgrowth of pathogenic bacteria 
(Gibson et al., 2015). However, these studies utilized crude fish oil in pharmacologicaly 
excessive doses (18% energy) and hence further studies are warranted to examine the 
relationship between nutritionally relevant maternal n-3 PUFA intake and offspring 
microbiota. In addition, the role of maternal n-3 PUFA intake in the context of offspring 
obesity and its association with gut microbiota has not been previously examined. 
Furthermore, there is a lack of evidence as to the differences between pre and post-natal 
n-3 PUFA status for offspring metabolic health. 
 Based on previous evidence reporting the critical opposing roles that n-3 and n-6 
PUFA play in microbiota-associated metabolic endotoxemia (Kaliannan et al., 2015), 
we aim to investigate this in the context of maternal n-6/n-3 PUFA status and 
subsequent effects on obese offspring. We hypothesize that, in comparison to a high 
maternal n-6/n-3 ratio, a balanced maternal n-6/n-3 ratio can reduce weight gain and 
inflammatory outcomes in obese offspring through modulation of the gut microbiota. To 






endogenous conversion of n-6 PUFA to n-3 PUFA (Kang et al., 2004). Therefore, using 
a single diet for both treatment groups, this model allows the generation of two 
phenotypes: (a) fat-1 mice with a balanced tissue n-6/n-3 ratio (~1:1) and (b) wild-type 
(WT) mice with a high n-6/n-3 ratio similar to the Western diet (>10:1). Our results 
show that a lower maternal n-6/n-3 ratio during gestation and/or lactation significantly 
reduces weight gain in offspring fed a HFD, which appears to be mediated through 
alterations in gut microbiota. 
 
 
2. MATERIALS AND METHODS 
2.1. Animals and diets 
Generation of transgenic fat-1 mice was performed as previously described (Kang et al., 
2004) followed by backcrossing onto a C57BL/6 background. Fat-1 phenotype was 
confirmed by gas-chromatography flame ionization detection (GC-FID) following 
identification of increased tissue n-3 PUFA compared with WT. Fat-1 genotype was 
confirmed by RT-PCR. Mice were housed in the Massachusetts General Hospital 
(MGH) animal facility in a biosafety room (Level 2) in hard top cages with filtered air. 
Mice were maintained in a temperature-controlled room (22– 24°C) with a 12h 
light/dark diurnal cycle. Food and water were provided ad libitum. A subset of 3-month 
old female C57BL/6 WT mice was purchased from Charles River Laboratories and 
allowed to acclimatize to the facility conditions for 1 week prior to mating. Fat-1 and 
WT mating pairs were fed a diet high in n-6 PUFA (AIN-76A with 10% corn oil) from 
LabDiet in order to maintain fat-1 and WT phenotypes. At postnatal day (PND) 28, 
male and female offspring were weaned onto a high fat diet (HFD) with 60% kcal from 
fat (D12492, Research Diets Inc). Detailed fatty acid profiles of both diets are outlined 






liquid nitrogen. All animal procedures in this study were performed in accordance with 
the guidelines approved by the MGH Subcommittee on Research Animal Care.  
 
2.2. Breeding and Cross fostering 
Three month-old female fat-1 and WT mice were mated with age-matched WT males. 
Mating pairs were housed in individual cages and males were separated from the 
females following confirmation of pregnancy. Within 48-hours of parturition, newborn 
litters were fostered to new mothers until weaning, at PND 28. Briefly, the newborn 
litter was removed from the biological mother’s cage then mixed with the bedding of 
the foster mother in the hand of the investigator. The litter was then placed in the empty 
nest of the new foster mother. The foster mother was held above the new litter until she 
urinated on the litter in order to disguise their scent. Foster mother pairs were chosen 
such that offspring were fostered to mothers whom had given birth within 48 hours to a 
litter of similar size. The cross-fostering procedure was carried out in order to generate 
offspring of four distinct experimental groups as follows: fat-1/WT group – fat-1 
biological mother, cross-fostered to WT mother; WT/fat-1 group – WT biological 
mother, cross-fostered to fat-1 mother; fat-1/fat-1 group – fat-1 biological mother, 
cross-fostered to new fat-1 mother; WT/WT group – WT biological mother, cross-
fostered to new WT mother. Cross-fostering was carried out in the fat-1/fat-1 and 
WT/WT groups as a control to the cross-fostering procedure in the other two groups. 
The study design is outlined in Fig. 1. 
 At PND 10, the tails of the offspring were clipped with a scissors and 
genotyping was performed on the tail tissue by RT-PCR. Following confirmation of 
genotype, fat-1 mice were removed from the litter such that only WT offspring 
remained. At PND28, WT offspring were separated from their mothers, grouped in 







2.3. Body weight, body composition and food intake 
Body weight and food intake were measured weekly using an electrical balance. Body 
composition (fat mass, lean mass, water mass) was assessed on the day of sacrifice 
using a Minispec mq bench-top NMR spectrometer (Bruker Instruments). 
 
2.4. Fatty acid analysis 
Fatty acid analysis of tail and liver tissues was performed as previously described (Kang 
and Wang, 2005). Briefly, frozen tissue samples were ground to a powder under liquid 
nitrogen using a mortar and pestle. Lipid extraction and fatty acid methylation was 
performed by the addition of 14% (w/v) boron trifluoride (BF3)-methanol reagent 
(Sigma-Aldrich) followed by heading at 100°C for 1h. Fatty acid methyl esters (FAME) 
were analyzed using a fully automated HP5890 gas chromatography system equipped 
with a flame-ionization detector (Agilent Technologies, Palo Alto, CA). The fatty acid 
peaks were identified by comparing their relative retention times with the commercial 
mixed standards (NuChek Prep, Elysian, MN), and area percentage for all resolved 
peaks was analyzed by using a PerkinElmer M1 integrator.   
 
2.5. Intestinal permeability 
Intestinal permeability was performed as described previously (Kaliannan et al., 2015). 
Briefly, mice were fasted for 6 h and then FITC-dextran (70kDA, Sigma-Aldrich, in 
PBS solution) was administered to mice by oral gavage at a dose of 600 mg/kg body 
weight. Following gavage, blood samples were collected from the facial vein after 90 
min. Serum was diluted with an equal volume of PBS, and fluorescence intensity was 
measured using a fluorospectrophotometer (Perkin-Elmer) with an excitation 
wavelength of 480nm and an emission wavelength of 520nm. Serum FITC-dextran 
concentration was calculated from a standard curve generated by serial dilution of 






2.6. Serum LPS 
Concentration of circulating serum LPS was measured using a ToxinSensor 
Chromogenic Limulus Amebocyte Lysate (LAL) Endotoxin Assay Kit (GenScript) 
according to manufacturers instructions. Prior to the assay, samples were diluted 50-fold 
with endotoxin-free water. Kit reagents were added to the serum samples followed by 
incubation at 37°C according to the assay protocol. Absorbance was read at 545nm and 
results generated from a standard curve. 
 
2.7. qPCR 
RNA extraction from tissue samples was carried out using TRIzol reagent (Invitrogen 
Life Technologies, Grand Island, NY), following the manufacturer’s instructions. RNA 
concentration (ng/ul) and purity (A260/280) of each sample was assessed using a plate 
reader. cDNA synthesis of RNA was performed using the  iScript cDNA Synthesis Kit 
(Bio-Rad) according to manufacturers instructions. qPCR was performed using SYBR 
Green reagent in a PRISM 9000 Light Cycler (Applied Biosystems). Primer sequences 
are detailed in Table S7. qPCR reactions were performed in triplicated and normalized 
to a house-keeping gene (β-actin). Gene expression was calculated using the ΔΔCt 
method.  
 
2.8. Stool DNA extraction and 16s sequencing 
Bacterial genomic DNA was extracted from mice fecal pellets using the QIAmp DNA 
Stool Mini Kit (Qiagen, UK) according to manufacturers instructions. DNA was 
quantified and purification was subsequently assessed by measuring absorbance and 
determining the A260/A280 ratio. DNA was stored at -20°C until analysis. 
16s sequencing library preparation was performed on DNA samples according to the 
Illumina 16S metagenomic sequencing library protocol in order to generate V3-V4 






specific for amplification of the V3-V4 region of the 16S rRNA gene (Forward primer 
5’ 
TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCAG; 
reverse primer 5’ 
GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGGTATCTA
ATCC). Clean-up and purification of the PCR product was performed using the 
Agencourt AMPure XP system (Labplan, Dublin, Ireland). Following clean-up and 
purification, a second PCR reaction was performed in order to incorporate a unique 
indexing primer pair to each sample (Illumina Nextera XT indexing primers, Illumina, 
Sweden). The PCR products were purified a second time using the Agencourt AMPure 
XP system. Quantification of samples was performed using the Qubit broad range DNA 
quantification assay kit (Bio-Sciences, Dublin, Ireland). Following quantification, 
samples were pooled in equimolar amounts (4nM) and sequenced at Clinical 




The 64-bit version of USEARCH (Edgar, 2013) and mothur (Schloss et al., 2009) is 
used in combination with several in-house programs for bioinformatic analysis of the 
sequence data. 
 Following tag identification and trimming, all sequences from all samples are 
pooled. Paired end reads are merged, truncating reads at a quality score of 4, requiring 
at least 100 bp overlap and a merged read length between 300 and 600 bp in length. 
Sequences with ambiguous bases, without perfect match to the primers, or 
homopolymer length greater than 8 are discarded and primer sequences trimmed. Reads 
are quality filtered, discarding reads with more than 5 expected errors and sequences are 






Sequences are clustered at 97 % sequence similarity, using the most abundant strictly 
dereplicated reads as centroids and discarding suspected chimeras based on internal 
comparison. Additional suspected chimeric OTUs are discarded based on comparison 
with the Ribosomal Database Project classifier training set v9 (Cole et al., 2014) using 
UCHIME (Edgar et al., 2011). Taxonomic assignment of OTUs is done using the 
method by Wang et al. (Wang et al., 2007) with mothur's PDS version of the RDP 
training database v14. 
 
2.10. Statistics 
Statistical analysis was performed using SPSS (v19, NY, USA) and Graphpad Prism 
(v6, CA, USA). One-way analysis of variance (ANOVA) was performed to assess 
differences between groups followed by Tukey’s or LSD post-hoc test. For the 16S 
sequencing data, non-parametric analysis was performed using the Kruskall-Wallis test 
followed by Mann-Whitney test. False Discovery Rate (FDR) analysis was calculated at 
p<0.05. Results are presented as mean ± standard error (SEM). Significance was 




3.1. Weights and Dietary Intake 
There were no significant differences in offspring weights at week 4 prior to 
introduction of the high fat diet (HFD) (Fig 2). In males, there were no significant 
differences in body weight gain between groups for the first five weeks on a HFD, 
however at week 6, WT/WT had gained significantly more weight than WT/fat-1 
(p<0.05). This effect was strengthened with continuation of the HFD and WT/WT 
continued to gain significantly more weight than all other groups throughout the 






gained 232% body weight, which was significantly greater (p=0.012) than all other 
groups (fat-1/WT – 189%; WT/fat-1 – 195%; fat-1/fat-1 – 197%). There was no 
significant difference in male food intake. 
 Interestingly, there were no differences in female body weight gain between 
groups following HFD feeding (Fig. 2), suggesting a gender difference of maternal n-3 
PUFA status on offspring weight gain. There was no significant difference in female 
food intake. 
 
3.2. Body composition 
Analysis of male body composition revealed that WT/WT displayed strong trends 
towards increased fat mass (p=0.08), reduced lean mass and increased subcutaneous fat 
weight (p=0.09) (Fig 3). There were no significant differences between female groups 
in body composition (Fig. S3).  
 
3.3. Fatty acid analysis 
The tail fatty acid profiles of mothers, offspring pre-HFD and offspring post-HFD are 
presented in table S3 and Fig 4. As expected, the n-6/n-3 PUFA ratio in tail tissue was 
significantly greater in WT mothers than fat-1 mothers (p<0.0001). Following four 
weeks of lactation, WT/WT male offspring displayed the highest tail n-6/n-3 ratio, 
which was significantly greater than all other groups (p<0.0001). Fat-1/fat-1 offspring 
displayed the lowest tail n-6/n-3 ratio. Interestingly, in the crossover groups, WT/fat-1 
offspring had a significantly lower n-6/n-3 ratio than fat-1/WT offspring. 
 Differences in adolescent tail n-6/n-3 ratio as a result of maternal genotype were 
eliminated following 3 months of HFD feeding. There were however, a small number of 
differences in individual tail fatty acids such that arachidonic acid (AA) was 
significantly greater in WT/WT offspring compared with all other groups (p=0.0004), 






differences in total n-6 PUFA, n-3 PUFA or the n-6/n-3 PUFA ratio in offspring liver 
(Table S4). Tail n-6/n-3 PUFA ratio pre-HFD positively correlated with total weight 
gain (R=0.24; p=0.006). Tail DHA pre-HFD negatively correlated with total weight 
gain (R=0.23; p=0.007). 
 
3.4. Microbiota 
16S Sequencing of the mothers, pre-HFD and post-HFD fecal microbiota generated a 
total of 23 million sequenced reads. Assessment of phylogenetic diversity using the 
Shannon Index revealed no significant differences between WT and fat-1 mothers or 
between post-HFD groups (Fig. 5A). However, microbial diversity as measured by the 
Shannon Index was significantly reduced in the WT/WT group compared with WT/fat-1 
prior to HFD feeding. Number of OTUs, Chao1 and Simpson indices were also assessed 
as measures of phylogenetic diversity (Fig. S9). Principle coordinate analysis (PCoA) 
revealed distinct clustering of WT and fat-1 mothers based on microbiota composition 
(Fig. 5B). Whole microbiome significance testing using PERMANOVA with Bray-
Curtis similarity index showed significant differences between fat-1 and WT mothers 
(p=0.0024). In the offspring, clustering was evident among treatment groups, as 
assessed using PERMANOVA with Bray-Curtis similarity index both pre HFD 
(p=0.0004) and post-HFD (p=0.0001). Both prior to and after HFD feeding, offspring 
clustered according to the lactating/foster mother’s genotype such that the fat-1/WT and 
WT/WT groups clustered together, and the fat-1/fat-1 and WT/fat-1 groups clustered 
together, according to Bray-Curtis similarity index.  
 Relative abundances of phylum level taxa revealed distinct differences between 
groups (Fig. 6). Firmicutes and Bacteroidetes, the two most abundant phyla, differed 
significantly in mothers and offspring groups.  In mothers, Firmicutes and 
Defferibacteres were significantly higher in WT mice compared with fat-1, whereas 






level taxa distribution appeared to be most significantly influenced by lactating/foster 
mother’s genotype as opposed to biological mother’s genotype. Hence, Firmicutes and 
the Firmicutes:Bacteroidetes ratio were also significantly greater in fat-1/WT offspring 
both pre-HFD and post-HFD. Firmicutes were also significantly greater in WT/WT 
offspring post-HFD. Consistent with the foster mother’s microbiota, fat-1/WT and 
WT/WT displayed significantly reduced Proteobacteria at both time points.  
 A number of significant differences were observed at family and genus levels 
also (Fig. 7 and 8). PCA analysis of family taxa revealed that Verrucomicrobiaceae 
contributed most strongly to the separation seen between fat-1 and WT mothers (Fig. 
S11). Due to the significant PCoA clustering between groups based on foster mother’s 
genotype, offspring were grouped according to the foster mother’s genotype and linear 
discriminant analysis effect size (LEfSe) was performed on these two groups (1. 
WT/fat-1 + fat-1/fat-1; 2. fat-1/WT + fat-1/fat-1) (Fig. 9 and 10). LEfSe analysis 
elucidated the observed phylum level differences such that offspring whom had a WT 
foster mother were more abundant in species within the Firmicutes phylum and 
offspring whom had a fat-1 foster mother were more abundant in species of the 
Bacteroidetes and Proteobaceria phyla. The elevated Proteobacteria were driven 
primarily by differences in Deltaproteobacteria, whereas Gammaproteobacteria 
appeared to be reduced (Fig. S10). Lachnospiraceae, a member of the class Clostridia, 
which is a member of the Firmicutes phyla, was significantly greater in WT mothers 
and in fat-1/WT and WT/WT offspring post-HFD. A similar trend was observed for 
Clostridia. Genera within the Lachnospiraceae family were also significantly elevated 
in fat-1/WT and WT/WT offspring, including Johnsonella, Coprococcus and 
Marvinbryantia. Members of the Proteobacteria phyla including Bilophila and 
Helicobacter were elevated in WT/fat-1 and fat-1/fat-1 groups. Verrucomicrobia 
appeared to be significantly elevated in fat-1/fat-1 offspring post-HFD, an effect which 






A number of the differences in post-HFD microbiota correlated with the previously 
observed phenotypes (Fig. 11). Firmicutes and Clostridia abundance displayed 
significantly positive correlations with offspring weight. Firmicutes and 
Lachnospiraceae abundance also positively correlated with the tail n-6/n-3 ratio prior to 
HFD feeding. Furthermore, Lachnospiraceae abundance positively correlated with 
intestinal permeability.  
 
3.5. Intestinal permeability  
The fat-1/fat-1 group exhibited the lowest intestinal permeability (p=0.05). Fat-1/fat-1 




Serum LPS was significantly lower in fat-1/WT compared with both fat-1/fat-1 and 
WT/WT (Fig. 11A). 
 
3.7. Adipose tissue inflammation 
There were no differences in mRNA expression of TNFa, F4/80 or CCL2 in 
subcutaneous adipose tissue however TLR4 expression appeared to be lower (p<0.05) in 
fat-1/WT compared with both fat-1/fat-1 and WT/WT (Fig S5).  
 
3.8. Cytokines 
There were no significant differences between groups in circulating serum IL-10, IL-1β, 










Much evidence exists indicating that obesity and its associated disorders have their 
origins in the fetal and neonatal periods (Oken and Gillman, 2003).  As the gut 
microbiota plays a critical role in the pathogenesis of these disorders and the chronic 
low grade-inflammation that defines them, nutrition research must now focus on 
maternal and early-life interventions that target the gut microbiota. The excessive global 
consumption of n-6 PUFA in place of n-3 PUFA has contributed to a trans-generational 
epidemic of microbiota-associated chronic disease. Hence, increased n-3 PUFA 
consumption provides huge potential as an effective therapeutic measure to stem the rise 
in the modern chronic disease epidemic. Here, we have shown that the maternal n-6/n-3 
ratio significantly regulates offspring weight gain during high fat feeding. We have 
shown for the first time, using a transgenic model, that maternal n-3 PUFA significantly 
reduce weight gain in high fat fed offspring in contrast to n-6 PUFA. We have also 
uniquely demonstrated that the differences in weight gain are associated with intestinal 
permeability and a modified gut microbiota in both mothers and offspring. Specifically, 
postnatal maternal n-3 PUFA appear to reduce the abundance of Firmicutes, 
Lachnospiraceae and Clostridia in offspring, which correlates with body weight, an 
effect that persists into adulthood. These results suggest that maternal tissue fatty acid 
content during gestation and milk fatty acid composition during lactation can 
significantly affect offspring weight, independent of offspring diet after lactation. 
Consequently, maternal n-3 PUFA intake may act as a suitable intervention to prevent 
excessive weight gain in offspring and the associated gut microbiota modifications that 
may have a causal effect. 
 Maternal n-3 PUFA status has previously been associated with offspring weight 
and adiposity in humans (Donahue et al., 2011). Maternal n-6 PUFA are positively 
associated and n-3 PUFA negatively associated with weight gain and fat mass 






may contribute to this. Firstly, maternal n-3 PUFA correlate with umbilical cord and 
infant n-3 PUFA (Donahue et al., 2009), therefore the beneficial effects on weight may 
be attributed to direct nutrient transport from mother to infant. This was demonstrated in 
the current study, in which fat-1/fat-1 mice had the lowest tail n-6/n-3 ratio at weaning 
demonstrating that the n-3 PUFA produced by the fat-1 mothers were vertically 
transmitted to the offspring both in utero and through the milk. It has previously been 
shown that the n-6/n-3 ratio is significantly lower in fat-1 milk than WT (Kang et al., 
2004). This reduced n-6/n-3 ratio in the offspring may therefore have had a direct 
impact on reduced weight gain through mechanisms involving reduced adipogenesis as 
has been described previously (Kim et al., 2015). The fat-1/WT group had a higher n-
6/n-3 ratio than the WT/fat-1 group. Interestingly, this suggests that the offspring n-3 
status is more influenced by the dietary n 3 PUFA during lactation, via milk, rather than 
maternal n 3 PUFA status during gestation. The lactation period in the current study was 
however slightly longer (4 weeks) than gestation (3 weeks), which may have 
contributed to the differences observed in fatty acid status. However, as discussed 
below, the obese phenotypes and microbiota of the offspring appeared to be much more 
heavily influenced by the foster mothers fatty acid status rather than the biological 
mothers fatty acid status suggesting that maternal n-3 PUFA status is more influential 
during the lactation period rather than gestation.  
 Interestingly, there appeared to be a strong gender difference between male and 
female offspring regarding weight gain as a result of maternal n-3 status. WT/WT males 
gained significantly more weight on a HFD than all other groups suggesting that 
maternal n-3 PUFA either in utero or during lactation could reduce weight gain in obese 
offspring. However, no significant differences were observed between groups in female 
offspring. Gender-dependent differences have been reported before regarding n-3 status 
and weight (Howe et al., 2014, Thorsdottir et al., 2007). It has been shown that fish oil 






but not in females (Thorsdottir et al., 2007) suggesting a gender-dependent reaction. 
Interestingly however, other clinical studies report conflicting evidence regarding the 
efficacy of n-3 in reducing weight in females and males (Howe et al., 2014). Females 
have a greater capacity to convert ALA to EPA and DHA (Burdge and Wootton, 2002, 
Burdge et al., 2003), which may contribute to such observations in humans. Indeed 
female sex hormones interfere with the activity of the desaturase and elongase enzymes 
involved in PUFA metabolism (Decsi and Kennedy, 2011, Childs et al., 2008) and 
hence it has been suggested that gender should always be considered in studies 
regarding n-3 PUFA (Lohner et al., 2013). In the present study, there did not appear to 
be a difference between male and female n-6/n-3 tail fatty acid ratios prior to HFD. 
However, it has previously been shown that sex differences occur in adipogenesis, 
which are mediated by the effect of female sex hormones (Greenhill, 2016). These 
differences are removed in ovarectomized mice (Stubbins et al., 2012). In addition to 
differences in weight, there were subtle differences in glucose tolerance pre-HFD, 
which were eliminated following HFD feeding (Fig. S1). Insulin sensitivity appeared to 
be differentially regulated post-HFD with the fat-1/fat-1 group displaying the lowest 
insulin area under the curve (AUC) following glucose administration (Fig. S2). Hence 
maternal n-3 status also appeared to subtly influence glucose metabolism. 
 Another mechanism by which the maternal fatty acid status may influence 
offspring weight is through immune regulation. It is possible that the lower n-6/n-3 ratio 
in fat-1 mothers dampened maternal and placental inflammation, which induced an anti-
inflammatory and anti-obesigenic environment in the offspring. This has been 
demonstrated previously using the same fat-1 model in which maternal obesity induced 
maternal and placental inflammation, which was transmitted to the offspring resulting in 
a number of metabolic disruptions that were reversed in offspring of fat-1 mothers 
(Heerwagen et al., 2013). Inflammation plays an important role in obesity and insulin 






adipogenesis (Greenberg and Obin, 2006). Interestingly however, circulating serum 
cytokines did not appear to differ between offspring groups (Fig. S6). This was also 
reflected in adipose tissue, where inflammatory gene expression in the offspring 
appeared to be mostly unchanged by maternal n-3 status. TLR4 expression however, 
was significantly increased in WT/WT mice. This result is consistent with that for 
circulating LPS, which is an agonist of TLR4. A similar trend in these data suggests that 
the differences in serum LPS induced the elevation in TLR4 expression, which may 
initiate low grade chronic inflammation and hence the observed increase in weight gain. 
However both of these increases were also observed in the fat-1/fat-1 group.  
 Finally, the differing microbiota profiles between fat-1 and WT mothers may 
have been passed somewhat onto the offspring thereby contributing to weight gain. The 
composition of an infant’s microbiota is strongly influenced by that of the mother 
(Bäckhed et al., 2015). Therefore, the anti-inflammatory fat-1 microbiota that has been 
described previously (Kaliannan et al., 2015) may have been partially passed on to the 
offspring thereby reducing the microbiota-associated weight gain. The gut microbiota 
have a well-established role in energy metabolism and obesity (Turnbaugh et al., 2009) 
by regulating energy harvest from macronutrients. The ratio of the two most dominant 
phyla, Firmicutes and Bacteroidetes, is considered a strong biomarker of weight gain 
(Turnbaugh et al., 2006). Firmicutes are known for more potent energy harvest capacity 
and are more abundant in states of obesity. This is thought to be due to their increased 
capacity to harvest energy from the diet. Interestingly, we found that Firmicutes were 
significantly higher in WT mothers than fat-1 mothers. This was then transmitted to the 
offspring such that fat-1/WT and WT/WT displayed higher Firmicutes than both other 
groups. This increase in Firmicutes correlated significantly with both weight and n-6/n-
3 status. One of the mechanisms by which Firmicutes contribute to obesity is through 
microbial fermentation of dietary polysaccharides that cannot be digested by 






chain fatty acids (SCFA) such as acetate and butyrate, which could contribute up to 
10% of caloric intake (Bergman, 1990). Interestingly, the observed differences in 
weight gain were independent of dietary intake, which did not differ, suggesting that the 
WT/WT microbiota displayed an increased capactity for energy harvest. Indeed, a 
number of genera within the Firmicutes phyla that are involved in SCFA production 
were elevated in WT/WT including Pseudobutyivibrio, Roseburia, Robinsoniella and 
Johnsonella. Previously it has been shown that SCFA and such SCFA-producing 
species are elevated in states of obesity (Turnbaugh et al., 2006).  
 Erysipelotrichaceae, Lachnospiraceae and Clostridia were also all elevated in 
WT/WT and fat-1/WT and have all previously been associated with obesity through 
disrupted lipid metabolism and cholesterol homeostasis (Nadal et al., 2009, Zhang et al., 
2009). Interestingly, the increase in Lachnospiraceae correlated positively with the 
observed increase in intestinal permeability in fat-1/WT and WT/WT animals. This 
correlation has been observed before in alcohol dependent subjects who display gut 
dysbiosis (Leclercq et al., 2014). Lachnospiraceae therefore, and the genera it 
encompasses, appear to be elevated by n-6 PUFA leading to increased gut permeability 
and weight gain. This effect was independent of changes to tight junction protein 
expression (Fig. S4). Proteobacteria and a number of associated genera appeared to be 
higher in fat-1 mothers and offspring with fat-1 foster mothers. This has been reported 
previously following fish oil feeding (Caesar et al., 2015). However, it has previously 
been reported that male fat-1 mice display lower Protebacteria than WT, contradicting 
the results found in the present study in females (Kaliannan et al., 2015). Proteobacteria 
are divided into a number of classes including Deltaproteobacteria, 
Alphaproteobacteria, Gammaproteobacteria and Epsilonproteobacteria. Interestingly, 
the observed increase in Proteobacteria in fat-1 mothers and their foster offspring were 
driven by Deltaproteobacteria, whereas Gammproteobacteria appeared to be similar or 






reducing species whereas Gammproteobacteria (enterobacteriaceae family) contain a 
number of pathogenic endotoxin-producing species such as Escherichia coli, that 
contribute to low-grade chronic inflammation and are elevated in states of metabolic 
disruption. Hence, the different Proteobacteria classes may be differentially regulated by 
n-3 PUFA and subsequently exert differential effects on metabolic health. Previously, it 
was shown that Bilophila wadsworthia, a genus within the Deltaproteobacteria class, 
was significantly elevated in offspring of mothers fed fish oil in pharmacological excess 
(Gibson et al., 2015). Hence, Proteobacteria abundance may be more closely regulated 
by maternal n-3 PUFA status rather than direct dietary intake and further research is 
warranted to evaluate this effect on metabolic health. The overall contribution of 
Desulfovibrionaceae did not appear to contribute strongly to separation between WT 
and fat-1 mothers in PCA loading (Fig. S11). Verrucomicrobiaceae, the family to which 
Akkermansia belong, appeared to contribute strongly to this separation, being more 
highly abundant in fat-1 mothers. Akkermansia has garnered a lot of interest in recent 
times as a potent regulator of metabolic health during obesity in both animals and 
humans (Dao et al., 2016, Schneeberger et al., 2015). 
 Interestingly, as with the n-6/n-3 ratio, the gut microbiota of the offspring 
appeared to strongly match that of the lactating/foster mother rather than the biological 
mother. Therefore, WT/WT and fat-1/WT had similar microbiota composition, as did 
WT/fat-1 and fat-1/fat-1. These microbiota outcomes correlated strongly with the fatty 
acid status, weight and other phenotypes. Indeed, it has been assumed that the fetus is 
sterile, however recent studies may suggest otherwise (Aagaard et al., 2014). The 
biological mother imprints a unique microbiota on the infant at birth (Bäckhed et al., 
2015). The results reported here suggest that the ‘birth microbiota’ is quickly and 
comprehensively altered by the foster mother’s microbiota, through differences in 
milk/dietary fatty acids following birth. These results would suggest that n-3 PUFA 






maternal fatty acid status during gestation. Furthermore, despite the differences in n-3 
and n-6 PUFA disappearing in adulthood after HFD, the observed differences in the 
microbiota persisted, suggesting that maternal fatty acid status and early neonatal 
feeding regime may have a permanent effect on the offspring microbiota throughout 
life.  
 This study has demonstrated for the first time using this unique transgenic model 
that maternal n-3 PUFA can significantly reduce weight gain in high fat fed offspring 
compared with maternal n-6 PUFA. This unique study design has demonstrated that the 
effect on weight is mediated by the gut microbiota, which is characterized during the 
post-natal period. Importantly, these effects on weight gain and gut microbiota 
composition induced by maternal n-3 status persist into adulthood even after the 
differences in fatty acid status disappear. These results have important implications for 
the current chronic disease epidemic. Obesity and related metabolic diseases partially 
originate in utero and during the neonatal period. Hence dietary interventions are now 
necessary during such early-life periods to prevent chronic disease risk. The gut 
microbiota is now appreciated as a root cause of chronic disease and hence a vital target 
for therapeutic dietary interventions. We have shown that a high maternal n-6/n-3 ratio 
can induce dysbiosis to the offspring microbiota, which persists throughout life. Re-
balancing of this maternal ratio by elevating n-3 PUFA, primarily during the lactating 
period, has the potential to reduce excess weight gain during periods of high fat/calorie 
intake and the associated gut dysbiosis. Hence, maternal n-3 PUFA supplementation 
may stem the increase in global obesity and its related disorders through interaction 
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Figure 1. Experimental design. fat-1 and WT mothers were mated whilst on a high n-6 PUFA 
diet (10% corn oil). At birth, WT offspring were cross-fostered to different mothers for the 
period of lactation (four weeks) to produce four experimental groups based on the mothers’ 
genotype (biological mother’s genotype/foster mother’s genotype): fat-1/WT, WT/fat-1, fat-
1/fat-1, WT/WT. During lactation, mothers were continued on a high n-6 PUFA diet. After 4 
weeks of lactation, offspring were weaned onto a high fat diet (HFD) (60% kcal from fat) for 3 


















































































































































Figure 2. Weight gain on a HFD. WT/WT male offspring gained significantly more weight on 
a HFD than all other groups (A and C). However there were no significant differences between 
female offspring groups following HFD feeding (B and D). Data shown as mean ± SEM. n= 5-
10 per group. *p < 0.05 and **p < 0.01, WT/WT vs. WT/fat-1; # p < 0.05 and ## p < 0.01 


































































































































Figure 3. Male offspring body composition. WT/WT male offspring trended towards greater 
weight (A), total fat mass (B), subcutaneous fat mass (C) and lower lean mass (D) although not 













Figure 4. Tail n-6/n-3 fatty acid ratio. WT mothers displayed a significantly greater tail n-6/n-
3 ratio compared with fat-1 mothers (A). Following lactation for four weeks and prior to HFD, 
WT/WT had significantly greater tail n-6/n-3 ratio compared with all other groups (B). 
However, after 3 months on a HFD, differences in tail n-6/n-3 fatty acid ratio were eliminated 
and there were no significant differences between groups (C). Total weight gain showed a 
significantly positive correlation with pre-HFD n-6/n-3 ratio (D) and a negative correlation with 
pre-HFD DHA (E). Data shown as mean ± SEM. n= 8-15 per group. Bars with different letters 

























































































































































































































Figure 5. Microbiota diversity. Phylogenetic diversity as measured by the Shannon index did 
not differ between mothers or post-HFD groups, however appeared to be reduced in WT/WT 
compared with WT/fat-1 before HFD feeding (A). Principle coordinate analysis (PCoA) 
revealed clustering of groups based on foster mother genotype (B). Data shown as mean ± SEM. 



























































































Figure 6. Phylum level distribution of fecal microbiota. Fecal microbiota composition 
differed significantly between groups at phylum level. Firmicutes appeared to be more abundant 
in WT mothers and offspring with WT foster mothers. This contributed to a significantly greater 
Firmicutes:Bacteroidetes ratio in fat-1/WT offspring. Data shown as mean ± SEM. n= 5-10 per 
















Figure 7. Phylum, family and genus level distribution of fecal microbiota. Fecal microbiota 
composition differed significantly between groups at different taxonomic levels. Trends 
observed in mothers appeared to be associated with those of foster offspring. RA (%), Relative 
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Figure 8. Heatmap of taxa of significantly different abundance between offspring groups.  Normalized data of fecal microbiota abundance revealed distinct 
differences between offspring groups. Microbiota composition appeared similar in groups of the same foster mother genotype. Data normalized per taxonomic read. 





















Figure 9. LEfSe analysis of pre-HFD differential taxa based on foster mother genotype. Least discriminant analysis of effect size (LEfSe) on clustered groups 
based on maternal genotype revealed that Firmicutes were more abundant in offspring of WT foster mothers whereas Bacteroidetes and Proteobacteria were more 























Figure 10. LEfSe analysis of post-HFD differential taxa based on foster mother genotype. Least discriminant analysis of effect size (LEfSe) on clustered groups 
based on maternal genotype revealed that Firmicutes were more abundant in offspring of WT foster mothers whereas Bacteroidetes and Proteobacteria were more 
abundant in offspring of fat-1 foster mothers. 
Chapter 4 
   
 
Figure 11. Fecal microbiota correlations with obese phenotypes. fat-1/fat-1 offspring 
displayed the lowest gut permeability, whereas fat-1/WT displayed the lowest circulating LPS 
(A). WT mothers, fat-1/WT and WT/WT offspring displayed significantly greater 
lachnospiraceae (B) and Firmicutes (D). Clostridia, the class to which lachnospiraceae belongs, 
correlated positively with offspring weight while lachnospiraceae correlated positively with pre-
HFD n-6/n-3 ratio and intestinal permeability (C). Firmicutes abundance also positively 
correlated with weight and pre-HFD n-6/n-3 ratio (E). Data shown as mean ± SEM. n= 5-10 per 
































































































































































































































































































































































































































































































































Figure S1. Glucose tolerance prior and post HFD. Maternal n-3 PUFA status did not 
significantly impact fasting glucose either prior to (A) or after 10 weeks (B) HFD feeding. 
WT/WT glucose was significantly higher than WT/fat-1 at two time points during the pre-HFD 
GTT (C) however no significant differences were observed post-HFD. No significant 
differences were observed in the AUC of the GTT either prior to (E) or after (F) HFD feeding. 





























































































































































































































Figure S2. Insulin sensitivity. Maternal n-3 PUFA status did not significantly impact baseline 
fasting glucose after 12 weeks HFD feeding (A). fat-1/fat-1 and WT/WT glucose were 
significantly lower than fat-1/WT at three time points during the ITT (B). fat-1/fat-1 AUC 
during the ITT was significantly lower than fat-1/WT (C). Data shown as mean ± SEM. n= 8-10 



















































































































































































































































Figure S4. Ileal tight junction protein expression. WT/WT trended towards lower occluding 

















Figure S5. Subcutaneous adipose tissue inflammatory gene expression. There were no 
significant differences in subcutaneous adipose tissue expression of CCL2, F4/80 or TNFα. 




































































































































Figure S6. Circulating serum cytokines. There were no significant differences in male 













Figure S7. Fasting insulin. There were no significant differences in fasting insulin or 
homeostatic model assessment of insulin resistance (HOMA-IR) in adult male offspring after 





















































Figure S8. Liver triglycerides. There were no significant differences in liver triglycerides in 





Figure S9. Alpha diversity of 16S microbiota. Phylogenetic diversity of mothers microbiota 
did not differ between groups. In pre-high fat diet (HFD) male offspring fat-1/WT diversity was 
higher than fat-1/fat-1 and WT/fat-1 offspring as assessed by number of operational taxonomic 
units (OTUs) and the Chao1 index. Fat-1/WT and WT/WT also displayed a greater number of 





























































































































































































































































Figure S10. Proteobacteria abundance. Deltaproteobacteria abundance was lower in WT 
mothers and offspring with WT foster mothers. Gammaproteobacteria however was either not 





































































































































































Figure S11. Family distribution. PCA clustering of top ten most abundant taxa at family level 
revealed that elevated Verrucomicrobiaceae in fat-1 contributed strongly to separation between 






































Table S1. Fatty acid profile of diet 
 
Fatty acid Diet 
  10% corn oil HFD 
C8:0 0.11 0 
C10:0 0.27 0.04 
C12:0 0.7 0.08 
C14:0 0 1.1 
C15 0 0.08 
C16 0 19.6 
C16:1 0.5 1.34 
C17:0 0 0.35 
C18:0 2.36 10.6 
C18:1 28.2 34.0 
C18:2 n-6 52.3 28.7 
C18:3 n-3 1.1 2.04 
C20:0 0 0.16 
C20:1 0 0.59 
C20:2 n-6 0 0.79 
C20:3 n-6 0 0.12 
C20:4 n-6 0 0.28 
C20:5 n-3 0 0 
C22:5 n-3 0 0.08 
C22:6 n-3 0 0 
SFA 18.2 32 
MUFA 28.4 36 
PUFA 53.4 32 
n-6 PUFA 52.3 29.9 
n-3 PUFA 1.1 2.1 
n-6/n-3 47.6 14.1 
 









   












































SFA, Saturated fatty acids; MUFA, Monounsaturated fatty acids; PUFA, Polyunsaturated fatty acids; HFD, High fat diet. Values with different 
superscript letters are significantly different between groups within timepoint. Data expressed as mean ± SEM. n=5-10 per group
Tail fatty acid profile 
  Mothers Pre-HFD (week 4) Post-HFD (week 17) 
  WT fat-1 fat-1/WT WT/ fat-1 fat-1 fat-1 WT/WT fat-1/WT WT/ fat-1 fat-1 fat-1 WT/WT 
SFA                     
12:0 0.6 ± 0.1 2.1 ± 0.3 3 ± 0.2 3 ± 0.2 2.3 ± 0.1 3 ± 0.2 1.4 ± 0
a  1.2 ± 0b      1.3 ± 0a b      1.3 ± 0a b      
14:0 0.1 ± 0 0.4 ± 0.1 0.2 ± 0 0.2 ± 0 0.1 ± 0 0.2 ± 0 0.3 ± 0 0.3 ± 0 0.3 ± 0 0.3 ± 0 
16:0 14.8 ± 0.3
a   18.3 ± 0.4b      16.4 ± 0.2 16.9 ± 0.2 16.2 ± 0.1 16.4 ± 0.3 12.7 ± 0.1 13 ± 0.2 12.7 ± 0.2 13 ± 0.4 
17:0 0.5 ± 0 0.5 ± 0 0.5 ± 0 0.5 ± 0 0.5 ± 0 0.5 ± 0 0.2 ± 0
a  0.2 ± 0a b      0.2 ± 0a b      0.2 ± 0b      
18:0 10.2 ± 0.3 11.6 ± 0.4 10.8 ± 0.3 10.9 ± 0.4 10.8 ± 0.4 10.4 ± 0.3 3.4 ± 0.1
a  4.4 ± 0.3a b      5 ± 0.7b      5 ± 0.4b      
20:0 1.5 ± 0.1 1 ± 0.1 1.1 ± 0.1 0.9 ± 0 1 ± 0.1 1.1 ± 0.1 0.4 ± 0
a  0.6 ± 0a b      0.5 ± 0a  0.6 ± 0.1b      
22:0 2.5 ± 0.2 1.6 ± 0.1 2.4 ± 0.4 1.9 ± 0.1 2.4 ± 0.2 1.9 ± 0.1 0.6 ± 0
a  0.6 ± 0a  0.5 ± 0a  0.9 ± 0.1b      
24:0 3.1 ± 0.2 2.8 ± 0.2 3.7 ± 0.2 3.4 ± 0.2 3.5 ± 0.2 3.6 ± 0.2 1.1 ± 0.1
a c    0.9 ± 0.1b      0.8 ± 0.1b      1.2 ± 0.1c   
Total SFA  29.8 ± 0.5 38.2 ± 0.8 39.4 ± 0.4 39 ± 0.6 38.2 ± 1.2 38.3 ± 0.7 20.4 ± 0.2
a   21.3 ± 0.4a b      21.4 ± 0.7a b      22.7 ± 0.7b      
MUFA                      
14:1 0.4 ± 0 0.4 ± 0 0.4 ± 0 0.4 ± 0 0.4 ± 0 0.4 ± 0 0.2 ± 0
a  0.2 ± 0a  0.2 ± 0a b      0.2 ± 0b      
16:1 6 ± 0.7 5.4 ± 0.2 3.4 ± 0.1 3.6 ± 0.2 3.3 ± 0.2 3.5 ± 0.2 11.4 ± 0.3
a  10.2 ± 0.3b      11.2 ± 0.2a b      10.4 ± 0.3a b      
17:1 0.5 ± 0.1 0 ± 0 0.4 ± 0 0.4 ± 0 0.5 ± 0 0.4 ± 0 0.5 ± 0 0.5 ± 0 0.5 ± 0 0.5 ± 0 
18:1 31.2 ± 1.4
a  30.1 ± 0.3b      22.1 ± 0.4 22.7 ± 0.4 22.7 ± 0.5 22.8 ± 0.4 38.5 ± 0.3a b      39.3 ± 0.7a  37.9 ± 1.5a b      35.7 ± 0.4b      
20:1 2.2 ± 0.1 2 ± 0.1 1.8 ± 0.1 1.7 ± 0.1 1.8 ± 0.1 2 ± 0.1 0.8 ± 0.1 1.3 ± 0.2 1.3 ± 0.1 1.3 ± 0.1 
22:1 1.6 ± 0.2 1.5 ± 0.1 1.2 ± 0.1 1 ± 0.1 1.5 ± 0.3 1.3 ± 0.1 0.3 ± 0
a  0.4 ± 0.1a b      0.5 ± 0.1a b      0.6 ± 0b      
24:1 1.6 ± 0
a  1.6 ± 0.1b      1 ± 0.1 1 ± 0.1 1.3 ± 0.1 1.1 ± 0 0.3 ± 0a  0.4 ± 0.1a b      0.3 ± 0a b      0.6 ± 0.1b      
MUFA  43.4 ± 1.9
a  40.9 ± 0.7b      30.3 ± 0.7 30.8 ± 0.7 31.4 ± 0.8 31.6 ± 0.5 52.1 ± 0.3a b      52.4 ± 0.8a  51.9 ± 1.3a b      49.3 ± 0.5b      
PUFA                       
n-6 PUFA         
  
  
   
  
18:2 n-6 15.5 ± 1 12 ± 0.6 16.5 ± 0.4 16.9 ± 0.4 16.9 ± 0.7 17.4 ± 0.3 20.9 ± 0.3 19.6 ± 0.4 20.5 ± 0.4 20 ± 0.3 
18:3 n-6 0 ± 0
a  0.2 ± 0b      0.1 ± 0 0.1 ± 0 0.1 ± 0 0.1 ± 0 0.1 ± 0 0.1 ± 0 0.1 ± 0 0.1 ± 0 
20:2 n-6 1.2 ± 0.2 0.9 ± 0.1 1.2 ± 0.1 1.2 ± 0 1 ± 0 1.1 ± 0.1 0.7 ± 0 0.7 ± 0.1 0.8 ± 0 0.9 ± 0.1 
20:3 n-6 0.3 ± 0.1 0.2 ± 0 0.7 ± 0 0.7 ± 0 0.5 ± 0.1 0.6 ± 0 0.3 ± 0 0.3 ± 0 0.3 ± 0 0.4 ± 0 
20:4 n-6 4.7 ± 0.7
a  0.8 ± 0.1b      9.1 ± 0.4 8.3 ± 0.4 8.8 ± 0.6 8.2 ± 0.4 2.7 ± 0.1a  2.6 ± 0.2a  2.3 ± 0.2a  3.4 ± 0.1b      
22:4 n-6 0.7 ± 0.1 0 ± 0 1.7 ± 0.1 1.4 ± 0.1 1.4 ± 0.1 1.7 ± 0.1 0.5 ± 0
a b      0.5 ± 0.1a b      0.5 ± 0a  0.7 ± 0b      
Total n-6 PUFA   0.9 ± 0.2a  14 ± 0.6b      29.2 ± 0.9 28.6 ± 0.9 28.7 ± 1.5 29.2 ± 0.9 25.3 ± 0.3 23.8 ± 0.6 24.4 ± 0.6 25.4 ± 0.3 
n-3 PUFA         
  
  
   
  
18:3 n-3 0.1 ± 0 2.2 ± 0.2 0.1 ± 0 0.1 ± 0 0.1 ± 0 0.1 ± 0 1.2 ± 0
a b      1 ± 0b      1.3 ± 0.1a  1.3 ± 0a  
20:3 n-3 0 ± 0
a  0.2 ± 0b      0 ± 0 0 ± 0 0 ± 0 0 ± 0 0.1 ± 0 0.1 ± 0 0.1 ± 0 0.2 ± 0 
20:5 n-3 0 ± 0
a  1.7 ± 0.2b      0 ± 0 0 ± 0 0 ± 0 0 ± 0 0.1 ± 0 1.2 ± 0.7 0 ± 0 0.1 ± 0 
22:5 n-3 0 ± 0
a  1.7 ± 0.2b      0.2 ± 0a  0.4 ± 0.1b      0.4 ± 0.1b      0.2 ± 0a  0.3 ± 0a  0.2 ± 0a b      0.2 ± 0b      0.3 ± 0a b      
22:6 n-3 0.8 ± 0.2 1.3 ± 0.1 0.9 ± 0
a b      1.1 ± 0.1b c     1.2 ± 0.1c     0.7 ± 0.1a  0.7 ± 0.1 0.8 ± 0.1 0.7 ± 0.1 0.8 ± 0.1 
Total n-3 PUFA  22.5 ± 1.8a  7 ± 0.6b      1.1 ± 0.1 1.6 ± 0.2 1.7 ± 0.1 0.9 ± 0.1 2.3 ± 0.1 2.5 ± 0.3 2.3 ± 0.1 2.5 ± 0.1 
n-6/n-3 38.1 ± 8
a  2.1 ± 0.2b      26.7 ± 1.1 18.6 ± 1.5 16.8 ± 1 33.5 ± 2.6 11.3 ± 0.3 10.3 ± 0.8 10.7 ± 0.4 10 ± 0.3 
Chapter 4 
   





  Liver 
  fat-1/WT WT/fat-1 fat-1/fat-1 WT/WT 
SFA          
12:0 0.5 ± 0 0.5 ± 0 0.5 ± 0 0.5 ± 0 
14:0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 
16:0 26.8 ± 0.3 25.9 ± 0.6 26.8 ± 0.8 25.1 ± 0.8 
17:0 0.2 ± 0 0.2 ± 0 0.2 ± 0 0.2 ± 0 
18:0 3.7 ± 0.2 5.5 ± 0.6 5 ± 0.5 4 ± 0.4 
20:0 0.1 ± 0a  0.2 ± 0b      0.2 ± 0b     c   0.2 ± 0a c   
22:0 0.1 ± 0 0.2 ± 0 0.2 ± 0 0.1 ± 0 
24:0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 
Total SFA  31.4 ± 0.4 32.6 ± 0.8 32.9 ± 1.3 30 ± 1.1 
MUFA          
14:1 0.1 ± 0 0.1 ± 0 0.1 ± 0 0.1 ± 0 
16:1 3.2 ± 0.3 2.6 ± 0.2 2.6 ± 0.2 2.9 ± 0.2 
17:1 0.3 ± 0 0.3 ± 0 0.3 ± 0 0.3 ± 0 
18:1 42.2 ± 0.6 36.5 ± 1.6 38.2 ± 1.9 39.3 ± 1.6 
20:1 1 ± 0.1 0.9 ± 0 0.9 ± 0.1 1 ± 0.1 
22:1 0.1 ± 0 0.1 ± 0 0.1 ± 0 0.1 ± 0 
24:1 0 ± 0 0 ± 0 0 ± 0 0 ± 0 
MUFA 46.8 ± 0.9 40.4 ± 1.8 42 ± 2.2 43.6 ± 1.8 
PUFA          
n-6 PUFA   
  
  
18:2 n-6 15.3 ± 0.4a  17.7 ± 0.6a b      17.4 ± 0.7a b      18 ± 0.5b      
18:3 n-6 0.3 ± 0 0.3 ± 0 0.4 ± 0 0.4 ± 0 
20:2 n-6 0.3 ± 0 0.3 ± 0 0.3 ± 0 0.4 ± 0 
20:3 n-6 0.8 ± 0a  0.9 ± 0a b      0.9 ± 0.1a b      1 ± 0b      
20:4 n-6 2.7 ± 0.1 4.4 ± 0.7 3.5 ± 0.3 3.5 ± 0.3 
22:4 n-6 0.3 ± 0 0.3 ± 0 0.3 ± 0 0.4 ± 0 
Total n-6 PUFA  19.7 ± 0.7a  24.1 ± 1.3b      22.7 ± 1.1a b      23.6 ± 0.7a b      
n-3 PUFA    
  
  
18:3 n-3 0.4 ± 0 0.5 ± 0 0.5 ± 0 0.5 ± 0 
20:3 n-3 0.1 ± 0 0 ± 0 0 ± 0 0 ± 0 
20:5 n-3 0.1 ± 0 0.2 ± 0 0.1 ± 0 0.1 ± 0 
22:5 n-3 0.3 ± 0 0.3 ± 0 0.3 ± 0 0.3 ± 0 
22:6 n-3 1.3 ± 0.1 2 ± 0.4 1.6 ± 0.2 1.8 ± 0.1 
Total n-3 PUFA  2.1 ± 0.2 3 ± 0.5 2.4 ± 0.3 2.8 ± 0.2 




SFA, Saturated fatty acids; MUFA, Monounsaturated fatty acids; PUFA, Polyunsaturated fatty acids. Values with 









Table S4. Mothers taxa significantly different between groups 
  Mothers 
Taxonomy fat-1 WT P-value 
FDR 
corrected 
Bacteroidetes,Bacteroidia,Bacteroidales,Porphyromonadaceae,Butyricimonas 0.003 3.452 0.013 0.204 
Bacteroidetes,Bacteroidia,Bacteroidales,Porphyromonadaceae,Odoribacter 0.716 0.508 0.042 0.230 
Bacteroidetes,Bacteroidia,Bacteroidales,Porphyromonadaceae,Tannerella 2.313 0.739 0.044 0.230 
Bacteroidetes,Flavobacteriia,Flavobacteriales,Cryomorphaceae,Wandonia 0.011 0.390 0.024 0.230 
Deferribacteres,Deferribacteres,Deferribacterales,Deferribacteraceae,Mucispirillum 1.298 5.810 0.015 0.206 
Firmicutes,Clostridia,Clostridiales,Clostridiales_Incertae_Sedis_XI,Sporanaerobacter 0.005 0.038 0.045 0.230 
Firmicutes,Clostridia,Clostridiales,Lachnospiraceae,Acetitomaculum 0.050 0.851 0.02 0.230 
Firmicutes,Clostridia,Clostridiales,Lachnospiraceae,Clostridium_XlVb 0.449 0.846 0.003 0.165 
Firmicutes,Clostridia,Clostridiales,Lachnospiraceae,Johnsonella 0.009 0.371 0.009 0.198 
Firmicutes,Clostridia,Clostridiales,Lachnospiraceae,Marvinbryantia 1.309 2.958 0.032 0.230 
Firmicutes,Clostridia,Clostridiales,Lachnospiraceae,Robinsoniella 0.198 1.068 0.046 0.230 
Firmicutes,Clostridia,Clostridiales,Peptococcaceae_1,Peptococcus 0.026 1.436 0.012 0.204 
Firmicutes,Clostridia,Clostridiales,Peptostreptococcaceae,Clostridium_XI 0.155 0.442 0.045 0.230 
Firmicutes,Clostridia,Clostridiales,Ruminococcaceae,Acetanaerobacterium 0.031 0.109 0.005 0.183 
Firmicutes,Clostridia,Clostridiales,Ruminococcaceae,Flavonifractor 0.940 2.119 0.032 0.230 
Proteobacteria,Alphaproteobacteria,Rhodospirillales,Rhodospirillaceae,Dongia 0.217 0.013 0.003 0.165 
Proteobacteria,Deltaproteobacteria,Desulfovibrionales,Desulfovibrionaceae,Bilophila 5.919 0.772 0.007 0.193 




   
 
Table S5. Pre-HFD taxa significantly different between groups 














Bacteroidetes,Bacteroidia,Bacteroidales,Marinilabiliaceae,Alkalitalea 0.006 6.365 4.904 0.002 0.001 0.012 
Bacteroidetes,Bacteroidia,Bacteroidales,Porphyromonadaceae,Barnesiella 11.199 20.345 14.573 3.905 0.021 0.062 
Bacteroidetes,Bacteroidia,Bacteroidales,Porphyromonadaceae,Butyricimonas 1.657 0.002 0.003 2.580 0.002 0.016 
Bacteroidetes,Bacteroidia,Bacteroidales,Porphyromonadaceae,Odoribacter 0.004 2.721 3.002 0.004 0.001 0.012 
Bacteroidetes,Bacteroidia,Bacteroidales,Porphyromonadaceae,Parabacteroides 15.235 6.274 8.647 18.275 0.014 0.051 
Bacteroidetes,Bacteroidia,Bacteroidales,Porphyromonadaceae,Tannerella 0.000 1.622 0.785 0.000 0.001 0.012 
Bacteroidetes,Bacteroidia,Bacteroidales,Rikenellaceae,Alistipes 0.604 5.917 6.241 1.006 0.001 0.012 
Bacteroidetes,Bacteroidia,Bacteroidales,Rikenellaceae,Rikenella 0.000 0.013 0.171 0.000 0.026 0.072 
Bacteroidetes,Flavobacteriia,Flavobacteriales,Cryomorphaceae,Wandonia 1.215 0.160 0.000 1.091 0.001 0.012 
Firmicutes,Clostridia,Clostridiales,Clostridiaceae_1,Clostridium_sensu_stricto 0.430 0.226 0.005 0.394 0.021 0.062 
Firmicutes,Clostridia,Clostridiales,Clostridiaceae_4,Thermotalea 0.051 0.003 0.011 0.066 0.004 0.024 
Firmicutes,Clostridia,Clostridiales,Clostridiales_Incertae_Sedis_XI,Sporanaerobacter 0.123 0.039 0.028 0.128 0.014 0.051 
Firmicutes,Clostridia,Clostridiales,Clostridiales_Incertae_Sedis_XII,Acidaminobacter 0.030 0.013 0.009 0.100 0.036 0.092 
Firmicutes,Clostridia,Clostridiales,Defluviitaleaceae,Defluviitalea 0.379 0.057 0.000 0.136 0.002 0.016 
Firmicutes,Clostridia,Clostridiales,Eubacteriaceae,Alkalibaculum 0.004 0.000 0.000 0.002 0.002 0.016 
Firmicutes,Clostridia,Clostridiales,Gracilibacteraceae,Gracilibacter 0.117 0.017 0.005 0.762 0.005 0.028 
Firmicutes,Clostridia,Clostridiales,Gracilibacteraceae,Lutispora 0.070 0.049 0.027 0.242 0.012 0.049 
Firmicutes,Clostridia,Clostridiales,Incertae_Sedis_XI,Dethiosulfatibacter 0.009 0.002 0.000 0.015 0.050 0.119 
Firmicutes,Clostridia,Clostridiales,Lachnospiraceae,Butyrivibrio 0.085 0.068 0.091 0.019 0.020 0.062 
Firmicutes,Clostridia,Clostridiales,Lachnospiraceae,Cellulosilyticum 0.011 0.000 0.002 0.115 0.015 0.053 
Firmicutes,Clostridia,Clostridiales,Lachnospiraceae,Johnsonella 0.183 0.061 0.003 0.321 0.006 0.028 
Firmicutes,Clostridia,Clostridiales,Lachnospiraceae,Lactonifactor 1.070 0.344 0.002 0.072 0.017 0.055 
Firmicutes,Clostridia,Clostridiales,Lachnospiraceae,Oribacterium 0.081 0.275 0.522 0.036 0.002 0.016 
Firmicutes,Clostridia,Clostridiales,Lachnospiraceae,Parasporobacterium 0.026 0.000 0.000 0.060 0.001 0.012 
Firmicutes,Clostridia,Clostridiales,Lachnospiraceae,Pseudobutyrivibrio 0.302 0.000 0.000 0.128 0.012 0.049 






Firmicutes,Clostridia,Clostridiales,Lachnospiraceae,Roseburia 0.394 0.217 0.101 0.795 0.006 0.028 
Firmicutes,Clostridia,Clostridiales,Peptococcaceae_1,Peptococcus 2.050 0.030 0.011 1.212 0.001 0.012 
Firmicutes,Clostridia,Clostridiales,Peptostreptococcaceae,Sporacetigenium 0.000 0.000 0.013 0.000 0.006 0.028 
Firmicutes,Clostridia,Clostridiales,Ruminococcaceae,Acetivibrio 0.196 0.030 0.031 0.491 0.003 0.019 
Firmicutes,Clostridia,Clostridiales,Ruminococcaceae,Butyricicoccus 0.013 0.002 0.000 0.006 0.014 0.051 
Firmicutes,Clostridia,Clostridiales,Ruminococcaceae,Clostridium_IV 2.856 1.092 1.354 1.861 0.049 0.117 
Firmicutes,Clostridia,Clostridiales,Ruminococcaceae,Flavonifractor 5.213 0.574 0.434 6.796 0.001 0.012 
Firmicutes,Clostridia,Clostridiales,Ruminococcaceae,Papillibacter 0.008 0.017 0.017 0.002 0.031 0.081 
Firmicutes,Clostridia,Clostridiales,Ruminococcaceae,Ruminococcus 0.025 0.002 0.008 0.026 0.030 0.080 
Firmicutes,Clostridia,Clostridiales,Ruminococcaceae,Saccharofermentans 0.068 0.219 0.088 0.287 0.017 0.055 
Firmicutes,Clostridia,Clostridiales,Ruminococcaceae,Sporobacter 0.119 0.002 0.002 0.085 0.002 0.016 
Firmicutes,Erysipelotrichia,Erysipelotrichales,Erysipelotrichaceae,Clostridium_XVIII 0.477 0.055 0.087 0.217 0.022 0.064 
Firmicutes,Erysipelotrichia,Erysipelotrichales,Erysipelotrichaceae,Turicibacter 0.774 0.215 0.014 0.587 0.017 0.055 
Proteobacteria,Alphaproteobacteria,Rhodospirillales,Rhodospirillaceae,Dongia 0.000 0.198 0.266 0.000 0.025 0.071 
Proteobacteria,Alphaproteobacteria,Rickettsiales,Rickettsiaceae,Orientia 0.032 0.006 0.000 0.002 0.003 0.019 
Proteobacteria,Deltaproteobacteria,Desulfovibrionales,Desulfovibrionaceae,Bilophila 0.021 2.800 3.334 0.009 0.003 0.019 
Proteobacteria,Deltaproteobacteria,Desulfovibrionales,Desulfovibrionaceae,Desulfovibrio 0.000 0.220 0.149 0.002 0.001 0.012 
Proteobacteria,Epsilonproteobacteria,Campylobacterales,Helicobacteraceae,Helicobacter 0.008 3.905 4.684 0.006 0.006 0.028 













Table S6. Post-HFD taxa significantly different between groups 














Actinobacteria,Actinobacteria,Coriobacteriales,Coriobacteriaceae,Enterorhabdus 0.042 0.040 0.023 0.085 0.017 0.053 
Bacteroidetes,Bacteroidia,Bacteroidales,Bacteroidaceae,Bacteroides 4.488 13.269 14.115 7.227 0.003 0.013 
Bacteroidetes,Bacteroidia,Bacteroidales,Marinilabiliaceae,Alkalitalea 1.026 4.100 3.535 0.004 <0.001 <0.001 
Bacteroidetes,Bacteroidia,Bacteroidales,Porphyromonadaceae,Butyricimonas 2.452 0.010 0.000 4.236 <0.001 <0.001 
Bacteroidetes,Bacteroidia,Bacteroidales,Porphyromonadaceae,Odoribacter 0.376 1.295 1.396 0.004 <0.001 <0.001 
Bacteroidetes,Bacteroidia,Bacteroidales,Porphyromonadaceae,Parabacteroides 9.759 1.050 2.154 8.437 <0.001 <0.001 
Bacteroidetes,Bacteroidia,Bacteroidales,Rikenellaceae,Rikenella 0.000 0.065 0.040 0.199 0.010 0.032 
Bacteroidetes,Flavobacteriia,Flavobacteriales,Cryomorphaceae,Wandonia 0.140 0.015 0.000 0.377 <0.001 <0.001 
Firmicutes,Bacilli,Lactobacillales,Lactobacillaceae,Lactobacillus 1.932 1.055 0.731 3.017 0.018 0.055 
Firmicutes,Clostridia,Clostridiales,Clostridiaceae_1,Anaerosporobacter 1.594 0.043 0.006 0.302 <0.001 <0.001 
Firmicutes,Clostridia,Clostridiales,Clostridiaceae_1,Clostridium_sensu_stricto 0.000 0.000 0.000 0.014 0.041 0.098 
Firmicutes,Clostridia,Clostridiales,Clostridiales_Incertae_Sedis_XI,Sporanaerobacter 0.080 0.022 0.009 0.102 0.007 0.025 
Firmicutes,Clostridia,Clostridiales,Clostridiales_Incertae_Sedis_XII,Guggenheimella 0.000 0.000 0.000 0.007 0.041 0.098 
Firmicutes,Clostridia,Clostridiales,Defluviitaleaceae,Defluviitalea 0.152 0.026 0.001 0.162 <0.001 <0.001 
Firmicutes,Clostridia,Clostridiales,Eubacteriaceae,Alkalibaculum 0.000 0.000 0.000 0.003 0.004 0.016 
Firmicutes,Clostridia,Clostridiales,Gracilibacteraceae,Gracilibacter 0.013 0.020 0.030 0.115 0.026 0.070 
Firmicutes,Clostridia,Clostridiales,Incertae_Sedis_XI,Dethiosulfatibacter 0.017 0.001 0.000 0.017 <0.001 <0.001 
Firmicutes,Clostridia,Clostridiales,Lachnospiraceae,Acetitomaculum 0.066 0.002 0.000 0.078 <0.001 <0.001 
Firmicutes,Clostridia,Clostridiales,Lachnospiraceae,Butyrivibrio 0.033 0.075 0.014 0.035 0.002 0.009 
Firmicutes,Clostridia,Clostridiales,Lachnospiraceae,Cellulosilyticum 0.015 0.000 0.000 0.033 <0.001 <0.001 
Firmicutes,Clostridia,Clostridiales,Lachnospiraceae,Clostridium_XlVb 1.721 1.600 0.950 1.475 0.032 0.080 
Firmicutes,Clostridia,Clostridiales,Lachnospiraceae,Coprococcus 0.077 0.066 0.017 0.055 0.001 0.005 
Firmicutes,Clostridia,Clostridiales,Lachnospiraceae,Johnsonella 1.471 0.044 0.022 1.011 <0.001 <0.001 
Firmicutes,Clostridia,Clostridiales,Lachnospiraceae,Marvinbryantia 6.508 2.741 2.439 8.098 <0.001 <0.001 
Firmicutes,Clostridia,Clostridiales,Lachnospiraceae,Moryella 0.068 0.028 0.101 0.083 0.032 0.080 






Firmicutes,Clostridia,Clostridiales,Lachnospiraceae,Pseudobutyrivibrio 0.642 0.012 0.000 0.198 0.001 0.005 
Firmicutes,Clostridia,Clostridiales,Lachnospiraceae,Robinsoniella 0.913 0.751 0.246 0.950 0.002 0.009 
Firmicutes,Clostridia,Clostridiales,Peptococcaceae_1,Peptococcus 2.944 0.304 0.190 1.801 0.004 0.016 
Firmicutes,Clostridia,Clostridiales,Ruminococcaceae,Acetanaerobacterium 0.042 0.028 0.024 0.160 <0.001 <0.001 
Firmicutes,Clostridia,Clostridiales,Ruminococcaceae,Acetivibrio 0.458 0.047 0.273 0.718 <0.001 <0.001 
Firmicutes,Clostridia,Clostridiales,Ruminococcaceae,Anaerotruncus 2.483 1.225 1.301 2.241 0.005 0.019 
Firmicutes,Clostridia,Clostridiales,Ruminococcaceae,Butyricicoccus 0.028 0.006 0.000 0.005 0.050 0.119 
Firmicutes,Clostridia,Clostridiales,Ruminococcaceae,Hydrogenoanaerobacterium 2.497 1.630 1.581 2.352 0.023 0.065 
Firmicutes,Clostridia,Clostridiales,Ruminococcaceae,Pseudoflavonifractor 5.418 4.643 3.152 6.997 0.001 0.005 
Firmicutes,Clostridia,Clostridiales,Ruminococcaceae,Ruminococcus 0.057 0.016 0.523 0.077 0.032 0.080 
Firmicutes,Erysipelotrichia,Erysipelotrichales,Erysipelotrichaceae,Allobaculum 0.067 0.034 0.045 0.152 0.001 0.016 
Firmicutes,Erysipelotrichia,Erysipelotrichales,Erysipelotrichaceae,Clostridium_XVIII 0.329 0.139 0.074 0.421 0.023 0.065 
Firmicutes,Erysipelotrichia,Erysipelotrichales,Erysipelotrichaceae,Coprobacillus 0.013 0.000 0.017 0.000 0.025 0.069 
Firmicutes,Erysipelotrichia,Erysipelotrichales,Erysipelotrichaceae,Holdemania 0.047 0.051 0.000 0.037 0.003 0.013 
Lentisphaerae,Lentisphaeria,Victivallales,Victivallaceae,Victivallis 0.000 0.000 0.000 0.423 <0.001 <0.001 
Proteobacteria,Alphaproteobacteria,Rhodospirillales,Rhodospirillaceae,Dongia 0.044 0.191 0.193 0.090 0.006 0.022 
Proteobacteria,Betaproteobacteria,Nitrosomonadales,Nitrosomonadaceae,Nitrosomonas 0.000 0.003 0.003 0.018 0.010 0.032 
Proteobacteria,Deltaproteobacteria,Desulfovibrionales,Desulfovibrionaceae,Bilophila 5.532 12.961 9.579 2.844 0.022 0.065 
Proteobacteria,Epsilonproteobacteria,Campylobacterales,Helicobacteraceae,Helicobacter 0.006 13.610 9.318 0.008 <0.001 <0.001 








   
Table S7. Primer sequences for qPCR 
Primers for qPCR 
Gene Forward Reverse 
TNFa TGGGACAGTGACCTGGACTGT TTCGGAAAGCCCATTTGAGT 
F4/80 TGACAACCAGACGGCTTGTG GCAGGCGAGGAAAAG ATAGTGT 
CCL2 AGGTCCCTGTCATGCTTCTGG  CTGCTGCTGGTGATCCTCTTG  
B-actin GACCCAGATCATGTTTGAGA GAGCATAGCCCTCGTAGAT 





Glucose tolerance test 
Glucose tolerance test (GTT) was performed as previously described (Kaliannan et al., 
2013) at weaning (PND 28) and following 13-15 weeks on a HFD. Due to the age and 
size of the animals at weaning, a number of small modifications were made to the GTT 
procedure compared with that performed at adulthood. Briefly, fasting blood glucose 
was measured using a glucometer following 5-6 h fasting. Glucose [20% solution in 
ddH20 (weaning); 10% solution in phosphate buffered saline (post-HFD)] was 
administered at 1g/kg body weight (weaning) or 2g/kg body weight (post-HFD) by i.p. 
injection (weaning) or gavage (post-HFD). A small incision was made in the tail and 
blood samples were collected at 15, 30, 60, 90 and 120 min post glucose administration 
to measure glucose levels. Glucose tolerance was assessed by calculating the 
incremental area under the curve (AUC) of the GTT. 
 
Insulin tolerance test 
Insulin tolerance test (ITT) was performed as previously described (Kaliannan et al., 
2013) following 13-15 weeks on a HFD. Briefly, fasting blood glucose was measured 
using a glucometer following 6 h fasting. Insulin (solution in PBS) was administered at 






blood samples were collected at 10, 20, 30, 40, 50 and 60 min post insulin 
administration to measure glucose levels. Insulin tolerance was assessed by calculating 
the incremental area under the curve (AUC) of the ITT. The homeostasis model 
assessment of insulin resistance [HOMA-IR = glucose (mg/dL) × insulin (mU/L)/405] 
was calculated as an insulin sensitivity index. 
 
Cytokines 
Serum cytokine levels (TNF-α, IL-1β, IL-6, MCP-1, and IL-10) were assessed using a 
Bio-Plex immunoassay kit (Bio-Rad) according to manufacturers instructions. Data 
acquisition and analysis was performed using Xponent softward (Luminex, Austin, TX). 
 
Liver triglycerides 
Liver triglycerides were quantified using commercial TAG reagent (Sigma, Aldrich) 



























The Anti-Inflammatory Effect of Omega-3-rich 
Algae-Derived Lipid Extracts on 
Lipopolysaccharide-Stimulated Human  













Algae contain a number of anti-inflammatory bioactive compounds such as omega-3 
polyunsaturated fatty acids (n-3 PUFA) and chlorophyll a, hence as dietary ingredients, 
their extracts may be effective in chronic inflammation-linked metabolic diseases such 
as cardiovascular disease. In this study, anti-inflammatory potential of lipid extracts 
from three red seaweeds (Porphyra dioica, Palmaria palmata and Chondrus crispus) 
and one microalga (Pavlova lutheri) were assessed in lipopolysaccharide  
(LPS)-stimulated human THP-1 macrophages. Extracts contained 34%–42% total fatty 
acids as n-3 PUFA and 5%–7% crude extract as pigments, including chlorophyll a,  
β-carotene and fucoxanthin. Pretreatment of the THP-1 cells with lipid extract from  
P. palmata inhibited production of the pro-inflammatory cytokines interleukin (IL)-6  
(p < 0.05) and IL-8 (p < 0.05) while that of P. lutheri inhibited IL-6 (p < 0.01) 
production. Quantitative gene expression analysis of a panel of 92 genes linked to 
inflammatory signaling pathway revealed down-regulation of the expression of 14 pro-
inflammatory genes (TLR1, TLR2, TLR4, TLR8, TRAF5, TRAF6, TNFSF18, IL6R, IL23, 
CCR1, CCR4, CCL17, STAT3, MAP3K1) by the lipid extracts. The lipid extracts 
effectively inhibited the LPS-induced pro-inflammatory signaling pathways mediated 
via toll-like receptors, chemokines and nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) signaling molecules. These results suggest that lipid extracts 
from P. lutheri, P. palmata, P. dioica and C. crispus can inhibit LPS-induced 
inflammatory pathways in human macrophages. Therefore, algal lipid extracts should be 










Inflammation is a complex physiological process involving activation of the immune 
system. It occurs following physical injury or invasion by pathogenic bacteria, viruses or 
tumor cells in the host (Calder, 2006). Inflammation is essential to identify and destroy 
invading pathogens and is vital for host health in acute disease states. However, in many 
cases, inflammation occurs at a chronic, subclinical level and if this process becomes 
unregulated and prolonged, the activated immune system can begin to damage host 
tissues and supplement chronic disease states such as cardiovascular disease (CVD) 
(Hansson, 2005), inflammatory bowel disease (IBD) (Fiocchi, 1998), obesity (Choy and 
Panayi, 2001, Gregor and Hotamisligil, 2011) and Alzheimer’s disease (AD) (Akiyama 
et al., 2000). Dietary interventions to control chronic inflammation may provide useful 
strategies for the management of such diseases (Rallidis et al., 2003, Calder et al., 2009, 
Esposito et al., 2004, Ruiz-Núñez et al., 2013), therefore the discovery of novel, 
effective, anti-inflammatory bioactives is warranted to identify long-term dietary 
therapies for inflammatory metabolic disorders. 
The use of synthetic pharmacological agents to inhibit inflammation has shown 
promise in metabolic diseases such as type 2 diabetes and CVD (Esser et al., 2014); 
however, chronic use of such drugs is often associated with adverse gastrointestinal side 
effects (Sostres et al., 2010). The application of natural anti-inflammatory compounds is 
desirable as a long-term strategy to suppress chronic inflammation and alleviate  
disease-associated symptoms. A number of dietary components have been shown to 
exhibit potent anti-inflammatory activity, and evidence suggests certain dietary changes 
may be key as long-term alternatives to pharmaceutical compounds (Calder et al., 2009). 
Long-chain n-3 polyunsaturated fatty acids (n-3 LC-PUFA), for example, have been 
demonstrated to reduce inflammation in both in vitro and in vivo studies (Calder, 2006, 






inflammatory mediators, termed eicosanoids, which inhibit inflammatory cytokine 
production and inflammatory gene expression (Wall et al., 2010). Indeed, the n-3  
LC-PUFA eicosapentaenoic acid (EPA, 20:5 n-3) and docosahexaenoic acid (DHA, 
22:6 n-3) inhibit interleukin-6 (IL-6) and interleukin-1β (IL-1β) production in human 
macrophages (Weldon et al., 2007, Mullen et al., 2010)]. It has been suggested that n-3 
LC-PUFA may play a role as nutritional therapeutic ingredients for the prevention and 
treatment of inflammatory diseases (Calder, 2013b). Certain polyphenols, pigments, and 
other plant bioactives have also demonstrated anti-inflammatory activity both in vitro 
and in vivo (González et al., 2011, Peng et al., 2011, Bai et al., 2005) suggesting 
potential for dietary ingredients to ameliorate symptoms of chronic inflammatory 
diseases. 
Marine and freshwater algae produce a number of bioactive compounds 
including peptides, carbohydrates, phenols, pigments, and lipids with potential health 
benefits (Lordan et al., 2011, Robertson et al., 2013). For example, marine macroalgae 
(seaweeds) typically contain around 2%–5% lipid on a dry weight basis, where up to 
70% of the total fatty acids can be PUFA (Dawczynski, 2007, Schmid et al., 2014). 
Some microalgae are reported to contain high protein, lipid (up to 60% of dry weight) 
and PUFA contents (up to 60% of total fatty acids), and have been exploited for their 
protein and lipid content for a number of nutritional and industrial purposes (Ratledge, 
2004, Ward and Singh, 2005). Both micro- and macroalgae may thus act as sources of 
essential vitamins, minerals, and bioactive pigments.  
Algae potentially represent an abundant and underexplored resource of health 
promoting functional food ingredients, which may be particularly useful in the Western 
diet, which is otherwise rich in meat products. Additionally, fish stocks are facing 
global decline alongside increasing toxin accumulation due to pollution (FAO Fisheries 
and Aquaculture Department, 2010, Branch et al., 2011, Kris-Etherton et al., 2002)], 






LC-PUFA and other bioactive marine ingredients (Adarme-Vega et al., 2012). Indeed, a 
number of whole algae-extracts and algae-derived compounds have exhibited anti-
inflammatory activity through the inhibition of pro-inflammatory cytokine and 
eicosanoid production, and reduction of expression of pro-inflammatory genes (Hwang 
et al., 2011, Jo et al., 2010, Khan et al., 2007, Vo et al., 2011, Park et al., 2008, Lee et 
al., 2013). Yang et al. found that extracts from five Korean seaweeds (Laurencia 
okamurae, Grateloupia elliptica, Sargassum thunbergii, Gloiopeltis furcata, and Hizikia 
fusiformis) reduced inflammation in the mouse macrophage cell line RAW 264.7 
through inhibition of the pro-inflammatory eicosanoid prostaglandin E2 (PGE2) and the 
pro-inflammatory cytokines IL-6 and tumor-necrosis factor α (TNFα) (Yang et al., 2010). 
Furthermore, Nauroth et al. demonstrated the anti-inflammatory activity of microalgal oil 
when fed to rats (Nauroth et al., 2010). In addition, Banskota et al. reported anti-
inflammatory effects of lipid extracts of Tetraselmis chuii, Chlorella sorokiniana and 
Chondrus crispus in RAW 264.7 macrophages (Banskota et al., 2013a, Banskota et al., 
2013b, Banskota et al., 2014). Accordingly, there is evidence to suggest that algal 
extracts may be beneficial as functional food ingredients to control inflammation. 
The aim of this study was to evaluate the anti-inflammatory activity of three 
algal species from the Irish coast and a microalga and to identify their potential as anti-
inflammatory functional food ingredients. To this end, lipid extracts of the edible and 
commercially valuable red macroalgae Porphyra dioica, Palmaria palmata, Chondrus 
crispus (all Rhodophyta) and Pavlova lutheri (Haptophyta) were characterized for their 
fatty acid, pigment, lipid and LC-PUFA partitioning profiles. Subsequently the anti-
inflammatory bioactivities of these extracts were assessed through their potential to 









2. METHODS  
2.1. Materials 
All chemicals and reagents were purchased from Sigma-Aldrich Ireland Ltd. (Arklow, 
Republic of Ireland) unless otherwise stated. Tissue culture plastics were purchased 
from Sarstedt (Wexford, Republic of Ireland). The human THP-1 monocytic cell line 
was purchased from the American Tissue Culture Collection (ATCC, LGC Standards, 
Middlesex, UK). Working solutions of bacterial lipopolysaccharide (LPS; Escherichia 
coli 055:B5) and phorbol-12-myristate-13-acetate (PMA) were stocked in RPMI 1640 
medium. 
 
2.2. Collection of Macroalgae and Biomass Preparation 
Samples of the three red algae Chondrus crispus, Stackhouse (Gigartinales,), Palmaria 
palmata (L.) F. Weber & D. Mohr (Palmariales) and Porphyra dioica, J. Brodie & L. 
M. Irvine (Bangiales) were collected in Galway Bay (Spiddal 53°14′22″ N, 9°18′52″ W) 
during March 2013. Algae were placed on ice for approximately 2–3 hours during 
transportation to the laboratory, rinsed with fresh water and cleaned of all visible 
epiphytes, if present, and frozen at −20 °C. Algal material was lyophilised using 
Labconco Freezone® (Kansas City, MO, USA) 6 freeze-dryer system and ground to fine 
powder for lipid extraction.  
Algal species were identified and extracts supplied by the Algal Biosciences 
Research Group of Dagmar Stengel (Botany and Plant Science, School of Natural 








2.3. Microalgal Strain, Culture Conditions and Biomass Preparation 
An axenic strain of Pavlova lutheri CCAP 931/6, formerly renamed Diacronema lutheri 
(Bendif et al., 2011), was obtained from the Culture Collection of Algae and Protozoa at 
the Scottish Marine Institute (SAMS Research Services Ltd., Oban, Scotland, UK) and 
cultivated in the laboratory at the National University of Ireland Galway. 
P. lutheri were cultivated under batch conditions on F/2-RSE medium in three 
15 L polycarbonate Nalgene® culture vessels at 15 °C and under continuous 
illumination (100 μmol photons m−2·s−1), provided by lumilux cool daylight fluorescent 
lamps (OSRAM L18W/865,Munich,Germany). F/2-RSE medium, a modified version of 
Guillard’s (1975) F/2 medium (Guillard, 1975) where filtered seawater is substituted by 
ReefSalt (H2Ocean, Pro+, Essex, IG6 3UT, England, UK), was used and complemented, 
as described by Guihéneuf et al. (Guihéneuf and Stengel, 2013)], with few modifications, 
a higher initial NaNO3 concentration (350 mg·L−1) and NaHCO3 supplementation (1 
g·L−1). Cultures were agitated by air-bubbling (~0.03%–0.04% CO2). 
P. lutheri cells were harvested after 50 days (late-exponential growth phase), 
just after nitrate-depletion was reached on day 40 in order to allow maximum 
accumulation of oil containing n-3 LC-PUFA as described by Guihéneuf et al. 
(Guihéneuf and Stengel, 2013), by centrifuging using a modified Alistar milk cream 
separator  
(80 L·h−1). Prior to lipid extraction, the fresh algal paste collected was frozen at −20 °C 
and freeze-dried as previously described. 
 
2.4. Lipid Extraction 
Total lipids were extracted by solid-liquid procedure using a modified version of Bligh 






biomass or freeze-dried microalgal powder was extracted with methanol:chloroform 1:1 
(v/v) in a glass bottle closed under nitrogen gas (N2) to limit oxidation, and stirred 
overnight at 4 °C. The first extract obtained was filtered and the remaining biomass re-
extracted 2–3 times similarly. All the filtered-extracts were then combined and Milli-Q 
water added to give a final chloroform:methanol:water ratio of 1:1:0.9 (v/v/v). After 
phase separation, the organic phase containing lipids (lower phase) was collected, and 
the extraction was repeated 2–3 times by adding chloroform to the remaining 
methanol:water phase. The combined organic phases containing the total crude lipid 
extract were then evaporated to dryness using a rotavapor (BÜCHI R-210 equipped with 
a Heating Bath B-491 and a Vacuum Pump V700, BÜCHI Labortechnik AG, 9230 
Flawil, Switzerland) under reduced pressure at 40 °C. 
 
2.5. Lipid Class Separation 
The lipid class separation procedure combined the method described by Sukenik et al. 
(Sukenik et al., 1989) using Sep-Pak silica cartridges to separate the neutral and polar 
lipids, and thin-layer chromatography procedures adapted from Williams (Williams, 
1978), Christie (Christie, 1982), and Henderson and Tocher (Henderson and Tocher, 
1992) to separate individual lipid classes. 
 
2.5.1. Lipid Separation by Silica Cartridge Chromatography  
A known amount of total crude lipid extract dissolved in chloroform was fractionated 
on reversed phase silica gel columns (Bond Elut™ JR-SI 500 mg, Agilent 
Technologies, Santa Clara, CA, USA) after an activation step with 5 mL of methanol 
followed by 5 mL of chloroform. Neutral lipids were eluted using 20 mL of chloroform, 






neutral and polar fractions obtained were evaporated to dryness using a rotary evaporator 
under reduced pressure at 40 °C and dissolved in a small volume of chloroform or 
methanol, respectively. 
 
2.5.2. Neutral and Polar Lipid Fractionation by Thin-Layer Chromatography 
(TLC) 
Both neutral and polar lipids were subjected to one-dimensional thin-layer 
chromatography (TLC) for lipid class separation and identification, using TLC plates 
coated with silica gel 60 (Silica Gel 60, 20 × 20 cm, 0.25 mm thickness, Merck, 
Darmstadt, Germany). Neutral lipids were eluted using petroleum ether:diethyl 
ether:acetic acid 80:20:1 (v/v/v). Polar lipids were eluted into individual lipids using a 
five-component mixture of chloroform:acetone:methanol:acetic acid:water 
50:20:10:10:5 (v/v). 
Two-dimensional TLC was later performed to confirm the tentative 
identification of polar lipid classes, using chloroform/methanol/water 65:25:4 (v/v) as 
first solvent, and a mixture of chloroform/acetone/methanol/acetic acid/water 
50:20:10:10:4 (v/v) as second solvent. A brief exposure to iodine vapor was used as 
general staining to visualize the different lipid spots subsequently recovered from the 
TLC plates. Each individual class was then subjected to gas chromatography (GC) for 
quantification of its fatty acid profile, after direct-transmethylation. Individual lipid 
classes were identified by comparison of Rf values to Rf values provided in the literature 
(Christie, 1982), by using specific lipid charring reagents as described by Mereiles et al. 
(Meireles et al., 2003), and/or by running commercial lipid standards (Avanti Polar 







2.6. Fatty Acid Analysis 
Fatty acid methyl esters (FAME) were obtained by transmethylation of an aliquot of 
total lipid extract, or by direct-transmethylation of the silica powder containing the 
different lipid class fractions and/or the freeze-dried algal powder, with dry methanol 
containing 2% (v/v) H2SO4 and heating at 80 °C for 1.5 h with continuous stirring under 
a nitrogen atmosphere as described by Schmid et al. (Schmid et al., 2014). 
Gas chromatographic analysis of FAME was performed on an Agilent 7890A 
GC (Agilent Technologies) equipped with a flame ionization detector and a fused silica 
capillary column (DB-WAXETR, 0.25 mm × 30 m × 0.25 µm, Agilent Technologies, 
Santa Clara, CA, USA). Hydrogen was used as a carrier gas. The injector and detector 
temperatures were 250 °C and 300 °C, respectively. The temperature was programmed 
at 140 °C for 1 min, raised from 140 to 200 °C at a rate of 15 °C·min−1, and then from 
200 to 250 °C at a rate of 2 °C·min−1. 
Identification of FAME was obtained by co-chromatography with authentic 
commercially available FAME standards (Supelco™ 37 Component FAME Mix, 
Supelco, Bellefonte, PA, USA) and FAME of fish oil (Menhaden Oil, Supelco). Fatty 
acid contents were quantified by comparison with a known amount of added 
pentadecanoic acid 15:0 (Pentadecanoic acid, 99%, Catalog No. A14664-09, Alfa 
Aesar, Heysham, England, UK) as internal standard. Results are expressed as the mean 
values of two replicates (n = 2) obtained from two analytical repetitions for each extract. 
 
2.7. Pigment Analysis 
Pigments were analyzed according to the method described by Wright et al. (Wright et 
al., 1991), modified by Bidigare et al. (Bidigare et al., 2005). A known amount of total 






(HPLC grade, Fischer Scientific, Loughborough LE11 5RG, England UK). After 
overnight at 4 °C to allow full re-dissolution of algal pigments, the samples were 
filtered before High Performance Liquid Chromatography (HPLC) analysis. 
Pigments were separated and quantified on a Agilent 1200 series HPLC (Agilent 
Technologies) equipped with a Diode Array Detector (DAD) and a Fluorescence 
Detector (FLD), and separated using a C18 column (150 mm × 4.6 mm inner diameter, 
Eclipse XDB-C18, Agilent Technologies). The gradient mobile phase consisted of 
80:20 (v/v) methanol/0.5 M ammonium acetate (pH = 7.2, with 0.1% (w/v) added 
butylated hydroxytoluene (BHT)), 87.5:12.5 (v/v) acetonitrile/Milli-Q water (0.1% (w/v) 
added BHT) and ethyl-acetate. Identification of algal pigments was obtained by 
comparison of peak retention times and spectra with commercial standards (DHI, 
Hørsholm, Denmark; Sigma-Aldrich, St. Louis, MO, USA). Pigment concentrations 
were calculated using standard curves obtained by injection of precisely quantified 
amounts of commercial pigment standards. Results are expressed as the mean values of 
two replicates (n = 2) obtained from two analytical repetitions for each extract. 
 
2.8. Cell Culture 
Human THP-1 monocytes were cultured in RPMI 1640 medium supplemented with 
10% (v/v) heat inactivated fetal bovine serum (FBS), L-glutamine and 0.5% (w/v) 
penicillin/streptomycin, and incubated at 37 °C in a 5% CO2 atmosphere. For 
monocyte-macrophage differentiation, cells were seeded at a density of 2 × 105 
cell·mL−1 in 12-well plates or 5 × 104 cell·mL−1 in 96-well plates, and differentiation 
was induced by exposing the cells to 10 ng·mL−1 phorbol-12-myristate-13-acetate 
(PMA) in 2.5% (v/v) FBS supplemented media for 72 h. Macrophages were 
subsequently treated with PMA-free media with 2.5% FBS for a further 24 h. Lipid 






sulfoxide (DMSO) and added to fresh culture medium at a concentration of 3 µg·mL−1 
total fatty acids and incubated for 24 h. Control cells were treated with DMSO alone at 
a concentration of 0.1% (v/v).  
 
2.9. Cytotoxicity Assay 
Cytotoxicity of the extracts was measured by MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay using the CellTiter 
96® AQueous One Solution Assay (Promega Corporation, Madison, WI, USA) according 
to manufacturer’s instructions. Briefly, cells were seeded in a 96-well plate for 24 h and 
then treated with the algal lipid extracts at different concentrations. Subsequently, 20 µL 
of MTS reagent was added into each well. Following incubation at 37 °C and 5% CO2 
for 4 h, the absorbance at 490 nm with reference wavelength of 610 nm was read using 
a microplate reader. For subsequent analysis, cells were treated with a concentration of 
extract that exhibited no significant reduction in cell viability.  
 
2.10. Cytokine Analysis 
For cytokine analysis, differentiated THP-1 macrophage cells were first pretreated with 
algal lipid extracts for 24 h followed by induction of pro-inflammatory response by 
treating with 0.1 µg·mL−1 LPS for 24 h. Following the LPS stimulation, cell culture 
supernatants were collected, centrifuged at 1000× g for 10 min and stored at −80 °C 
until further analysis. Abundance of cytokine (TNFα, IL-6, IL-8, IL-1β, IL-12p70, 
IFNγ, IL-10) in the cell culture supernatants was performed using the MSD Human 
proinflammatory 7-plex Ultra-sensitive electrochemiluminescent (ECL) assay (Meso 
Scale Discovery (MSD), Gaithersburg, MD, USA). Briefly, 25 µL of supernatant 






antibodies. The plate was then sealed and incubated for 1 h at room temperature with 
vigorous shaking (300 rpm). Detection antibody (25 µL) was then added to the wells 
and the plate was sealed and incubated for 1 h at room temperature with continuous 
shaking (300 rpm). The plate was then washed three times with phosphate-buffered 
saline (PBS) containing 0.05% Tween-20 prior to the addition of 150 µL read buffer. 
The plate was then read in a SECTOR Imager (Meso Scale Discovery) and 
quantification of individual cytokines was performed following the supplier’s 
guidelines. 
 
2.11. Preparation of RNA and cDNA Synthesis 
Total RNA was extracted from THP-1 macrophages using a Qiagen RNeasy Mini Kit 
(Qiagen, Manchester, UK) according to the manufacturer’s protocol. RNA was dissolved in 
20 μL of nuclease-free water and then subjected to deoxyribonuclease I (DNase I) 
treatment to eliminate the genomic DNA contamination. RNA yield was assessed by 
measuring absorbance at 260 nm using a Nano-drop ND-1000 spectrophotometer 
(Thermo Fischer Scientific, Waltham, MA, USA). Sufficient RNA purity was 
determined by a 260:280 nm absorbance ratio of ≥1.8 and by visualizing on a 1.5% 
(w/v) RNA agarose gel. Total RNA (1 µg) was reverse-transcribed to cDNA using a 
RevertAid H Minus First Strand cDNA synthesis Kit (Fermentas GmbH, St. Leon-Rot, 
Germany) according to the manufacturer’s protocol. 
 
2.12. Quantitative Real-Time PCR Analysis 
The quantitative expression of a panel of 96 genes (list of genes provided in 
supplementary Table S1) involved in the inflammatory signaling cascade in human was 






GmbH, Mannheim, Germany). This is a customized array designed by Sigma-Aldrich 
Corp. that enables screening of 92 different genes involve in inflammatory signaling 
pathways and 4 internal reference genes in human. For the PCR array experiment, 25 
µL cDNA (after 1:5 dilution) from each individual wells within a single treatment group 
were pooled. Real-time reverse transcriptase PCR was performed on a 20 µL reaction 
mixture per well containing 1 µL pooled cDNA, 9 µL water and 10 µL SYBR green 
master mix (Applied Biosystems, Foster City, CA, USA). The thermal cycle conditions 
were 94 °C for 30 s followed by 60 °C for 1 min, for 40 cycles. The mRNA abundances 
were expressed in crossing point (Cp) values, the number of PCR cycles after which the 
PCR product crosses a threshold value. In this experiment, a Cp value of 35 was 
considered as the cut-off limit. 
Normalization of the expression of 92 target genes included in the PCR array 
was performed based on three reference genes (beta actin (ACTB), glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) and beta glucuronidase (GUSB)) and following 
2−ΔΔCp method. Briefly, average ΔCp was calculated as the difference of Cp values of 
any target gene minus average of the Cp value of the three reference genes. Then, fold 
change was calculated as 2 /2 . A fold difference 
cut-off point was set at ≥2.5. 
Validation of the PCR array data was performed through evaluation of the 
quantitative expression of three target genes (TLR8, TLR1 and TRAF5) and one 
reference gene (GAPDH) in each of the replicate samples on the LightCycler 480 
instrument (Roche Diagnostics GmbH). The PCR reaction (10 µL) contained 1 µL 
cDNA (following 1:5 dilution), 3 µL nuclease free water, 1 µL forward and reverse 
primer and 5 µL SYBR green master mix (Roche Diagnostics GmbH). The thermal 
cycle conditions were as follows: 94 °C for 10 min followed by 40 cycles of 94 °C for 






values <35 were used for analysis. The mRNA abundance of three target genes (TLR8, 
TLR1 and TRAF5) were normalized against the expression of GAPDH.  
 
2.13. Statistical Analysis 
Statistical analysis was performed using GraphPad Prism version 6.0 for Windows 
(GraphPad Software). Extract composition results are expressed as the mean values of 
two replicates (n = 2) ± standard deviation (SD) obtained from two analytical repetitions 
for each extract. Cytokine production and qPCR results are presented as means ± 
standard error of the mean (SEM) of at least three independent experiments. To assess 
whether differences between the exposures were significant, multiple comparisons were 
performed using one-way analysis of variance (ANOVA) followed by Dunnett’s 
Multiple Comparison Test or Fisher’s least significant difference test. A p-value of ≤0.05 




3.1. Fatty Acid Composition of Algal Lipid Extracts 
The fatty acid composition, expressed as % of total fatty acids of the algal lipid extracts 
are shown in Table 1. Each extract contained a broad spectrum of medium to long-chain 
saturated and unsaturated fatty acids. Total saturated fatty acid (SFA) content was 
similar across all four algal species, ranging from 28% to 32.4% of total saturated fatty 
acids. SFA content was dominated by palmitic acid (16:0) in the three seaweed species 
(P. palmata, P. dioica and C. crispus) ranging from 22.3% to 28.1%, whereas the 
dominant SFA in the P. lutheri (microalgal) extract was myristic acid (14:0) at 14.3%, 






Total monounsaturated fatty acid (MUFA) content ranged from 6.1%–8.8% in 
the three red seaweed species whereas P. lutheri displayed 19.5% of total fatty acids as 
MUFA, of which palmitoleic acid (16:1 n-7) was most abundant with 14.4%. Oleic acid 
(18:1 n-9) was another MUFA present at high levels, ranging from 1.7% in P. dioica to 
5.5% in C. crispus. 
Polyunsaturated fatty acids (PUFA) were more dominant than SFA and MUFA 
in all extracts, ranging from 51.9% to 64.6% of total fatty acids. Of these PUFA, n-3 
fatty acids were present in greater quantities than n-6 PUFA in all extracts. EPA was the 
most abundant PUFA and the most abundant fatty acid in all extracts, ranging from 
27.7% in P. lutheri to 57.9% in P. palmata. DHA accounted for 10.5% of total fatty 
acids in P. lutheri and was present in undetectable or very low quantities in all other 
extracts. Of note, P. lutheri contained 5% stearidonic acid (SDA, 18:4 n-3). 
Additionally the n-6 LC-PUFA arachidonic acid (ARA, 20:4 n-6) was present in very 
high quantities in C. crispus at 19.9% of total fatty acids. The ratio of n-6/n-3 fatty acids 
was <0.2 in P. lutheri, P. palmata and P. dioica (0.09, 0.04, and 0.17, respectively) 
whereas C. crispus had an n-6/n-3 ratio of 0.66 due to its higher proportion of n-6 ARA. 
 
3.2. Pigments 
Pigment contents of the different extracts are detailed in Table 2. Individual pigment 
values are expressed as % molar and total pigment values are expressed as % of dry 
weight crude extract. Pigments concentrations were relatively low but substantial in all 
extracts, ranging from 4.9% to 6.8% of the crude extract. Chlorophyll a and its 
degradation products were most abundant in all extracts accounting for 41.1%–53% of 
total pigments. β-carotene and zeaxanthin were the only other pigments detected in the 
red seaweed extracts ranging from 19.2%–30.2% and 22.8%–27.5%, respectively. 






and their degradation products, were also present in relatively high proportions (26.9% 
and 16.1%, respectively) in P. lutheri, alongside a number of other pigments (i.e., β-
carotene, cys-fucoxanthin, and chlorophyll c). 
 
3.3. Lipid Class Composition and LC-PUFA Partitioning 
The lipid class composition of each lipid extract and the distribution of the major LC-
PUFA (SDA, ARA, EPA and DHA) within the different lipid fractions are detailed in 
Figure 1. 
In P. lutheri, the triacylglycerol (TAG) and glycolipid families represent 
together 67.1% of total fatty acids. The neutral lipid fraction, composed by TAG 
(24.1%), diacylglycerols (DAG, 0.8%), monoacylglycerols (MAG, 1.3%), and free fatty 
acids (FFA, 8.4%) accounted for 34.5% of total fatty acids. The polar lipid fraction was 
mainly composed of monogalactosyldiacylglycerols (MGDG, 15.2%), 
digalactosyldiacylglycerols (DGDG, 18.0%) and sulfoquinovosyldiacylglycerols 
(SQDG, 9.8%), which represent a total glycolipid proportion of 43% of total fatty acids. 
Other unidentified lipid classes accounting together for 12.2% of total fatty acids were 
also found in the polar lipid fraction. 
In the red seaweeds (P. palmata, P. dioica, C. crispus), TAG and FFA represent 
the main neutral lipid classes with 11.1%–13.4% and 4.3%–8.1% of total fatty acids, 
respectively. The polar fraction was essentially composed of MGDG (17.0%–23.1%), 
DGDG (17.4%–21.7%) and SQDG (16.8%–25.4%), representing 71.6%–76.9% of total 
fatty acids. Phospholipids (11.1%–16.4%) such as diphosphatidylacylglycerols (DPG), 
phosphatidylethanolamines (PE), phosphatidylglycerols (PG), phosphatidylcholines 







Despite small differences between species, LC-PUFA were mainly partitioned into the 
glycolipid (MGDG, DGDG and SQDG) and TAG fractions. In P. lutheri, DHA was 
also substantially incorporated into the other unidentified lipid classes (11.3% of the 
total DHA); EPA was also incorporated into the PG of P. dioica (10.1% of the total 
EPA). 
 
3.4. Inhibition of Inflammatory Cytokine Production in Lipopolysaccharide (LPS)-
Stimulated THP-1 Macrophages 
The effects of THP-1 macrophage exposure to the four algal lipid extracts on 
lipopolysaccharide (LPS)-stimulated IL-6, IL-8 and TNFα production are shown in 
Figure 2. Following 24 h-exposure to P. lutheri lipid extract, the production of the pro-
inflammatory cytokine IL-6 (p < 0.01) was significantly downregulated in comparison 
to the carrier control. Incubation of the THP-1 cells with P. palmata lipid extract 
significantly reduced production of IL-6 (p < 0.05) and IL-8 (p < 0.05), whereas 
incubation with C. crispus lipid extract led to significantly increased production of 
TNFα relative to the carrier control (p < 0.05). P. dioica did not appear to significantly 
influence the production of any of the examined cytokines. There were no significant 
responses in IFNγ, IL-12p70, IL-10 or IL-1β production by THP-1 cells following 
exposure to any of the algal lipid extracts. 
 
3.5. Inhibition of Inflammatory Gene Expression by Algal Lipid Extracts 
In order to assess the anti-inflammatory effects of the algal lipid extracts in the THP-1 
macrophages, quantitative expression of a panel of 92 inflammatory marker genes was 
evaluated. Of the 92 target genes analyzed, 16 genes were differentially expressed 






of toll-like receptor 1 (TLR1) and toll-like receptor 8 (TLR8) and TNF receptor 
associated factor 5 (TRAF5) were consistently downregulated by the lipid extracts from 
all four algal species. In addition, P. dioica extract downregulated nine other pro-
inflammatory genes including pro-inflammatory markers toll-like receptor (TLR4) and 
signal transducer and activator of transcription 3 (STAT3). Other genes that were 
downregulated by algal lipid extracts predominantly represent pro-inflammatory 
pathways such as those sharing toll-like receptors, TNF receptor associated factors, 
chemokine, cytokines and their receptors. While the lipid extracts from all four algal 
species predominantly indicated an inhibitory effect on the pro-inflammatory genes, the 
up-regulation of NOS2 by P. palmata and PTGER1 by P. lutheri and P. dioica indicated 
activation of a pro-inflammatory response which may be due to the fact that the crude 
lipid extracts may contain certain compounds with pro-inflammatory activities. 
 
3.6. Validation of PCR Array Results through Quantitative PCR (qPCR) 
For the validation purpose, three genes (TLR1, TLR8 and TRAF5) were selected for 
qPCR analysis given that these genes were consistently downregulated by all four algal 
lipid extracts as evident in the PCR array data. The oligonucleotide sequences for the 
primers used for quantitative PCR for these genes are outlined in Table 4. The effects of 
the four algal lipid extracts on TLR1, TLR8 and TRAF5 gene expression in LPS-
stimulated macrophages are shown in Figure 3. Compared to the carrier control, 
exposure of the THP-1 cells to the lipid extracts from P. lutheri, P. palmata and P. 
dioica resulted in inhibition of TLR1, TLR8, and TRAF5 mRNA abundances indicating 
consistency of the PCR array data which were generated through gene expression 
analysis in the pooled cDNA samples. For the C. crispus lipid extract, a reduction in the 
expression of these genes was least pronounced due to a high standard deviation (SD) 







In this study we investigated the anti-inflammatory activity of lipid extracts of four algal 
species in human THP-1 macrophages. The fatty acid, pigment and lipid class, and LC-
PUFA partitioning profiles of three red seaweeds (Palmaria palmata, Porphyra dioica, 
Chondrus crispus) and one microalga (Pavlova lutheri) were identified, which contained 
high proportions of n-3 PUFA (34%–42% of total fatty acids) and 5%–7% pigments 
including chlorophyll a, β-carotene, and fucoxanthin. When exposed to human THP-1 
macrophages for 24 h, lipid extracts of P. lutheri (p < 0.01) and P. palmata significantly 
(p < 0.05) suppressed LPS-induced production of the pro-inflammatory cytokine IL-6, 
compared with the untreated control. Similarly, P. palmata (p < 0.05) lipid extract 
significantly reduced production of the pro-inflammatory cytokine IL-8 compared with 
the control. All extracts inhibited the expression of a number of inflammatory genes in 
THP-1 macrophages, including those involved in toll-like receptor activity and 
chemokine and cytokine-linked signaling pathways. These results suggest that the algal 
lipid extracts examined have potential to suppress inflammation through inhibition of 
inflammatory cytokine production and down-regulation of genes involved in a number 
of inflammatory signaling pathways. 
The results provide additional compositional data of lipid extracts from these 
four algal species based on fatty acid, pigment, and lipid profiles. In accordance with 
previous reports, this study demonstrated algal LC-PUFA are mainly partitioned into 
complex polar lipids constituting the membranes and in a less extent into TAG of some 
species with the ability to accumulate TAG containing LC-PUFA. Each algal species 
contained high proportions of n-3 PUFA (34%–62% total fatty acids), with EPA being 
the most abundant fatty acid in all extracts, ranging from 28% to 58% of total fatty 
acids. Indeed, P. lutheri has been widely examined for the ability to produce high 






studied to maximize n-3 LC-PUFA production (Guedes et al., 2010, Tatsuzawa and 
Takizawa, 1995, Meireles et al., 2003, Volkman et al., 1989). Similarly, red seaweeds, 
including those examined in this study, have also been identified as rich sources of EPA 
and desirable n-6:n-3 PUFA ratios (Schmid et al., 2014). Macroalgal lipid composition, 
however, is susceptible to seasonal variation and it has been shown that pigment and 
LC-PUFA levels are optimized under low light and temperature conditions as observed, 
for example, in winter (Schmid et al., 2014). 
Indeed, n-3 LC-PUFA within algae are primarily incorporated into complex 
lipid classes such as MGDG, DGDG, and SQDG (Guihéneuf et al., 2010, Sanina et al., 
2004, Robertson et al., 2013). Banskota et al. have previously demonstrated that polar 
lipids isolated from red algae demonstrate stronger anti-inflammatory activity than pure 
EPA isolated from the same species (Banskota et al., 2014), suggesting that the entire 
polar lipid structure contributes to anti-inflammatory activity. Hence, the polar lipid 
structures, into which the fatty acids are incorporated in the species examined in this 
study, may contribute to the observed inhibition of cytokine production and 
inflammatory gene expression. Interestingly however, the C. crispus extract 
significantly increased production of TNFα, a proinflammatory cytokine. The reason for 
this may be due to the synergistic effect of a number of bioactive pigments and fatty 
acids in the extract including ARA, which was present in high quantities in the C. 
crispus extract and which is recognized as a pro-inflammatory fatty acid (Kuehl and 
Egan, 1980). Chlorophyll a, β-carotene, fucoxanthin, and zeaxanthin have all previously 
demonstrated anti-inflammatory activity (Park et al., 2014, Bai et al., 2005, Heo et al., 
2010, Nidhi et al., 2015) and hence may have contributed to the anti-inflammatory 
activity observed in this study. Chlorophyll a is of particular interest as it was present 
from 2.1 to 3.1 g/100 g crude extract. However, due to the extremely diverse fatty acid 
and pigment composition of the extracts, it is not possible to attribute the observed 






synergistic effects between many bioactives including fatty acids and pigments, which 
contribute to the observed anti-inflammatory effects in a number of pathways. 
The results presented here expand on previous findings showing that algal 
extracts inhibit inflammation in vitro. Yang et al. reported anti-inflammatory activity in 
five Korean seaweed extracts in mouse RAW 264.7 macrophages, in which IL-6, TNFα 
and prostaglandin E2 (PGE2) production were inhibited (Yang et al., 2010). Hwang et 
al. reported similar results for an extract from Sargassum hemiphyllum in the same cell 
line (Hwang et al., 2011). In addition, both Khan et al. and Ishihara et al. isolated pure 
PUFA from Undaria pinnatifida extracts and also demonstrated their anti-inflammatory 
activity (Khan et al., 2007, Ishihara et al., 1998). Our data provide novel evidence for 
the anti-inflammatory activity of algal extracts and show for the first time that P. 
lutheri, P. palmata, P. dioica and C. crispus lipids can inhibit induced inflammatory 
response in human macrophages. Hence these results suggest that these algal species, as 
dietary ingredients, may have the potential to suppress chronic inflammation in vivo; 
however further work is warranted to assess if the in vitro activity is translated to an in 
vivo model.  
It is likely that the crude mix of fatty acids, polar lipids and pigments in the 
extracts influenced a number of inflammatory pathways in the cell, as seen by the wide 
range of genes altered in the gene expression array. LPS is an agonist of toll-like 
receptor 4 (TLR4), a membrane-bound receptor that activates the nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-κB) pathway that leads to a pro-
inflammatory response (Chow et al., 1999)]. In the present study, treatment of the 
macrophages with P. dioica extract downregulated expression of TLR4 by more than 
four folds, indicating inhibition of NF-κB mediated pro-inflammatory pathway, 
however TLR4 expression was not altered by any of the other extracts. In the present 
study, a number of genes involved in NF-κB signaling were significantly downregulated 






pathogen-associated molecular pattern (PAMP) recognition and NF-κB activation, was 
downregulated by all extracts and has previously been shown to be altered by unsaturated 
and saturated fatty acids (Lee et al., 2004). STAT3 and MAP3K1 are signaling 
molecules also involved in NF-κB activation through the JAK-STAT (Janus kinase-
signal transducer and activator of transcription) and JNK kinase pathways respectively, 
which have been shown to be susceptible to change in expression by PUFA and a 
carotenoid extract of Dunaliella salina (Zeyda et al., 2003, Li et al., 2005, Yang et al., 
2013). These genes were significantly downregulated by lipid extracts of P. dioica and 
P. lutheri, further elucidating a role that such extracts play in the downregulation of the 
NF-κB pathway. Moreover, a lipid extract from the cyanophyte Nostoc commune which 
contained n-3 PUFA, β-carotene and a number of other bioactives has previously been 
demonstrated to inhibit inflammatory response in macrophages through inhibition of 
NF-κB signaling.  
In this study, we also evaluated the effect of algae-derived lipid extract on the 
expression of NOS2 gene in LPS-stimulated THP-1 cells. While the mRNA levels of 
NOS2 gene were not affected by the extracts from P. lutheri, P. dioica and C. crispus, 
the expression was increased by the P. palmata lipid extracts. A higher NOS gene 
expression is likely to increase the level of inducible nitric oxide (iNOS) that mediates 
pro-inflammatory response. LPS was reported to stimulate iNOS production in THP-1 
cells (Wang et al., 2013). In the present experiment, the high NOS2 gene expression by 
P. palmata lipid extracts could be due to the failure of this extract to suppress the LPS 
induced NOS2 gene expression and/or exaggerations of the iNOS mediated pro-
inflammatory response in THP-1 cells. Due to the presence of crude and complex 
mixture of fatty acids and pigments in the extract, it was difficult to speculate the 
precise bioactive compound/s that drives such an increase in the NOS2 gene expression 
or whether such a response is translated into higher iNOS leading to a pro-inflammatory 






such as arachidonic acid, which have previously demonstrated immune enhancing 
activities (Chew and Park, 2004, Cranmer-Byng et al., 2015), and that are present in the 
crude lipid extracts of P. palmata contributed to an increase in NOS2 expression, as was 
previously reported for an extract of Ulva rigida in murine RAW 264.7 macrophages 
(Leiro et al., 2007). Hence, isolation and purification of individual bioactive compounds 
from the algal crude lipid extract and understanding their molecular mode of action will 
provide further details of the immune modulatory potential of these novel bioactives.  
The present study explored the anti-inflammatory bioactivity of algal lipid 
extracts containing a crude mixture of fatty acids, pigments, and polar lipids, each of 
which may affect a number of related and unrelated gene expression and cytokine 
production, and the identification of individual anti-inflammatory pathways affected by 
the bioactive component; their precise molecular mode of action warrants further study. 
Of the species studied, lipid extract from C. crispus appeared to display the lowest anti-
inflammatory potential. This may be due to its high content of n-6 ARA, which has been 
associated with pro-inflammatory properties. Extracts from P. lutheri and P. palmata 
were the most potent extracts in inhibiting inflammatory cytokine production, whereas 
those from P. dioica inhibited the expression of more inflammatory genes than any of 
the other species tested. As microalgae tend to have much higher lipid contents than 
macroalgae, are more efficient producers of n-3 LC-PUFA and contain more diverse 
pigment profiles, as observed here, P. lutheri may pose the best potential as an anti-
inflammatory functional food ingredient. 
In conclusion, we demonstrated for the first time that lipid extracts from P. 
lutheri, P. palmata, P. dioica and C. crispus downregulated LPS-induced pro-
inflammatory responses in human macrophages through inhibition of IL-6 and IL-8 
production. This anti-inflammatory mechanism of algal lipid extract is most likely due 
to alteration in the expression of genes that encode signaling molecules linked to the 






these extracts is attributable to a synergistic effect of bioactive compounds such as 
pigments and n-3 LC-PUFA incorporated into complex lipid structures which have 
previously been shown to exert similar anti-inflammatory effects. However further work 
is warranted to identify which compound exert the strongest biological effects. The 
bioactivity of these novel algal-lipid extracts as anti-inflammatory functional food 
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Table 1. Fatty acid composition of the four algal lipid extracts. 
Extracts 
(% Total fatty acids) 
Pavlova lutheri Palmaria palmata Porphyra dioica Chondrus crispus 
Average SD Average SD Average SD Average SD 
Saturated fatty acids (SFA)        
12:0 0.19 0.14 0.16 0.05 0.32 0.13 0.42 0.15 
14:0 14.26 0.47 4.51 0.35 0.53 0.10 1.98 0.39 
16:0 12.84 0.19 22.27 0.40 28.12 1.19 27.33 0.50 
18:0 0.68 0.02 1.69 0.07 2.16 0.11 2.71 0.05 
Sum of SFAs 27.97 0.61 28.63 0.63 31.14 1.51 32.44 0.90 
Monounsaturated fatty acids (MUFA)        
14:1 0.55 0.01 0.51 0.07 0.54 0.12 0.48 0.11 
15:1 1.66 0.09 1.53 0.14 1.51 0.02 1.69 0.27 
16:1 n-7 14.36 0.45 1.17 0.20 2.37 0.09 0.58 0.08 
18:1 n-9 2.60 0.07 2.18 0.02 1.72 0.02 5.47 0.02 
18:1 n-7 0.31 0.05 0.73 0.01 0.68 0.00 0.59 0.01 
20:1 n-9 n.d.  n.d.  1.62 0.04 n.d.  
Sum of MUFAs 19.49 0.54 6.12 0.11 8.44 0.06 8.82 0.24 
Polyunsaturated fatty acids (PUFA)        
16:2 n-6 0.85 0.22 n.d.  n.d.  n.d.  
16:2 n-4 1.68 0.11 n.d.  n.d.  n.d.  
16:4 n-3 0.62 0.13 n.d.  n.d.  n.d.  
18:2 n-6 0.59 0.02 0.65 0.01 1.64 0.01 1.58 0.05 
18:3 n-6 2.09 0.04 0.26 0.01 0.56 0.01 0.49 0.01 
18:3 n-3 1.13 0.01 0.65 0.01 1.34 0.02 0.23 0.00 
18:4 n-3 4.98 0.08 2.16 0.04 1.58 0.01 0.25 0.01 
20:2 n-6 n.d.  1.06 0.15 0.87 0.02 0.37 0.05 
20:3 n-6 n.d.  n.d.  2.21 0.35 0.19 0.16 
20:4 n-6 0.60 0.02 0.67 0.01 3.03 0.07 19.85 0.82 
20:5 n-3 27.67 0.37 57.94 0.89 46.35 0.91 33.47 0.21 
22:5 n-3 1.17 0.20 n.d.  n.d.  n.d.  
22:6 n-3 10.47 0.38 1.15 0.24 n.d.  n.d.  
Sum of PUFAs 51.85 0.84 64.55 0.87 57.57 1.35 56.42 1.29 
n-3 46.04 1.05 61.91 0.71 49.26 0.93 33.94 0.20 
n-6 4.13 0.18 2.64 0.17 8.31 0.44 22.47 1.10 
Ratio n-6/n-3 0.09 0.01 0.04 0.00 0.17 0.01 0.66 0.03 
Others 0.69 0.30 0.70 0.12 2.85 0.14 2.32 0.61 
Data are expressed as % of total fatty acid methyl esters (FAME) and are presented as mean 










Table 2. Pigment composition of four algal lipid extracts. 






Pigments (% Molar) Average SD Average SD Average SD Average SD 
chlorophyll a + deg. 41.10 0.05 52.03 0.05 53.02 0.37 43.95 0.30 
β-carotene 7.05 0.09 25.17 0.34 19.15 0.27 30.22 0.09 
zeaxanthin n.d.  22.80 0.38 27.53 0.59 25.84 0.40 
diadinoxanthin + diatoxanthin + deg. 16.11 0.03 n.d.  n.d.  n.d.  
cys-fucoxanthin 5.51 0.01 n.d.  n.d.  n.d.  
chlorophyll c + deg. 3.36 0.08 n.d.  n.d.  n.d.  
fucoxanthin + deg. 26.87 0.07 n.d.  n.d.  n.d.  
Pigments (% crude extract) 6.80 0.05 6.03 0.41 5.13 0.06 4.87 0.04 
Data are expressed as % molar and are presented as mean values ± standard deviation (SD); 








Table 3. Effect of algal lipid extracts treatment followed by lipopolysaccharide (LPS) exposure on the differential expression of a panel of 




Name Fold change Gene description and function 
P. lutheri TLR8 Toll-like receptor 8 −3.33 PAMP recognition and activation of innate immunity. Mediates cytokine production through activation of NF-κB  
  TLR1 Toll-like receptor 1 −4.16 Interacts with TLR2 for immune activation through PAMP recognition. 
  TRAF5 TNF receptor-associated factor 5 −2.69 Mediates signal transduction of the TNF receptor family. Mediates NF-κB and JNK activation 
  MAP3K1 Mitogen-activated protein kinase 1 −2.63 Activates protein kinase signal transduction cascade such as the ERK and JNK kinase pathways and NF-κB pathway. 
  PTGER1 Prostaglandin E receptor 1 +2.58 Encodes a receptor for PGE2. Down-regulates COX2 and hence resolves inflammation. 
P. palmata TLR8 Toll-like receptor 8 −2.91 PAMP recognition and activation of innate immunity. Mediates cytokine production through activation of NF-κB  
  TLR1 Toll-like receptor 1 −3.99 Interacts with TLR2 for immune activation through PAMP recognition. 
  TRAF5 TNF receptor-associated factor 5 −2.73 Mediates signal transduction of the TNF receptor family. Mediates NF-κB and JNK activation 
  NOS2 Nitric oxide synthase 2 +2.83 Encodes nitric oxide synthase which mediates tumoricidal and bactericidal actions in macrophages 
P. dioica CCR1 Chemokine (C-C motif) receptor 1 −3.46 Acts as a receptor for chemokines such as MIP-1α and MCP-3 which assist in immune cell recruitment 
  TLR8 Toll-like receptor 8 −3.29 PAMP recognition and activation of innate immunity. Mediates cytokine production through activation of NF-κB  
  TLR2 Toll-like receptor 2 −4.25 Interacts with TLR1 for PAMP recognition leading to  NF-κB activation and cytokine production 
  TLR1 Toll-like receptor 1 −2.5 Interacts with TLR2 for immune activation through PAMP recognition. 
  TRAF5 TNF receptor-associated factor 5 −3.37 Mediates signal transduction of the TNF receptor family. Mediates NF-κB and JNK activation 
  TNFSF18 TNF (ligand) superfamily, member 18 −2.93 Regulates T-cell activities by lowering the threshold for T-cell activation. 
 TRAF6 TNF receptor-associated factor 6 −2.99 Mediates signal transduction from TNF receptors and Toll/IL-1 receptors. 
 MAP3K1 Mitogen-activated protein 3 kinase 1 −3.63 Activates protein kinase signal transduction cascade such as the ERK and JNK kinase pathways and NF-κB pathway. 
 STAT3 Signal transducer and activator of transcription 3 −3.56 Activated by cytokines to create transcription factors that form part of JAK-STAT signaling cascade. 
 CCR5 Chemokine (C-C motif) receptor 5 −2.72 Chemokine receptor, expressed in macrophages involved in immune cell recruitment. 
 TLR4 Toll-like receptor 4 −4.44 PAMP recognition and activation of inflammatory cascade. Specifically recognises LPS 
 IL6R Interleukin 6 receptor −2.54 Binds with low affinity to the inflammatory cytokine IL-6 regulating immune response and acute phase reactions. 
 PTGER1 Prostaglandin E receptor 1 +2.7 Encodes a receptor for PGE2. Down-regulates COX2 and hence resolves inflammation. 
C. crispus IL23 Interleukin 23 −4.19 Activates STAT4 and stimulates production of IFNγ Associated with autoimmune inflammation and tumorigenesis.  
  TLR8 Toll-like receptor 8 −2.59 PAMP recognition and activation of innate immunity. Mediates cytokine production through activation of NF-κB  
  CCL17 Chemokine (C-C motif) ligand 17 −3.33 Encodes a cytokine that is a chemotactic factor for T-lymphocytes. Recruitment and activation of mature T-cells 
  TLR1 Toll-like receptor 1 −3.25 Interacts with TLR2 for immune activation through PAMP recognition. 
  TRAF5 TNF receptor-associated factor 5 −2.76 Mediates signal transduction of the TNF receptor family. Mediates NF-κB and JNK activation 
  TRAF6 TNF receptor-associated factor 6 −3.04 Mediates signal transduction from TNF receptors and Toll/IL-1 receptors. 
Values are expressed as fold change in gene expression relative to the dimethyl sulfoxide (DMSO) vehicle control. Negative values represent gene down-regulation and positive values represent gene 
up-regulation. A fold difference cut-off point was set at ≥2.5. PAMP: pathogen-associated molecular pattern; NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells; TNF: tumor necrosis 
factor; JNK: c-Jun N-terminal kinase; ERK: extracellular signal-regulated kinase; PGE2: prostaglandin E2; COX2: cyclooxygenase 2; STAT4: signal transducer and activator of transcription 4; MIP-1α: 





Table 4. Oligonucleotide sequences of forward and reverse primers for 
quantitative real-time PCR (qPCR).  
Gene name Primers Nucleotide sequence (5′ to 3′) Tm (°C) 
GAPDH Forward ACAGTTGCCATGTAGACC 55.7 
 Reverse TTTTTGGTTGAGCACAGG 59.9 
TLR1 Forward CCCTACAAAAGGAATCTGTATC 58.2 
 Reverse TGCTAGTCATTTTGGAACAC 57.8 
TLR8 Forward TGGAAAACATGTTCCTTCAG 60.1 
 Reverse TGCTTTTTCTCATCACAAGG 60.4 
TRAF5 Forward GGAATGGCTTATTCAGAAGAG 59.4 
 Reverse CCACAAACTGGTACTCTATAC 52.8 


























Figure 1. Distribution of fatty acids within lipid classes in (A) Pavlova lutheri,  
(B) Palmaria palmata, (C) Porphyra dioica, (D) Chondrus crispus. * Identified using Rf values 
from the literature using similar migration solvent systems without using standards; " Sum of 
other unidentified polar lipids, i.e., phospholipids and betaine lipids; No symbol: Identified 
using Rf values from the literature and standards; EPA: eicosapentaenoic acid; DHA: 
docosahexaenoic acid; TAG: triacylglycerol; FFA: free fatty acids; DAG: diacylglycerols; 
MAG: monoacylglycerols; MGDG: monogalactosyldiacylglycerols; DPG: 
diphosphatidylacylglycerols; SG: acylated sterol glycosides; PE: phosphatidylethanolamines; 
PG: phosphatidylglycerols; DGDG: digalactosyldiacylglycerols; SQDG: 










Figure 2. Effects of algal lipid extracts exposure on interleukin-6 (IL-6), IL-8 production and 
tumor necrosis factor α (TNFα) production in lipopolysaccharide (LPS)-stimulated THP-1 
macrophages. THP-1 macrophages were exposed to the respective algae-lipid extracts or the 
vehicle control (dimethyl sulfoxide, DMSO) for 24 h and incubated with 100 ng·mL−1 LPS for a 
further 24 h. Values represent mean ± standard error (SE) normalized to DMSO control. * p ≤ 
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Figure 3. Validation of PCR array results through quantitative PCR. Effects of algal lipid 
extracts exposure on expression of TLR1, TLR8, and TRAF5 genes in lipopolysaccharide (LPS)-

















An assessment of the techno-functional and sensory 
properties of yoghurt fortified with an omega-3-rich 













Marine microalgae are potential sources of functional bioactive compounds such as 
omega-3 polyunsaturated fatty acids (n−3 PUFA), pigments and minerals. In this study, 
plain yoghurt was manufactured with or without a food grade lipid extract of the 
microalgae species Pavlova lutheri (0.25% and 0.5% w/v). Techno-functional 
properties, fatty acid analysis and sensory characteristics were evaluated over 28 days 
storage to assess the suitability of yoghurt as a vehicle for the microalgal extract. 
Inclusion of the extract at 0.25% and 0.5% w/v had no significant impact on yoghurt 
composition, viscosity, pH, starter culture viability (for 21 days) or whey separation. 
Addition of the extract dose-dependently increased concentrations of total n−3 PUFA (p 
< 0.0001) in the yoghurt. Sensory analysis revealed that supplemented yoghurts were not 
well accepted by the panellists compared with the control yoghurt. These results suggest 
that techno-functional properties of yoghurt are unaffected following manufacture with a 
lipid extract of P. lutheri. In addition, incorporation of this extract into yoghurt is a 
suitable method to increase n−3 PUFA concentration, however further research is 
warranted to improve the perceived negative sensory attributes associated with the 













1. INTRODUCTION  
One of the biggest changes in the modern ‘Western diet’ has been in the quantity and 
quality of fat consumption (Simopoulos, 1999). Despite much focus being placed on 
saturated fatty acid (SFA) consumption in recent times (Siri-Tarino et al., 2010), the 
dietary ratio of omega-6 (n-6) to omega-3 (n-3) polyunsaturated fatty acids (PUFA) has 
changed drastically. n-3 and n-6 PUFA are primary constituents of mammalian cell 
membranes and are essential for a number of structural and functional cellular 
mechanisms. Long chain n-3 PUFA (n-3 LC-PUFA) in particular, are essential for foetal 
neurodevelopment (Innis, 2008) and have also shown consistent cardioprotective 
(Adkins and Kelley, 2010), neuroprotective (Bazinet and Layé, 2014), anti-obesigenic 
(Buckley and Howe, 2009) and anti- inflammatory (Calder, 2006) properties. n-6 PUFA 
however, typically have opposing physiological effects to n-3 PUFA, particularly with 
regard to inflammation (Kaliannan et al., 2015), and increased consumption has been 
associated with a number of chronic inflammatory diseases (Patterson et al., 2012). 
Historically, dietary ratios of n-6/n-3 PUFA consumption were 1:1 however this has 
increased rapidly to approximately 15:1 in recent times in the western diet leading to 
relative n−3 deficiency (Simopoulos, 2002).  
Oily fish such as salmon, mackerel and anchovies are potent sources of the n-3 
PUFA, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), and increased 
consumption has been associated with reduced risk of cardiovascular disease (Kromhout 
et al., 1985), certain cancers (Fernandez et al., 1999) and mental illness (Hibbeln, 1998). 
However declining global fish stocks and pollutant accumulation pose significant threats 
to n-3 PUFA consumption from fish sources (FAO Fisheries and Aquaculture 
Department, 2010). Algae, particularly marine microalgae, are also potent sources of n-3 
PUFA and hence pose potential as novel alternative sources of EPA, DHA and other 





microalgae can be optimized based on culture conditions (Guihéneuf and Stengel, 2013) 
and hence much research has now begun to examine the most suitable algal species for 
the industrial production of n−3 PUFA (Robertson et al., 2013).  
n−3 PUFA production from microalgae has many advantages over other marine 
sources including selective fatty acid accumulation, sustainability, and increased 
bioavailability (Kagan et al., 2015). However, the sensory properties of marine n-3 
PUFA-rich oils are limited by characteristic ‘fishy-tastes’ which are viewed negatively 
by the consumer (Van Elswyk, 1997). Fortification of carrier foods with marine n−3 
PUFA-rich oils has the potential to mask some of the negative sensory properties of 
marine oils and may allow easier incorporation of n-3 PUFA into habitual diets 
(Lovegrove et al., 1997). Dairy products have previously proven successful carriers for 
bioactive nutraceuticals (Let et al., 2007). O′Sullivan et al. examined the potential for 
milk to act as a carrier for algal extracts (O'Sullivan et al., 2014). Yoghurt, in particular, 
has been widely studied as a vehicle for the delivery of functional ingredients including 
probiotics, prebiotics and antioxidants. Previously, yoghurt was proven a suitable carrier 
for fish oil to increase plasma n-3 PUFA status (McCowen et al., 2010). However, there 
are limited data on the incorporation of n−3 PUFA from algae into vehicle food 
products.  
We previously reported the high n−3 PUFA and bioactive pigment contents in 
lipid extracts from a number of algal species and subsequently demonstrated the anti-
inflammatory effects of these extracts in human THP-1 macrophages (Robertson et al., 
2015). In this study, we investigate the potential for yoghurt to act as a carrier food for 
one of these extracts, from the microalgal species Pavlova lutheri, and assess fatty acid 
profile, techno-functional (pH, composition, starter culture viability, rheology, syneresis, 






2. MATERIALS AND METHODS  
2.1. Microalgal strain, culture conditions, biomass preparations  
An axenic strain of Haptophyte P. lutheri CCAP 931/6, formerly renamed Diacronema 
lutheri (Bendif et al., 2011), was obtained from the Culture Collection of Algae and 
Protozoa at the Scottish Marine Institute (SAMS Research Services Ltd., Oban, 
Scotland, UK) and cultivated in the laboratory at the National University of Ireland 
Galway.  
P. lutheri was pre-cultivated under batch conditions on a modified F/ 2 medium 
(Guillard, 1975) in 15 L polycarbonate Nalgene® culture vessel at 15 °C and under 
continuous illumination (100–120 μmol photons m− 2 s− 1), provided by lumilux cool 
daylight fluorescent lamps (OSRAM L18W/865, Germany). F/2 medium was composed 
and complemented as described previously (Guihéneuf and Stengel, 2013) with few 
modifications; i.e. using natural filtered seawater, an initial NaNO3 concentration of 200 
mg L− 1 and no NaHCO3 supplementation. The medium was sterilized by autoclaving 
for 20 min at 120 °C, and vitamins were filtered and added when the medium cooled to 
room temperature. Cultures were agitated by air-bubbling.  
After 8 days of batch-cultivation in polycarbonate Nalgene® culture vessel, the 
12 L of P. lutheri pre-culture was transferred to a custom-made 75 L low-cost flat panel 
photobioreactor (FP-PBR 120 × 95 × 7 cm, adapted and similar to one previously 
patented (Boussiba and Zarka, 2005)), containing 60 L of fresh F/2 medium 
supplemented with 1 g L− 1 NaHCO3. Growth conditions were similar to those used for 
pre-cultivation (i.e. continuous light of 100–120 μmol photons m− 2 s− 1 and 
temperature of 15 °C). Light was provided on one side of the FP-PBR which consisted 
of a plastic bag placed between two frames. Compressed-air was bubbled at a rate of 50 





exchange. P. lutheri was cultivated using a semi-continuous mode during a total period 
of 60 days. 60 L of culture was harvested at 20 day intervals. After each harvesting 
event, the remaining culture was topped-up with 60 L of fresh F/2 medium. For each 
cultivation cycle, nitrate was depleted after approximately 16 days and kept for 4 
additional days. This process allows the accumulation of lipid and triacylglycerols 
containing n-3 LC-PUFA triggered by nitrogen limitation and inorganic carbon 
(NaHCO3) availability as described previously (Guihéneuf and Stengel, 2013). 
Microalgal cells were harvested by centrifugation using a modified Alistar milk cream 
separator 80 L h− 1, and the fresh algal paste collected were frozen at −20 °C and 
freeze-dried using Labconco Freezone® (Kansas City, MO, USA) 6 freeze-dryer 
system.  
 
2.2. Lipid extraction  
Total lipids were extracted by solid–liquid procedure using the microalgal food grade 
lipid extraction method as previously described (Ryckebosch, 2011). Briefly, 50 g of 
freeze-dried microalgal biomass was extracted with 250 mL of hexane/isopropanol (3:2, 
v/v) in a glass bottle closed under nitrogen gas (N2) to limit oxidation, sonicated for 1 h 
and stirred overnight at 4 °C. The first extract obtained was filtered and the remaining 
biomass re-extracted 2 times similarly. All the filtered extracts were combined and the 
total crude lipid extract was evaporated to dryness using a rotavapor (BÜCHI R-210 
equipped with a Heating Bath B-491 and a Vacuum Pump V700, BÜCHI Labortechnik 
AG, 9230 Flawil, Switzerland) under reduced pressure at 40 °C.  
Since the food grade extract was not washed with water as in the traditional lipid 
extraction method of Bligh and Dyer (Bligh and Dyer, 1959) using a 
chloroform/methanol/water mixture, it may have contained not only lipids but also more 





the extract, the non-lipid polar components were eliminated by dissolving an aliquot of 
the extract in 8 mL of chloroform/methanol (1:1) and washed with 2 mL of water. The 
upper layer containing the non-lipid constituents was removed, while the bottom layer 
containing the lipids was dried under N2 flow and weighed. The non-lipid part of the 
extract was estimated at approximately 8–10% of the total food grade lipid extract.  
 
2.3. Pigment analysis  
Pigment analysis was carried out by high performance liquid chromatography (HPLC) 
following the method by Wright et al. (Wright et al., 1991) with modifications by 
Bidigare et al (Bidigare et al., 2005) as previously described (Robertson et al., 2015).   
 
2.4. Yoghurt manufacture  
Yoghurt production and analyses were performed in triplicate batches. All techno-
functional analyses were carried out at 7 day intervals. Prior to yoghurt production, P. 
lutheri extract was added to milk (Avonmore low fat (1.5%) milk, Glanbia Consumer 
Foods, Dublin Ireland) at 0.25% and 0.5% w/v and mixed for 5 min by mechanical 
homogenizing at 1000 rpm (Silverson L4RT, East Longmeadow, MA, USA). Control 
and enriched milk samples were then heated in a waterbath at 63 °C for 10 min before 
homogenization at 500 bar (APV 1000, SPX Flow, Crawley, West Sussex, UK) to aid 
dissolution of the algal extract. Milk samples were then heated in a waterbath at 93 °C 
for 15 min. Samples were subsequently cooled to 42 °C before addition of starter culture 
(YC-380 — 0.03% w/v, Lactobacillus delbrueckii subsp. bulgaricus and Streptococcus 
thermophilus, Chr. Hansen, Denmark) as per manufacturer's instructions. Samples were 
placed in an incubator at 42 °C and agitated for 15 min to achieve a homogenous 
culture. Incubation was continued at 42 °C until a pH of 4.3 was reached. Yoghurt 





up to 28 days at 4 °C.  
 
2.5. Compositional analysis  
Yoghurt pH was measured every 7 days using a standard pH meter (Mettler Toledo 
MP220; British Standards Institution, 1976). Moisture and fat contents were assessed 
using the SMART Trac rapid moisture/fat analyser as per manufacturer's protocol (CEM 
Corporation, North Carolina, USA). Ash content was assessed using a muffle furnace by 
heating the samples at 550 °C for 12 h according to the method of the Association of 
Official Analytical Chemists (AOAC, 1995). Protein nitrogen content was assessed by 
Kjeldahl method (International Dairy Federation, 2001) and values were multiplied by 
6.38 to obtain total protein values. Carbohydrate content was calculated by difference.  
 
2.6. Bacterial enumeration  
Enumeration of starter cultures was carried out in duplicate via standard bacterial 
culture. Briefly, 10 g of yoghurt was added to 90 mL sterile maximum recovery diluent 
(MRD, Oxoid, Fannin Healthcare, Dublin, Ireland) in a sterile stomacher bag and 
stomached for 30 s (Stomacher, Lab-Blender 400, Seward, Thetford, Norfolk, UK). Ten-
fold serial dilutions of the diluted yoghurt were then performed in sterile MRD. 
Streptococcus thermophilus was cultured and enumerated on M-17 agar (Difco 
laboratories, Detroit MI, USA) supplemented with 0.5% sterile lactose solution (Oxoid, 
Fannin Healthcare, Dublin, Ireland) under aerobic conditions at 42 °C. L. delbrueckii 
subsp. bulgaricus (L.bulgaricus) was cultured and enumerated on MRS agar (Difco) 
under anaerobic conditions at 37 °C. Results are expressed as log10CFU (colony 







2.7. Syneresis  
The extent of syneresis/whey separation was examined in duplicate according to Keogh 
and O′Kennedy (Keogh and O'Kennedy, 1998). Briefly, 20 g yoghurt samples were 
centrifuged at 3000 g for 10 min at 4 °C. Supernatants were removed, weighed and 
expressed as a percentage of original yoghurt weight.  
 
2.8. Rheology  
Rheology was carried out using an AR-2000ex rheometer (TA Instruments, Crawley, 
UK) using parallel plate geometry (60 mm) at 20 °C according to the method of Kearney 
et al (Kearney et al., 2011). Prior to rheological analysis, samples were stirred 20 times. 
Briefly, a pre-shear was carried out at 200 s− 1 for 1 min followed by equilibration for 1 
min. The sample was then sheared from 0.01 to 200 s− 1, held at 200 s− 1 for 1 min, 
then sheared from 200 to 0.01 s− 1 over 2 min. Results are expressed as mean mPa 
values at 200 s− 1 shear rate.  
 
2.9. Colorimetry  
Colorimetry was carried out using a standard colorimeter in duplicate (Minolta Chroma-
Meter CR-400, Mason Technology Ltd., Dublin 8, Ireland). Calibration was carried out 
using a white tile (C: Y = 93.6, x = 0.3130, y = 0.3193). Yoghurt samples (2 mL) were 
placed in transparent cuvettes, colour was measured and Yxy values were converted 
under the L*a*b* colour space, where ‘L*’ represents lightness, ‘a*’ represents 
greenness and ‘b*’ represents yellowness.  
 
2.10. Fatty acid analysis  





was carried out as previously described (Robertson et al., 2015).  
Fatty acid analysis of yoghurt was performed as follows: Lipids were extracted 
from 2 g yoghurt samples using 2:1 v/v chloroform:methanol. Methylation was 
subsequently carried out by the addition of 10 mL 0.5 N NaOH and by heating at 90 °C 
for 10 min, followed by 10 mL 14% BF3 in methanol and further heating at 90 °C for 10 
min (Park and Goins, 1994). Fatty acid methyl esters (FAMEs) were recovered in 
hexane and dried over anhydrous sodium sulphate for 1 h followed by storage at −20 °C 
until analysis.  
Fatty acid analysis was performed by gas chromatography-flame ionization 
detection (GC-FID). FAMEs were separated using GC (Agilent 7890B, Agilent 
Technologies, Santa Clara, CA, USA) fitted with a flame ionization detector, using a 
Chrompack CP Sil 88 column (Chrompack, JVA Analytical, 100 m × 0.25 mm internal 
diameter, 0.25 μm film thickness) and helium as the carrier gas. The column oven was 
held at 80 °C for 8 min and increased by 8.5 °C/min to a final column temperature of 
200 °C. Automatic sample injection (CTC Autosampler, Model 80) was performed on a 
Multimode Inlet on-column temperature programmable injector, with an injection 
volume of 0.5 μl. Peaks were integrated using the Agilent OpenLAB Chemstation 
software (Version A.01.06.111). Identification of peaks was carried out by comparison 
of retention times with pure FAME standards (Nu-Chek Prep, Elysian, MN, USA).  
 
2.11. Sensory analysis  
Sensory analysis was performed in the University College Cork Food Sensory 
Laboratory on day 7 (n = 20 assessors) and day 28 (n = 14 assessors) using naïve 
untrained assessors (aged 20 to 50 yr). Both hedonic (colour, flavour, texture, 
acceptability) and intensity (thickness, odour, off-odour, sour taste, yoghurt flavour, off-





Analysis was performed in panel booths conforming to international standards 
(ISO 8589:2007). Coded yoghurt samples were presented to assessors in random order 
to prevent first order and flavour carryover effects. Water was provided to assessors to 
cleanse their palate in between tastings. Assessors were provided with a 10 cm line scale 
and required to indicate degree of liking on the scale from 0 (extremely dislike) to 10 
(extremely like).  
 
2.12. Statistics  
Data represent results from triplicate trials. Statistical analysis was carried out using 
GraphPad Prism (6.0, San Diego, CA, USA). Results were subject to one-way or two-
way ANOVA (analyses of variances) followed by Tukey's multiple comparison tests. 
Sensory data were subject to ANOVA-Partial Least Squares Regression (APLSR) using 
Unscrambler Software, version 9.8 (CAMO ASA, Trondheim, Norway). Statistical 
significance for the relationships determined in the quantitative APLSR was derived by 
analysis of jack-knifing of regression coefficients, which is based on cross-validation 
and stability plots (Martens and Martens, 1999, Martens and Martens, 2001). Results are 
expressed as mean ± standard error of the mean (SEM). Results were considered 













3. RESULTS AND DISCUSSION  
 
3.1. Extract fatty acid and pigment profile  
Table 1 shows the fatty acid profile of the food grade P. lutheri extract prior to inclusion 
in yoghurt. As reported previously (Guihéneuf et al., 2010, Robertson et al., 2015), P. 
lutheri is a potent producer of n−3 PUFA, particularly EPA, DHA and relatively large 
amounts of stearidonic acid (SDA, 18:4 n−3). Here, these results demonstrate that more 
than 50% of fatty acids within the extract are n−3 PUFA, with EPA being the most 
abundant fatty acid in the extract at 9g/100g crude extract. SDA and DHA make up 
2.2% and 3.5% of the extract respectively. In addition, n−6 PUFA content within the 
extract is relatively low, at 1.5%, which contributes to a low n−6/n−3 ratio of 0.1. These 
data demonstrate that P. lutheri lipid extracts are good sources of n-3 PUFA and hence 
offer potential as functional nutraceuticals. More importantly, these results highlight that 
food grade lipid extraction using hexane/isopropanol achieves similar fatty profiles 
compared to conventional extractions using other organic solvents (Robertson et al., 
2015). In addition to n−3 PUFA, HPLC analysis identified 11% of the P. lutheri extract 
to be composed of pigments including fucoxanthin (26% of total pigments), chlorophyll 
a (28%) and β-carotene (13%), similar to previous reports (Robertson et al., 2015), and 
as outlined in Table 2. Fucoxanthin, chlorophyll a and β-carotene have previously 
demonstrated bioactive functionalities, especially with regard to resolving inflammation 
(Peng et al., 2011, Bai et al., 2005) and hence offer additional functional benefits to n-3 
PUFA. Indeed, it is possible that the extract contains a number of additional unidentified 
lipid soluble compounds not identified here including carotenoids, proteins and sterols 
The lipid partitioning profile of this extract, however, has previously been defined 






3.2. Yoghurt composition  
Table 3 shows yoghurt composition on day 7 following incorporation of the P. lutheri 
extract at 0.25% or 0.5%. Moisture, carbohydrate, protein fat and ash contents were not 
significantly altered by the addition of the extract at 0.25% or 0.5%. In addition, 
composition of the supplemented yoghurts was similar to those previously reported 
following addition of an algal oil to yoghurt (Chee et al., 2005). Despite the 
incorporation of lipid extracts into the fortified yoghurts, fat content did not significantly 
differ between any of the yoghurts. However, a trend was observed for increasing fat 
content from the control (1.5% fat) to the 0.25% supplemented (1.56% fat) to the 0.5% 
supplemented (1.64% fat) yoghurts. Due to the crude method of extraction from the 
algal biomass, it is possible that a substantial proportion of the algal extract was non-
lipid, suggesting that addition of 0.25% extract into the yoghurt may not be reflected by 
a 0.25% increase in total fat content. In addition, slight variations in lipid content 
between batches of commercial milk may have contributed to the lack of significance in 
total lipid content between yoghurts. However, low-fat milk was used for the yoghurt 
production suggesting that, despite the addition of the lipid extracts, each yoghurt fell 
within the ‘low-fat’ (<3g fat/100 g solids) and ‘low sugar’ (<5g sugars/100 g solids) 
categories of the European Food Safety Authorities (EFSA) health claims (EFSA, 2006). 
Overall, addition of the algal extract did not negatively impact the macronutrient 
composition of yoghurt.  
 
3.3. pH and starter culture viability  
Fig. 1a displays pH content of the yoghurts following production over 28 days of 
storage. Addition of the extract at either concentration did not significantly alter the pH 
of the yoghurt at any of the time points. At day 1, pH of the control, 0.25% and 0.5% 





day 28. The low pH of yoghurt is dependent on the growth of starter culture lactic acid 
bacteria (LAB). LAB produce an acidic environment which contributes to yoghurt 
flavour and can inhibit the growth of spoilage microorganisms and hence contribute to 
the long shelf-life of yoghurt (Lindgren and Dobrogosz, 1990). A commercial starter 
culture mix (Hansen YC-380) was used for yoghurt production, containing strains of 
LAB species L. bulgaricus and S. thermophilus. Mean viable counts of L. bulgaricus 
were between 106 and 107 cfu·mL−1 in each of the yoghurts on day one, as outlined in 
Fig. 1b. Viable counts were not significantly different between the yoghurts at any of the 
time points, staying at ~ 106 cfu·mL− 1 until day 28, at which point L. bulgaricus in the 
0.5% supplemented yoghurt dropped to ~ 104 cfu·mL− 1. Viable counts of S. 
thermophilus were ~1010 cfu·mL−1 in each of the yoghurts at day 1, which stayed 
constant in the control yoghurt between ~109 and 1010 cfu·mL− 1 over 28 days, as seen 
in Fig. 1c. A non-significant decline in viable S. thermophilus counts was observed in 
both supplemented yoghurts from day 7 onward in comparison to the control yoghurt. 
Viable counts were between 107 and 108 cfu.ml− 1 in the supplemented yoghurts 
between day 7 and day 21, until day 28, at which point S. thermophilus declined 
significantly in both supplemented yoghurts compared with the control yoghurt.  
 The incorporation of microalgae into fermented milk products has been 
examined previously (Beheshtipour et al., 2013). Beheshtipour et al. examined the 
addition of Chlorella vulgaris and Arthrospira platensis into yoghurt and reported that 
addition of the microalgae significantly increased growth of starter culture LAB 
compared to control during fermentation, which the authors suggest may be attributed to 
the array of amino acids, proteins and vitamins within the algal biomass (Beheshtipour 
et al., 2012). This is similar to the data reported in the present study, in which L. 





compared to control on day 1. The results reported here, however, demonstrate a trend 
towards reduced S. thermophilus growth over 28 days storage in contrast to previous 
data for microalgal fortification. The nature and species of the extract used in this study 
may explain these differences. Algal extracts have previously demonstrated 
antimicrobial activity (Lordan et al., 2011). In addition, pure DHA and alpha linolenic 
acid (ALA) have been shown to inhibit Lactobacillus growth and adhesion (Kankaanpää 
et al., 2001). The addition of fish oil to yoghurt has also been reported to decrease LAB 
counts over a 28 day period (Estrada et al., 2011). Hence the crude lipid composition of 
these extracts may have contributed to the non-significant decrease in starter culture 
viability over 21 days as previously shown for other marine oils (Estrada et al., 2011). 
The observed decline in S. thermophilus growth in the supplemented yoghurt was 
statistically significant at day 28 which has been observed previously in both marine oil 
supplemented and control yoghurts (Estrada et al., 2011). Hence fortification of yoghurt 
with the extract at either 0.25% or 0.5% for 21 days did not negatively affect starter 
culture viability in comparison with control.  
 
3.4. Syneresis  
There were no observed differences in rate of syneresis between control and 
supplemented yoghurts over 28 days of storage, as shown in Fig. 2. Syneresis values 
were 62.8%, 65.3%, and 64.1% for control, 0.25% and 0.5% for yoghurts respectively 
on day 1 and trended towards a non-significant increase to 68.2%, 66.3% and 66.1% 
respectively on day 28. Mean increase in syneresis value from day 1 to day 28 was 
5.4%, 1% and 2% for the control, 0.25% and 0.5% supplemented yoghurts respectively. 
Syneresis involves spontaneous rearrangement of the yoghurt gel network resulting in 
separation of whey. Reduced syneresis is associated with more desirable sensory traits in 





between control and fortified yoghurts, are comparable to previous reports for marine 
oil-supplemented yoghurts (Estrada et al., 2011). As was observed with the composition 
and starter culture viability, fortification of the yoghurt with 0.25% or 0.5% P. lutheri 
lipid extract did not negatively affect the separation of whey in the yoghurt. Moreover, a 
non- significant trend was observed between day 1 and day 28 in which the increase in 
syneresis was less apparent in the 0.25% supplemented (1% increase) and 0.5% 
supplemented (2% increase) yoghurts in comparison with the control yoghurt (5.4% 
increase in syneresis), suggesting that incorporation of the extract may reduce the rate of 
syneresis after 28 days. These data are comparable to previous reports in which n−3 rich 
oil extracts improved (Dal Bello et al., 2015, Tamjidi et al., 2012) or did not negatively 
affect yoghurt syneresis (Estrada et al., 2011).  
 
3.5. Rheology  
Fig. 3 demonstrated there were no significant differences in viscosity between yoghurts 
at any of the time points over 28 days as measured by resistance to a stress of 200 s−1 
shear rate. The control and 0.25% yoghurt had viscosity values of 57 (±11) and 65 (±10) 
mPa·s respectively on day 1 which declined to 49 (±12) and 47 (±8) mPa·s by day 28. 
The 0.5% supplemented yoghurt exhibited viscosity of 43 (±5) on day 1, which 
increased slightly to 49 (±4) by day 28. Rheological properties of yoghurt are dependent 
on a number of factors including species of starter inoculation, concentration of starter 
inoculation, handling and storage. Yoghurt exhibits pseudoplastic fluid properties and 
hence increased viscosity may prevent textural and structural damage to the yoghurt gel 
matrix. In addition, increased viscosity has been associated with improved sensory 
properties, and previous investigations have examined the use of exopolysaccharide and 
B-glucan producing bacteria as techniques to increase yoghurt viscosity (London et al., 





increase viscosity. Previous reports in fish oil-enriched yoghurt have suggested marine 
oil enrichment reduces viscosity over 21 days of storage (Tamjidi et al., 2012). Hence, 
these results are promising, suggesting that this algal extract does not interfere with 
textural properties of the yoghurt and hence does not impact negatively on viscosity as 
previously reported for other n−3 PUFA sources.  
 
3.6. Colour  
Fig. 4 outlines colorimetric measurements for each of the yoghurts under the L*a*b* 
colour space during the 28 days storage. Colorimetric measurements remained relatively 
stable over 28 days storage in all three yoghurts, suggesting storage did not alter colour 
in each of the individual yoghurts. There were significant differences at all time points 
between the control yoghurt and supplemented yoghurts. The control yoghurt 
demonstrated similar values for ‘L*’ (Lightness) (Fig. 4a) and ‘-a*’ (Greenness) (Fig. 
4b) and ‘b*’ (Yellowness) (Fig. 4c) as reported previously for yoghurt and milk (Hashim 
et al., 2009, O'Sullivan et al., 2014) with values remaining at ~ 80, ~ − 3, and ~ 5 
respectively for the three colour measurements over the 28 day storage period. Both 
0.25% and 0.5% supplemented yoghurts, however, displayed significantly lower ‘L*’ 
values (p < 0.0001) and significantly higher ‘–a*’ (p < 0.0001) and ‘b*’ (p < 0.0001) 
values at each of the time points compared with control. Differences between the control 
and 0.5% supplemented yoghurt were more pronounced for both ‘L*’ and ‘-a*’ values 
compared with the 0.25% yoghurt, reflecting the contribution of the higher 
concentration of the extract on the extent of surface colour intensity. In addition, there 
was a significant difference in ‘b*’ value (p < 0.05) between 0.25% and 0.5% 
supplemented yoghurts at day 14.  
The reduced ‘lightness’ and increased ‘Greenness’ and ‘Yellowness’ 





other pigments in the extract including chlorophyll a, β-carotene, fucoxanthin, 
diadinoxanthin and diatoxanthin (Robertson et al., 2015). O′Sullivan et al. previously 
demonstrated similar changes in Greenness and Yellowness values following 
enrichment of milk with seaweed extracts (O'Sullivan et al., 2014). Results from sensory 
analysis (Fig. 5) suggest that the significant changes in colour are associated negatively 
with sensory properties. Removal of pigments in the extract through refined extraction 
procedures may reduce such dramatic changes in colour and hence improve sensory 
properties, however it is likely that such pigments contribute to the previously observed 
bioactivity of the extract (Robertson et al., 2015). The influence of the extract on the 
appearance of the yoghurts is shown in Fig. 4d.  
 
3.7. Fatty acid analysis  
GC analysis revealed a number of significant differences between the yoghurts with 
respect to fatty acid profiles as reported in Table 4. As outlined in Table 1, the P. lutheri 
extract was primarily composed of n−3 PUFA, hence it was hypothesised that 
incorporation of the extract into the yoghurt during fermentation would enhance n−3 
PUFA concentration of the yoghurt. In the control yoghurt, SFA made up 62.7% of the 
total observed fatty acids whereas these values were lower in the 0.25% and 0.5% 
supplemented yoghurts at 59.4% and 57.2% respectively. In particular, stearic acid 
(18:0) was present in significantly lower concentrations in both the 0.25% supplemented 
(p < 0.01) and 0.5% supplemented (p < 0.01) yoghurts. Palmitic acid (16:0) (p < 0.01) 
and arachidic acid (20:0) (p < 0.05) were also significantly lower in the 0.5% 
supplemented yoghurt compared with control.  
Addition of fish oil to yoghurt has previously been shown to reduce 
concentrations of SFA (Estrada et al., 2011), similar to the findings presented here for an 





cardio-metabolic outcomes (Micha and Mozaffarian, 2010) and hence foods with 
reduced SFA may be beneficial for consumer preference. There was a trend towards a 
reduction in total monounsaturated fatty acids (MUFA) in the supplemented yoghurts, 
which was primarily attributed to significantly reduced proportion of oleic acid (18:1c 
n−9) in both the 0.25% (p < 0.05) and 0.5% (p < 0.01) yoghurts. However a small but 
significant increase was seen in palmitoleic acid (16:1 n−7) in the supplemented 
yoghurts, which was likely attributed to the relatively high concentration of this fatty 
acid within the extract (Table 1).  
There were few small changes in concentrations of n-6 PUFA within the 
yoghurts. An increase in total PUFA in the supplemented yoghurts however, was 
primarily driven by significantly increased levels of a number of n−3 fatty acids. Despite 
being present in relatively low concentrations in the P. lutheri extract, ALA was 
significantly increased in both the 0.25% (p < 0.05) and 0.5% (p < 0.01) supplemented 
yoghurts. ALA has demonstrated anti-inflammatory activity in addition to providing 
physiological health benefits through its conversion to EPA and DHA (Simopoulos, 
1999). SDA, EPA, DHA and total n−3 PUFA were all dose dependently increased in the 
yoghurt following supplementation of the extract (p < 0.0001). ALA was the only n−3 
PUFA detected in the control yoghurt, whereas SDA, EPA and DHA were not present in 
detectable levels. EPA, the most abundant fatty acid within the extract, increased to 
3.1% of total fatty acids in the 0.25% supplemented yoghurt (p < 0.0001) and to 4.8% in 
the 0.5% supplemented yoghurt (p < 0.0001). In addition to the increases in SDA and 
DHA, this led to a respective seven-fold (p < 0.0001) and ten-fold (p < 0.0001) increase 
in concentration of total n−3 PUFA in the 0.25% and 0.5% supplemented yoghurts 
compared to the control. Moreover, the increase in n−3 PUFA led the n6/n3 ratio of the 
yoghurt to decline from 2.2 in the control to 0.3 and 0.2 in the 0.25% and 0.5% 





Yoghurt has previously been assessed as a carrier food for n-3 PUFA-rich oils 
(Dal Bello et al., 2015, Chee et al., 2005). The global decline in n−3 PUFA intake has 
led to research examining foods to act as vehicles for n-3 PUFA for incorporation into 
habitual diet. n-3 PUFA-supplemented yoghurt has been demonstrated as a suitable 
method to increase plasma DHA and reduce plasma AA in human subjects (McCowen 
et al., 2010). In this study, a crude algal lipid extract significantly increased 
concentrations of DHA and EPA in yoghurt in addition to increases in other fatty acids 
such as SDA, which has previously demonstrated cardio-protective and anti-tumorigenic 
activity (Whelan, 2009). These data are the first to report details of a yoghurt enriched 
with an n-3 PUFA-rich lipid extract from P. lutheri. The results thus suggest that this 
algal extract is a suitable method to enhance n-3 PUFA content of yoghurt and hence 
deliver a wide range of essential n−3 PUFA and bioactive pigments to the consumer. It 
is necessary to note indeed that yoghurt contains a number of other shorter chain fatty 
acids other than those reported here, particularly caproic (6:0), caprylic (8:0) and capric 
(10:0) acids. However, it was not within the scope of this study to examine these fatty 
acids, in addition no changes were observed to these fatty acids previously, following 
addition of an n-3 PUFA-rich oil to yoghurt (Estrada et al., 2011).  
 
3.8. Sensory analysis  
Hedonic and descriptive sensory analysis from naïve untrained assessors on days 7 and 
28 revealed a number of significant differences between the yoghurts as outlined in Fig. 
5 and Table S1. Significance of regression correlations are outlined in Table S1 as 
positive or negative values. In general, positive values indicate preferable, and negative 
scores indicate non-preferable scores for each of the sensory attributes. Analysis was 
carried out at two time points to assess whether storage altered sensory attributes of each 





Hedonic analysis revealed that supplementation of the yoghurt at both concentrations 
was negatively correlated with all metrics (‘colour’, ‘liking of flavour’, ‘liking of 
texture’ and ‘overall acceptability’) on day 7 (p < 0.001) and day 28. Negative 
correlations with scores for ‘colour’ correlate with the colorimetric surface colour 
measurements of the yoghurt outlined in Fig. 5c. Higher ‘-a*’ (Greenness) and ‘b*’ 
(Yellowness) values likely contributed to the negative scores in the hedonic sensory 
analysis. Tamjidi et al. found similar results in which fish oil supplemented yoghurts 
scored lower for flavour and overall acceptance (Tamjidi et al., 2012) and O′Sullivan et 
al. also reported negative correlations for sensory, colour and overall acceptability 
scores in milk enriched with algal extracts (O'Sullivan et al., 2014).  
Descriptive sensory analysis found no significant differences between yoghurts 
for ‘odour’ or ‘sour taste’ on day 7 or day 28. ‘Thickness’ was significantly negatively 
correlated with both supplemented yoghurts on day 7 (p < 0.05) however not on day 28. 
Results from viscosity measurements (Fig. 3) showed non-significant differences at day 
7 but not at day 28 and hence may reflect the data seen here in the sensory analysis. 
‘Yoghurt flavour’ was also negatively correlated for both supplemented yoghurts at both 
time points. ‘Fishy taste’ has previously been negatively correlated with both 
supplemented yoghurts and contributed greatly to the separation of correlation loadings 
as seen in Fig. 5c. ‘Fishy taste’ has previously shown negative correlation with sensory 
attributes in yoghurt enriched with algal oil (Chee et al., 2005) and in milk enriched with 
seaweed extracts (O'Sullivan et al., 2014), and hence poses sensory issues for 
enrichment of carrier foods with marine nutraceuticals. Indeed, methods such as 
microencapsulation or the addition of flavourings may help improve sensory attributes 








The novel data reported in this study reveal that yoghurt is a suitable food to act as a 
carrier for an n-3 PUFA-rich lipid extract from P. lutheri. In general, addition of the 
extract did not affect overall quality measures of the yoghurt. Moreover, addition of the 
extract to the yoghurt significantly increased concentrations of n-3 PUFA in the yoghurt. 
Incorporation of n−3 PUFA into vehicle foods may be an effective strategy to enhance 
tissue n-3 PUFA status and hence improve inflammatory and metabolic clinical 
outcomes. The P. lutheri lipid extract used in the present study has previously exhibited 
high bioactive pigment content, high n-3 PUFA content and potent anti-inflammatory 
activity in vitro. Therefore, this extract, as an active ingredient in yoghurt, may exhibit 
potential as an anti-inflammatory functional food and confer a health benefit following 
consumption, however further research in warranted to address this in vivo. Indeed, for 
commercial production of such a food, more extensive sanitation and purification of the 
extract may be required. Further research is warranted to assess how such purification 
procedures may influence the composition and bioactivity of the extract. The limitations 
to this, from a consumer perspective however, can be attributed to negative correlations 
with sensory scores. Colorimetry and sensory analysis indicated that supplementation of 
the extract into the yoghurt contributed to poor acceptability. However, due to the 
minimal impact that the extract had on other functional properties of the yoghurt, further 
research into methods to improve sensory quality may pose potential for such algal 
extracts to become commercial nutraceuticals in yoghurt or other carrier foods and act as 
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Table 1. Fatty acid composition of a food-grade lipid extract of P. lutheri 
 
Fatty acids  P. lutheri extract 
Saturated fatty acids (SFA)  
14:0 3.21 ± 0.19 
16:0 2.99 ± 0.35 
18:0 0.10 ± 0.01 
Total SFA 6.30 ± 0.53 
Monounsaturated fatty acids (MUFA)  
14:1 0.26 ± 0.04 
15:1 0.20 ± 0.02 
16:1c n-7 4.07 ± 0.49 
18:1t n-9 0.57 ± 0.08 
18:1t n-7 0.17 ± 0.01 
Total MUFA 5.27 ± 0.63 
Polyunsaturated fatty acids (PUFA)  
n-6 PUFA 
 16:2 n-6 0.34 ± 0.04 
18:2 n-6 0.32 ± 0.04 
18:3 n-6 0.46 ± 0.06 
20:4 n-6 0.40 ± 0.32 
Total n-6 PUFA 1.52 ± 0.39 
  n-3 PUFA 
 16:4 n-3 0.36 ± 0.05 
18:3 n-3 0.56 ± 0.08 
18:4 n-3 2.21 ± 0.34 
20:5 n-3 8.90 ± 1.40 
22:5 n-3 0.33 ± 0.09 
22:6 n-3 3.48 ± 0.66 
Total n-3 PUFA 15.85 ± 2.58 
Other PUFA 1.77 ± 0.20 
Total PUFA 19.15 ± 3.13 
n6/n3 0.10 ± 0.01 
 







Table 2. Pigment composition of a food-grade lipid extract of P. lutheri 
 
Pigments (% Molar) P. lutheri extract 
diadinoxanthin + diatoxanthin + deg. 2.82 ± 0.01 
chlorophyll a + deg. 4.00 ± 0.42 
fucoxanthin + cys-fucoxanthin + deg. 2.75 ± 0.08 
β-carotene 1.10 ± 0.01 
chlorophyll c + deg. 0.30 ± 0.01 
Total Pigments 10.96 ± 0.35 
 
Data are expressed as g/100g of crude extract and are presented as mean values ± standard 

















Table 3. Mean composition of supplemented and control yoghurts 
 
Composition % 
  Moisture Carbohydrate Protein Fat Ash 
Control 89.7±0.1  4.7±0.2  3.4±0.1  1.5±0.1  0.7±0.1  
0.25% 89.6±0.1  4.8±0.1  3.3±0.1  1.56±0.1  0.7±0.1  
0.5% 89.5±0.1  5.0±0.2  3.2±0.1  1.64±0.1  0.7±0.1  
 






















Table 4. Fatty acid profiles of supplemented and control yoghurts 
 
  Yoghurt FA profile 
g/100g total fatty acids Control 0.25% 0.5% 
Saturated fatty acids (SFA) 
   14:0 12.6 ± 0.3 12.6 ± 0.3 12 ± 0.3 
16:0 34 ± 0.7 32.3 ± 0.5 30.8 ± 0.7 * 
18:0 15.8 ± 0.2 14.4 ± 0.3 * 14.3 ± 0.2 * 
20:0 0.2 ± 0.1 0.2 ± 0.1 0.1 ± 0.1 * 
Total SFA 62.7 59.4 57.2 
Monounsaturated fatty acids (MUFA) 
   16:1c n-7 1.6 ± 0.1 2.7 ± 0.1 * 3.3 ± 0.1 *# 
18:1t n-9 5.9 ± 0.4 5.3 ± 0.4 4.9 ± 0.2 
18:1c n-9 26.3 ± 0.4 24.2 ± 0.4 * 23.5 ± 0.4 * 
18:1 t n-7 0.6 ± 0.1 0.7 ± 0.1 * 0.8 ± 0.1 *# 
Total MUFA 34.9 33.4 32.7 
Polyunsaturated fatty acids (PUFA) 
   n-6 PUFA 
   18:2 n-6  1.2 ± 0.1 1.1 ± 0.1 1.1 ± 0.1 
18:3 n-6 0.5 ± 0.1 0.2 ± 0.1 * 0.3 ± 0.1 * 
20:4 n-6 n.d. 0.2 ± 0.1 * 0.2 ± 0.1 * 
Total n-6 PUFA 1.7 ± 0.1 1.5 ± 0.1 1.7 ± 0.1 
    n-3 PUFA 
   18:3 n-3  0.8 ± 0.1 0.9 ± 0.1 * 0.9 ± 0.1 * 
C18:4 n-3  n.d. 0.5 ± 0.1 * 0.8 ± 0.1 *# 
20:5 n-3 n.d. 3.1 ± 0.3 * 4.8 ± 0.1 *# 
22:6 n-3 n.d. 1.2 ± 0.1 * 2 ± 0.1 *# 
Total n-3 PUFA 0.8 ± 0.1 5.7 ± 0.4 * 8.4 ± 0.1 *# 
Total PUFA 2.5 6.7 10.1 
n6:n3 2.2 0.3 0.2 
 
Data expressed as g/100g of total fatty acid methyl esters (FAME) and are presented as mean 
values of triplicate trials ± standard error of the mean (SEM).  
* significantly different vs. control yoghurt (p<0.05) 
























Figure 1. pH values and starter culture counts. (A) pH values of yoghurts over the storage 
period. (B) L. bulgaricus survival over the storage period. (C) S. thermophilus survival over the 
storage period. Data are expressed as means of triplicate trials. Control yoghurt, black line and 
circles; 0.25% supplemented yoghurt, light grey line and squares; 0.5% supplemented yoghurt, 



















Figure 2. Syneresis values of the yoghurts. Data are expressed as means of whey separation 
values ± standard error of the mean (SEM) of triplicate trials. Control, black bars; 0.25% 




























Figure 3. Rheology of stirred yoghurts over the storage period. Data are expressed as mean 
mPa.s of triplicate trials. Control yoghurt, black line and circles; 0.25% supplemented yoghurt, 


























Figure 4. Colorimetry of the yoghurts over the storage period. (A) ‘L*’ Lightness values of the 
yoghurts over the storage period. (B) ‘-a*’ Greenness values of the yoghurts over the storage 
period. (A) ‘b*’ Yellowness values of the yoghurts over the storage period. Control, black bars; 
0.25% supplemented yoghurt, white bars; 0.5% supplemented yoghurt, grey bars. Values are 
means ± standard error of the mean (SEM) of triplicate trials. * significantly different vs. control 
yoghurt (p<0.05). # significantly different vs. 0.25% yoghurt (p<0.05). (D) Image of the control, 























Figure 5. Sensory analysis of the yoghurts at day 7 and day 28 of storage. (A) Intensity sensory 
values of the yoghurts at day 7. (B) Intensity sensory values of the yoghurts at day 28. Control 
yoghurt, black line; 0.25% supplemented yoghurt, light grey line; 0.5% supplemented yoghurt, 
dark grey line. (C) APLSR plot for the yoghurts. Circles represent sensory descriptors; Circles 



























Table S1. Significance of regression coefficients (ANOVA values) for hedonic and 
intensity sensory analysis of yoghurt as derived by jack-knife uncertainty testing   
 
 
Descriptor  Storage Time, days / Treatment 
 Control  0.25%  0.5% 
Hedonic 7  28  7  28  7  28 
Colour 0.000***  0.000***  -0.000***  -0.001**  -0.000***  -0.000*** 
Liking of flavour 0.000***  0.000***  -0.000***  -0.002**  -0.000***  -0.000*** 
Liking of texture 0.000***  0.000***  -0.000***  -0.013*  -0.000***  -0.009** 
Overall 
acceptability 
0.000***  0.000***  -0.000***  -0.002**  -0.000***  -0.000*** 
            
Intensity            
Thickness 0.021*  0.024*  -0.02*  -0.088  -0.015*  -0.054 
Odour 0.865  0.863  0.863  -0.864  -0.865  -0.864 
Off-odour -0.000***  -0.000***  -0.002**  0.002**  0.000***  0.001** 
Sour taste 0.541  0.558  0.561  -0.554  -0.554  -0.541 
Yoghurt flavour 0.000***  0.000***  -0.000***  -0.003**  -0.000***  -0.000*** 
Off-flavour -0.000***  -0.000***  0.001***  0.002**  0.000***  0.000*** 
Fishy taste -0.000***  -0.000***  0.000***  0.001**  0.000***  0.000*** 
 
Data expressed as significance of regression coefficients (p values); *P < 0.05, **P < 0.01, ***P 



































There is a plethora of evidence for the health benefits of omega-3 polyunsaturated fatty 
acids (n-3 PUFA), which have been scrutinized in the scientific literature as much, if not 
more than any other nutrient. The monumental shift in the dietary ratio of n-6/n-3 PUFA 
over the last number of decades has likely contributed to this research (Simopoulos, 
2002). n-3 PUFA play critical roles in cardiovascular health through processes that 
regulate cholesterol metabolism, atherogenesis and hypertension (Wang et al., 2006). As 
discussed in Chapters 1.1 and 2, brain health is critically dependent on n-3 PUFA by 
regulating neurogenesis, synaptic plasticity and neurotransmitter activity (Bazinet and 
Layé, 2014). Metabolic health is uniquely modified by n-3 PUFA through interactions 
with glucose homeostasis, adipogenesis and inflammation (Calder, 2006, Kim et al., 
2015). Bone health (Weiss et al., 2005), tumorigenesis (Larsson et al., 2004), liver 
function (Parker et al., 2012) and a number of other physiological functions appear to be 
strongly influenced by n-3 PUFA. Indeed, as fatty acids form an integral component of 
the phospholipid bilayer in all mammalian cell membranes, it is evident that n-3 PUFA 
and other fatty acids play integral structural and functional roles in human tissues. 
Interestingly, however, many clinical trials involving n-3 PUFA supplementation have 
failed to replicate the promising results observed in animal studies (Du et al., 2015), 
leading many to question the true significance of dietary n-3 PUFA. Many of these 
conflicting results may be attributed to ineffective supplementation doses, confounding 
dietary factors and most importantly, differences in baseline tissue fatty acid 
composition, which widen inter-individual differences. 
The recent discovery of the significance of the gut microbiota however, primarily 
as a result of advanced sequencing technologies, unveiled a novel mechanism and target 
through which n-3 PUFA may exert their beneficial health effects. Indeed, recent 





microbiota composition in comparison to n-6 PUFA or saturated fatty acids (SFA) 
(Kaliannan et al., 2015, Caesar et al., 2015). A number of dietary n-3 PUFA 
supplementation studies suggest that n-3 PUFA have a direct interaction with the 
commensal gut microbiota (Patterson et al., 2014, Robertson et al., 2016). However, 
transgenic studies using the fat-1 model suggest that there is also an indirect relationship 
between n-3 PUFA and the microbiota through altered tissue fatty acid status and a 
modified intestinal environment mediated by inflammation and antimicrobial peptide 
production (Kaliannan et al., 2016). Therefore, the observed variation in n-3 PUFA 
supplementation efficacy in clinical trials may also be somewhat attributed to underlying 
differences in the gut microbiota.  
Research investigating the interaction between n-3 PUFA and the gut microbiota, 
using deep sequencing technologies, while still a novel area of research appears to be 
expanding (Patterson et al., 2014, Caesar et al., 2015). These studies have shed light on 
the compositional effects that dietary lipids exert on the gut microbiota, however none 
have yet examined these interactions in the context of different ages or disease contexts. 
This thesis aimed to achieve this, to examine the interaction of n-3 PUFA with the gut 
microbiota in the context of different ages and disease contexts, notably obesity and 
behavioural deficits. Secondly, from a translational viewpoint, this thesis aimed to 
examine algae as novel source of bioactive n-3 PUFA and its potential as a functional 
food to increase n-3 PUFA intake. 
n-3 PUFA account for a significant proportion of lipids in the brain and play vital 
roles in the fetal and neonatal developing brain. Moreover, n-3 PUFA have been shown 
to prevent some of the processes that contribute to neurodegeneration (Bazinet and 
Layé, 2014). Adjacently, the gut microbiota plays a crucial role in central nervous 
system (CNS) development and functioning, which has implications for mammalian 





PUFA, was assessed within the gut-brain-microbiota axis. The data presented 
highlighted the crucial role of n-3 PUFA in early-life and adult behaviours. n-3 PUFA 
deficiency significantly impaired communicative behaviour in very early-life while 
being significantly enhanced by n-3 PUFA supplementation. These neurobehavioural 
differences induced by varying n-3 PUFA availability were augmented at later stages of 
life whereby n-3 PUFA supplementation enhanced cognition at both adolescence and 
adulthood, and n-3 PUFA deficiency induced depressive-like behaviour and impaired 
social behaviour in adulthood. Some of these n-3 PUFA-induced behavioural alterations 
have been reported previously, however the mechanisms behind them remain unclear. n-
3 PUFA supplementation reduced the corticosterone response to a forced stress 
suggesting that their role in negative feedback within the hypothalamic-pituitary-adrenal 
(HPA) axis may contribute to the alterations in stress and depressive-like behaviours. 
Furthermore, n-3 PUFA deficiency induced changes to the immune response resulting in 
muted systemic lipopolysaccharide (LPS)-responsiveness, which was previously 
observed in offspring of high fat diet-fed mothers (Myles et al., 2013). Disruptions 
within the immune system also play strong roles in behavioural disorders (Dantzer et al., 
2008). 
 We also closely tracked the development of the gut microbiota at both 
timepoints, i.e. adolescence and adulthood, to examine whether the behavioural 
alterations were associated with modifications to the gut microbiome. Indeed, a number 
of beneficial species known to positively enhance CNS functioning and behaviour, 
including Bifidobacterium, Lactobacillus and the Bifidobacterium/Enterobacteriaceae 
ratio, trended towards higher abundance in n-3 PUFA supplemented mice in adolescence 
and became significantly greater in adulthood. Conversely, n-3 PUFA deficiency 
induced a greater ratio of Firmicutes:Bacteroidetes, a marker of obesity, and 





liver disease (NAFLD) (Jiang et al., 2015). These novel findings not only characterized 
the composition of the adolescent and adulthood gut microbiota following n-3 PUFA 
supplementation or deficiency but also revealed that this altered microbiota is closely 
associated with comprehensive changes to CNS functioning and behaviour. Hence, the 
previously observed benefits of n-3 PUFA for brain health may be mediated through the 
gut microbiota and hence gut microbiota-targeted interventions may provide novel 
therapeutic strategies for neuropsychiatric disorders.  
Although much knowledge has been gained from microbiota research regarding 
its composition under different disease states and its use as a therapeutic target for 
intervention, there is still a lack of knowledge regarding its functionality. It has been 
estimated that in the human body, microbial cells outnumber human cells by 10:1, 
however the microbial gene count compared with humans may be as high as 100:1 
(Hamady and Knight, 2009). Therefore, there is still a lot of knowledge to be gained 
surrounding the functional activity and output of the microbiota rather than its 
composition alone. Advances in metabolomics technologies will help to achieve this. In 
Chapter 3, using a similar experimental design as in Chapter 2, an investigation was 
performed to examine the cecal microbiota composition of n-3 deficient and n-3 
supplemented mothers and their offspring, in addition to the metabolic output of the 
microbiota in the cecal content. A unique cecal metabolite signature has previously been 
identified in a high fat diet (Daniel et al., 2014), and a unique liver metabolite signature 
following n-3 PUFA supplementation (Depner et al., 2013). We first showed that low n-
3 PUFA intake induced a state of ‘dysbiosis’ or microbial imbalance in the cecal 
microbiota of both mothers and their offspring by elevating relative abundance of 
Tenericutes, Anaeroplasma and Coriobacteriaceae. Conversely, n-3 PUFA 
supplementation reduced Lachnospiraceae abundance and the Firmicutes:Bacteroidetes 





to that of the fecal microbiota as was reported previously in Chapter 2 (Robertson et al., 
2016). Microbiota composition differs between the intestinal segments likely reflecting 
different roles in digestion and absorption for each region (Marteau et al., 2001).  
The subsequent metabolomics analysis revealed that n-3 PUFA supplementation 
stimulated an increase in the production of cecal metabolites involved in energy 
metabolism, namely fumaric acid, malic acid and α-ketoglucaric acid. It has previously 
been reported that these energy metabolites and others involved in the tricarboxylic acid 
(TCA) cycle were increased in the serum of conventionally raised animals compared 
with germ free animals, suggesting the microbiota plays a crucial role in energy 
metabolism (Velagapudi et al., 2010). However, there is conflicting evidence about the 
upregulation or downregulation of these metabolites in different animal models of 
obesity, therefore more research is warranted to identify their true role in metabolic 
disease. Using targeted analysis, we also observed a significant decrease of cecal short 
chain fatty acids (SCFA) in n-3 deficiency. SCFA play a number of immunomodulatory 
roles in the gut as well as maintaining intestinal epithelial integrity (den Besten et al., 
2013). Therefore, these results suggest that a lack of n-3 PUFA could contribute to the 
impaired intestinal homeostasis observed in chronic metabolic disease. Finally the 
alterations to microbiota composition and function in n-3 deficiency were associated 
with a reduced ratio of IL-10/TNFα in stimulated spenocytes, a marker of increased 
inflammation. This in-depth analysis provides novel data about how n-3 PUFA and 
indeed, lack of n-3 PUFA, interact with the intestinal environment, notably microbiota 
composition but also function. This study and others could provide useful information 
for future dietary interventions in human subjects that target the microbiota and the 
plethora of metabolites that it produces.  
As previously discussed, a transgenic model of endogenous n-3 PUFA 





interaction with the gut microbiota through the diet but also an indirect relationship by 
modifying the inflammatory activity of the intestinal environment (Kaliannan et al., 
2015). The fat-1 model is important for nutrition research, especially related to the 
microbiota, as it eliminates the confounding effects of feeding different diets and in 
addition allows any observed effect to be attributed solely to n-3 PUFA, rather than 
other nutrients that may be present in dietary oils. This model however, has not been 
used to examine maternal n-3 PUFA status on the offspring microbiota and subsequent 
metabolic outcomes. Maternal n-3 PUFA status during pregnancy significantly regulate 
offspring growth and weight through a number of mechanisms, however it is not known 
whether an altered microbiota is one of these. In Chapter 4, the fat-1 model was utilized 
to examine whether maternal n-3 PUFA status could influence offspring weight gain in 
the context of obesity. Interestingly, it was observed that higher maternal n-3 PUFA 
status either during gestation or lactation significantly reduced weight gain in high fat 
diet (HFD)-fed offspring compared with high maternal n-6 PUFA (wild-type, WT). 
However this effect was only observed in male offspring, not females. The significant 
changes in weight were associated with differences in the intestinal environment. 
Maternal n-3 PUFA significantly reduced intestinal permeability in the offspring. In 
addition, comprehensive alterations were observed to the microbiota in mothers, which 
appeared to be transferred to the offspring both before introduction of the HFD and 
after. Firmicutes, Clostridia and Lachnospiraceae were all elevated in offspring of mice 
whom had a WT mother during lactation, which correlated with weight gain, n-6/n-3 
ratio and intestinal permeability. Interestingly the mothers n-3 PUFA status and 
microbiota during lactation appeared to have a greater effect on offspring phenotypes 
and microbiota than the biological mother. These results suggested that maternal n-3 





the context of offspring obesity and that it is associated with comprehensive alterations 
to the gut microbiota. 
Despite the comprehensive literature reporting the health benefits of n-3 PUFA, 
there are a number of barriers to achieving global increased consumption. The main 
metabolically active n-3 PUFA, eicospentaenoic acid (EPA) and docosahexaenoic acid 
(DHA), are formed through the elongation of their precursor a-linoleic acid (ALA). 
ALA is typically found in plant sources such as flaxseed oil, and itself has been reported 
to exert a number of health promoting bioactivites. EPA and DHA are only obtained 
from marine sources such as oily fish and have been reported to exert more potent anti-
inflammatory, cardioprotective and neuroprotective properties than ALA (Anderson and 
Ma, 2009). The enzymatic conversion of ALA to EPA and DHA is an inefficient process 
in mammalian tissues therefore it is recommended to directly increase consumption of 
EPA and DHA from marine sources such as oily fish. There are doubts however, over 
the sustainability of fish, as global stocks appear to be rapidly declining (Branch et al., 
2011). Indeed, pollution also poses threats to fish production and consumption. Algae, 
particularly microalgae, pose potential as a novel sustainable, industrial and economical 
alternative for n-3 PUFA production than fish (Robertson et al., 2013). A number of 
microalgae species have been closely studied for their ability to produce n-3 PUFA 
under varying environmental conditions, however little is known about the bioactivity of 
algal n-3 PUFA and their potential as functional ingredients. In Chapter 5, a number of 
macroalgal and microalgal lipid extracts were examined for their n-3 PUFA and 
bioactive pigment composition in addition to their anti-inflammatory activity in vitro. 
Previous studies had reported the fatty acid profiles of the algae species involved, while 
in this study, an in-depth analysis of the pigment and lipid partitioning profiles of each 
extract was performed. The lipid partitioning profiles are of particular interest as it has 





classes such as triglycerides and phosphoplipids (Rossmeisl et al., 2012). The algae lipid 
extracts were rich in n-3 PUFA with EPA being the most abundant fatty acid in each 
extract. Human THP-1 macrophages were subsequently stimulated with LPS to mimic in 
vivo inflammation. Exposure of the algae extracts to the stimulated macrophages 
significantly dampened the production of inflammatory cytokines including IL-6 and IL-
8. In addition, an array of inflammatory gene expression assays were performed which 
identified a number of genes involved in toll-like receptor activity and chemokine 
activity that were down-regulated by the extracts. There is growing evidence of the 
bioactivity of n-3 PUFA algal oils. However, due to the differing fatty acid profiles and 
lipid partitioning profiles in particular, algal oils may significantly differ to fish oils in 
their bioactivity. Furthermore, little research into algal oil bioactivity has provided 
mechanistic evidence for their observed effects. The market for vegetarian sources of n-
3 PUFA is increasing and hence more research is warranted to identify suitable species 
for production and their potential health benefits. The results presented here not only 
characterized the lipid and pigment profiles of novel extracts but also provided 
mechanistic evidence as to how such extracts dampen inflammation. This may have 
further implications for intestinal health. The immune system is uniquely regulated by 
the intestinal environment through interaction with the gut microbiota. Indeed, as n-3 
PUFA modulate microbiota and inflammation as described in Chapters 2 to 4, it is 
possible that these n-3 PUFA-rich algae extracts have similar effects. Hence, there is 
potential for these extracts to act as anti-inflammatory functional ingredients, as was 
investigated in Chapter 6. 
Another barrier to n-3 PUFA consumption is undesirable sensory attributes of 
fish and fish oil. Therefore, some research has begun to examine various food matrices 
that could act as carriers for n-3 PUFA-rich oils. Dairy products in particular appear to 





which to incorporate functional ingredients into habitual diets. Due to the previously 
reported high n-3 PUFA composition and potent anti-inflammatory activity of a lipid 
extract from the microalgae P. lutheri in Chapter 5 (Robertson et al., 2015), the study 
outlined in Chapter 6 aimed to investigate whether yoghurt could act as a suitable carrier 
for the extract. The data reported that the primary techno-functional properties of the 
yoghurt (pH, whey separation, rheology, starter culture viability and macronutrient 
composition) were all unaffected by addition of the extract during processing at two 
different doses (0.25% and 0.5%). Another study reported similar results using a 
different algal extract (Chee et al., 2005). Furthermore, addition of the extract to the 
yoghurt dose-dependently increased n-3 PUFA content of the yoghurt. However, 
extensive sensory analysis reported that the supplemented yoghurt was not well accepted 
under a number of sensory parameters. The novel data reported in this study reveal that 
yoghurt is a suitable food to act as a carrier for an n-3 PUFA-rich lipid extract from P. 
lutheri. Incorporation of n-3 PUFA into vehicle foods may be an effective strategy to 
enhance tissue n-3 PUFA status and hence improve inflammatory and metabolic clinical 
outcomes as has been suggested previously for enriched yoghurt (McCowen et al., 
2010). Although there were perceived negative sensory attributes, the lack of effect of 
the extract on the techno-functional properties of the yoghurt as well as the increasing n-
3 PUFA content warrants further research into how sensory properties could be 
improved in order to commercially manufacture such a product.  
The data presented in this thesis reveals a novel mechanism by which n-3 PUFA 
mediate health and disease, through interaction with the microbiota. Furthermore, this 
has been reported in the context of different ages (mothers, adolescence, adulthood) and 
disease states (obesity, inflammatory disorders and behavioural deficits). Increasing 
evidence is showing that a perturbed microbiota can be a causal factor in a number of 





therapeutically effective. However, microbiota research is only in its infancy therefore 
further insights into gastrointestinal ecology and its interaction with the diet will aid in 
future disease interventions and preventative measures. Uniquely, this thesis has also 
reported evidence for potential novel methods of increasing n-3 PUFA production and 
consumption. The use of algae as novel sustainable sources of n-3 PUFA may help to 
increase n-3 PUFA intake. With further research, this may benefit gut microbiota and 
inflammation-linked chronic disease through novel sustainable foods. From a public 
health perspective, such research may aid public health recommendations in order to 
define recommended intake levels for n-3 PUFA, which currently are lacking. Indeed 
increasing awareness about the health benefits of n-3 PUFA and the risks of high dietary 
n-6 PUFA may improve public nutrition and health outcomes.  
Despite much research already reporting the beneficial health effects of n-3 
PUFA, their interaction with gut microbiota is relatively unexplored in addition to their 
bioactivity from algae. The data presented here represents the beginning of such 
research however further work is necessary. Ongoing research should address and 
consider this n-3 PUFA-microbiota interaction in different disease states. Clinical trials 
of n-3 PUFA supplementation in certain inflammatory diseases such as inflammatory 
bowel disease (IBD) have generated conflicting and inconclusive results. Future 
research should examine whether a lack of effect in n-3 PUFA clinical trials involving 
disorders such as IBD are due to differences in gut microbiota composition and function. 
Regarding metabolic health and the data generated from chapter 4, further research is 
warranted to examine whether the observed effects on weight are truly mediated by 
changes to the gut microbiota. A co-housing study or germ free study in which the 
microbiota of the fat-1 mother’s offspring is transplanted into that of the WT mother’s 
offspring would answer such a question. Indeed, as low-dose antibiotics induce a similar 





n-3 PUFA can protect against such antibiotic-induced disturbances in the offspring. 
Importantly, the observed gender difference should be further addressed. A similar co-
housing or germ-free design could be employed to further investigate the behavioural 
and neurological outcomes observed in chapter 2, to assess whether a true gut-
microbiota-brain interaction exists in this design. Indeed, the longer term effects on 
ageing brain health and the associated interaction between n-3 PUFA and the microbiota 
would answer important questions related to dementia. Finally, to further develop the 
knowledge and research regarding algae-derived n-3 PUFA, research that compares the 
anti-inflammatory effect or anti-obesigenic effect of algae oils in comparison to fish oil 
is warranted in addition to their interaction with the gut microbiota. By continuing the 
research described in chapters 5 and 6 using in vivo or clinical models of obesity or 
inflammatory disease, important knowledge would be obtained regarding the true 
potential for algae to replace fish as a source of n-3 PUFA and act as viable functional 
foods.  
Such research could help promote greater global n-3 PUFA intake in place of 
other dietary lipids and help stem and prevent the growing epidemic of obesity, 
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